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Abstract 
Introduction: The hypothesis of this study is that prognostic and predictive markers defined 
by immunohistochemistry (IHC) and other histopathologic characteristics of a primary 
breast carcinoma tumour, together with gene expression profiling of the tumour, DNA 
methylation profiling and microRNA (miRNA) will identify lymph node status in breast 
cancer patients and allow selection of patients for sentinel lymph node biopsy (SLNB) or 
axillary lymph node dissection (ALND) in addition to providing prognostic information.  
Methods: A web-based database of breast cancer patients was constructed using Distiller, 
SlidePath (Leica Microsystems, Germany) software. A MindMap was used to determine 
subgroupings and structure of the database. Three patient cohorts were identified from 
separate sources and patient records were identified using Systematized Nomenclature of 
Medicine (SNOMED) coding as a search parameter. Data was extracted into Microsoft 
Excel and uploaded into Distiller. 
3200 patient reports were retrieved from a private pathology database, 1834 from a public 
hospital and 5200 from a separate public pathology hospital. Haematoxylin and eosin 
(H&E) slides from 645 patients were reviewed from the initial dataset to confirm the 
imported data and reliability of pathology information. This included tumour type, tumour 
grade and size, presence or absence of lymphatic and vascular permeation, margin type, 
lymphocytic infiltration, lymph node status and number of involved lymph nodes. Survival 
data was also obtained from the Queensland Cancer Registry under HREC approval to 
evaluate applications of the data for prognostic information. A breast cancer cluster was 
incorporated into the project and evaluated to ascertain if there were commonalities 
between the tumours which would offer potential insight into causes of breast cancer or 
prognostic information. 
Tissue microarrays (TMAs) were constructed to enable evaluation of 
immunohistochemistry markers and TMAs were evaluated for correlation with clinical 
parameters. Epigenetic biomarkers were also evaluated and correlated with different 
parameters in triple negative breast carcinoma (TNBC). 
Results: Biomarkers evaluated on TMAs successfully correlated with clinical outcome in 
breast carcinoma patients and an artificial neural network (ANN) model was constructed to 
predict modular grade in breast cancer patients. This ANN model enabled the subdivision 
of Grade 2 breast carcinomas into Grade 1 and Grade 3 carcinomas and correlated with 
patient survival. Epigenetics models were also able to stratify TNBC patients into 
prognostic groups. 
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However, an ANN was not able to be successfully developed to predict lymph node status 
and similarly epigenetics was also not able to predict lymph node status. An analysis of a 
breast cancer cluster also showed that the cluster tumours were similar to sporadic breast 
cancers and a distinctive pattern was not identified.  
The project has enabled the identification of markers to subclassify breast carcinomas into 
a molecular grade and to develop a number of immunohistochemistry and epigenetic 
biomarkers that correlate with prognosis in breast cancer. 
However, the data from this project suggests that it is not possible to predict lymph node 
status form the primary tumour characteristics with sufficient clinical accuracy to forgo 
sentinel lymph node biopsy. It also suggests that lymph node metastases and distant 
metastases are separate independent events. Lymph node metastases are associated 
with a complex phenotype that is not defined a single genetic mutation and the elucidation 
of the events resulting in this biological cascade are still to be defined. 
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Chapter 1 
General Introduction 
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1.1. Hypothesis 
The hypothesis of this study is: 
Prognostic and predictive markers defined by immunohistochemistry (IHC) and other 
histopathologic characteristics of the primary tumour, together with gene expression 
profiling of the tumour, DNA methylation profiling and  microRNA (miRNA) will identify 
lymph node status in breast cancer patients and allow selection of patients for sentinel 
lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). 
1.2. Aims 
 To develop a model for prediction of lymph node involvement in early breast cancer 
using histologic, phenotypic, expression profiling, DNA methylation, miRNA and 
genotypic tumour characteristics including IHC markers of cell surface receptor 
molecule expression, oncogenes, tumour suppression genes and metastasis 
suppression genes.   
 To develop an artificial neural network algorithm to predict lymph node status in 
breast carcinoma patients from initial core biopsy prior to initial surgery. 
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1.3. Introduction 
The spread of cancer from the point of origin was first termed “metastasis” by Jean Claude 
Recamier in 1829 (Recamier, 1829). Despite advances in treatment of cancer both in 
surgical techniques, chemotherapy and targeted therapy, the majority of cancer deaths are 
due to metastatic disease. The spread of tumour cells that are resistant to therapy occurs 
from the primary tumour site to distant sites, where they grow, multiply and impact on 
patient survival.  
 
Most invasive tumours can metastasize, with three pathways of spread to distant organs: 
direct seeding of surfaces and cavities such as the peritoneal cavity, lymphatic spread and 
haematogenous spread (Figure 1). 
 
 
 
 
 
 
 
Figure 1: “Routes to metastasis development (a) Schematic diagram showing possible routes 
tumour cells could conceivably take during their journey through the body. Disseminating tumour 
cells can leave the primary tumour and enter the blood directly. If they enter the lymphatic system 
they might lodge in lymph nodes and eventually grow out as lymph node metastasis. Alternatively 
they could enter the blood stream, for example via the thoracic duct or possibly also via high 
endothelial venuoles (HEV). Once in the blood stream, disseminating tumour cells that survive might 
either self-seed the primary tumour, re-enter the lymphatic system or extravasate into organs. 
Tumour cells shed into the blood by metastases might also participate in self-seeding. (b) Illustration 
of possible fates of disseminated tumour cells. Once tumour cells have extravasated and invaded 
vital organs, they either die, enter dormancy or grow out as metastases. A number of factors, 
including those depicted in the figure, have been implicated in regulating dormancy” (Sleeman et al., 
2011). 
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Dissemination of non-neoplastic cells results in the death of the cell or homing to a 
particular site e.g. bone marrow precursors. In contrast metastasizing neoplastic cells are 
not subject to these regulatory influences.  
 
Any primary tumour contains a heterogeneous cell population and for a primary tumour to 
metastasize requires completion of a complex series of events and interaction with 
multiple host factors (Fidler, 1991). In 1973 experiments indicated metastasis was a 
selective process and in 1977 it was identified that malignant tumours were heterogeneous 
with subpopulations of tumour cells with widely differing metastatic properties (Fidler, 
1991). This study showed that the number of lung metastases was proportional to the 
number of viable tumour cells, however clumps of tumour cells resulted in an increased 
number of metastatic lesions compared to the injection of an equal number of single 
tumour cells (Fidler, 1991). New techniques have allowed us to gain some insights into the 
pathogenesis of metastasis (Tarin, 2006).  Multiple steps and multiple genes are required 
for metastasis to occur: the neoplastic cells must dissociate from the primary tumour, enter 
the lymphatic system, vascular system or a body cavity, survive during transport, exit the 
circulation and grow at a distant site (Eccles and Welch, 2007). This process is extremely 
inefficient and of the approximately 4 million cells per gram of tumour per day entering the 
circulation less than 0.01% develop into metastatic tumours at other sites (Eccles and 
Welch, 2007). Many circulating tumour cells are apoptotic or dead and many others are 
eliminated by shearing forces in the circulation (Sleeman et al., 2011). In addition many 
circulating tumour cells have the ability to extravasate successfully, but will not form 
metastases (Sleeman et al., 2011).  
 
Functional genomics has allowed the recognition of tissue-specific metastasis genes for 
bone and lung sites (Kang, 2006) , but this has not occurred for lymph node metastases. A 
number of mechanisms have been implicated in this process including selectins, 
chemokines and their receptors and the concept of premetastatic niches (Sleeman et al., 
2011). 
 
All studies have some limitations and this may account for the failure to identify features in 
primary tumours that relate to lymph node metastases. Immunohistochemistry (IHC) 
studies are usually small and retrospective. Gene expression profiling studies are 
generally restricted to fresh or frozen tissue, use an admixture of tumour and stromal cells 
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and rely on biostatistical processing to obtain any useful information. Animal models may 
not accurately reflect human tissue features and xenografts usually do not contain 
supporting human stromal cells. For human studies there is usually little histopathological 
data (Urquidi and Goodison, 2007) and poor data quality may adversely impact on 
downstream data. 
 
In particular, contaminating cells may alter the results obtained with expression 
microarrays. Harrell et al (Harrell et al., 2007) analysed differences between primary 
tumours and lymph node metastases using tumour sections and laser capture 
microdissection samples. Less than 1% (30) of genes that varied in expression levels 
between tumours and the nodal metastases were common to both methods. 
 
Eccles et al (Eccles et al., 2007) recently reviewed lymphatic metastasis in breast cancer 
and concluded that lymph node metastasis is an important prognostic factor, however, 
there were a number of unresolved issues and questions. These included: 
a) Whether lymph node metastasis is an indicator or governor of metastasis to distant 
organs. 
b) Is lymphangiogenesis required for lymphatic metastasis? 
c) Is there a gene signature or other reliable predictor of lymphatic metastasis in 
primary tumours? 
d) What factors are rate limiting for lymphatic metastasis? 
e) What is the relative importance of active verses passive mechanisms? 
f) How do tumour cells survive in the nodes and escape immune surveillance? 
g) Is targeting lymphatic metastasis a viable therapeutic option in cancer? 
 
Adjuvant antiangiogenesis therapy has not improved overall survival in cancer patients 
and mice models of lymph node metastases has shown no effect of antiangiogenesis 
therapy on the growth or vascular density of lymph node metastases (Jeong et al., 2015). 
This suggests that lymphatic metastasis, whilst being a prognostic marker in cancer, may 
not be a viable therapeutic option for targeted therapy. 
Many studies have attempted to define the mechanisms of tumour dissemination in a wide 
range of tumour types. One of the most widely studied has been breast cancer.  
This thesis focuses on lymphatic spread of tumour cells in breast cancer to provide insight 
into potential patient benefit and treatment therapeutics for breast cancer patients. For 
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breast cancer, the inability to predict the lymph node status in patients means that a 
second operative procedure, an axillary lymph node dissection, is currently required if a 
metastasis is detected in the sentinel lymph node biopsy at the first operation. 
1.4. Breast Cancer 
Breast cancer is the leading cause of cancer-related deaths in women world-wide 
(Hinestrosa et al., 2007) and is the second most common cancer in Australian women. 
More than 13,000 new cases are diagnosed each year in Australia (AIHW and NBCC, 
2006), increasing from 11,000 in 2000 (Welfare, 2000),of which 2,200 are in Queensland. 
Approximately 2,700 deaths from breast cancer occur annually in Australia of which 465 
were in Queensland in 2003. The number of hospital separations in Australia for women 
increased from 15,831 in 1995-96 to 23,598 in 2003-4 (AIHW and NBCC, 2006). 
 
In recent years vast resources have been devoted to attempting to identify and develop 
biomarkers to help determine which treatments provide the greatest benefit to any given 
patient with breast cancer. This may be either to select patients for a particular therapy to 
spare patients from unnecessary or toxic therapy of no benefit. This is considered to be 
the goal of individualized or personalized medicine. Despite these efforts, biomarker 
research has generally resulted in ambiguous data with inconclusive findings or insufficient 
evidence. Molecular profiling may increase the effectiveness of our prognostic profiling, but 
is still only based on population statistics and is not truly individualized to define treatment 
for specific patients.  
1.5. Breast Pathology 
The breast is a modified skin sweat gland that develops into a complex functional structure 
in the female, but remains as a rudimentary structure in the male.  
 
There has been a gradual increase in the incidence of breast cancer in older women over 
the last 10 years, but this has probably been due to the introduction of mammographic 
screening programs. In 1994, the mortality rate from breast cancer started to decline and 
currently only about 20% of patients are expected to die from the disease. 
 
Ninety-five percent of breast carcinomas are adenocarcinomas with other types such as 
sarcomas comprising less than 5%. Carcinoma in-situ indicates that the lesion is still 
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confined within the basement membrane. Invasive carcinoma infiltrates into the adjacent 
tissue. Larger invasive lesions may cause dimpling of the skin or invade into underlying 
muscle or chest wall. Lymphatic permeation may occur and lead to thickening of the skin 
(peau d’orange). Approximately 30% of patients will have lymph node metastases at the 
time of presentation, although many of these will not be palpable. 
 
The aetiology of breast cancer is multifactorial and involves reproductive factors, hormone 
levels and lifestyle (Ellis et al., 2003). Breast cancer is uncommon in women under the age 
of 25 except in some familial cases and seventy-seven percent of cases occur in women 
above the age of 50 (Ellis et al., 2003). 
1.6. Somatic genetics of breast cancer 
As with other tumours, breast cancer develops through an accumulation of genetic 
abnormalities by gene mutations, amplification and deletions. No karyotypic hallmarks of 
breast cancer have been identified (Ellis et al., 2003). Some particular genetic 
abnormalities have been associated with specific types of breast carcinoma (Thor et al., 
2002), but in the majority of cases there are no cytogenetic markers to allow subtyping. 
Invasive micropapillary carcinoma showed loss of the short arm of chromosome 8 in 16 of 
16 cases analysed by comparative genomic hybridization (Thor et al., 2002). Comparisons 
have also been performed between invasive ductal carcinoma and invasive lobular 
carcinoma (Turashvili et al., 2007).  
1.7. Hallmarks of cancer 
There are six hallmarks of cancer that comprise the biological capabilities that define 
cancer (Hanahan and Weinberg, 2011, Hanahan and Weinberg, 2000). These six 
characteristics include sustaining proliferative signalling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating 
invasion and metastasis (Figure 2). Genomic instability underlies all of these features. 
These characteristics have been used to develop drugs that affect the different pathways, 
however, no well-defined molecular characteristics have been identified to determine a 
metastatic phenotype. 
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When the hallmarks of cancer hypothesis was first published in 2000, the mechanisms of 
metastasis were essentially unknown (Hanahan and Weinberg, 2000). Epithelial tumours 
have changes in the expression of cell adhesion molecules such as E-cadherin with 
changes in morphology, undergoing epithelial-to-mesenchymal transition (EMT). In breast 
carcinoma, lobular carcinomas usually lack E-cadherin, and the lack of expression of E-
cadherin by immunohistochemistry staining has been used to differentiate lobular 
carcinoma from ductal carcinoma. However, the presence of E-cadherin does not exclude 
metastatic potential as the majority of ductal carcinomas will express this cell adhesion 
molecule, and a number of these carcinomas will metastasise. Other adhesion molecules 
associated with cell migration are often upregulated in metastatic tumours (Hanahan and 
Weinberg, 2011). Whilst extensive research has been performed on metastasis and the 
process of metastasis, the exact pathways are still largely unknown although EMT may 
play a role. Kimbung at al (Kimbung et al., 2015) have identified four main groups of genes 
involved in the metastatic cascade:  metastasis initiation genes, metastasis progression 
genes, metastasis virulence genes and metastasis suppressor genes. 
 Figure 2: Drugs that interfere with each of the acquired capabilities necessary for tumour growth and 
progression have been developed and are in clinical trials or in some cases approved for clinical 
use in treating certain forms of human cancer (Hanahan and Weinberg, 2011).  
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It is also interesting to note, that for haematological metastasis to develop, groups of 
tumour cells are more likely to form a metastasis compared to individual tumour cells. 
Recently, quantification of circulating tumour cell clusters (CTC clusters) in blood has 
shown that whilst they comprise less than 3% of total CTCs, clusters are responsible for 
more than 50% of metastatic lesions (Bottos and Hynes, 2014). RNA analysis of the CTC 
clusters identified increased expression of plakoglobin within the clusters (Aceto et al., 
2014). The experiments only examined haematogenous dissemination and CTCs, with no 
data available for lymphatic dissemination. 
 
Inhibitors of c-Met have been developed, but these have had very limited impact on patient 
care. Abnormalities in the HGF/MET pathway have been reported in multiple tumour types 
and these changes are associated with tumour stage and prognosis. As this pathway has 
been associated with invasion and metastasis, the MET pathway has become a potential 
therapeutic strategy in oncology development in the last two decades. A number of novel 
therapeutic agents including monoclonal antibodies and small molecule inhibiters, have 
been tested in patients with different tumour types in clinical studies (Zhang et al., 2011), 
but the results have generally been disappointing (Van Der Steen et al., 2015).  A Phase 
III clinical trial of Onartuzumab, a MET inhibitor, in NSCLC has been abandoned after the 
drug failed to show any clinically meaningful efficacy.  This drug also failed in a late-stage 
trial involving triple-negative breast cancers. 
1.8. Stem cell hypothesis of breast cancer heterogeneity 
Breast carcinomas are heterogeneous with an admixture of cells. The biological 
mechanisms that result in breast cancer progression and metastatic disease are still poorly 
understood, but cells can be identified in vascular and lymphatic vessels on histological 
assessment. The approach used in this thesis attempts to overcome the heterogeneity of 
the primary tumour by selecting the cells most likely to have the metastatic phenotype. 
There are two current theories that attempt to explain tumour heterogeneity. These are the 
cancer stem cell hypothesis and the clonal evolution model. Campbell and Polyak 
(Campbell and Polyak, 2007) have reviewed these two models. The cancer stem cell 
hypothesis is that there are a small number of tumour cells with stem cell-like properties. 
These cells are responsible for initiation, growth and spread of disease (Cariati and 
Purushotham, 2008). These cells can self-renew indefinitely and survive chemotherapy 
(Fillmore and Kuperwasser, 2008). The differentiation of these cells leads to the bulk of the 
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tumour and the cellular heterogeneity. The cancer stem cell hypothesis accounts for 
metastatic disease by the dissemination of these stem cell-like cancer cells and the 
resistance to chemotherapy accounts for tumour recurrence after treatment (Cariati and 
Purushotham, 2008, Stingl and Caldas, 2007, Cobaleda et al., 2008). This concept is not a 
new one and was first proposed by Cohnheim (Cohnheim, 1875) more than a century ago.  
 
The supporting evidence for the stem cell hypothesis is that the tumour traits could be 
explained by cells originating from self-replicating stem cells and these cells exhibit 
pathways associated with stem cells. One of the main arguments to support the stem cell 
theory is that only a small number of cells are tumourigenic when transplanted into mice. 
There may be other reasons why this is the case (Kelly et al., 2007, Wicha, 2007) and 
conclusive proof is still lacking. A large amount of work has been based on leukaemia, but 
recent studies have identified putative breast cancer stem cells identified by the surface 
marker CD44. Al-Hajj et al (Al-Hajj et al., 2003, Al-Hajj and Clarke, 2004) showed that 
CD44+/CD24- phenotype breast cancer cells could form tumours when injected into nude 
mice. 
 
The second theory is the clonal evolution model which postulates the acquisition of 
mutations within a tumour and natural selection of the most aggressive clone drives 
tumour progression. New subpopulations of tumour cells occur resulting in tumour 
heterogeneity. Any tumour cell may acquire the metastatic or chemoresistant phenotype 
(Campbell and Polyak, 2007). This theory was first proposed by Nowell (Nowell, 1976) in 
1976. Some tumour traits can be explained by this theory such as monoclonality, 
proliferative capability and heterogeneous cell populations. This would also explain the 
development of chemotherapy resistance and resistance to other treatments such as 
tamoxifen and trastuzumab. There is also data showing that primary tumours and 
metastases are similar genetically (Campbell and Polyak, 2007). Data from DCIS studies 
also supports this hypothesis (Allred et al., 2008). The most convincing evidence has been 
obtained using laser capture microdissection. Every major type of tumour contains a 
number of subpopulations with different abnormalities (Campbell and Polyak, 2007). 
Similar data has been obtained in breast cancers with matched primary and metastatic 
tumours (Campbell and Polyak, 2007). Shipitsin et al (Shipitsin et al., 2007) determined 
molecular profiles on distinct cancer cell populations and concluded that the finding of 
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genetic differences supported the clonal evolution hypothesis. However, Ailles et al (Ailles 
and Weissman, 2007) disputed this conclusion and argue that the data from this study 
support the cancer stem cell hypothesis. 
 
A number of concerns have been raised over the methods used to identify cancer stem 
cells from solid tumours: 
a) Cells are usually isolated from a mixture of fresh tumour cells and the process of 
isolating the cells may promote selection bias.  
b) The cells selected may not be representative of the entire tumour depending on the 
ratio of tumour cells to stroma and when frozen tissue is used for the isolation of 
nucleic acid, the cell population is almost always heterogeneous. 
c) Studies in mice are not comparable to humans as they usually do not include 
human stromal elements (Campbell and Polyak, 2007).  
In their review of the two different models, Campbell and Polyak (Campbell and Polyak, 
2007) propose a combined clonal evolution model that incorporates some features of both 
hypotheses.  
In support of cancer stem cells of cancer stemcell-ness, highly tumorigeneic and 
metastatic cells have been identified in different tumour types (Li et al., 2015). In this 
recent study, the small molecular BBI608 inhibited spherogenesis and Stat3-driven 
transcription, resulting in suppression of metastasis and cancer relapse in xenograft 
models (Li et al., 2015). The inhibition of metastasis was related to evaluation of direct 
injection of colorectal cancer cells into the splenic capsule of nude mice, but did not 
evaluate lymph node metastases in this model (Li et al., 2015). 
1.9. Prognostic markers in Breast Cancer 
In current clinical practice for breast cancer, the standard prognostic factors that guide 
adjuvant systemic treatment decisions include tumour size, histologic subtype, nuclear or 
histologic grade, oestrogen and progesterone receptor status, and axillary lymph node 
status.  A measure of the limitation of these factors in predicting outcome is exemplified by 
the observation that recurrence rates are approximately 25% in lymph node negative 
breast cancer patients who will often not receive adjuvant therapy (McGuire and Clark, 
1992). 
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There have been more than 100 variables described to attempt to predict prognosis or 
response to therapy in breast cancer patients, but only a limited number have entered 
clinical practice. A predictive factor is defined as a clinical or pathologic feature that 
determines the likelihood of a response to a particular treatment. A prognostic factor is 
defined as a clinical or pathologic biomarker that determines patient outcome or survival. A 
biomarker may be both predictive and prognostic. For a factor to be useful, it must be 
technically validated, clinically validated and influence clinical decision making. A large 
proportion of studies have used immunohistochemistry (IHC) to assess the expression of 
different antigens in breast cancer cells compared to normal tissue. Limitations of these 
studies include variation in patient selection, different primary antibody clones, different 
cut-off criteria, interlaboratory variation and reproducibility of the methodology. 
 
In addition, molecular techniques including DNA microarray analysis have indicated a 
large number of genes are involved in the progression of breast carcinoma. More than 
3000 genes have been implicated in distinguishing oestrogen receptor (ERp) positive 
tumours from ERp-negative tumours (Talisuna et al., 2003). 
 
1.9.1. Grade 
Breast cancer is graded according to the Elston-Ellis modified Scarff, Bloom, Richardson 
grading system also known as the Nottingham modified Bloom and Richardson system 
(Bloom and Richardson, 1957, Elston and Ellis, 1991). In this grading system, there are 
three components assessed for assignment of grade to a tumour: Tubule formation, 
nuclear pleomorphism and mitotic rate. Each component is assigned a number from 1 to 3 
and the components are totalled to obtain a value out of 9. Tumours with a score of 5 or 
less are graded as Grade 1 (G1), 6-7 are Grade 2 (G2) and 8-9 as Grade 3 (G3) tumours. 
The grade of tumour shows significant correlation with  breast cancer specific survival 
(Burke and Henson, 1997, Nicholas, 1997, Roberti, 1997, Ellis et al., 1992) for patients 
with lymph node metastases and those without nodal metastases at 5, 10 and 15 years. 
The evaluation of tubule formation and mitotic rate provide independent prognostic 
information (Frkovic-Grazio and Bracko, 2002). 
Untreated G1 patients have a 5 year survival rate of approximately 95%, whereas those 
patients with G2 or G3 tumours have 5 year survival rates of approximately 75% and 50% 
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respectively. Grade is also associated with lymph node metastases and lymph node 
positivity increases significantly with high-grade tumours (Iwasaki et al., 1998, Ashturkar et 
al., 2011). 
However, there is significant interobserver variability in the evaluation of histological grade 
by pathologists (Harvey et al., 1992, Robbins et al., 1995, Frierson et al., 1995, Dalton et 
al., 1994, Dalton et al., 2000) and the usefulness in patient prognosis has been questioned 
(Younes and Laucirica, 1997, Hayes et al., 2001). Grade 2 tumours comprise 
approximately 50% of all breast cancers and it has been proposed that refinement of this 
group may improve the prognostic value of tumour grading (Sotiriou et al., 2006, Ivshina et 
al., 2006) as Grade 2 tumours usually show the lowest degree of concordance (Rakha et 
al., 2010a). 
1.9.1.1. Molecular Grade 
Because of the limitations of histological grading a number of molecular techniques 
including gene expression profiling (Ivshina et al., 2006, Sotiriou et al., 2006) have been 
used to attempt improve the current grading system. Sotiriou et al developed a 97-gene 
expression profile associated with histologic grade and found that the gene expression 
profile was correlated more strongly with relapse-free survival compared to histologic 
grade (Sotiriou et al., 2006). Similarly Ma et al (Ma et al., 2003) and Ivshina et al (Ivshina 
et al., 2006) have also developed histologic grade signatures and the latter enabled the 
refinement of the G2 tumours into different subgrades with clinical implications (Ivshina et 
al., 2006). The Genomic Grade Index (Filho et al., 2010, Ignatiadis and Sotiriou, 2008b, 
Toussaint et al., 2009) has been further developed for both frozen and formalin fixed 
paraffin embedded tissue (FFPE). Ma et al (Ma et al., 2008) developed a PCR-based five 
gene molecular grade index (MGI) for applications with FFPE material. The rationale for 
this approach was that it may be more easily implemented into a diagnostic laboratory. 
The MGI has been validated in a separate patient cohort (Jerevall et al., 2011) and has 
also been used with HOXB13:IL17BR for prognosis in lymph node negative patients 
(Habel et al., 2013) . 
 
1.9.2. Lymph node status 
Lymph node metastasis is the main prognostic factor in breast carcinoma.  
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The mechanism of lymph node metastasis and its involvement in further tumour 
dissemination is poorly understood. Breast cancer metastasis follows the sequence of 
invasion into surrounding tissue, penetration into vessels, spread to distant sites and 
growth at those sites. Breast cancers, in addition to other tumour types, have a 
predilection to spread to regional lymph nodes (Sleeman, 2000). Once metastasis has 
commenced, there may be many sites for tumour deposition. Some metastatic deposits 
may be explainable by purely mechanical forces that trap tumour cells, however there are 
favoured sites such as the brain and bones that suggest homing mechanisms.  
 
Eccles et al (Eccles et al., 2007) have reviewed lymphatic metastases including 
mechanisms by which tumour cells may enter lymphatic vessels. Tumours can interact 
with lymphatic vessels by the production of growth factors and possibly by tumour 
contribution to the structure of tumour-associated lymphatic vessels (Eccles et al., 2007). 
Figure 2 shows the possible paths for metastasis in 
breast cancer (Mumprecht and Detmar, 2009). It is 
unknown whether tumour cells need to actively 
invade into lymphatic vessels or whether this is a 
passive process (Bockhorn et al., 2007) and also 
unknown is the mechanism by which tumour cells 
select either vascular or lymphatic permeation 
(Wong and Hynes, 2006). These processes may 
occur in series 
or parallel and 
may be 
determined by distinct molecular mechanisms. If 
entry into the lymphatic or vascular channels is not the rate-limiting step then other 
mechanisms must determine the ability of tumour cells to exit the circulation and proliferate 
at the metastatic sites. 
 
If the cancer stem cell hypothesis is the preferred model for breast cancer, then only 
cancer stem cells should be capable of giving rise to breast cancer metastases. In support 
of this theory is the finding that the majority of breast cancer cells identified in the bone 
marrow are CD44+/CD24-/low (Balic et al., 2006). It has also been demonstrated that these 
cells express genes involved in pathways associated with cell motility, invasiveness and 
Figure 3: Schematic of tumour-induced 
lymphangiogenesis at the tumour site and in 
lymph nodes with metastasis to lymph nodes 
and distant sites (Mumprecht and Detmar, 
2009). 
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chemotaxis (Shipitsin et al., 2007, Liu et al., 2007). However, the CD44+/CD24-/low 
phenotype was insufficient to identify cells that were able to establish in vivo metastases 
(Sheridan et al., 2006), and only a subpopulation of these cells may be able to perform this 
function. 
 
Clinical studies suggest that there is no survival difference between patients whose 
regional lymph nodes have been removed, compared to those who receive no or partial 
dissection of the nodes (Veronesi et al., 1999, Gervasoni et al., 2000, Thiele and Sleeman, 
2006). Therefore this data suggests lymph node metastases are an indicator of systemic 
disease, rather than having a role in systemic dissemination per se (Eccles et al., 2007), 
but there are a number of caveats on this interpretation including the role of disturbance of 
lymphatic drainage due to surgical intervention. Peritumoural lymphatic invasion was 
associated with distant recurrence and overall survival in a recent study (Arnaout-Alkarain 
et al., 2007) and this may indicate a role for nodal metastases in seeding distant 
metastases. However, it may simply indicate that tumour cells disseminate to all sites 
independently. 
 
Animal models have been used to evaluate distant dissemination of tumour cells in human 
cancers. In a number of experimental studies an increase in lymphangiogenesis also 
resulted in increased lymph node and distant metastases (Hirakawa et al., 2007, Krishnan 
et al., 2003, Skobe et al., 2001), but this is not a consistent finding. Vascular endothelial 
growth factor (VEGF-C) overexpression in melanomas and fibrosarcomas increased nodal 
metastases, but did not influence lung metastases (Padera et al., 2002). Conversely the 
suppression of lymphangiogenesis induction from the tumour resulted in reduced 
metastases in the regional nodes and in the lung (Krishnan et al., 2003). Similarly the 
suppression of VEGFR3 and VEGFR2 by antibodies in a breast cancer model (Roberts et 
al., 2006) resulted in a reduction in regional and distant metastases. The combination of 
both antibodies inhibited lung and lymph node metastases more effectively than either 
antibody alone. 
 
Whilst in rats the removal of lymph nodes and primary tumour results in prevention of 
distant metastases this does not seem to be the same in humans (Ward and Weiss, 1989). 
Tumour cells may be found in the bone marrow of breast cancer patients who have early 
stage disease by standard staging systems. Genetic analysis of these cells shows that 
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they are not identical to lymph node metastases (Schmidt-Kittler et al., 2003, Woelfle et al., 
2003), but whether this is due to additional changes or cellular selection is unknown. 
 
Auchincloss published the results of a study in 1963 involving 204 patients between the 
years of 1951-1953 (Auchincloss, 1963). This article reviewed the survival of 107 patients 
with lymph node metastases and noted that only those patients with axillary metastases 
who have three or fewer nodes involved stood much chance of being cured by radical 
mastectomy. 
 
The cellular and molecular mechanisms of lymphangiogenesis and lymphatic metastasis 
have been extensively studied and reviewed by Eccles et al (Eccles et al., 2007) and are 
detailed in Table 1. 
 
Table 1: Lmphangiogenic cytokine expression, lymphangiogenesis and lymphatic metastasis in human breast cancer. 
 
Material Observation Reference 
107 breast cancers and 22 
normal breast samples 
HER2 overexpression correlated with VEGF-A, 
C and D (measuered by IHC) with a trend 
towards shortened survival 
(Yang et al., 
2002) 
51 breast cancers Association between HER2 and VEGF-C 
(measured by IHC) but no correlation between 
VEGF-C and LNM or LVI 
(Hoar et al., 
2003) 
177 primary invasive breast 
cancers 
High expression of VEGF-A and VEGF-C (IHC) 
but not VEGF-D was associated with LVD, 
MVD, LNM and distant metastases 
(Mohammed 
et al., 2007a) 
113 and 55 primary breast 
cancers 
High expression VEGF-C correlated with high 
LVD, LVI, LNM and poor DFS and OS 
(Nakamura et 
al., 2005) 
113 primary breast cancers High expression of nitrotyrosine (NO activity) 
correlated with VEGF-C expression by IHC and 
LNM 
(Nakamura et 
al., 2006) 
33 primary breast cancers 
and 7 normal breast samples 
No correlation between VEGF-C mRNA and 
LVI or LNM; VEGF-D levels decreased in 
tumours and inversely correlated with LNM 
(Land et al., 
2003) 
107 invasive primary breast 
cancers, LN+ 
Significant correlations between VEGF-C 
expression in tumour and TAM (measured by 
IHC) LVD, LVI and peritumoural inflammatory 
reaction, CFS and OS 
(Sebastian et 
al., 2006) 
217 breast cancers No correlation between VEGF-C and other 
prognostic indicators in a diverse patient 
population 
(Yavuz et al., 
2005) 
80 cases of invasive 
micropapillary carcinoma of 
the breast 
Positive correlation between VEGF-C and 
VEGFR-3, higher peritumoural LVD and LVI 
(Li et al., 
2006) 
180 invasive breast cancers Intratumoural lymphatic vessels in 12% cancers 
and peritumoural vessels in 94%. High 
peritumoural LVD correlated with LNM and poor 
DFS and OS. No correlation with VEGF-C 
expression. 
(Bono et al., 
2004) 
177 invasive breast cancers VEGF-C correlated with poor DFS and OS and 
simulataneous detection of VEGFR-3 increased 
(Nakopoulou 
et al., 2007) 
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prognostic value 
29 invasive breast cancers VEGF-C and VEGF-D expression correlated 
with LVD. MVD and LVD correlated with LNM 
(Choi et al., 
2005) 
98 breast cancers VEGF-C protein expression correlated with LVI 
and poor DFS 
(Noguchi et 
al., 1993) 
303 node-negative breast 
cancers 
LVI was the only significant predictor of distant 
recurrence and OS in a multivariate analysis 
(Arnaout-
Alkarain et 
al., 2007) 
702 breast cancers, median 
8-year follow up 
Nanometastases detected in LN in 13% of pN0 
patients were a strong indicator of distant 
metastatic relapse 
(Querzoli et 
al., 2006) 
68 invasive breast cancers 
and 13 normal samples 
VEGF-B expression was associated with lymph 
node status, but not MVD 
(Gunningham 
et al., 2001) 
207 invasive breast 
carcinomas and 15 normal 
samples 
VEGF-D expression was associated with HIF-
1α  but not lymph node status, LVI, DFS of OS 
(Seidman et 
al., 2001) 
105 invasive breast cancers VEGF-D expression correlated with HER2 
expression, LNM and poor DFS and OS 
(Nakamura et 
al., 2003) 
75 invasive breast cancers No evidence of lymphangiogenesis and 
intratumoural lymphatic vessels (IHC) 
(Williams et 
al., 2003) 
23 normal samples, 7 
fibrocystic disease, 32 DCIS, 
55 invasive breast 
carcinomas 
No evidence of intratumoural 
lymphangiogenesis, but increased peritumoural 
LVD compared with non-malignant conditions 
or DCIS 
(Malkas et 
al., 2006) 
13 normal, 11 hyperplastic 
lesions, 21 DCIS, 40 invasive 
breast cancers 
MVD increased during progression from normal 
to invasive cancer, but there was little evidence 
of lymphangiogenesis or intratumoural 
lymphatic vessels 
(Vleugel et 
al., 2004) 
109 invasive breast cancers Only peritumoural LVI, not BVI correlated with 
LNM; the former was an independent 
prognostic marker 
(Van den 
Eynden et 
al., 2006) 
121 ductal carcinomas LVD, VEGF-C and VEGF-D in primary tumours 
did not correlate with progression or survival. 
However, LVD inside LNM correlated with 
survival. VEGF-D was associated with 
intralymphatic tumour cells 
(van der 
Schaft et al., 
2007) 
87 patients with breast 
cancer and 10-year follow up 
VEGF-C expression did not correlate with LNM, 
LVI, DFS or OS. However expression of CD44 
v7-8 correlated with poor DFS and OS 
(Watanabe et 
al., 2005) 
123 breast cancer patients LVI using D2-40 IHC was related to high grade, 
negative hormone receptor status and worse 
prognosis 
(Marinho et 
al., 2008) 
103 cases of IMPC and 96 
cases of IDC 
Expression of SDF1 and CXCR4 significantly 
correlated with number of nodes 
(Liu et al., 
2009) 
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The various 
factors 
associated 
with 
lymphangiogenesis are illustrated in Error! Reference source not found.3. Mumprecht and 
etmar (Mumprecht and Detmar, 2009) have also recently reviewed lymphangiogenesis 
and cancer metastasis. This article reviewed the evidence for tumour-induced 
lymphangiogenesis as a predictive indicator for lymph node metastases and possible 
targets for prevention of nodal metastasis. However, the evidence for correlation between 
angiogenic cytokines and lymphatic vessel density or lymph node metastases is 
circumstantial and the mechanisms in clinical metastasis remain to be established.  
The presence or absence of lymph node metastases has been included in the TNM 
classification system (Singletary et al., 2003, Singletary and Greene, 2003) with 
modifications to the original scheme based on the method of detection of lymph node 
metastases and the size of the deposits. There is still debate about the prognostic 
significance of small tumour deposits (Dowlatshahi et al., 1997b, Mansi et al., 1999, 
Dowlatshahi et al., 1997a, Steinhoff, 1999, Querzoli et al., 2006, Mittendorf and Hunt, 
2007, Chen et al., 2007, Grabau et al., 2007, Marinho et al., 2006, Maibenco et al., 2006, 
Herbert et al., 2007). These were first documented by Pickren in 1961 (Pickren, 1961) with 
a review of the pathology of the cases included in Auchincloss’s study (Auchincloss, 
1963). Serial sections were taken from 51 patients in which previous routine sectioning 
had not shown nodal metastases. Additional occult metastases were found in 22%. The 5 
Figure 4: “Signalling pathways in 
lymphangiogenesis and possible points 
for therapeutic intervention. Key points for 
intervention are lymphangiogenic 
cytokines, their receptors and downstream 
signalling pathways using antibodies or 
“decoy” receptors for extracellular targets 
and small molecule drugs (such as kinase 
inhibitors and chaperone inhibitors) for 
intracellular targets. In the latter case, 
pathways common to both tumour cells 
and endothelial cells downstream of key 
RTK (eg. The PI3 kinase pathway) may 
provide added benefit by inhibiting both 
tumour and (lymph) endothelial cell 
functions. Therapeutic benefit may also be 
obtained by limiting production of 
lymphangiogenic cytokines in tumour (or 
host) cells by inhibiting activated 
oncogenes (eg EGFR, HER2, MET, RAS) 
or mediators of hypoxic or inflammatory 
responses (HIF-1α, NOS, COX-2). Finally, 
processes mediating key cellular 
interactions between tumour cells and 
LECs may provide novel, if challenging 
new targets. These may include cell 
adhesion, chemotaxis and 
transendothelial migration potentiated by 
(for example) integrins, CAMs, 
chemokines, CD44 etc” (modified from 
Eccles et al (Eccles et al., 2007)). 
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year survival rate of 91% was similar to that for patients with no occult metastases (89%). 
Herbert et al (Herbert et al., 2007) in a study assessing isolated tumour cells in lymph 
nodes showed no difference in patient survival or disease free survival over 2.5 years for 
16 patients, similar to this initial study. However, Querzoli et al (Querzoli et al., 2006) 
demonstrated that nanometastases are a strong risk factor for disease-free survival and 
metastatic relapse in breast cancer patients.  
1.9.3. Sentinel lymph node biopsy (SLNB) 
Early lymph node involvement gave rise to the concept of sentinel lymph node biopsy. The 
sentinel lymph node is the first lymph node in a lymphatic drainage area that receives 
lymph flow from the primary tumour. Therefore it should be the first lymph node to develop 
metastatic disease.  
 
For small invasive breast carcinoma, sentinel lymph node biopsy is rapidly becoming the 
standard of care and is replacing axillary lymph node dissection as the preferred means to 
evaluate nodal status in patients (Ozmen and Cabioglu, 2006, Bedrosian et al., 2000, 
Moffat, 2001, Borgstein et al., 1997, Bower, 1997, Cohen et al., 2000, Cox et al., 1998, 
Dixon, 1998, Donohoe, 2001, Jani et al., 2003, Kollias et al., 1999, Krag et al., 1998, Krag 
et al., 1993, Kunkler et al., 1999, Masters et al., 1998, Nieweg et al., 1997, Rovere and 
Bird, 1998, Rozenberg et al., 1999, Schillaci and Scopinaro, 1997, Schrenk et al., 2000, 
Schwartz et al., 2002, Schwartz and Meltzer, 2003, Singletary and Greene, 2003, 
Thornton, 1999, Tsang, 1999, Ung and Wetzig, 1999, Veronesi, 1997, Veronesi et al., 
1997, Wong, 2002, Mansel et al., 2006).   This appears to result in decreased morbidity for 
patients with reduced relative risks of lymphoedema and sensory loss, as reported in the 
ALMANAC trial (Mansel et al., 2006). Of concern however is the fact that if the sentinel 
lymph node is positive, the patient must undergo a full axillary lymph node dissection, 
resulting in a second procedure. 
 
Analysis of the sentinel node should also indicate whether more widely disseminated 
disease is present, however about 20% of patients with node-negative disease will go on 
to develop distant metastases (Rosen et al., 1981). Whilst this data suggests that about 
20% of systemic metastases are derived from tumour cells that bypass the lymphatic route 
(Fisher et al., 2004), this may depend on the method of detection of metastases in the 
lymph node and the initial lymph node status may have been a false negative result. 
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For many tumour types there may be little survival advantage to removal of the lymph 
nodes, but it is also possible that in some cases, the lymph nodes act as reservoirs to 
seed distant metastases (Sleeman et al., 2011).  
1.9.4. miRNA and metastasis 
MicroRNAs (miRNA) are non-coding regulatory RNAs that were originally discovered 
because of the role in controlling the timing of C. elegans larval development. More than 
900 human minas have been identified and these are catalogued and annotate in a 
database (miRBase)(2011, Kozomara and Griffiths-Jones, Griffiths-Jones, Griffiths-Jones 
et al., 2008, Griffiths-Jones, 2006, Griffiths-Jones et al., 2006). 
 
The primary transcripts of miRNA (pri-miRNA) are transcribed by RNA polymerase II 
before capping, polyadenylation and maturation of a hairpin loop structure by Drosha into 
pre-miRNA (Hurst et al., 2009b). The stem-loop pre-miRNA is exported out of the nucleus 
and further processed in the cytoplasm by Dicer to yield a functional single-stranded 
mature RNA construct of 20 to 22 bases (Sayed and Abdellatif, 2011). This process is 
illustrated in Figure 5. 
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The interaction of a miRNA with its target RNA can result in mRNA cleavage or 
translational repression (Gotte, 2010). A number of miRNAs have been implicated in 
critical steps in the metastasis pathway in solid tumours (Hurst et al., 2009b), including 
epithelial-mesenchymal transition, apoptosis and angiogenesis (Hurst et al., 2009b). 
These critical steps are outlined in Figure 6. 
Figure 5: “An illustration of the steps and molecules involved in the processing and function of 
minaRNAs. The first processing step occurs in the nucleus, where pri-miRNA is cleaved via the 
enzymes Drosha and Pasha. The pre-miRNA hairpin structure is then exported to the cytoplasm via 
exportin-5. In the cytoplasm it assembles in RISC which includes Dicer, argonaute (Ago) protein, 
PW182 a P-body protein, the human immunodeficiency virus transactivating response RNA-binding 
protein (TRBP), and fragile X mental retardation protein (FMRP1). In RISC, the loop of the pre-
minas is cleaved and the mature strand is used to direct the complex to its target site in the 3=-UTR 
of an mRNA. RISC is involved in 3 different functions: inhibition of translation initiation, inhibition of 
translation elongation, or mRNA deadenylation, which would result in mRNA degradation. These 
functions require additional recruitment of eukaryotic initiation factor 6 (eIF6). Inhibition of translation 
initiation is a result of disengagement of the 80S ribosomal complex in a cap (m7GpppG)-dependent 
manner that is partly attributed to the recruitment of the anti-association factor eIF6 by the RISC 
complex, or competition of Ago2 with eukaryotic initiation factor 4E (eIF4E) or eIF4G. Deadenylation 
occurs via interaction of Ago2 with chromatin assembly factor 1 (CAF1) and, thus, recruitment of the 
CCR4-NOT protein complex that harbours both chemokine (C-C motif) receptor (CCR4) and CAF1 
deadenylase enzymes, in addition to a second deadenylation step involving the PABP-dependent 
poly(A) nuclease 2 (Pan2)-Pan3 deadenylase complex” (Sayed and Abdellatif, 2011). 
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Profiles of miRNA expression have been specifically documented for breast  
cancer with correlations between miRNA expression and invasion, recurrence, metastasis 
and survival (Shi et al., 2010). A more detailed breakdown of miRNAs associated with 
breast cancer metastasis is illustrated in Figure 7. 
 
Figure 6: Critical steps in metastasis altered by metastamir. 
Pro- and antimetastatic metastamir are listed with the steps in the metastatic cascade of which they 
affect. The metastamir that have been functionally tested for metastasis in vivo are highlighted in red 
(Hurst et al., 2009b). 
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Figure 7: “miRNAs control breast cancer metastasis by influencing multiple metastatic steps. (1) 
miRNAs involved in regulation of EMT: miR-205 and miR-200, may dominate EMT and metastasis 
by inhibiting the expression of transcriptional repressors of E-cadherin ZEB1 and ZEB2. miR-
103/107 modulates the expression of DICER, causing an extensive downregulation of mature 
miRNAs, including miR-200. miR-9 could inhibit the expression of E-cadherin by binding to the 3′ 
UTR of E-cadherin, whereas the expression of miR-9 in breast cancer cells could be activated by 
Myc. Enhanced invasion and metastatic potential mediated by c-Myc and MUC1 could be blocked by 
miR-145. miR-10b may inhibit HOXD10, leading to an increased invasiveness and metastasis of 
tumor cells. As a downstream target gene of HOXD10, miR-7 was suggested to negatively regulate 
the metastatic capability of breast cancer cells by inhibiting EGFR and PAK1 expression. miR-31 
regulates a cohort of EMT related genes including RhoA. (2) miRNAs involved in remodeling of 
tumor microenvironment: miR-335 may modify tumor microenvironment by directly influencing the 
expression of TnC that can reduce cell-ECM interaction. miR-21 affects tumor invasion and 
metastasis by targeting an inhibitor of MMPs, TIMP3. miR-146 negatively regulated NF-κB 
activation, which promotes the activities of MMPs by repressing TrAF6 and IrAK1 in the Toll-like 
receptor and IL-1 signaling pathways, leading to the downregulation of the NF-κB target genes IL-8, 
IL-6, and MMP-9. miR-17/20 may regulate tumor microenvironment by inhibiting the secretion of the 
cytokines required for metastasis. (3) miRNAs associated with local invasion: miR-373 and miR-520c 
exerted the pro-invasive functional effects partially by preventing the translation of CD44. miR-21 
may affect tumor invasion by targeting TPM1. miR-126 targets CrK, which was involved in the events 
required for tumor cell migration. miR-31 regulated a cohort of invasion/metastasis-related genes, 
including ITGA5, RDX, and RhoA. (4) miRNAs associated with anoikis resistance: miR-7 may 
regulate EGFR and PAK1 expression, influencing tumor cell survival. miR-661 may repress MTA1 
and regulate anchorage-independent growth of breast cancer cells. miR-30 may inhibit anoikis 
resistance and metastasis by targeting Ubc9 and ITGB3. miR-31 may inhibit apoptosis and anoikis 
by affecting the expression of RhoA, RDX, and ITGA5. (5) miRNAs involved in tumor cell 
colonization: let-7 can inhibit proliferation and mammosphere formation of tumor cells by interfering 
with the expression of HMGA2 and Ras. miR-17/20 may inhibit breast cancer cell proliferation by 
negatively regulating cyclin D1. Mir-126 may suppress cell cycle progression. miR-145, miR-21, miR-
205, and miR-200 inhibit tumor cell colonization by regulating IRS-1, Bcl-2, Her3, and BMI1, 
respectively. (6) miRNAs involved in angiogenesis: miR-205 may inhibit the suppression of VEGF-A 
expression by binding to the putative miR-205 site in the 3′ UTR of VEGF-A. Downregulation of E-
cadherin by miR-9 allows liberation of β-catenin, which then translocates to the nucleus and 
activates the expression of VEGF, resulting in increased tumor angiogenesis. Upregulation of miR-
132 in endothelial cells enhanced neovascularization in breast tumors by inhibiting endothelial p120 
Ras GAP expression. miRNAs in red rectangles play stimulatory roles in breast cancer metastasis; 
miRNAs in blue may inhibit breast cancer metastasis” (Shi et al., 2010). 
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Specific miRNAs have been associated with multiple steps in invasion and metastasis: 
Tumour microenvironment modification (miR-335, miR-17/20, miR-146), Breast cancer 
stem cell phenotype formation (let-7, miR-200, MiR-30), Epithelial-mesenchymal transition 
(miR-200, miR-10b, miR-145, miR-103/107, miR-9), local invasion (miR-21, miR-126, miR-
373, miR-520), survival in vasculature (miR-7, miR-661, miR-17/20) and proliferation at 
distant sites (miR-200, let-7) (Shi et al., 2010, Sayed and Abdellatif, 2011).  
 
As indicated in Figure 6, the downregulation of miR-200c has been implicated in epithelial-
mesenchymal transition by releasing ZEB1 and suppressing E-cadherin (Hurteau et al., 
2007) and miR-200 family members are specifically lost in metastatic breast cancer cells 
that lack E-cadherin (Sayed and Abdellatif, 2011). Other miRNAs have been identified 
through profiling of human breast cancer cell lines with various metastatic potential and 
this approach identified miR-335 and miR-206 as being reduced during metastasis 
(Tavazoie et al., 2008). Another miRNA associated with metastasis is miR-31. It has been 
reported to be downregulated ~ 4 –fold in tumour cells compared to normal cells with a 
reduction of ~100-fold in metastatic cells (Valastyan and Weinberg, 2010, Valastyan et al., 
2009b). There is reduced expression of miR-31 in breast, prostate, ovarian and gastric 
carcinomas, but there is reported up-regulation in colorectal, liver and head-and-neck 
cancers (Valastyan and Weinberg, 2010). Other miRNAs have been found to promote 
metastasis including miR-10b (Ma et al., 2007a), miR-373 and miR-520c (Huang et al., 
2008). miR-10b is induced by Twist (Yang et al., 2004) and directly targets HoxD10 which 
is involved in metastasis (Ma et al., 2007a).  
 
However, despite the promising results from the recent publications on miRNAs,there is 
still a lack of data in clinical samples and the impact of dysregulation of miRNAs on 
pathological processes including metastatic dissemination. 
 
1.9.5. Molecular Classification of Breast Cancer 
Molecular techniques have been applied to breast cancer to attempt to improve the 
prognostic and predictive value of the current classification systems because of the 
limitations. Gene expression profiling was used (Hu et al., 2006, Weigelt et al., 2005a, 
Perou et al., 2000) to molecularly classify breast cancer into five groups: luminal (A & B), 
HER2-enriched, basal-like and normal-like. This classification provided prognostic 
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information and predicted response to chemotherapy (Viale, 2012) but had significant 
practical limitations. The original assay was based on fresh frozen tissue and was not 
applicable to formalin fixed paraffin embedded material. This meant that this molecular 
classification was not able to be implemented into routine diagnostic practice. In an 
attempt to overcome the limitation of the assay, alternate methodologies were developed 
as surrogate markers to obtain similar information that could be used to improve the 
classification of breast cancer. Immunohistochemistry (IHC) for oestrogen receptor (ER), 
progesterone receptor (PR), HER2 and Ki-67 were used to approximate the molecular 
classification of breast cancer. ER, PR have been in use for more than 20 years as the 
standard of care to select patients for hormonal therapy as part of a treatment regime. 
HER2 IHC in Australia is relatively poorly performed and the standard of care for HER2 
assessment is in-situ hybridisation (ISH) (Torlakovic et al., 2015, Torlakovic et al., 2014, 
Francis et al., 2007a). Ki-67 was implemented as a proliferation marker and these four 
biomarkers were used to mimic the molecular classification derived from gene expression 
profiling (ER+/PR+/HER2-/Ki-67low=luminal A; ER+/PR+/HER2-/Ki-67high=luminal B; 
HER2+ = HER2; ER-/PR-/HER2- = basal). However, the classes defined by gene 
expression profiling and those defined by IHC do not completely overlap (Viale, 2012). 
More recently, a gene expression approach using quantitative real-time reverse 
transcription-polymerase chain reaction (qRT-PCR) for 50 genes (PAM50) has been 
developed that works on FFPE tissue (Parker et al., 2009), however, this has not entered 
routine clinical practice as it requires specialised equipment that is not routinely available 
in a diagnostic pathology laboratory. 
1.9.6. Epigenetics and metastasis 
Epigenetics has emerged in the last decade as potential biomarkers in cancer. Epigenetic 
modifications do not change the DNA coding, and include changes such as aberrant gene 
promoter DNA methylation and histone protein modifications. DNA hypermethylation and 
DNA hypomethylation both occur in a variety of cancers (Ehrlich, 2002). For epigenetic 
studies, the degree of methylation is usually compared to normal tissues. In cancer, 
hypermethylation of the genome usually occurs in CpG islands in gene regions. This is in 
contrast to the areas of hypomethylation which occur in cancer and are seen in 
heterochromatic DNA repeats, dispersed retrotransposons and endogenous retroviral 
elements (Ehrlich, 2002). 
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Hypermethylation of CpG islands in the promoter region of genes leads to epigenetic 
inactivation of genes associated with cancer regulation and this may account for tumour 
development or disease progression. Since metastatic disease and lymphatic metastases 
occur as part of cancer progression, a possible cause of metastasis may be due to 
epigenetic modifications, rather than DNA somatic mutations. 
Melchers et al (Melchers et al., 2015) looked at 28 methylation markers in oral and 
oropharyngeal squamous cell carcinoma and the association with lymph node metastases. 
In this study two hypermethylated genes, MGMT and DAPK1 were associated with lymph 
node status. MGMT methylation was associated with a negative lymph node status and 
tumours also showed reduced protein expression with immunohistochemistry. DAPK1 
methylation was associated with a positive lymph node status, but hypermethylation did 
not associate with protein expression on immunohistochemistry (Melchers et al., 2015). 
In colorectal cancer, DNA hypermethylation of the promoter of GCNT2 is associated with 
aberrant expression of GCNT2 and hypomethylation of GCNT2 variant 2 has been shown 
to be associated with lymph node metastasis in primary colorectal carcinoma (Nakamura 
et al., 2015). A CpG island methylator phenotype (CIMP) has also been identified in 
colorectal carcinoma where hypermethylation of a number of genes is associated with 
malignancy (Tahara et al., 2014, Toyota et al., 1999). Hypermethylation of CpG islands 
and a correlation with lymph node metastases has also been examined in melanoma and 
breast cancer. In melanoma, Cadherin-11 (CDH11) was shown to be  hypermethylated in 
the cell Ines derived from lymph node metastases from patient tumours, but was 
unmethylated in the cell lines derived from the primary tumour (Carmona et al., 2012). 
Other groups have also identified aberrant methylation patterns in melanoma and 
correlated these patterns with lymph node metastases (Huynh and Hoon, 2012). 
In breast carcinoma, ID4 hypermethylation has been reported to occur more frequently in 
lymph node-positive tumours, compared to lymph node-negative patients (67% vs. 19 %, 
respectively) and multivariate logistic regression showed that ID4 methylation was a 
significant risk factor for nodal metastasis (Huynh and Hoon, 2012). In a separate analysis 
of 151 breast cancers for the methylation status of six genes, hypermethylation of GSTP1 
and/or RARβ2 was significantly associated with patients who had macroscopic disease in 
a sentinel lymph node compared with those with microscopic or no sentinel lymph node 
metastases (Huynh and Hoon, 2012). In this study, hypermethylation of CDH1 was 
reported to be higher in the sentinel lymph node metastasis compared to the primary 
tumour, but this was not confirmed in a separate study (Huynh and Hoon, 2012). Whilst 
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these studies indicate that epigenetic events may play a role in metastasis in the early 
stages of solid tumours including breast cancer, the genes involved have not been well 
defined. It is also possible that the changes identified in the lymph node metastases are 
due to the microenvironment of the lymph node itself and not the causation of the nodal 
metastasis. 
1.10. Prediction of lymph node status in breast cancer 
1.10.1. Prediction of non-sentinel lymph node (NSLN) metastases 
following SLNB 
Clinicopathological models have been developed to predict the risk of patients having 
additional lymph node metastases with a positive sentinel node (Cserni, 2007, Cserni et 
al., 2007, Chagpar et al., 2006, Coutant et al., 2008, Lambert et al., 2007, Bevilacqua et 
al., 2007, Alran et al., 2007, Pal et al., 2007, Konecny et al., 2003, Kapur et al., 2007, 
Ponzone et al., 2007, Dauphine et al., 2007, Bassi et al., 2006, Smidt et al., 2007, Werling 
et al., 2003, Degnim et al., 2005, Carmon et al., 2006, Van Zee et al., 2003, van Deurzen 
et al., 2007). The MD Anderson Cancer Centre model developed a mathematical scoring 
system to estimate the risk of a patient having a non-SLN metastasis (Werling et al., 2003) 
and this has been further validated using an external database (Lambert et al., 2007). A 
separate model was developed by the Memorial Sloan-Kettering Cancer Center (MSKCC) 
(Van Zee et al., 2003). All of these models however have used relatively limited 
pathological information. Dauphine et al (Dauphine et al., 2007) evaluated three scoring 
systems and whilst these provide additional information, their predictability remains less 
than optimal. These current studies indicate that axillary lymph node dissection is still 
required if the sentinel node is positive, as involvement of non-sentinel lymph nodes 
cannot be predicted with any degree of accuracy and non-sentinel nodes may be involved 
in up to 60% of cases.  
1.10.2. Prediction of axillary lymph node involvement 
The prediction of axillary nodal involvement from features of the primary tumour 
characteristics was described in 1967 (Kouchoukos et al., 1967) and larger evaluations 
have occurred since (Gann et al., 1999). Kouchoukos et al (Kouchoukos et al., 1967) 
assessed 432 breast cancers and classified them into 4 subtypes based on histological 
appearance. The histological appearance, size of the primary tumour and the type of 
margins were evaluated to assess the usefulness in predicting axillary lymph node 
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involvement. The accuracy of predicting lymph node involvement for invasive tumours did 
not exceed 70%.  
 
The presence or absence of lymph node metastases is the most powerful predictor of 
disease outcome (McGuire, 1987, Foster, 1996, Weigelt et al., 2005c). Gann et al (Gann 
et al., 1999) commented in 1999 that the difficulty of using predictive models to avert 
axillary lymph node dissection should not be underestimated. In this study, lymph node 
status was assessed on 18,025 patients. A number of factors were associated with lymph 
node status including tumour size and grade, older age, white race, an inner quadrant 
tumour site, various histologic patterns, negative ERp and PR status and DNA content. 
They also noted that the benefits of using models to predict lymph node status include 
lower surgical morbidity and cost; however, a patient who is affected by an incorrect 
decision will either forgo a significant survival advantage or unnecessarily suffer the 
morbidity of chemotherapy. 
 
Lymphovascular invasion is associated with lymph node status (Guarnieri et al., 2001, 
Kurosumi et al., 2001, Anan et al., 2000, Promish, 1999, Olivotto et al., 1998) but, as there 
is not an absolute correlation, is insufficient for accurate prediction. A number of 
biomarkers, detected using different methodologies, have been added to the 
morphological features in an effort to improve the predictive utility of any models. Potential 
biomarkers and methods include cell surface markers detected by flow cytometry (Menard 
et al., 1995, Mattfeldt et al., 2004, Mannweiler et al., 2002, Ravdin et al., 1994, Friedman 
and Freedman, 1994, Ahlgren et al., 1994), more accurate detection of lymphovascular 
invasion using IHC for identification of lymphatic and vascular channels (Braun et al., 
2007, Van den Eynden et al., 2006, Mohammed et al., 2007b), MR-determined metabolic 
phenotype (Bathen et al., 2007, Sitter et al., 2006), MR imaging of lymph 
nodes(Mussurakis et al., 1997), free circulating tumour DNA with mutation analysis 
(Umetani et al., 2006), aberrant DNA methylation patterns (Umetani et al., 2005), IHC 
biomarkers on the primary tumour (Skobe et al., 2001, Bono et al., 2004, Gunningham et 
al., 2001, Li et al., 2006, Nakamura et al., 2005, Nakamura et al., 2003, Nakamura et al., 
2006, Noguchi et al., 1993)and proteomics to identify metastasis associated factors 
(Kreunin et al., 2007, Nakagawa et al., 2006). 
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There have been a limited number of microarray studies performed to attempt to predict 
nodal status by the identification of genes that are differentially expressed in lymph node 
metastases compared to primary tumours (Weigelt et al., 2005c, Lee et al., 2003, Montel 
et al., 2005, Feng et al., 2006, Hao et al., 2004). 
 
Two of these studies used xenograft models of breast cancer (Lee et al., 2003, Montel et 
al., 2005). Using MDA MB 435 breast carcinoma cells, one study compared primary 
tumour cells from this cell line with cells derived from axillary nodal metastases (Lee et al., 
2003). Thirty-six up-regulated genes and 17 down-regulated genes were identified in the 
primary tumours with increased metastatic potential. These genes included CD73, integrin 
α1, integrin β5, HIF1α and genes associated with tumour-matrix interactions. Montel et al 
(Montel et al., 2005) used the same model and identified 50 differentially expressed genes 
including the RAS oncogene family of genes and MMP14. None of the genes generally 
accepted as mediators of lymph node metastases were identified in these studies. These 
studies used different platforms, different types of samples and different sites of sampling, 
all of which may have had an effect on the results. 
 
Four studies used patient derived samples. Twenty-six primary tumours and the matched 
lymph node pairs were evaluated in one study (Feng et al., 2006). 21 up-regulated and 58 
down-regulated genes were identified in the nodal metastases including genes associated 
with collagen, basement membrane-interacting molecules and MMPs.  
 
A second study evaluated 15 primary tumours and the lymph node pairs (Hao et al., 2004). 
71 up-regulated and 67 down-regulated genes were identified including those for L-
selectin, EphA2, ephrin B3, IGFBP5 and zinc proteins. Interestingly, MMP2 and fibronectin 
1 gene expression levels did not correlate with protein expression as determined by IHC. 
 
A third study of 15 primary tumours and matched lymph node pairs using expression 
microarrays found no common gene that was differentially regulated (Weigelt et al., 
2005c). The pattern of gene expression was different across samples and a classifier 
could not be developed to predict the nodal status of 295 primary tumours. 
 
A fourth study evaluated 89 primary tumours, 70 with lymph node metastases and 17 
without to identify a metagene signature associated with lymph node status and 
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recurrence in 90% of cases (Huang et al., 2003). This study by Huang et al (Huang et al., 
2003) did identify patterns of expression associated with nodal status in 89 Taipei patients, 
however when this was evaluated in a second patient dataset, lymph node status could 
only be accurately predicted in 50% of cases (Weigelt et al., 2005c). The data from this 
study suggested that lymph node metastases occurs independently of distant metastases 
(Weigelt et al., 2005c). 
 
A recent study also evaluated lymph node metastases and their matched primary breast 
cancers using gene expression profiling (Suzuki and Tarin, 2007). In this study it was 
observed that the metastases had very similar expression signatures to their parent 
tumours and a small number of genes were consistently differentially expressed. The 
conclusion from this study was that the data is most consistent with the coexistence of a 
number of cell clones in the primary tumour, each possessing randomly different parts of 
the gene expression pattern required to accomplish metastasis, co-evolving to metastatic 
status, but collectively possessing an “average” signature typical of distant metastases. 
This reinforces the clinical observation that in most patients with small tumours, metastasis 
is not inevitable. 
 
Ellsworth et al (Ellsworth et al., 2011) performed gene expression profiling on 76 breast 
cancer patients. Statistical analysis of the expression profile of tumours with and without 
lymph node metastases showed significant differences in the expression level of 15 
probes corresponding to 11 genes (Downregulated genes: ABCC8, BATF, IGFBP6, 
MRPL40, SLC27A2; Upregulated genes: AURKA, KIAA1609, KIF23, PLCB1, RPL13, 
TCP1, TGFA). The number of genes differentially expressed did not differ significantly and 
hierarchical clustering analysis was able to correctly classify 90% of the lymph node-
negative tumours (37/41), but only 66% of the lymph node-positive tumours (23/35) 
(Ellsworth et al., 2011). Possible reasons identified by the authors for the failure to identify 
a gene signature include the study design, biological properties of the primary breast 
cancers, molecular heterogeneity, the microenvironment and inherent host susceptibility 
(Ellsworth et al., 2011). 
 
Gene expression profiling has been used to predict metastasis from low-risk breast cancer 
patients (Thomassen et al., 2007) and a 14-gene predictor has been described with a 
sensitivity of 83% and a specificity of 76% (Ma et al., 2007b). Urquidi and Goodson 
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(Urquidi and Goodison, 2007) combined genomic signatures of breast cancer metastasis 
from tissue based studies and animal models. Whilst this was not specific for lymph node 
metastases a number of points were noted in this study. Future directions to improve data 
quality included the provision of more accurate histopathological data and microdissection 
of tumour cell populations with separation from stromal cells. It was also noted in this 
article that genomic approaches are unlikely to be adequate as a sole prognostic and 
predictive platform in breast cancer and that validation of array data should be performed 
at the protein level wherever possible.  
 
Using patient tissues it has been possible to develop a number of prognostic signatures for 
distant metastases, but there has been a limited ability to develop a classifier to predict 
lymph node status from features of the primary tumour. However, none of the signatures 
for nodal metastases have been sufficiently robust to have entered clinical practice and do 
not offer any significant advantages over routine pathological features such as 
lymphovascular invasion.  
 
A number of studies have also been carried out in other cancers to evaluate primary 
tumours and lymph node metastases (Hoang et al., 2005, Xi et al., 2005, O'Donnell et al., 
2005, Chu et al., 2006). Overall, a number of genes seem to be differentially expressed in 
association with lymph node metastases including matrix proteins, basement membrane-
cell interaction molecules, proteases, cell signalling and oncogenes (Feng et al., 2006, Lee 
et al., 2003, Hoang et al., 2005, Xi et al., 2005, O'Donnell et al., 2005, Chu et al., 2006). 
 
Patani et al (Patani et al., 2007) reviewed predictors of axillary lymph node status in breast 
cancer and concluded that no single marker or combination of markers was sufficiently 
accurate to obviate the need for axillary nodal staging. They also conclude that the aim in 
future studies must be to reliably identify patients in whom axillary node surgery can be 
safely omitted. 
 
Cavalli (Cavalli, 2009) also reviewed the molecular markers of breast axillary  lymph node 
metastasis and came to similar conclusions. Clinico-histopathological parameters fail to 
accurately classify breast cancers according to clinical behaviour. A summary of the most 
common markers is presented in Table 2 (Cavalli, 2009). 
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Table 2: Most common markers associated with axillary lymph node breast metastasis. 
 
Method 
Type of 
Assessment 
Range of 
Assessment 
Markers References 
IHC Protein expression Target proteins CCND1, CD44, 
COX2, EGFR, 
HER2, HPA, LYVE1 
(Patani et 
al., 2007, 
Park et al., 
2007, Cho et 
al., 2008) 
CISH Gains and 
amplification/losses 
and deletions 
Target 
genes/chromosomal 
regions 
CCND1, EGFR, 
HER2 
(Carlsson et 
al., 2004, 
Chang et al., 
2004, Cho et 
al., 2008) 
RT-PCR mRNA expression Target transcripts CCND1, COX2, 
CY19, HER2, MAM, 
MMP2, MMP9, 
MUC1, NM23, 
VEGF 
(Manzotti et 
al., 2001, 
Sakaguchi 
et al., 2003, 
Backus et 
al., 2005, 
Abdul-
Rasool et 
al., 2006, 
Revillion et 
al., 2008) 
FISH Gains and 
amplification/losses 
and deletions 
Target 
genes/chromosomal 
regions 
BP1, ER, HER2, PR (Nathanson 
et al., 2006, 
Santinelli et 
al., 2008, 
Cavalli et al., 
2008) 
Expression 
arrays 
mRNA expression Entire genome BRF2, CCNE2, 
CD44, COL9A1, 
ESM1, FLT1, GSTπ, 
HER2, MCM6, 
MMP2, MMP9, MP1, 
MUC1, MYC, OSF2, 
RAB6B, RAB11FIP, 
TOP2A 
(Bertucci et 
al., 2000, 
van 't Veer 
et al., 2002, 
van de 
Vijver et al., 
2002, Huang 
et al., 2003, 
Weigelt et 
al., 2003, 
Weigelt et 
al., 2005a, 
Feng et al., 
2006, Hu et 
al., 2009, 
Ahr et al., 
2001, Ahr et 
al., 2002, 
West et al., 
2001, 
Sotiriou et 
al., 2003, 
Ramaswamy 
et al., 2003) 
Conventional 
cytogenetics 
Chromosome 
alterations 
(numerical and 
structural) 
Entire genome +1q, del(6)(q23), +8, 
+9q, del11)(p15), -
13, del(17)(p13), -
17, -19, -21, -22, 
del(X)(q25), HSRs 
(Emerson et 
al., 1993, 
Pandis et 
al., 1993, 
Herrington 
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et al., 1995, 
Pandis et 
al., 1996, 
Cavalli et al., 
1997, 
Adeyinka et 
al., 2000, 
Wuicik et al., 
2007, Piao 
and 
Malkhosyan, 
2002, 
Teixeira et 
al., 2002, 
Zafrani et 
al., 1992) 
CGH DNA copy number 
changes (only 
quantitative) 
Entire genome +1p, -1q, -2q, -4q, -
5q, +6p, ++8q, 
++9q, +11p, +11q, 
+12q, -13q, +16, 
+17p, +17q, -18p, -
18q, ++19, ++20q, -
21, -22, -Xq 
(Kuukasjarvi 
et al., 1997, 
Nishizaki et 
al., 1997, 
Weber-
Mangal et 
al., 2003, 
Torres et al., 
2007, 
Friedrich et 
al., 2008, 
Cavalli et al., 
2003, 
Santos et 
al., 2008) 
Array CGH DNA copy number 
changes (only 
quantitative) 
Entire genome +1p36, +1q32, 
+1q41, +6q21, 
+8q13, +8q24, -
11p15, ++11q13, 
++17q12, -17p13, -
19p13, -19q13, 
++20q13, -22q11 
(van Beers 
and 
Nederlof, 
2006, 
Climent et 
al., 2007, 
Chin et al., 
2007, Han et 
al., 2006, Li 
et al., 2008) 
miRNA 
microarray 
Differential 
expression 
Custom miRNA 
containing 326 
human miRNA 
genes 
miR-450a, miR-
148a, miR-30b, miR-
150, miR-155, miR-
99b, miR-125b, miR-
205, miR-130b, miR-
24, miR-99a 
(Baffa et al., 
2009) 
+: Gain; ++: Amplification; -: Loss; del: Deletion; p: Short arm; q: Long arm 
Despite these advances in technology and information about the metastatic process, the 
accurate prediction of future metastasis remains elusive. Failure to accurately predict 
which tumours will metastasize shows the inability of histological features to fully reflect 
the complex molecular biology of breast cancer (Cavalli, 2009). This review concluded that 
the characterization of genetic alterations present in the first metastatic site in the axilla, 
the sentinel lymph node (SLN), is a logical step to define the molecular evolution of 
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primary tumours to a metastatic state, and is probably representative of the initial genetic 
events that occur in the early metastatic process. 
1.10.3. Artificial neural networks and prediction of lymph node 
metastases in breast cancer 
 
Artificial neural network models (ANN) have been used in a variety of medical applications 
(Alvager et al., 1994, Astion and Wilding, 1992b, Astion and Wilding, 1992a, Bostwick and 
Burke, 2001, Burke, 1994, Burke et al., 1997, Cicchetti, 1992, Cross et al., 1995, De 
Laurentiis and Ravdin, 1994, Egmont-Peterson et al., 1994, Eleuteri et al., 2003, Floyd et 
al., 1994, Fujita et al., 1992, Hammerston, 1993, Jorgensen et al., 1996, Lundin et al., 
1999, Mackiln et al., 1991, Marchevsky et al., 1998, Naguib and Sherbert, 1997, Pedersen 
et al., 1996, Ravdin and Clark, 1992, Ravdin et al., 1992, Schillen, 1991, Shultz, 1996, 
Truong et al., 1995, Wilding et al., 1994, Wu et al., 1993, Jerez et al., 2005) and a number 
of these relate to either survival (Burke et al., 1997, Lundin et al., 1999, Ravdin and Clark, 
1992, Ravdin et al., 1992, Jerez et al., 2005) or prediction of lymph node status (Naguib et 
al., 1997, Grey et al., 2003, Tez et al., 2007, Marchevsky et al., 1999, Naguib et al., 1999) 
in breast cancer. Kuo et al (S.-J. Kuo, 2008) used a neural network model with three-
dimensional power Doppler ultrasound to classify malignant lesions of the breast. The 
accuracy of the model was 84.6%, sensitivity 90.3%, specificity 79.4%, positive predictive 
value 80% and the negative predictive value was 90%. Jamarani et al (Jamarani et al., 
2005) used a neural network to develop an intelligent system for the identification of 
microcalcification clusters in digitized mammograms as an aid to radiological diagnosis. 
 
Naguib et al (Naguib et al., 1997) developed an artificial neural network model (ANN) to 
predict nodal metastases in breast cancer. Using 9 of a possible 12 markers, this model 
was correctly able to predict axillary involvement in 84% of patients in the test set of 31 
patients. Marchevsky et al (Marchevsky et al., 1999) evaluated prognostic factors for 
prediction of nodal status using an ANN. The model developed correctly classified 89% 
(40 of 55 unknown cases) with a sensitivity of 80%, specificity of 97.2%, a positive 
predictive value of 93.8% and a negative predictive value of 87.5%. Bourdes et al 
(Bourdes et al., 2007) analysed 2535 consecutive breast cancer patients and compared 
logistic regression with artificial neural network models. Parameters for specific mortality 
were: sensitivity 80.5% for logistic regression, neural network varLR 86.7% and neural 
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network varNN 87.5%; specificity 77.9% for logistic regression, neural network varLR 
76.0% and neural network varNN 77.3%; false negative rate 19.5% for logistic regression, 
neural network varLR 13.3% and neural network varNN 12.5%; false positive rate 22.1% 
for logistic regression, neural network varLR 24.0% and neural network varNN 22.7%; 
positive predictive value 17.4% for logistic regression, neural network varLR 17.2% and 
neural network varNN 18.2%. The predictive performance of the neural network for breast 
cancer-specific mortality and disease-free survival was at least as good as that of logistic 
regression and significantly better for disease-free survival. The results underline the 
predictive accuracy of neural network models compared with multivariate linear models 
and their usefulness as predictive tools. Lisboa et al (Lisboa et al., 2007, Lisboa et al., 
2008) used the same database for a time-to-event analysis using neural networks. This 
study compared neural network modelling to Cox regression for mortality and treatment 
failure. One of the main advantages of the neural network methodology for modelling time-
to-event data is the ability to infer smooth estimates for the hazard without requiring a 
priori assumptions about proportionality (Lisboa et al., 2008). The breast cancer specific 
mortality study confirmed that successful risk-staging can be performed with both the Cox 
regression model and the neural network model. The neural network model appeared to 
be more specific to identify patients at the extremes of high and low risk. For disease-free 
survival, the neural network model appeared to generalize better than Cox regression. 
 
Lancashire et al (Lancashire et al., 2008) have applied neural network modelling to gene 
expression profiling data. The amount of data generated by gene expression profiling 
experiments requires novel data analysis technologies. Lancashire et al (Lancashire et al., 
2008) used neural networks to identify an optimal subset of predictive gene transcripts 
from microarray data. This study applied neural networks to analysis of breast cancers in 
regards to oestrogen receptor status and axillary lymph node status using a microarray 
dataset. A logistic regression model gave poor predictive performance with a median 
accuracy of 78% for ER status and 56% for lymph node status. Using neural network 
models eight gene transcripts were identified that discriminated ER positive and negative 
phenotypes with an accuracy of 100% and similarly seven genes were identified to predict 
lymph node status. Validation was performed using a different dataset and gene 
transcripts on 89 samples. 88% were correctly classified on ER status with a sensitivity of 
90% and a specificity of 80%. 83% of samples were correctly classified on lymph node 
status with a sensitivity of 87% and a specificity of 80%. 
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Fuzzy logic algorithms (Seker et al., 2002, Seker et al., 2003) have also been used to 
predict outcome in breast cancer and Jarman et al (Jarman et al., 2008) have also 
developed an integrated decision support framework incorporating a number of different 
mechanisms including the Nottingham Prognostic Index and a rule-extraction method 
derived from a neural network model. 
 
A gap still exists between the amount of research into breast cancer and the integration of 
knowledge into diagnostic practice. This proposal aims to develop a practical methodology 
incorporating new technologies into an approach which directly benefits patients. It 
incorporates such tested prognostic and predictive biomarkers as oestrogen receptor and 
pathological features, but intends to enhance the usefulness of these with gene expression 
profiling targeted at lymphatic spread and nodal metastasis. By this combined approach, it 
is hoped that this project will advance our understanding of breast cancer progression and 
begin to enable individualized therapy for patients.  
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Chapter 2 
Materials and Methods. 
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2.1. Project Outline 
The working hypothesis of this project is that the tumour cells present in the primary 
tumour follow the metastatic cascade by disseminating into lymphatic vessels and then 
extravasating in lymph nodes to form metastatic deposits. A proportion of the cells derived 
from the primary tumour are able to form metastatic deposits and if the process is similar 
to haematogenous dissemination and CTCs then clumps of tumour cells are more likely to 
form metastases than individual tumour cells. Cells within lymphatic spaces would be 
expected to have the required molecular and phenotypic characteristics to complete the 
metastatic pathway to the lymph nodes; to invade into lymphatic channels, survive transit, 
attach to the lymphatic endothelium, extravasate into the lymph node tissue and form a 
new tumour deposit in a different environment. Therefore using a combination of different 
biomarkers, it should be possible to look at characteristics of the primary tumour and 
possibly the cells in the lymphatic spaces to compare breast carcinomas that metastasis to 
lymph nodes to those that do not have lymph node metastases. 
 
TMAs will be constructed from a breast cancer database with primary tumour 
characteristics to evaluate potential biomarkers based on published information. In 
addition, a sample will be selected with primary tumour, cells from the lymphatic channels 
and lymph node metastasis to evaluate the feasibility of miRNA sequencing. In the latter 
case, cellular material will be captured using laser capture microdissection (LCM) from 
paraffin embedded tissue and subject to miRNA sequencing and discovery performed 
using an Applied Biosystems SOLiD V4 Next Generation Sequencer.  
2.2. Selection of samples 
Archival formalin fixed paraffin embedded (FFPE) patient samples have been identified 
that have clinical characteristics covering a mixture of breast cancer phenotypes including 
different grades, tumour size and lymph node status. In some cases lymphovascular 
invasion (LVI) is also identified in the samples.  
 
 
 
In 2011, a breast cancer cluster was identified at the ABC studio in Brisbane. Fifteen 
female patients were diagnosed with breast cancer and an epidemiological analysis of this 
group of patients indicated that the probability of a causal link was high and it would be 
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extremely unlikely that this cluster was due to chance. The tumours from these patients 
were retrieved and examined with a variety of methods including light microscopy, 
immunohistochemistry, in-situ hybridization and gene expression profiling to ascertain if 
the tumours were similar to each other and if this cohort would provide information that 
may be useful for predicting lymph node status. These samples were case matched to 
samples within the breast cancer database. 
2.3. Construction of Database 
A web-based database was constructed using Distiller, SlidePath (Leica Microsystems) 
software. A MindMap was used to determine subgroupings and structure of the database. 
Three patient cohorts were identified from separate sources and patient records were 
identified using Systematized Nomenclature of Medicine (SNOMED) coding as a search 
parameter. Data was extracted into Microsoft Excel and uploaded into Distiller. 
 
3200 patient reports were retrieved from a private pathology database (Data 1), 1834 from 
a public hospital (Data 2) and 5200 from a separate public pathology hospital (Data 3). 
Haematoxylin and eosin (H&E) slides from 645 patients were reviewed from Data 1 and 
pathology information was recorded. This included tumour type, grade and size, presence 
or absence of lymphatic and vascular permeation, margin type, lymphocytic infiltration, 
lymph node status and number of involved lymph nodes. 
Table 3: Morphological classification of samples used for TMA construction. 
 Positive_nodal_status 
Tumour_type_modified  
 N Y Total 
#na 0 1 1 
Cribriform 1 0 1 
Ductal 255 186 441 
Ductal/Lobular 5 4 9 
Lobular 15 14 29 
Lobular/Ductal 0 1 1 
Mucinous 2 0 2 
Papillary 1 1 2 
Papillary/Cribriform 1 0 1 
Tubulolobular 0 1 1 
    
Total 280 208 488 
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Table 4: Correlation of tumour grade and lymph node status in samples used for TMA construction. 
 Positive_nodal_status 
Grade    
 N Y Total 
1 111 46 157 
2 97 81 178 
3 65 80 145 
#na 7 1 8 
    
Total 280 208 488 
 
2.4. Construction of Tissue microarrays 
A number of tissue microarrays have been constructed using a Beecher ATA-27 
automated instrument and a Beecher Galileo semi-automated instrument. TMAs were 
constructed in duplicate with 0.6 mm cores. Normal control tissue was included in each 
TMA with cores of liver used for orientation. The archival samples are managed through a 
SlidePath Distiller and TMAs have been constructed with approximately 1000 patient 
samples. Scoring sheets have been developed to perform IHC scoring on-line with 
integration of image analysis for the TMA virtual images. 
 
Tissue microarrays are a relatively new approach to utilize tumour material in a more 
efficient way (Kononen et al., 1998, Eguiluz et al., 2006). Cores or pieces of tissue are 
arrayed in a new paraffin block and the presence of multiple tumours in a single block 
increases the rate of analysis and decreases the costs associated with using multiple 
antibodies for IHC.  
The first multitissue array was described in 1986 by Battifora (Battifora, 1986). 
Modifications of these techniques have occurred over the last 20 years. The core tissue 
techniques described by Kononen (Kononen et al., 1998) have been the most widely 
accepted. The area of interest was identified on a glass microscope slide and the 
corresponding core was removed from the paraffin block and inserted into the donor block 
with the two instruments.  
 
The TMA sections have been assessed using immunohistochemistry (IHC) and in situ 
hybridization (ISH). The TMA slides have been scanned using an automated scanner 
(Hamamatsu Nanozoomer) and the generated images have the potential to be analysed 
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using image analysis software. The software can assess nuclear, cytoplasmic and 
membrane staining as well as morphometry of cells.  
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Chapter 3 
FRANCIS, G. D., JONES, M. A., BEADLE, G. F. & STEIN, S. R. 2009. Bright-field in 
situ hybridization for HER2 gene amplification in breast cancer using tissue 
microarrays: correlation between chromogenic (CISH) and automated silver-
enhanced (SISH) methods with patient outcome. Diagn Mol Pathol, 18, 88-95. 
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3.1. Bright-field in-situ hybridization using TMAs  
3.1.1. Introduction 
 
Previous studies have shown that TMA methodology is accurate, particularly with breast 
cancer (Callagy et al., 2003, Camp et al., 2000, Gancberg et al., 2002b, O'Grady et al., 
2003, Park et al., 2003, Kay et al., 2004, Simon et al., 2005, Mengel et al., 2003, Zhang et 
al., 2003, Rui and Lebaron, 2005, Al Kuraya et al., 2004, Ruiz et al., 2005, Watanabe et 
al., 2005, Warford, 2004, Giltnane and Rimm, 2004, Mobasheri et al., 2004, Torhorst et al., 
2001, Aaltonen et al., 2006, Anna et al., 2006). In a recent study, Henriksen et al 
(Henriksen et al., 2007) assessed the semi-quantitative evaluation of a number of 
immunohistochemistry assays on 2mm TMAs compared to whole tissue sections. This 
study showed that ER, PR, AIB1, COX-2, HER2 and IGF-IR on TMA blocks were 
comparable to whole tissue sections. TMA results for a number of parameters were 
evaluated and compared to whole tissue sections. 
 
3.1.2. Results 
Introduction: HER2 gene amplification or overexpression occurs in 15-25% of breast 
cancers and has implications for treatment and prognosis. The most commonly used 
methods for HER2 testing are fluorescence in-situ hybridization (FISH) and 
immunohistochemistry (IHC). FISH is considered to be the reference standard and more 
accurately predicts response to trastuzumab, but is technically demanding, expensive and 
requires specialized equipment. In-situ hybridization is required to be eligible for adjuvant 
treatment with trastuzumab in Australia. Bright Field in-situ hybridization (BRISH) is an 
alternative to FISH and uses a combination of in-situ methodology and a peroxidase-
mediated chromogenic substrate such as diaminobenzidine (CISH™) or multimer 
technology coupled with enzyme metallography (SISH) to create a marker visible under 
bright field microscopy. CISH™ was introduced into diagnostic testing in Australia in 
October 2006. SISH methodology is a more recent introduction into the testing repertoire. 
An evaluation of CISH™ and SISH performance to assess patient outcome was performed 
using tissue microarrays. 
Materials and Methods: Tissue microarrays were constructed in duplicate using material 
from 593 patients with invasive breast carcinoma and assessed using CISH™ and SISH. 
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Gene amplification was assessed using the American Society of Clinical Oncology/College 
of American Pathologists guideline and Australian HER2 Advisory Board criteria (Single 
probe: Diploid, 1-2.5 copies/nucleus; polysomy >2.5-4 copies/nucleus; Equivocal, >4-6 
copies/nucleus; low level amplification, >6 -10 copies/nucleus and high level amplification 
>10 copies/nucleus; Dual probe HER2/CHR17 ratio: Non-amplified <1.8, Equivocal 1.8-
2.2, Amplified >2.2).  
Results:  
Results were informative for 337 tissue cores comprising 230 patient samples. 
Concordance rates were 96% for HER2 single probe CISH and SISH and 95.5% for single 
probe CISH™ and dual probe HER2/CHR17 SISH. Both bright field methods correlated 
with IHC results and with breast cancer specific survival. 
Conclusion:  
HER2 SISH testing combines the advantages of automation and bright field microscopy to 
facilitate workflow within the laboratory, improves turnaround time, and correlates with 
patient outcome. 
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Introduction 
ERBB2 (HER2) amplification was originally described as occurring in 20-25% of breast 
carcinomas in 1989(Slamon et al., 1989).  
With the development of targeted therapy in both metastatic and adjuvant settings the 
assessment of HER2 status is critical in the treatment of breast cancer patients. 
Trastuzumab, a humanised mouse monoclonal antibody was developed to target tumours 
with overexpression of HER2. Other targeted therapy such as the tyrosine kinase inhibitor, 
lapatinib (Rusnak et al., 2001, Chang, 2007), is in clinical trials. 
HER2 overexpression has been linked to a poor prognosis in breast carcinoma patients 
(Slamon et al., 1987, Gusterson et al., 1992, Ferretti et al., 2007, Peiro et al., 2007a, 
Ryden et al., 2007). Most studies have indicated overexpression is associated with a poor 
response to hormonal therapy and that these patients receive increased benefit from 
anthracycline-based chemotherapy (Thor et al., 1998, Paik and Park, 2001, Paik et al., 
1998, Masood and Bui, 2002, Dhesy-Thind et al., 2007).  
HER2 testing can be performed by a number of methods, either evaluating protein 
expression or gene copy number. The two most common methods are 
immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) (van de Vijver, 
2002). A number of variables including fixation time, antibody selection, retrieval time and 
laboratory technique (Gancberg et al., 2002a, Wolff et al., 2007) will have an impact on the 
results obtained by these techniques. Inter-observer interpretative variability also occurs 
(Pathologists, 2002). 
The majority of pathology laboratories are able to perform IHC and this methodology is 
relatively inexpensive and easily integrated into routine diagnostic work. Turnaround time 
is rapid and the method can be automated.  The interpretation of the staining is subjective 
and at best semiquantitative.  
The gold (reference) standard for HER2 evaluation is considered to be FISH, however it is 
technically demanding, expensive, does not produce a permanent archival slide, and 
requires specialized equipment (Bartlett et al., 2001, Diaz, 2001). 
A number of studies have noted discordant results between FISH and IHC results (Bartlett 
et al., 2001, Konecny and Slamon, 2002, Perez et al., 2002). To further confuse the issue, 
the initial clinical correlations were performed with an IHC antibody that is no longer 
available (Perez et al., 2002). Logically, it would seem that protein expression would more 
accurately reflect the response to targeted therapy, but a number of studies have indicated 
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that gene amplification is a more accurate predictor (Elkin and Schnitt, 2004, Mass et al., 
2005, Riou et al., 2001). 
Alternative methodologies have been developed because of these constraints. These 
include enzyme-linked immunosorbent assay for the extracellular domain in serum, Bright 
field in-situ hybridization (BRISH) such as chromogenic in-situ hybridization (CISH) and 
real-time polymerase chain reaction (van de Vijver, 2002, Zhao et al., 2002, Dandachi et 
al., 2002).  
BRISH uses a combination of in-situ hybridization with a detection system using a staple 
chromogen similar to IHC. The slides are visible under bright field microscopy and show 
correlation with tumour morphology. Extensive correlation studies have been performed 
with CISH and both IHC and FISH (Dandachi et al., 2002, Zhao et al., 2002, Hauser-
Kronberger and Dandachi, 2004, Peiro et al., 2007b). CISH shows very good correlation 
with FISH (Arnould et al., 2003, Gupta et al., 2003, Park et al., 2003, Bilous et al., 2006). 
In addition to the CISH methodology a number of other BRISH techniques are available. 
These include silver autometallography (Sinczak-Kuta et al., 2007), dual colour ISH 
(Laakso et al., 2006, Shipley, 2006) and automated silver enhanced in-situ hybridization 
(SISH)(Dietel et al., 2007). A recent study has been performed comparing the performance 
of FISH with SISH in 99 patients (Dietel et al., 2007) and an evaluation of ISH 
methodology by Sinczak-Kuta(Sinczak-Kuta et al., 2007) indicated that they are equivalent 
tools for evaluating HER2 gene amplification. A small number of studies have evaluated 
the prognostic significance of HER2 gene amplification by CISH(Dandachi et al., 2002, 
Joensuu et al., 2003). Two recent studies evaluated the prognostic implications of HER2 
status in lymph node negative breast cancer using CISH(Peiro et al., 2007a, Peiro et al., 
2007b) and a third study used CISH to assess the prognostic significance of HER2 gene 
amplification in metastatic breast cancer. The current study was performed to evaluate the 
clinical performance of SISH and CISH, both bright field methods with patient outcome in 
primary breast cancer. 
 
Methods 
Breast carcinoma patients were retrieved from a database between 1990 and 2002. 
Tissue microarrays (TMAs) were constructed with material from 589 patients. Duplicate 
0.6mm x 0.6mm cores were removed from the donor blocks and placed into a total of 8 
recipient blocks. All slides were reviewed by a single pathologist to confirm the 
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morphological features of the tumours. The study used paraffin embedded blocks of 
tumour that had undergone fixation in 10% buffered formalin and routine processing. The 
fixation protocols and processing times varied.  
 
HER2 Immunohistochemistry 
IHC was performed on the TMAs using the HercepTest™ (Dako, CA).  
Tissue sections were dewaxed in xylene, rehydrated in graded alcohols followed by 
antigen retrieval in Citrate buffer pH6.0 as specified by the manufacturer. Counter staining 
was performed with haemotoxylin. 
IHC staining was evaluated semiquantitatively using the HercepTest™ system for HER-2. 
In Australia, a score of 3+ is regarded as positive, 2+ is equivocal and and 1+ and 0 are 
negative. 
 
1.11. HER2 Chromogenic in-situ hybridization 
HER2 CISH was performed using Invitrogen (Carlsbad, CA), CISH pre-treatment kit; CISH 
HER2 probe and Immunodetection Kit. Sections were de-paraffinised and HIER was 
performed using Pre-treatment 1 solution from the Invitrogen pre-treatment kit in Biocare’s 
Decloaking Chamber followed by incubation in Pre-treatment 2 enzyme. Sections were de-
hydrated and HER-2 probe added to the section and sealed using a glass coverslip and 
liquid cement.  A thermal cycler was used for probe hybridization followed by overnight 
incubation at 37 deg C.  On day 2 Immunodetection was performed using the Invitrogen 
CISH Immunodetection kit after a stringency wash according to the manufacturer’s 
instructions. Gene amplification was assessed using the American Society of Clinical 
Oncology/College of American Pathologists guideline and Australian HER2 Advisory 
Board criteria (Diploid, 1-2.5 copies/nucleus; polysomy >2.5-4 copies/nucleus; Equivocal, 
>4-6 copies/nucleus; low level amplification, >6 -10 copies/nucleus and high level 
amplification >10 copies/nucleus). 
 
HER2 Silver enhanced in-situ hybridization 
HER2 SISH was performed on an automated instrument, Ventana Benchmark® (Ventana 
Medical Systems, Tucson, AZ) as per the manufacturer’s protocols for the INFORM™ 
HER2 DNA probe and Chromosome 17 probes. Testing for the HER2 gene and 
chromosome 17 was performed on sequential sections. Both probes are labeled with 
dinitrophenol. Denaturation occurs on the instrument with enzyme digestion in Protease 3 
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for 8 minutes. The detection system uses a multimer labeled with goat anti-rabbit antibody 
horse radish peroxidase as the linking step. Visualization occurs with the sequential 
addition of silver acetate as the source of ionic silver, hydroquinone and hydrogen 
peroxide to give a black metallic silver precipitate at the probe site. Counterstaining is 
performed with Hamatoxilin II on the instrument. The time taken for the complete run is 6.5 
hours. Both HER2 and Chromosome 17 detection can be performed on the same slide 
run. Gene amplification was assessed using the American Society of Clinical 
Oncology/College of American Pathologists guideline and Australian HER2 Advisory 
Board criteria for single HER2 probe testing (Diploid, 1-2.5 copies/nucleus; polysomy >2.5-
4 copies/nucleus; Equivocal, >4-6 copies/nucleus; low level amplification, >6 -10 
copies/nucleus and high level amplification >10 copies/nucleus) and for dual HER2/CHR17 
probe testing (Non amplified ratio <1.8; Equivocal ratio, 1.8-2.2; Gene amplification, > 2.2). 
 
Scores were counted by a single pathologist (GF) with blinding to patient outcome and IHC 
scores.  
Statistical analysis and Kaplan-Meier plots were performed using SPSS 15.0 for Windows 
(SPSS Inc, Chicago IL). 
 
Results:  
Results were available on 337 tissue cores and 230 patient samples for both methods. 
Two of the 339 cores containing tumour (0.6%) were non-informative with SISH testing. 
Twenty-four of the 428 cores containing tumour (5.6%) were non-informative with CISH 
testing. The difference in core numbers for CISH and SISH was due to tissue loss due to 
block sectioning. Approximately 20 sections were utilized between the performance of the 
CISH and subsequent SISH testing.  
Tumour features of the cases are listed in Table 1. The median time of patient follow up is 
139.3 months. 
IHC correlation was similar for single probe CISH and single probe SISH (Tables 2 & 3). A 
single discrepant result was identified with the dual probe HER2/Chr17 ratio with one case 
showing 3+ IHC staining but a normal HER2/Chr17 ratio (Table 4). Images of 
representative TMA cores are illustrated in Figures 1 & 2 for IHC, CISH and SISH. 
Correlation between individual cores and patient samples was high for the single probe 
CISH and SISH with Pearson’s R 0.945, R-Square 0.89 and Spearman correlation 0.747 
(Figure 3). Using the five subcategories for classification of HER2 status with both single 
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probes, there was agreement in 88% of patient specimens (Table 5). Compacting the 
subcategories into 3 clinically significant categories; diploid/polysomy, equivocal and 
amplified, there was agreement in 96% of cases (Table 6). Discrepancies occurred in the 
equivocal categories in both methods. When single probe CISH was compared to the 
SISH HER2/chr 17 ratio the concordance for the clinically significant categories was 95.6% 
(Table 7). Again, discrepancies occurred in the equivocal groups. In the single case 
indicated above, single probe results showed low HER2 gene amplification with both CISH 
and SISH, but the HER2/Chr17 ratio was within the normal range indicating high level 
polysomy.  
A Bland-Altman analysis (Figure 4) shows that there is no evidence of bias between the 2 
methods (mean difference = -0.002, 95% confidence interval: -0.19 to 0.19) and in most 
cases the difference between the 2 methods will be a maximum count of +/- 2.9. 
Patient outcome was evaluated using Kaplan-Meier plots for breast cancer specific 
survival. The plots show virtually identical survival statistics (Figure 5). 
 
Discussion: 
HER2 testing has developed over a number of years, and whilst the role of HER2 as a 
predictive biomarker is now relatively well defined, the role as a prognostic marker is 
based on retrospective studies with inconsistent results(Ferretti et al., 2007, Todorovic-
Rakovic et al., 2007). 
In Australia from the 1st October 2006, ISH testing is required for patients to be eligible for 
adjuvant trastuzumab in conjunction with chemotherapy. The intent is that all new cases 
are tested by ISH for HER2. The rationale for this decision is based on the results for 
Quality Assurance testing for HER2 IHC in Australia(Francis et al., 2007b). IHC may still 
be performed as an additional test. Some laboratories in Australia currently test all new 
primary breast cancer cases with ISH. However, as an interim measure patients can still 
be triaged using IHC and then have ISH testing performed on all 2+ and 3+ cases to 
confirm HER2 gene amplification. Cases with 1+ IHC staining can also be tested by ISH if 
there is a suspicion that the IHC is incorrect. This testing algorithm was developed as 
there were insufficient laboratories that were able to introduce ISH testing on all new 
primary breast cancer cases within the timeframe required for implementation. There are 
currently 19 laboratories in Australia that perform CISH testing and one laboratory that 
performs FISH testing for HER2. 
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The correlation studies indicate that the two bright field methods are similar with a 
concordance rate above 95% as specified in the ASCO/CAP HER2 testing guidelines 
(Wolff et al., 2007) and this correlation is similar to the previous ISH evaluation(Sinczak-
Kuta et al., 2007). The Bland-Altman plot shows no evidence of bias in the two methods. 
However, whilst correlation between technical methods is useful, ultimately it is the ability 
of the test to define patient groups that is the most critical. Kaplan-Meier plots for breast 
cancer specific survival curves were generated using both single probe assays and the 
dual probe SISH assay in addition to the results obtained for HER2 IHC testing. The two 
bright field ISH methods generate curves showing virtually identical results. Whilst the 
groups of patients are not corrected for hormone receptor status and treatment, the curves 
show that HER2 gene amplified tumours have a worse outcome compared to HER2 
negative tumours. This indicates the clinical usefulness of these assays in evaluating 
HER2 status in primary breast cancer. Kaplan-Meier survival curves were also generated 
using the HER2 IHC results. There were three categories for staining. The curves are 
similar to the ISH curves with the IHC negative (0 & 1+ staining) cases overlying the curve 
for non-amplified cases. The patients with equivocal (2+ staining) and positive (3+ 
staining) tumours showed slightly divergent outcomes. No patient received trastuzumab 
within these groups. It could be argued from these results that HER2 IHC is an acceptable 
method of predicting HER2 status as defined by patient outcome. However, in diagnostic 
laboratories, the results are more variable. An audit was performed for laboratories 
performing HER IHC testing in Australasia (Francis et al., 2007b). Whilst the average 
results for HER2 3+ staining fell within acceptable levels (17.1%), there was marked 
variation in individual laboratory’s results from 5% to more than 60% reported as positive. 
With bright field ISH testing there are a small number of equivocal results with a HER2 
single probe method require testing using a dual probe method, either dual probe bright 
field ISH or FISH. Equivocal cases with single probe CISH therefore would be tested with 
a dual probe system and the results from this methodology would be issued as the final 
report. Equivocal results on a dual probe system require full evaluation of both the mean 
HER2 cell count and the IHC results for interpretation. There will however be a small 
number of patients where the tumour response to trastuzumab will be uncertain and 
testing for protein and gene expression by all available methods will fall into the equivocal 
ranges. 
From a workflow perspective, SISH offers the advantage of automation with a 6 hour 
protocol. CISH requires an overnight incubation and is manual with increased labour 
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requirements. The automation is more readily integrated into the laboratory’s processes, 
but does require a Ventana instrument to perform the analysis. 
 
Conclusion:  
BRISH testing for HER2 gene amplification in breast cancer has recently been developed 
to enable diagnostic laboratories to perform this assessment in the routine work 
processes. SISH is a recently developed method that offers the advantages of bright field 
ISH coupled with automation for HER2 gene amplification testing. It has a high 
concordance with CISH and FISH (Dietel et al., 2007) and fulfills the requirements for 
diagnostic testing. HER2 SISH correlation with HER2 IHC is similar to that of CISH in this 
study. Both of these bright field methods show a correlation with breast cancer specific 
survival in this patient cohort confirming the clinical utility of this methodology. 
A Quality Assurance Program has been developed for bright field HER2 ISH testing 
through the Royal College of Pathologists of Australasia Quality Assurance Program. This 
program incorporates both HER2 CISH and HER2 SISH methodology. This will enable the 
introduction of this testing methodology into diagnostic laboratories. 
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Clinicopathological characteristics of Patients with Breast Cancer 
Characteristic n % 
Age at Diagnosis   
      50 years or less 74 32.2 
       > 50 years 155 67.4 
       Unknown 1 0.4 
Menopausal status   
       Premenopausal 27 11.7 
       Pregnant 1 0.4 
       Perimenopausal 8 3.5 
       Postmenopausal 117 50.1 
       Unknown 77 33.5 
Tumour type   
       Ductal NOS 200 87 
       Ductal/Lobular 6 2.6 
       Lobular 14 6.1 
       Cribriform 1 0.4 
       Mucinous 2 0.9 
       Papillary 1 0.4 
       Papillary/Cribriform 1 0.4 
       Tubulolobular 1 0.4 
       Unknown 4 1.7 
Histological Grade   
      GI 78 33.9 
      GII 91 39.6 
      GIII 51 22.2 
      Unknown 10 4.3 
Tumour Size   
      <10mm 2 0.9 
      10-20mm 121 52.6 
       >20-50mm 80 34.8 
       >50mm 8 3.5 
       Unknown 19 8.3 
Hormone receptor status   
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       ERp+PRp+ 147 63.9 
       ERp+PRp- 24 10.4 
       Erp-PRp+ 15 6.52 
       Erp-PRp- 44 19.1 
Lymph node status   
      Positive 78 33.9 
      Negative 97 42.2 
      Unknown 55 23.9 
Patient outcome   
      Death from disease 59 25.7 
      Death from other causes 26 11.3 
      Alive 143 62.2 
      Death from unknown cause 2 0.9 
Table 1: Clinicopathological characteristics of patient cohort. 
 
 
IHC HER2 
status 
CISH HER2 status  
 Diploid Polysomy Equivocal Low 
amplification 
High 
amplification 
Total 
0 106 6 2 0 0 114 
1 60 10 3 0 1 74 
2 3 3 1 5 5 17 
3 0 0 0 4 19 23 
Total 169 19 6 9 25 228 
 
Table 2: Comparative data for HER2 IHC (HercepTest™) and CISH status. 
 
 
IHC HER2 
status 
SISH HER2 status  
 Diploid Polysomy Equivocal Low 
amplification 
High 
amplification 
Total 
0 105 7 0 1 0 113 
1 60 13 0 0 1 74 
2 4 0 3 3 7 17 
3 0 0 0 3 20 23 
Total 169 20 3 7 28 227 
 
Table 3: Comparative data for HER2 IHC (HercepTest™) and SISH HER2 gene copy status. 
 
 
IHC HER2 
status 
SISH HER2/CHR17 ratio status  
 Diploid Equivocal Low 
amplification 
High 
amplification 
Total 
0 111 1 0 0 112 
1 70 1 0 1 72 
2 5 1 3 7 16 
3 1 0 1 21 23 
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Total 187 3 4 29 223 
 
Table 4: Comparative data for HER2 IHC (HercepTest™) and SISH HER2/CHR17 ratio status. 
 
 
 
Figure 3: Scatterplot of results for 337 individual TMA cores for HER2 gene copy number 
comparing CISH and SISH. 
 
 
CISH HER2 
status 
SISH HER2 status  
 Diploid Polysomy Equivocal Low 
amplification 
High 
amplification 
Total 
Diploid 163 8 0 0 0 170 
Polsomy 6 11 2 0 0 19 
Equivocal 3 1 0 2 0 6 
Low 
amplification 
0 0 1 4 4 9 
High 
amplification 
0 0 0 1 24 25 
Total 172 20 3 7 28 230 
 
Table 5: Comparative data for HER2 gene amplification status based on average mean cell count 
for patient samples on TMA cores. 
 
 
 
 
 
 
CISH HER2 status SISH HER2 status  
 Diploid/Polysomy Equivocal Amplification Total 
Diploid/Polysomy 188 2 0 189 
Equivocal 4 0 2 6 
Low amplification 0 1 33 34 
Total 192 3 35 230 
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Table 6: Comparative data for HER2 gene amplification status based on average mean cell count 
for patient samples on TMA cores with clinical groups. 
 
 
 
CISH HER2 
status 
SISH HER2/CHR17 ratio status  
 Diploid Equivocal Low 
amplification 
High 
amplification 
Total 
Diploid 165 2 0 0 167 
Polsomy 18 1 0 0 19 
Equivocal 5 0 1 0 6 
Low 
amplification 
1 0 2 5 8 
High 
amplification 
0 0 1 24 25 
Total 189 3 4 29 225 
 
Table 7: Comparative data for HER2 gene amplification status based on average CISH mean cell 
count for patient samples on TMA cores and SISH HER2/CHR17 ratio. 
 
 
 
 
Figure 1:  Representative TMA HER2 staining with IHC, CISH and SISH. 
 
A) IHC 2+ membrane staining (Aperio ScanScope® T2 x20) 
B) CISH, Gene amplification (Zeiss AxioImager x630) 
C) SISH HER2 gene amplification (Zeiss AxioImager x630) 
D) SISH Chr 17 (Zeiss AxioImager x630) 
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Figure 2:  Representative TMA HER2 staining with IHC, CISH and SISH. 
 
A) IHC 3+ membrane staining (Aperio ScanScope® T2 x20) 
B) CISH, Gene amplification (Zeiss AxioImager x630) 
C) SISH HER2 gene amplification (Zeiss AxioImager x630) 
D) SISH Chr 17 (Zeiss AxioImager x630) 
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Figure 4: Bland-Altman comparison of CISH count and SISH count. 
Limits of agreement (Reference Range for difference): -2.932 to  2.928 
Mean difference: -0.002 (CI -0.192 to  0.188)  
Range :  1.200 to 22.490 
Pitman's Test of difference in variance: r = -0.000, n = 230, p = 0.998 
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Figure 5: Kaplan-Meier plots for breast cancer specific survival. 
Codes: CISH A= low and high amplified cases; CISH N=diploid, polysomy and equivocal cases; SISH A= low 
and high amplified cases; SISH N=diploid, polysomy and equivocal cases;SISHH2CA= low and high 
amplified cases utilizing the HER2/CHR17 ratio; SISHH2CN= diploid, polysomy and equivocal cases utilizing 
the HER2/CHR17 ratio;IHC E= 2+ IHC staining, IHC N= 0 & 1+ IHC staining and IHC P= 3+ IHC staining. 
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Chapter 4 
WEE, E. J., PETERS, K., NAIR, S. S., HULF, T., STEIN, S., WAGNER, S., BAILEY, P., 
LEE, S. Y., QU, W. J., BREWSTER, B., FRENCH, J. D., DOBROVIC, A., FRANCIS, G. 
D., CLARK, S. J. & BROWN, M. A. 2012. Mapping the regulatory sequences 
controlling 93 breast cancer-associated miRNA genes leads to the identification of 
two functional promoters of the Hsa-mir-200b cluster, methylation of which is 
associated with metastasis or hormone receptor status in advanced breast cancer. 
Oncogene, 31, 4182-95. 
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4.1.1. Introduction 
There are more than 2000 microRNAs (miRNAs) which regulate an estimated 30% of 
human genes (McGuire et al., 2015). Differential expression of miRNAs have been shown 
to correlate with metastatic disease in breast cancer and have been associated with 
lymphatic metastases, however, the expression does not appear to be specific for lymph 
node metastases and different miRNAs have been associated with metastases in other 
tumour types (McGuire et al., 2015). The breast cancer database was utilised to select 
tumours with associated lymph node metastases to perform miRNA analysis and evaluate 
the regulation of miRNAs. 
4.1.2. Results 
MicroRNAs (miRNAs) are small non-coding RNAs of B20 nt in length that are capable of 
modulating gene expression post-transcriptionally. Although miRNAs have been implicated 
in cancer, including breast cancer, the regulation of miRNA transcription and the role of 
defects in this process in cancer is not well understood. In this study we have mapped the 
promoters of 93 breast cancer- associated miRNAs, and then looked for associations 
between DNA methylation of 15 of these promoters and miRNA expression in breast 
cancer cells. The miRNA promoters with clearest association between DNA methy- lation 
and expression included a previously described and a novel promoter of the Hsa-mir-200b 
cluster. The novel promoter of the Hsa-mir-200b cluster, denoted P2, is located B2 kb 
upstream of the 50 stemloop and maps within a CpG island. P2 has comparable promoter 
activity to the previously reported promoter (P1), and is able to drive the expression of 
miR-200b in its endogenous genomic context. DNA methylation of both P1 and P2 was 
inversely associated with miR-200b expression in eight out of nine breast cancer cell lines, 
and in vitro methylation of both promoters repressed their activity in reporter assays. In 
clinical samples, P1 and P2 were differentially methylated with methylation inversely asso- 
ciated with miR-200b expression. P1 was hypermethylated in metastatic lymph nodes 
compared with matched primary breast tumours whereas P2 hypermethylation was 
associated with loss of either oestrogen receptor or progesterone receptor. 
Hypomethylation of P2 was associated with gain of HER2 and androgen receptor 
expression. These data suggest an association between miR-200b regulation and breast 
cancer subtype and a potential use of DNA methylation of miRNA promoters as a 
component of a suite of breast cancer biomarkers. 
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Introduction 
 
Breast cancer is a heterogeneous disease that can be classiﬁed on the basis of a number 
of characteristics including tumour size, histological subtype and grade, oestrogen (ER) 
and progesterone (PR) receptor and HER2 expression, axillary lymph node (LN) status 
and expression proﬁle (Sorlie et al., 2001). Some of these features have been associated 
with disease characteristics and can therefore be used to inform patient management. For 
example, patients with tumours that test positive for ER and HER2 can be treated with 
tamoxifen and Herceptin®, respectively, and have a signiﬁcantly better prognosis than 
those that test negative for these markers. However, the heterogeneity that exists even 
within breast cancer subgroups deﬁned by multiple markers means that for the vast 
majority of breast cancer cases, predicting outcome remains a challenge, and thus 
additional informative biomarkers are urgently needed. 
Breast cancer results from abnormalities in the quality or quantity of certain gene products, 
including coding and non-coding genes. MicroRNAs (miRNAs) are small non-coding RNAs 
B20 nt in length that are capable of modulating gene expression post-transcriptionally 
(Cullen, 2004; Boyd, 2008; Bartel, 2009). MiRNAs can exhibit either tumour suppressor or 
oncogenic roles by modulating key cellular processes in cell-cycle progression, apoptosis 
and invasion (Bartels and Tsongalis, 2009; Mirnezami et al., 2009; Visone and Croce, 
2009). In several studies, differential miRNA expression has been shown to distinguish 
normal and breast tumour tissue, breast cancer subtypes, ER,  PR  and  HER2 status, and 
to predict lymph node status and invasiveness (Iorio et al., 2005; Mattie et al., 2006; 
Foekens et al., 2008; Yan et al., 2008; Lowery et al., 2009). Together, these studies 
suggest a potential diagnostic and prognostic use of miRNAs as biomarkers in breast 
cancer. 
Quantitative defects in miRNAs arise through several mechanisms, including aberrant 
DNA methylation. Human DNA methylation usually occurs at the number 5 carbon of 
cytosine of a CpG dinucleotide motif. High densities of CpGs, termed CpG islands (CGIs) 
are usually associated with promoter elements and methyla- tion of which usually leads to 
gene repression. Aberrant DNA methylation of miRNA genes has been associated with 
several cancers (Lujambio et al., 2007; Lehmann et al., 2008; Lodygin et al., 2008), 
suggesting a possible use of miRNA DNA methylation as a prognostic tool. For example, 
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miR-9-1 and miR-34a are hypermethylated in breast cancer (Lehmann et al., 2008; 
Lodygin et al., 2008). In addition, the mir-200b cluster (miR- 200b, -200a and -429), has a 
CGI associated promoter B4 kb upstream of the sequence encoding the mature miRNA 
(Bracken et al., 2008), and aberrant DNA methylation of this sequence is associated with 
loss of miR-200 expression in colon (Han et al., 2007), bladder (Wiklund et al., 2011) and 
pancreatic (Li et al., 2010) cancers. The contribution of miR-200b cluster gene methylation 
to breast cancer has not yet been reported. Although much is known about the biogenesis 
and function of miRNAs, relatively little is known about the transcriptional regulation of 
miRNA genes. To date, a limited number of miRNA promoters have been experimentally 
characterized and only recently have several miRNA promoter prediction algorithms 
emerged (Zhou et al., 2007; Fujita and Iba 2008; Linhart et al., 2008; Marson et al., 2008; 
Ozsolak et al., 2008; Wang et al., 2009). These studies show that miRNA promoters lie 
anywhere from a few bases upstream of the stemloop to tens of kilobases   upstream 
(Linhart et al., 2008; Marson et al., 2008; Ozsolak et al., 2008; Wang et al., 2009). 
Furthermore, several miRNAs have multiple promoters (Ozsolak et al., 2008; Wang et 
al.2009; Monteys et al., 2010). 
In this study, 93 miRNAs previously associated with breast cancer, were prioritized for 
experimental analysis using bioinformatics to look for CGI-associated promoters. The CGI-
associated promoters of 15 miRNAs were mapped and methylation determined in a panel 
of nine breast cancer cell lines. A novel promoter for the miR-200b cluster and its role in 
regulating miR-200b expression was investigated. The relationship between methylation of 
this promoter and the previously described miR-200b cluster promoter with miRNA-200b 
expression and clinical characteristics in breast cancer are described. 
 
Results 
 
Fifty-ﬁve miRNAs previously implicated in breast cancer are located within 5 kb of a 
predicted CGI 
To identify candidate promoters for which methylation could be associated with breast 
cancer development, a list of 93 miRNAs implicated in breast cancer was collated from the 
literature (Supplementary Table 1). Using CpGPlot and CGI searcher, 55 (59%) of these 
miRNAs had a predicted CGI within 5 kb upstream of the region encoding their 50 
stemloop. The Core Boost_HM promoter prediction algorithm was used to predict 
regulatory elements controlling the transcription of the 55 miRNA-associated CGIs. This 
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algorithm uses PolII chip binding, histone modiﬁcations and DNA motifs associated with 
promoters to predict putative transcription start sites (TSS) (Wang et al., 2009). Putative 
promoters were deﬁned by a CpG promoter prediction cutoff score of 0.5, representing a 
90% likelihood of TSS within 500 bp of the predicted region. Figure 1 summarizes the 
process. 
 
 
Figure 1: Overview of the miRNA selection approach performed in this study. A literature 
review of miRNAs implicated in breast cancer was followed by in silico and molecular 
studies in human breast cancer cell lines. Analysis of methylation in clinical breast cancer 
specimens was performed on miR-200b. 
 
Experimental validation of predicted novel promoters of 15 miRNAs 
To determine if these predicted CpG promoter sequences had experimentally detectable 
promoter activity, a 600– 1000 bp of genomic sequences around the predicted site was 
cloned upstream of a luciferase gene and assayed for reporter activities in either MCF7 or 
MDA-MBD-231 breast cancer cell lines. When a miRNA had more than one predicted 
promoter, a fragment encompassing each prediction was cloned. Their genomic locations 
are detailed in Figures 2 and 3 and Supplementary Table 1. The previously described 
promoters of the miR-17 cluster (Yan et al., 2009) and the miR-200b cluster (Bracken et 
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al., 2008) were included as positive controls whereas a non-CoreBoost_HM predicted 
fragment in miR-17 cluster was used to control for background promoter activity. 
Twenty-two novel promoters from 15 miRNAs exhibited at least ﬁvefold activity compared 
with the promoter-less pGL3-basic control in at least one cell line (Figures 4–6a).  As 
expected, the previously described promoters of miR-17 and miR-200b clusters had strong 
promoter activity whereas the non-CoreBoost_HM predicted fragment had no detectable 
promoter function (Figures 3d and 4a). The 15 miRNAs with experimentally validated 
promoters are miR-9-1, miR-9-3, miR- 10b,    miR-22,    miR-124-1,    miR-124-2,   miR-
124-3, the miR-130b cluster, miR-193b, miR-200b cluster, miR-210, miR-320a, miR-335, 
miR-373 and miR-663. Three promoters were mapped for the miR-124-3 loci; two 
promoters were mapped for miR-9-1, 22, 124-1, 124- 2, 193b and 200b; and one promoter 
was mapped for miR-9-3, 10b, 130b, 210, 320a, 335, 373 and 663. To map the minimal 
promoters regions and to facilitate methylation analysis, promoter fragments of the 15 
miRNAs were ﬁne mapped to B300 bp (Figures 2, 3 and 6b). 
 
The miR-200b cluster P2 promoter is sufﬁcient to drive expression of miR-200b 
To determine whether the P2 promoter could drive the expression of miR200b in its 
endogenous genomic context, low miR-200b expressing MDA-MB-231 cells (Gregory et 
al., 2008), were transfected with a miR-200b minigene spanning the P2, but not the P1, 
promoter and the sequence corresponding to the mature miR-200. This minigene was 
generated by replacing the luciferase coding sequence of pGL3-basic with the miR-200b 
genomic sequence (Figure 6c).  The introduction of the miR-200b minigene resulted in an 
eightfold increase in mature miR-200b expression over the pGL3-basic control (Figure 6c). 
Deletion of the minimal promoter in the minigene reduced miR-200b expression by 50% 
(Figure 6c). Collectively, these results indicate that the P2 promoter can regulate miR-
200b, and very possibly mir-200a and 429, as a polycistronic primary transcript (Bracken 
et al., 2008). 
 
The miR-200b cluster P1 and P2 promoters are independent 
To address the hypothesis that P1 and P2 promoters function synergistically to enhance 
expression of the miR-200b cluster, a 2.5-kb fragment encompassing both promoters was 
cloned upstream of the luciferase gene and assayed for reporter activity in MDA-MB-231 
cells, in which only P2 was observed to be functional, and MCF7 cells, in which functional 
activity was observed for both promoters. As predicted, the P1 þ P2 fragment produced 
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similar reporter activity to the P2 fragment alone in MDA-MB-231 cells (P ¼ 0.34) (Figure 
6a). In contrast, in MCF7 cells, the reporter activity of P1 þ P2 was not signiﬁcantly greater 
than the activity of P1   (P ¼ 0.4), but was signiﬁcantly stronger than P2 (Po0.05) (Figure 
6a). Also, the activity of P2 alone and P1 þ P2 were also signiﬁcantly higher (Po0.05) in 
MCF7 than in MDA-MB-231 cells (Figure 6a). Taken together, this data suggests that the 
P1 and P2 promoters function independently. 
 
The miR-200b cluster has multiple TSS 
To complement the promoter mapping experiments, attempts were made to map the TSS 
of P2. Classical 50 RACE PCR was employed to determine the TSS of P2 using RNA from 
MDA-MB-231 cells transfected with the P2 construct to enrich for P2 derived transcripts. 
However, repeated attempts with the classical 50 RACE protocol were unsuccessful, 
consistently producing non- speciﬁc smears (data not shown). Successful ampliﬁcation of 
template controls indicated that the cDNA synthesis had worked and that this result was 
more likely to reﬂect heterogeneity in miR-200b cluster transcripts. An alternative ‘PCR 
walk’ approach to mapping the TSS was performed using a single transcript-speciﬁc 
reverse primer and various forward primers toward the 50 end of the cDNA transcript. The 
longest transcript extended from -3032 bp to -2447 bp upstream of the 50 stemloop as 
indicated by loss of PCR ampliﬁcation (Figure 6d). This observation was in agreement with 
the both the minigene and the luciferase reporter assays. To further test the hypothesis 
that miR- 200b has multiple TSS, publicly available breast cancer speciﬁc RNA-Sequence 
and RNA PolII–chip data were analysed at the miR-200b loci (Figure 6e). Multiple RNA-
sequence peaks were observed along the CGI for T47D and MCF7 cells indicating 
expression from the CGI. Furthermore, multiple RNA PolII binding   signals in MCF7 cells 
were detected along the associated CGI suggesting multiple TSS. A strong RNA PolII 
signal overlapping P1 also suggested preferential transcription from P1 in MCF7 (Figure 
6e). 
 
Methylation of miR-200b cluster and miR-335 promoters is associated with reduced 
miRNA expression 
DNA methylation of the minimal promoters of the 15 miRNA was assessed by methylation-
sensitive high-resolution melt analysis (Wojdacz and Dobrovic, 2007) in a panel of nine 
breast cancer cell lines. The proximal miR-9-1 promoter was not included as methylation 
of this promoter had been previously described (Lehmann et al., 2008). The miR-17 cluster 
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promoter was also excluded because the high density of CG dinucleotides made it 
unsuitable for methylation-sensitive high- resolution melt analysis. Promoter methylation 
was then compared with miRNA expression in the same cell lines. Mir-200b cluster and 
miR-335 promoter methylation were inversely associated with miRNA expression. For 
miR-200b cluster, eight out of the nine cell lines displayed an inverse association (Figure 
7a, Supplementary Figure 2). Although only MCF7 highly expressed miR-335, MCF7 also 
had the lowest methylation compared with the remaining eight, which were fully 
methylated and had minimal miR-335    expression (Supplementary Figure 1A). However, 
since the inverse association was stronger in miR-200b, P1 and P2 promoters represented 
better candidates for further analysis. In contrast, the miR-210 and miR-320a promoters 
were unmethylated in all nine cell lines although DNA methylation was not associated with 
miRNA expression for miR-9, miR-10b, miR-124, miR- 373 and miR-663 (Supplementary 
Figure 1). 
 
The minimal miR-200b cluster promoters are regulated by DNA methylation 
The novel P2 promoter had comparable activity to P1 in MCF7 cells, but unlike P1, was 
functional in both cell lines tested (Figure 6a). The minimal P2 promoter maps to -2228/-
1993 bp upstream of the miR-200b 50 stemloop (Figure 6b). To conﬁrm that DNA methyla- 
tion directly repressed promoter activity, P1 and P2 were cloned into a CpG-free reporter 
construct (Klug and Rehli, 2006) and in vitro methylated by SssI DNA methylase. 
Methylated P1 and P2 constructs displayed a signiﬁcant reduction in promoter activity, 
compared with their mock methylated constructs when transfected into T47D cells, in 
which both promoters are endogenously methylated and functional (Figure 7b).   This 
suggests that DNA methylation represses miR200b cluster promoter activity. 
 
miR-200b P1 and P2 promoters are differentially methylated  in  primary  breast tumours 
To study DNA methylation of the miR-200b promoters, Sequenom MassArray was 
performed on Grade 3 FFPE clinical samples. In all cases, P1 and P2 were differen- tially 
methylated in both tumours and lymph nodes (Figures 8a and b). In addition, P1, but not 
P2, was hypermethylated in lymph nodes compared with matched primary tumours 
(Figures 8c and d). To determine if hypermethylation was associated with expression of 
the miR-200b cluster in primary tumours, qPCR for miR-200b was performed on tumour   
samples from which RNA was available. P1 hypermethylation was associated with loss of 
miR-200b expression in seven out of nine samples (Supplementary Figure 3A) whereas 
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P2 was found to be associated with loss of miR- 200b expression in six out of seven 
samples tested (Supplementary Figure 3B). These suggested that hypermethylation of 
miR-200b cluster promoters could regulate miRNA expression in tumours. 
 
Methylation of the miR-200b P2 promoter is associated with ER, PR, HER2 and androgen 
receptor expression in primary breast tumours 
To ascertain whether DNA methylation of the miR-200b cluster promoters is associated 
with expression of routinely used breast cancer biomarkers, ER, PR and HER2, 
methylation was assessed in patients positive and negative for expression of these 
receptors. Methylation of P2, but not P1, was signiﬁcantly higher in tumours that were ER 
or PR negative (Figures 9a and b, respectively). Hypermethylation of P2 was also 
associated with HER2 positivity (Figure 9c). Androgen receptor, a potential breast cancer 
biomarker (Hu et al., 2011) and regulator of the miR-200 family, (Xu et al., 2010; Waltering 
et al., 2011) was also associated with hypermethylation of P2 (Figure 9d). Although the 
mir- 200b cluster is involved in metastasis, which in turn affects prognosis, no evidence of 
an association between DNA methylation and survival was found. 
 
Discussion 
Transcriptional regulation of miRNA genes is poorly understood and only a few miRNA 
promoters have been reported. A comprehensive understanding of miRNA promoters is a 
prerequisite for their use as genetic or epigenetic biomarkers. In this report, novel CGI- 
associated miRNA promoters were mapped and ana- lysed for associations between DNA 
methylation and miRNA expression. In all, 59% of the miRNAs examined were associated 
with a CGI within 5 kb upstream, similar to the estimated proportion of CGI- associated 
coding genes and was consistent with previous estimations for miRNA promoters (Ozsolak 
et al., 2008; Corcoran et al., 2009). Twenty-two novel promoters were identiﬁed and shown 
to be active in reporter assays. MiR-10b had a previously described promoter (Ma et al., 
2007; Zhou et al., 2007) immediately upstream of the mature miRNA sequence (Figure 2). 
However, we could not detect promoter activity for this fragment in the breast cancer cells 
tested (Figure 4c). We were also unable to detect any activity in fragments encompassing 
Core- Boost_HM predicted promoter regions for miR-125a in the cell lines used (Figures 3 
and 4i). A likely explanation was that neither cell line expressed miR-125a. 
In all, 7 of 15 miRNAs had two or more promoters in close proximity, usually at either ends 
of the associated CGI. Although it was not clear how the multiple promoters function in 
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regulating their miRNA genes or why the promoters were usually at either end of the CGI, 
it was evident that regulation of miRNAs is a complex process. The miR-200b cluster 
(miR-200a, miR-200b and miR-429) is an example of a miRNA with promoters at either 
end of the CGI. The P1 promoter, located at the distal end of the CGI, was predicted 
(Bracken et al., 2008) based on the presence of a 50 EST, the presence of E-Box motifs 
and the presence of a CGI, which is commonly associated with promoters of coding 
genes. Further, a 7.5-kb primary transcript of the miR-200b cluster was described using a 
‘PCR walk’ approach and P1 promoter activity was demonstrated using a luciferase 
reporter assay. Using a similar approach, a novel promoter, P2, is described here. P2 was 
predicted B2.5 Kb downstream of P1 (Figure 3) by the CoreBoost_HM promoter prediction 
algorithm (Wang et al., 2009), which utilizes empirical data such as ESTs, RNA PolII 
binding and histone modiﬁcation proﬁles in addition to DNA motifs associated with core 
promoters to accurately predict active promoter sites. We demonstrate that the P2 
promoter has an activity similar to that of the P1 promoter (Figure 6a), is functional in 
breast cancer cell lines (Figures 6a and  7b)  and is able to drive the expression of miR-
200b in its endogenous genomic context (Figure 6c). Thus, the P2 promoter is likely to be 
important in the regulation of the miR-200b cluster. Deletion of the P2 minimal promoter 
also reduced miR-200b levels by 50% (Figure 6c), and may indicate multiple TSS as 
previously suggested (Wiklund et al., 2011). In addition, DNA methylation of both miR-
200b promoters repressed miR-200b expression in eight out of nine breast cancer cell 
lines studied (Figure 7), suggesting regulation by DNA methylation. However, the precise 
role of P1 and P2 in regulating the cluster is unclear. In our reporter assays, P1 and P2 
seemed to function independently (Figure 6a). In clinical samples, DNA methylation at P1 
was also different compared with P2 in both tumour and lymph node metastases (Figures 
8a and b), thus supporting the hypothesis that the two promoters have different regulatory 
roles. This hypothesis is supported by other studies in bladder cancer cells, where a region 
encompassing P2, but not P1, was unmethylated and expressed high levels of miR-200b 
(Wiklund et al., 2011). Taken together, the evidence suggests that the P1 and P2 
transcripts are regulated by different mechanisms and this could in turn have a role in 
regulating metastasis. 
Of the eight cell lines studied, MCF7 did not show an inverse association between 
methylation and miRNA expression (Figure 7a). A minority of patients also did display a 
reciprocal relationship between promoter methylation and miRNA levels (Supplementary 
Figure 3).  In previous studies (Han et al., 2007; Wiklund et al., 2011), miRNA repression 
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by DNA methylation is usually accompanied by histone modiﬁcations associated with gene 
silencing.  Thus, other    mechanisms including chromatin remodelling or post-
transcriptional regulatory events may account for this inconsistency. Perhaps these 
repressive histone marks were absent in these cases thus resulting in open chromatin that 
was readily expressed. 
In this study we describe, for the ﬁrst time, differential methylation of the P1 and P2 region 
of the miR-200b cluster in breast cancer. The differential methylation is functional is 
evidenced by our observations that DNA methylation is inversely associated with miR-
200b expression in both breast cancer cell lines (Figure 7) and clinical samples 
(Supplementary Figure 3). These are consistent with the previously reported tumour 
suppressive role of miR-200b (Korpal and Kang, 2008). They are also consistent with 
previous reports of  aberrant DNA methylation of the miR-200b cluster proximal CGI, 
containing both P1 and P2, in colon, bladder  and  pancreatic  cancers  (Han   et  al.,  
2007;  Li et al., 2010; Wiklund et al., 2011). 
Loss of ER and PR expression was also associated with DNA methylation at P2 in breast 
tumours (Figures 9a and b). Patients with tumours that express these receptors often have 
a better prognosis because they respond well to treatments such as Tamoxifen. We 
hypothesize that methylation at P2, is likely to be associated with a lower level of miRNA 
expression, resulting in a more aggressive tumour (Korpal and Kang, 2008) that is 
unresponsive to these therapies and generally associated with poor prognosis. Using 
publicly available ER Chip-sequence data (Schmidt et al., 2010), ER bound to a putative 
ER response element just downstream of P1 upon ER stimulation in MCF7s (Figure 6e). In 
a microarray study (Klinge, 2009), miR- 200a and miR-200b were signiﬁcantly upregulated 
in MCF7 after 6 h of E2 induction. However, in a similar independent study, miR-200a and 
200c were found to be signiﬁcantly downregulated after 48 h of E2 induction (Maillot et al., 
2009). Although the studies seemed to have conﬂicting conclusions, they do suggest a 
possible regulatory mechanism between ER and the miR-200   family. 
A double negative feedback regulatory relationship between the miR-200 family and ZEB1 
(Bracken et al., 2008; Burk et al., 2008) has been shown to regulate the delicate balance 
between mesenchymal and epithelial cellular states. Based on this data, we propose that 
miR- 200b is repressed in the early stages of tumourigenesis in order to promoter EMT 
and thus the spread of the tumour, followed by later induction of miR-200b to promote 
mesenchymal–epithelial transition and thus establishment of the tumour cells at a distant 
site (for example, lymph node). Our data is consistent with this as we show only P1 was 
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hypermethylated in matched lymph nodes compared with their primary tumours.  This 
coupled with miRNA repression, suggests a DNA methylation mechanism for EMT 
initiation in addition to the previously described TGFB/ZEB pathway. At P2, no differential 
methylation between primary tumours and matched lymph node and thus possibly 
maintaining base levels of miR-200 is consistent with the mesenchymal–epithelial 
transition observed in mouse models. Metastatic murine breast cancer cells expressing 
low levels of miR-200 were able to invade distant tissue but unable to colonize. However, 
when miR-200 was over- expressed, these cells could form macroscopic tumours at 
distant sites (Dykxhoorn et al., 2009).  Further support for this model comes from studies 
in the bladder cancer (Wiklund et al., 2011) where hypomethylation of the P2 region was 
sufﬁcient for miR-200b cluster expression. This hypomethylation could also possibly 
account for the elevated levels of the miR-200 family, observed in other cancers (Hiroki et 
al., 2010; Li et al., 2010; Lee et al., 2011). 
Collectively, the evidence presented here indicates that miR-200b cluster regulation is 
complex and is regulated transcriptionally by at least two distinct promoters that are 
sensitive to DNA methylation. The novel P2 promoter functions independently of P1 and 
can drive the expression of miR-200b. However, the precise roles of P1 or P2 and under 
what conditions they are utilized is still not clear and will require further examination. 
 
 
Figure 2 UCSC screenshots of miRNA candidates and their associated genomic features. 
Bars representing miRNAs are shown in   red, CGIs in green, promoter and methylation-
sensitive high-resolution melt analysis fragments in black. Annotated genes are marked in 
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blue. Orientation of genes and fragments are indicated by directional arrows. 
CoreBoost_HM promoter predictions are shown as black peaks. 
 
 
Figure 3 UCSC screenshots of miRNA candidates and their associated genomic features. 
Bars representing miRNAs are shown in   red, CGIs in green, promoter and methylation-
sensitive high-resolution melt analysis fragments in black. Annotated genes are marked in 
blue. Orientation of genes and fragments are indicated by directional arrows. 
CoreBoost_HM promoter predictions are shown as black peaks. 
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Figure 4 (a–i) Promoter activities of miRNA candidates. miRNA promoter activity in cells 
expressed in RLU±the s.e.m. Data were generated from three independent experiments. 
Promoter fragments are labelled 1, 2 or 3 and A, B or C indicates the sub-fragment of that 
respective promoter. 
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Figure 5 (a–g) Promoter activities of miRNA candidates. miRNA promoter activity in cells 
expressed in RLU±the s.e.m. Data were generated from three independent experiments. 
Promoter fragments are labelled 1, 2 or 3 and A, B or C indicates the sub-fragment of that 
respective promoter. 
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Figure 6 miR-200b cluster has two functional promoters. (a) Promoter activities of miR-
200b P1 and P2 in MCF7 and MDA-MB-231 cells. Reporter activity is expressed in 
RLU±the s.e.m. Data were generated from three independent experiments. White bars 
represent activity in MDA-MB-231 cells whereas grey bars represent activity in MCF7 
cells. (b) Luciferase activities of various miR- 200b P2 50 and 30 truncations. Graphical 
representation of the various reporter fragments in relation to their genomic locations and 
their associated reporter activities expressed in RLU. Error bars represent s.e. of three 
separate experiments. (c) Top: relative location of the minigene to P2, Hsa-mir-200b and 
the CGI. Grey box represents the region deleted in the minigene promoter KO construct. 
Bottom: MDA-MB-231 cells were transfected with pGL3-basic, miR200b minigene or 
miR200b minigene promoter KO plasmids and assayed for mature miR-200b expression 
by TaqMan real-time PCR±s.e. (d) Top: schematic of the miR-200b P2 luciferase 
construct. 
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The white arrow represents the P2 promoter followed by the luciferase gene. Primers R1, 
R2, A to D are represented small arrows. Bottom: DNA agarose gel of the 50   PCR walk 
using the R2 primer with either Primer A, B, C or D, as labelled above each lane. 
(e) RNA-sequence proﬁles in T47D and MCF7 and RNA Polymerase II (RNA PolII) chip 
proﬁle of MCF7 at the miR-200b locus. Peaks in RNA-sequence tracks represent 
expression detected at that region. Peaks represent RNA PolII binding in RNA PolII track. 
Horizontal bars indicate the location of the miR-200b cluster, CGI and oestrogen response 
element. 
 
 
Figure 7 DNA methylation represses miR-200b P1 and P2 activity in breast cancer cells. 
(a) DNA methylation and miR-200b expression levels in a panel of nine breast cancer cell 
lines. Top: black bars represent the percentage methylation. Bottom: miR-200b expression 
was assessed by qPCR. Expression is shown relative to RNU6B and bars represent the 
mean±s.e. of two independent experiments. (b) Reporter activity of miR-200b P1 and P2 
methylated by SssI DNA methylase (white) compared with mock methylated plasmids 
(grey)±s.d. of two separate experiments. 
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Figure 8 Differential methylation of P1 and P2 in clinical samples. (a) Log10 ratios of P1 to 
P2 in 26 primary tumours. (b) Log10 ratios of P1 to P2 in 23 lymph nodes (LN). Positive 
values: P1>P2; negative values: P1oP2. Graph heights represent magnitude of difference 
in methylation between P1 and P2. (c) Mean methylation proﬁle in matched tumours and 
LN with horizontal s.e. bars for individual CpG units. t-Test P-value as indicated. (d) Box 
plot of the average methylation in tumours and LN. ( þ ): median, box: 25–75 percentile, 
whiskers: max/min, N: sample size, Mann–Whitley P-values as indicated. 
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Figure 9 P2 methylation is associated with ER, PR, HER2 and AR receptor status. (a) 
Methylation status of ER positive (pos) and ER negative (neg) cohorts. (b) Methylation 
status of PR pos and PR neg cohorts. (c) Methylation status of HER2 pos and HER2 neg 
cohorts. (d) Methylation status of AR pos and AR neg cohorts. Left: mean methylation 
proﬁle with horizontal s.e. bars for individual CpG units. t-Test P-value as indicated. Right: 
108 
 
box plot of the average methylation in tumours and LN. ( þ ): median, box: 25–75 
percentile, whiskers: max/min, N: sample size, Mann–Whitley P-values as indicated. 
 
Materials and methods 
 
Bioinformatics 
A list of 93 miRNAs implicated in breast cancer was generated by literature review. 
Genomic sequences þ 5 and -1 kb of the 
50 stemloop of each miRNA were analysed for CGIs using CpGPLot and CpG Island 
Searcher. Putative promoters are deﬁned by a CoreBoost_HM score of at least 0.5 (Wang 
et al., 2009) within this 6 kb window. Initial 600–1000 bp fragments overlapping the 
predicted sites were cloned and assayed for promoter activity as described later. This 
process is illustrated in Figure 1. 
RNA Polymerase II Chip-sequence data mapped to human genome HG18 was obtained 
from the National Center for Biotechnology Gene Expression Omnibus, GEO accession 
number GSE14664. RNA-sequence data (Wang et al., 2008) mapped to human genome 
HG18. RNA Polymerase II and RNA-sequence data were visualized on integrative 
genome viewer using the data ranges indicated. 
 
Cell culture 
Breast cancer cell lines MDAMB157, MDAMB231, MDAMB436, MDAMB468, MCF7, 
T47D, ZR75-1,   Hs578T and BT549 were obtained from American Type Culture Collection 
(ATCC, Manassas, VA, USA) and cultured according to the manufacturer’s   
recommendations. 
 
Patient samples 
Human breast tumours and matching lymph node metastases were collected from 56 
patients, as approved by local Human Ethics committees, who underwent surgical 
resection and did not undergo preoperative radiochemotherapy at Princess Alexandra 
Hospital between 1988 and 2000. All patients were female aged from 30 to 94 years old, 
with a median age of 56 years. ER, PR and HER2 receptor status of each patient were 
determined by a qualiﬁed pathologist. Details are provided in the Supplementary 
Information. 
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DNA extractions and puriﬁcations 
Genomic DNA from cell lines was extracted using the NucleoSpin Tissue Prep kit 
(Macherey-Nagel, Germany) according to the manufacturer’s instructions.  Plasmid DNA 
was puriﬁed using the Miniprep Kit (Qiagen, Doncaster, VIC, Australia). For human tumour 
samples, four FFPE tumour- rich tissue cores (1 x 0.6 mm) were crushed and digested 
with proteinase K at 55 1C for 2 days. Genomic DNA was puriﬁed using the PureGene kit 
(Qiagen) according to the manufac- turer’s instructions. 
 
Generation of plasmid constructs 
All promoter reporter constructs were cloned into pGL3-Basic (Promega, Sydney, NSW, 
Australia) unless otherwise speciﬁed. For the in vitro methylation plasmids, P1 and P2 
fragments were cloned into a CpG-free luciferase reporter construct pCpG-basic (Klug and 
Rehli, 2006; a gift from Klug and Rehli). PCR was performed using KapaHiFi polymerase 
(Kapa Biosystems, Woburn, MA, USA). All constructs were conﬁrmed by sequencing. All 
primers used and cloning details are provided in the Supplementary. 
 
Transfections and reporter assays 
All transfections used a 3-ml: 1 mg ratio of Fugene (Roche, Castle Hill, NSW, Australia) 
tranfection reagent to DNA.   For luciferase assays, either MCF7 or MDA-MB-231cells 
were co- transfected with 400 ng of promoter construct and 10 ng of RL-TK plasmid 
(Promega) as a transfection control and harvested and assayed for reporter activity after 
48 h. The Dual-Glo luciferase Assay kit (Promega) was used as recommended by the 
manufacturer. Fireﬂy luciferase levels were normalized to Renilla luciferase levels and 
expressed relative to pGL3-basic levels (RLU). Statistical analysis was performed using 
unpaired two-tailed t-test. 
For minigene experiments, MDA-MB-231 cells were grown to 60–70% conﬂuence in 6-well 
plates, and transfected with    1 mg of DNA and harvested after 72 h. 
 
Identiﬁcation of TSS of Hsa-mir-200b 
Total RNA from MCF7 transfected with the P2 luciferase reporter construct was extracted 
using Trizol (Invitrogen) and DNaseI (NEB, Ipswich, MA, USA) treated. First strand cDNA 
was reverse transcribed using SuperSciptIII (Invitro- gen) using a luciferase speciﬁc 
primer, R1, at 50 1C. This then served as a template for PCR ampliﬁcation. PCR ‘walking’ 
towards the 50 end was performed using primers A to D with R2. All PCR products were 
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visualized on a 1% agarose gel. Primer sequences are given in Supplementary Table 3. 
Classical 50 RACE was perform as previously described (2005). 
 
Quantitation of miRNAs 
Total RNA was extracted from cell lines using Trizol (Invitrogen). RNA from clinical 
samples was extracted using miRNeasy kit (Qiagen). For miR200b and miR335 
experiments, cDNA was made from total RNA using TaqMan MicroRNA Reverse 
Transcription Kit (Applied Biosystems, Mulgrave, VIC, Australia) with both reverse 
transcription miRNA and RNU6B (loading control) primers in the same reaction. Real-time 
PCR was performed using the TaqMan microRNA Assay (Applied Biosystems) according 
to the manufacturer’s instructions. For all other miRNAs, the Qiagen miScript PCR system 
for miRNA quantiﬁcation was used with the RNU6B loading control. Changes in 
expression levels were calculated using DDCt method (Livak and Schmittgen, 2001). 
 
Bisulﬁte modiﬁcation and methylation-sensitive high-resolution melt analysis 
2 mg of DNA extracted from cell lines was subjected to bisulﬁte modiﬁcation with 
MethylEasy Xceed kit (Human Genetic Signatures, Randwick, NSW, Australia) according 
to manufacturer’s instructions. PCR ampliﬁcation and methylation- sensitive high-
resolution melt analysis (Wojdacz and Dobrovic, 2007) was performed in duplicate on the 
RotorGene Q (Qiagen). Primers were designed according to the principles outlined 
(Wojdacz and Dobrovic, 2007) to control for PCR bias and are shown in Supplementary 
Tables 4 and 5. PCR conditions are provided in the Supplementary. Bisulﬁte treated 
CpGenome Universal Methylated DNA (Chemicon, Milli- pore, Kilsyth, VIC, Australia) and 
DNA from the appropriate cell lines were used as positive/methylated and 
negative/unmethylated controls, respectively. WGA DNA made with the GenomiPhi kit 
(Amersham GE Healthcare, Rydalmere, NSW, Australia) was used as unmethylated 
controls for miR335 and miR663. Included in the analysis of each region, controls were 
mixed in 25, 50 and 75% methylated to unmethylated template ratios. 
 
In vitro methylation of plasmid DNA 
DNA was methylated using SssI (NEB) as previously described (Klug and Rehli, 2006). 
Brieﬂy, plasmids were incubated with SssI (2.5 U/mg) with 160 mM S-adenosylmethio- 
nine at 37 1C for 4 h and  supplemented  with  an additional 160 mM of S-
adenosylmethionine for another 4 h at 37 1C. Mock methylated plasmids controls were 
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treated similarly but without enzyme. Plasmids were recovered by phenol/chroloform, 
followed by ethanol precipitation, transfected into T47D cells and luciferase assays 
performed. 
 
Sequenom MassArray 
Genomic DNA from clinical samples was bisulﬁte converted with EZ-96 DNA methylation 
kit (Zymo Research, Irvine, CA, USA). Methylation levels in clinical samples were 
determined using Sequenom MassArray, performed according to manufacturer’s 
recommendations for T-cleavage chemistry protocol and analysed between a 1640 and 
7000 mass window (Coolen et al., 2007). Average methylation of each patient is deﬁned 
as the average percent methylation of all CpG units in each amplicon. Average 
methylation of each CpG cluster (or proﬁle) is deﬁned as the average percent methylation 
of the cohort for that speciﬁc CpG cluster. In all, 0–100% methylation are represented by 
0.0 to 1.0. Primer sequences are provided in Supplementary Table 4. 
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Supplemental Data 
Contains supplemental materials and methods, five tables and three figures. 
 
Supplemental Materials and Methods 
Generation of plasmid constructs 
All promoter reporter constructs were cloned into pGL3-Basic (Promega) unless otherwise 
specified. A list of primers used is provided in Supplementary Tables 2 and 3. The miR-
200b minigene was cloned by removing an XbaI digest fragment from the P2 construct 
and replacing the gap with a 2925bp PCR amplified genomic DNA fragment -2643bp to 
+282bp relative to the 5’ stem loop of miR-200b. The minigene with the minimal promoter 
deleted was made by designing primers that would PCR amplify outward from the minimal 
promoter. This 7.5kb PCR fragment was then allowed to self-ligate. For the in vitro 
methylation plasmids, the BamHI/HindIII fragment of the P2 construct was subcloned into 
a CpG-free luciferase reporter construct pCpG-basic while P1 was PCR amplified and 
inserted into the HindIII site of the pCpG-basic plasmid (a gift from Klug et al).  PCR was 
performed using KapaHiFi polymerase (Kapa Biosystems). All constructs were confirmed 
by sequencing. 
 
Transfections and reporter assays 
For luciferase assays, either MCF7 or MDA-MB-231cells were grown to 60-70% 
confluence in 24-well plates prior to transfections. Cells were co-transfected with 400ng of 
promoter construct and 10ng of RL-TK plasmid (Promega) as a transfection control. 
Transfected cells were incubated at 37°C and harvested for luciferase assays after 48hrs. 
Luciferase assays were performed using the Dual-Glo luciferase Assay kit (Promega) as 
recommended by the manufacturer. Luminescence was detected on a Beckman DTX plate 
reader. Firefly luciferase levels were then normalized to Renilla luciferase levels and 
expressed relative to pGL3-Basic levels (RLU). Statistical analysis was performed using 
unpaired two-tailed t-test. 
 
For minigene experiments, either MCF7 or MDA-MB-231 cells were grown to 60-70% 
confluence in 6-
 reagent 
to DNA was used. 
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Bisulfite modification and methylation sensitive high resolution melt analysis.  
2g of DNA extracted from cell lines was subjected to bisulfite modification using the 
MethylEasy Xceed kit (Human Genetic Signatures) according to the manufacturer’s 
instructions. PCR amplification and MS-HRM was performed in duplicate on the 
RotorGeneTM Q (Qiagen). Primers were designed according to the principles outlined 
(Wojdacz and Dobrovic, 2007) to control for PCR bias and are shown in Supplementary 
Table 4 and 5. PCR was performed in a total volume of 20µl containing: 1x Buffer, 4mM 
MgCl, 200µM of each dNTP, 200nM of each primer, 5µM Syto9 dye (Invitrogen), 0.5U 
HotStarTaq polymerase (Qiagen) and 2ng of bisulphite modified template. The 
amplification conditions consisted of 15min at 95°C, followed by 50 cycles of 20sec at 
95°C, 30sec at the appropriate annealing temperature (Tm) and 30sec at 72°C, followed 
by one cycle of 1min 30sec at 72°C and an MS-HRM step from 70°C to 90°C rising by 
0.1°C/sec. Bisulfite treated CpGenomeTM Universal Methylated DNA (Chemicon, 
Millipore) and DNA from the appropriate cell line were used as positive/methylated and 
negative/unmethylated controls, respectively. WGA DNA made with the GenomiPhi kit 
(Amersham) was used for miR335 and miR663. To create a range of methylated dilutions, 
these controls were mixed in 25, 50 and 75% methylated to unmethylated template ratios. 
These standards were included in the analysis of each region. 
 
Patient samples 
Human breast tumours and matching lymph node metastases were collected from 56 
patients, as approved by local Human Ethics committees, who underwent surgical 
resection and did not undergo preoperative radiochemotherapy at Princess Alexandra 
Hospital between 1988 and 2000. All patients were female aged from 30-94 years old, with 
a median age of 56 years. The tissues were formalin fixed paraffin embedded (FFPE) with 
routine histological examination using hematoxylin and eosin (H&E) confirming all as 
invasive Grade III ductal adenocarcinomas. Tumour-rich tissue in each biopsy was 
distinguished from surrounding normal tissue in H&E-stained sections by a qualified breast 
pathologist. 4µM sections were cut from the TMA blocks, transferred on to glass slides, 
deparaffinised and immunostained using anti-ER (SP1), anti-PR, (SP2), anti-HER2/neu 
(4B5) antibodies (pre-diluted; Ventana Medical Systems) the anti-AR antibody (Biocare 
Medical, 1:50), and counterstained with 3,3’-Diaminobenzidine (DAB) and hematoxylin. 
Staining was performed with the BenchMark® automated slide stainer (Ventana) using the 
iVIEW® DAB detection kit with additional Avidin and Biotin Blockers according to the 
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manufacturer’s instructions. Analysis of strained sections was performed by a qualified 
breast pathologist. The presence of tumour tissue was first confirmed by examining the 
counterstain, and then all tumour sections were given a score for ER, PR, HER2 
expression.  
 
Supplementary figure legends 
Table 1: List of miRNAs implicated in breast cancer. Sequences -5kb to +1kb of the 5’ 
stemloop were assessed for CGIs. Strong CGIs are denoted in green, weak CGIs in yellow 
and non-CGIs in red. Expression levels in normal and cancer tissue are indicated in green 
for low expression and red for high expression. Known methylated miRNAs are labelled as 
methylated. 
 
Table 2-5: Lists of primers used and their genomic coordinates on UCSC genome 
browser. The human genome NCBI36/ Hg18 March 2006 build was used. 
 
Figure 1: Methylation levels determined by MS-HRM and miRNA expression in breast 
cancer cell lines 
A: DNA methylation and miR-335 expression levels in a panel of 9 breast cancer cell lines.  
B: DNA methylation and miR-10b expression levels in a panel of 9 breast cancer cell lines.  
C: DNA methylation and miR-9 expression levels in a panel of 9 breast cancer cell lines.  
D: DNA methylation and miR-663 expression levels in a panel of 9 breast cancer cell lines.  
E: DNA methylation and miR-124 expression levels in a panel of 9 breast cancer cell lines.  
F: DNA methylation and miR-373 expression levels in a panel of 9 breast cancer cell lines.  
Top Panels: Black bars represent the percentage methylation. Bottom Panels: miRNA 
expression was determined by qPCR. Expression is shown relative to RNU6B and bars 
represent the mean + standard deviation of two independent experiments. 
G: MS-HRM profile of the miR-210 promoter 
H: MS-HRM profile of the miR-320a promoter 
 
Figure 2A-E: miR-200b P1 and P2 MS-HRM profiles in MDA-MB-436, MDA-MB-468, 
T47D, ZR-75-1, MCF7, MDA-MB-157, MCF10a, HS-578-T and MDA-MB-231 cells. Blue, 
violet, red, orange, khaki lines represent 100%, 75%, 50%, 25% and 0% methylation 
standards respectively. The melt profile of the cell line is in black.  
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Figure 3. Hypermethylation is associated with loss of miR-200b in primary tumours. 
(A)Top: Average P1 methylation in primary tumours. Bottom: miR200b expression.  
(B)Top: Average P2 methylation in primary tumours. Bottom: Relative miR-200b levels in 
tumours. 
 
 
 
Supplementary Table 1 
miRNA ID 
-5K 
CpG 
-4k 
CpG 
-3k 
CpG 
-2k 
CpG 
-1k 
CpG 
+1k 
CpG 
 
Normal Exp BC exp 
 BC 
methylation 
Status 
hsa-mir-124-1        up down  methylated 
hsa-mir-124-3        up down  methylated 
hsa-mir-191        down up   
hsa-mir-126        up down   
hsa-mir-196b        unknown unknown   
hsa-let-7i        down up   
hsa-mir-210        down up   
hsa-mir-148a        up down  methylated 
hsa-mir-663        up down  methylated 
hsa-mir-9-1        up down  methylated 
hsa-mir-127        up down   
hsa-mir-320a        up down   
hsa-mir-124-2        up down  methylated 
hsa-mir-203        down up   
hsa-mir-125b-1        up down   
hsa-mir-136        down up   
hsa-mir-301b        down up   
hsa-mir-202        down up   
hsa-mir-125a        up down   
hsa-mir-365-1        up down   
hsa-mir-7-3        down up   
hsa-mir-152        up down  methylated 
hsa-mir-320b-2        up down   
hsa-mir-200a        up down   
hsa-mir-200b        up down   
hsa-mir-429        up down   
hsa-mir-24-2        unknown unknown   
hsa-mir-27a        down up   
hsa-mir-181d        down up   
hsa-mir-17        up down   
hsa-mir-18a        up down   
hsa-mir-19a        up down   
hsa-mir-19b-1        up down   
hsa-mir-20a        up down   
hsa-mir-196a-1        unknown unknown   
hsa-mir-34a        up down  methylated 
hsa-mir-10b        down up   
hsa-let-7a-3        up down   
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hsa-mir-141        up down   
hsa-mir-200c        up down   
hsa-mir-27b        up down   
hsa-mir-365-2        up down   
hsa-mir-24-1        unknown unknown   
hsa-mir-373        down up   
hsa-mir-196a-2        unknown unknown  methylated 
hsa-mir-497        up down   
hsa-mir-320b-1        up down   
hsa-mir-335        up down   
hsa-mir-15b        unknown unknown   
            
miRNA ID 
-5K 
CpG 
-4k 
CpG 
-3k 
CpG 
-2k 
CpG 
-1k 
CpG 
+1k 
CpG 
 
Normal Exp BC exp 
 BC BC 
methylation 
Status 
Status 
hsa-mir-16-2        unknown unknown   
hsa-mir-22        unknown unknown   
hsa-mir-125b-2        up down   
hsa-mir-451        down up   
hsa-mir-21        unknown unknown   
hsa-mir-143        up down   
hsa-mir-145        up down   
hsa-mir-489        up down   
hsa-let-7a-1        up down   
hsa-let-7f-2        up down   
hsa-let-7a-2        up down   
hsa-mir-101-1        up down   
hsa-mir-204        up down   
hsa-mir-205        up down   
hsa-mir-206        up down   
hsa-mir-30a        up down   
hsa-mir-31        up down   
hsa-mir-320c-1        up down   
hsa-mir-320c-2        up down   
hsa-mir-320d-1        up down   
hsa-mir-320d-2        up down   
hsa-mir-146b        unknown unknown   
hsa-mir-16-1        unknown unknown   
hsa-mir-146a        unknown unknown   
hsa-mir-181a-1        down up   
hsa-mir-181b-1        down up   
hsa-mir-181b-2        down up   
hsa-mir-222        down up   
hsa-mir-221        down up   
hsa-mir-29b-1        down up   
hsa-mir-29b-2        down up   
hsa-mir-29c        down up   
hsa-let-7f-1        down up   
hsa-mir-98        down up   
hsa-mir-122        down up   
hsa-mir-128-1        down up   
hsa-mir-128-2        down up   
hsa-mir-155        down up   
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hsa-mir-7-1        down up   
hsa-mir-7-2        down up   
hsa-mir-516a-1        down up   
hsa-mir-516a-2        down up   
hsa-mir-520c        down up   
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Supplementary Table 2: Primers for cloning miRNA promoters 
Assay name  Primer sequences 5'→3'* 
Position (UCSC Genome 
Browser, March 2006)  
Amplicon 
size (bp) 
miR124-1 prom1A Hind3 F CCCAAGCTTGGGAACAGCGACGTCTTCCAAAG chr8:9798613-9799100 488 
miR124-1 prom1A Kpn1 R GGGGTACCCCACTGCAGCAGGCGAGTTC   
    
miR124-1 prom1B Hind3 F CCCAAGCTTGGGTGCAGCTCCAGACAATGAAA chr8:9798752-9799100 308 
    
miR124-1 prom2A Hind3 F CCCAAGCTTGGGCACCAGCACACGTCATTCTC chr8:9801030-9801870 841 
miR124-1 prom2A Mlu1 R CGACGCGTCGCACTTCTGCGCCTCTAATC   
    
miR124-1 prom2B R AGTCAGGTGTCGATTTGACG chr8:9801573-980187 339 
    
miR124-2 prom1A Kpn1 F GGGGTACCCCCTTTAACATTCCTTCC chr8:65444604-65445773 1170 
miR124-2 prom1A Hind3 R CCCAAGCTTGGGCTCGTTGCCAGAAGTTGTTG   
    
miR124-2 prom1B Hind3 R CCCAAGCTTGGGAGGCAGCTGTTTCCTCAGAA chr8:65444604-65445031 428 
    
miR124-2 prom1C Kpn1 F GGGGTACCCCGCGCGGAGCTAGGCTGAG chr8:65445362-65445773 412 
    
miR124-2 prom2A Kpn1 F GGGGTACCCCGGACTGCACAGAAGGACCAT chr8:65452806-65453362 557 
miR124-2 prom2A Hind3 R CCCAAGCTTGGGAGGGTGAGGGAAGTTGACCT   
    
miR124-3 prom1A Kpn1 F GGGGTACCCCAAGGGTCAAGAGGTGGTGAG chr20:61276620-61277438 819 
miR124-3 prom1A Hind3 R CCCAAGCTTGGGCCTCTTGGAGTCCTGAGTAGC   
    
miR124-3 prom1B Hind3 R CCCAAGCTTGGGCAACTTCGCTACGGGTCAG chr20:61276620-61277438 292 
    
miR124-3 prom1C Kpn1 F GGGGTACCCCGTGTTTCCTCCCCTCCT chr20:61276849-61277174 326 
miR124-3 prom 1C Hind3 R CCCAAGCTTGGGCTGGGGTCTGTGCTTC   
    
miR124-3 prom2A Kpn1 F GGGGTACCCCGTTTCCTTGGGTCTCCGTGT chr20:61279113-61279546 434 
miR124-3 prom2A Hind3 R CCCAAGCTTGGGAAGGGAGCCAGGCAAGT   
    
miR124-3 prom3A Kpn1 F GGGGTACCCCATCCGTCTTCGCGATTCC chr20:61280027-61280333 307 
miR124-3 prom3A Hind3 R CCCAAGCTTGGGAATCAAGGTCCGCTGTGAAC   
    
miR24-2 prom1A Hind3 F CCCAAGCTTGGGACAACTCTCTGCCCACCTTG chr19:13814191-13814881 691 
miR24-2 prom1A Kpn1 R GGGGTACCCCGGGGGACAGGACAGAGAAAC   
    
miR24-2 prom2 Hind3 F CCCAAGCTTGGGACAGGAAGCAAATCCCATCC chr19:13808435-13809052 617 
miR24-2 prom2 Kpn1 R GGGGTACCCCGGCCTGTATCTTGGAGCTTG   
    
miR125a prom1A Kpn1 F GGGGTACCCCTCTGCGTCAGGCTTCTCTG chr19:56884218-56884704 487 
miR125a prom1A Hind3 R CCCAAGCTTGGGCTCAGGGACCCAGGAGTG   
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miR663 prom1A Hind3 F CCCAAGCTTGGGCGTGATTCTCGTCCATCCTC chr20:26137015-26137328 248 
miR663 prom1A Kpn1 R GGGGTACCCCGCTCGTCGCCTACTGTGG   
    
miR663 prom2A Hind3 F CCCAAGCTTGGGCACTCAACCGCCTCGAAC chr20:26138069-26138411 565 
miR663 prom2A Kpn1 R GGGGTACCCCTTACGTGGCAGCACTCTTG   
    
miR373 prom1A Kpn1 F GGGGTACCCCAACCTGCGGAGAAGATACC chr19:58982822-58983365 543 
miR373 prom1A Hind3 R CCCAAGCTTGGGCCGTGTTAGCCAGGATGG   
    
miR373 prom1B  Hind3 R CCCAAGCTTGGGCATCCGTTGATATGGGC chr19:58982822-58983047 226 
    
miR373 prom1C Kpn1 F GGGGTACCCCGCCCATATCAACGGATGC chr19:58983030-58983365 336 
    
miR22 prom1A Kpn1 F GGGGTACCCCTCGCCTGCTCTTTAGGACTC chr17:1565993-1566592 600 
miR22 prom1A Hind3 R CCCAAGCTTGGGTCCTCGTAGCTCCTGACACAC   
    
miR22 prom1B Hind3 R CCCAAGCTTGGGCTCCAGGCTCCGATCAGC chr17:1566277-1566592 316 
    
miR22 prom1C Kpn1 F GGGGTACCCCAGCTGATCGGAGCCTGGAG chr17:1565993-1566295 303 
    
miR22 prom2A Kpn1 F GGGGTACCCCTTGGACTGAGTGTCAGCA chr17:1564534-1564954 421 
miR22 prom2A Hind3 R CCCAAGCTTGGGCGTTTGAAAGAAGGTCAGC   
    
miR9-3 prom1A Kpn1 F GGGGTACCCCGCGTCCCTAAACCTTGTCAC chr15:87711583-87712265 683 
miR9-3 prom1A Hind3 R CCCAAGCTTGGGAGAAACGGGCCTCCCTTAG   
    
miR9-3 prom1B Kpn1 F GGGGTACCCCGATCCCTGGACTGACGT chr15:87711848-87712047 200 
miR9-3 prom1B Hind3 R CCCAAGCTTGGGCTCCCCTGCTCCCCGTTC   
    
miR9-3 prom1C Kpn1 F GGGGTACCCGGGGAGCAGGGGAGAAAT chr15:87712034-87712265 230 
    
miR193b prom1A Kpn1 F GGGGTACCCCTTGTCTGGGCTGCGATTG chr16:14304079-14304666 588 
miR193b prom1A Hind3 R CCCAAGCTTGGGAGAAACCAGAAACGCCACTC   
    
miR193b prom2A Kpn1 F GGGGTACCCCGCCCCCTGTTTGAAGCAC chr16:14303238-14303914 677 
miR193b prom2A Hind3 R CCCAAGCTTGGGAAGAAGGGGAGCACTCA   
    
miR193b prom2B Hind3 R CCCAAGCTTGGGCTGCACCCGGCCTCCAC chr16:14303607-14303914 397 
    
miR10b prom1A Kpn1 F GGGGTACCCCAAAGGGAGGCTGAATTGCTC chr2:176720135-176720974 840 
miR10b prom1A Bgl2 R GAAGATCTTCTAACAGAAGTGAGCGCCTTG   
    
miR10b prom1B Kpn1 F GGGGTACCCCGAGTGGGCGGATAGAAGAAA chr2:176720708-176720974 267 
    
miR10b prom2A  Kpn1 F GGGGTACCCCGAAGGTAAATGCGCGACTTC chr2:176722816-176723177 362 
miR10b prom2A Hind3 R CCCAAGCTTGGGCAGGTAGCCTAATGGGCTTG   
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miR301b prom1A Kpn1 F GGGGTACCCCAAAAGGCGGGCAAAGTTC chr22:20336232-20337076 845 
miR301b prom1A Hind3 R CCCAAGCTTGGGACCCCAGACTAGGGGGTTG   
    
miR301b prom1B Hind3 R CCCAAGCTTGGGAGGGTTAGACGGAAGAGG chr22:20336232-20336583 352 
    
miR9-1 prom1A Kpn1 F TTTTGGTACCAACGCCTTTCTGAGTTG chr1:154656653-154657412 760 
miR9-1 prom1A Bgl2 R AAAAAGATCTTGTATCCTCTGGTGCTGGTC   
    
miR9-1 prom1B Bgl2 R AAAAGGTACCTCAACTCCACTCGTGTCC chr1:154656653-154656970 318 
    
miR9-1 prom2A Kpn1 F AAAAGGTACCAGGCAGCAAGAGGCTGAG chr1:154657818-154658415 598 
miR9-1 prom2A Bgl2 R AAAAAGATCTGCTCTAGGGGTGGGAAAG   
    
miR9-1 prom2B Kpn1 F AAAAGGTACCTCGGCGGAGGCTAAGAG chr1:154657818-154658118 301 
    
miR9-1 prom2C Bgl2 R AAAAAGATCTCTTAGCCTCCGCCGAG chr1:154658101-154658416 316 
    
miR17 prom1A Kpn1 F TTTTGGTACCGTCGAGTCCCAGGGAGAG chr13:90797558-90798148 591 
miR17 prom1A Bgl2 R TTTTAGATCTGCCTGCGCTTTACTACGAC   
    
miR17 prom1B Kpn1 F TTTTGGTACCTAATGAGGGAGTGGGGCTTG chr13:90797886-90798148 263 
    
miR17 prom1C Kpn1 F TTTTGGTACCGCGCGCAGAGCTTGTTA chr13:90797642-90797968 327 
miR17 prom1C Bgl2 R TTTTAGATCTGCACCTCGAAGGACCATGTG   
    
miR17 prom2A Kpn1 F AAAAGGTACCAAGTGGAAGCCAGAAGAGGAG chr13:90800420-90800746 327 
miR17 prom2A Bgl2 R AAAAAGATCTGCATAATCCCTAATGGGGAAG   
    
miR210 prom1A Kpn1 F AAAAGGTACCAAACCAGGCAGAGCCAGAG chr11:558382-559119 738 
miR210 prom1A Bgl2 R AAAAAGATCTCTCGGCCCAACTTCAG   
    
miR210 prom1B Kpn1 F AAAAGGTACCAGACGTGCAGAAAAGAACG chr11:558382-558631 250 
    
miR210 prom1C Bgl2 R AAAAAGATCTCGTTCTTTTCTGCACGTCTG chr11:558611-559119 509 
    
miR210 prom1D Kpn1 F AAAAGGTACCGAGCCCGGGCCATACCAC chr11:558528-558777 250 
miR210 prom1D Bgl2 R AAAAAGATCTACCGCAACGCAGCCAGTG   
    
miR210 prom 1E Bgl2 R AAAAAGATCTCTCGGCCCAACTTCAG chr11:558382-558777 396 
    
miR320a prom1A F AGAGGGGTAGGCTTGAGAGG chr8:22158500-22159077 578 
miR320a prom1A Bgl2 R AAAAAGATCTAGCGCCGCCTGATAAATAC   
    
miR320a prom1B Kpn1 F CCCCGGTACCCAGGTGAGAGCCTTTG chr8:22158500-22158752 253 
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miR320a prom1C Bgl2 R AAAAAGATCTCAAAGGCTCTCACCTGGGT chr8:22158743-22159087 345 
    
miR335 prom1A Kpn1 F TTTTGGTACCCCTCTCACGGTTCAGTACCC chr7:129918665-129919256 592 
miR335 prom1A Bgl2 R TTTTAGATCTGGCAGCTACAGCCACTCC   
    
miR335 prom1B Blg2 F TTTTAGATCTAACTCATCAGGGGAGGGTTT chr7:129918879-129919256 378 
    
miR335 prom1C Bgl2 R TTTTAGATCTGAGGTGCCGGGGTGT chr7:129918879-129919192 314 
    
miR335 prom1D Bgl2 R TTTTAGATCTCGACTTTTAGAGCCCACCC chr7:129918879-129919142 264 
    
 
Supplementary Table 3: Primers for miRNA-200b promoter experiments 
Assay name  Primer sequences 5'→3'* 
Position (UCSC Genome 
Browser, March 2006)  
Amplicon 
size (bp) 
miR200b P1 Kpn1 F TTTTGGTACCGCAGAGGTGGAGAGGCGAGAGT chr1:1087797-1088137 341 
miR200b P1 Hind3 R TTTTAAGCTTGGGGCCTCGGGAGGGAAGAG   
    
miR200b P2 Kpn1 F TTTTGGTACCTTTTACAGCCCGGATCACTG chr1:1089316-1090354 1039 
miR200b P2 Hind3 R TTTTAAGCTTCGCTTTCTTGTCAACCGTC   
    
P1+P2 Hind3 F TTTTAAGCTTGGGAGGCAGAGGTGGAGAG chr1:1087791-1090354 2564 
P1+P2 Hind3 R TTTTAAGCTTCGCTTTCTTGTCAACCGTC   
    
-2447/-1993bp Hind3 F TTTTAAGCTTACGCAGAGGGAAGAACCTG chr1:1089901-1090354 454 
-2447/-1993bp Hind3 R TTTTAAGCTTCGCTTTCTTGTCAACCGTC   
    
-2228/-1993bp Hind3 F TTTTAAGCTTAGCCTGTGCAGGTGGGAC chr1:1090120-1090354 235 
-2228/-1993bp Hind3 R TTTTAAGCTTCGCTTTCTTGTCAACCGTC   
    
-2228/-2037bp Hind3 F TTTTAAGCTTAGCCTGTGCAGGTGGGAC chr1:1090120-1090310 191 
-2228/-2037bp Hind3 R TTTTAAGCTTGTGCCGGTTGAGGTGTTG   
    
-3032/-2447bp Kpn1 F TTTTGGTACCTTTTACAGCCCGGATCACTG chr1:1089316-1089900 585 
-3032/-2447bp Kpn1 R TTTTGGTACCCAGGTTCTTCCCTCTGCGT   
    
miR-200b minigene Kpn1 F TTTTGGTACCTTTTACAGCCCGGATCACTG chr1:1089315-1092628 3314 
miR-200b minigene Xba1 R TTTTTCTAGAATTCCGGGGTCTCTGAGATG   
    
miR-200b minigene  Promoter KO F GACGGTTGACAAGAAAGCG   
miR-200b minigene  Promoter KO R GTCCCACCTGCACAGGCT   
    
P1 in vitro methylation F TTTTAAGCTTGGGAGGCAGAGGTGGAGAG   
P1 in vitro methylation R TTTTAAGCTTGGGGCCTCGGGAGGGAAGAG   
    
5'PCR Walk primer A TTTTACAGCCCGGATCACTG   
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5'PCR Walk primer B ACGCAGAGGGAAGAACCTG   
5'PCR Walk primer C AGCCTGTGCAGGTGGGAC   
5'PCR Walk primer D GACGGTTGACAAGAAAGCG   
5'PCR Walk primer R1 GCCTTATGCAGTTGCTCTCC   
5'PCR Walk primer R2 TCTTCCAGCGGATAGAATGG   
 
Supplementary Table 4: Primers for miR-200b DNA methylation experiments 
Assay name  Primer sequences 5'→3'* 
Position (UCSC 
Genome Browser, 
March 2006)  
Amplicon 
size (bp) 
# CpG 
assessed 
Tm 
(˚C) 
P1 MS HRM F GGCGGGGAGTATTGTTTTTTG chr:1088073-1088347 275 16 64 
P1 MS HRM R CCGATCCACGAAACTAAATACTCTACC     
      
P2 MS HRM 1 F CGTATTTTTGGATTTTTGGAGGAGT chr:1089737-1090055 319 27 60 
P2 MS HRM 1 R AACCTACCCGACGAACTTAATCAATA     
      
P2 MS HRM 2 F GTCGGGCGTTTTTATTTTATTTTAGTT chr:1090095-1090224 130 8 62 
P2 MS HRM 2 R CGCCCCAACAAAAAATTCTCTA     
      
P1 Sequenom F 
AGGAAGAGAGTTATGGGAGTTTAGGGGAT
ATATT 
chr1:1087998-1088221 224 17 60 
P1 Sequenom R CAGTAATACGACTCACTATAGGGAGAAGGC
TATTCAAACCTACACAAATAAA 
    
      
P2 Sequenom F 
AGGAAGAGAGGGGGAGGGTTGGATTTTAT
AT 
chr1:1089990-1090222 233 17 60 
P2 Sequenom R CAGTAATACGACTCACTATAGGGAGAAGGC
TCCCCAACAAAAAATTCTCTA 
 
 
 
 
 
Supplementary Table 5: Primers for all other miRNA methylation experiments 
Assay name  Primer sequences 5'→3'* 
Position (UCSC Genome 
Browser, March 2006)  
Amplicon 
size (bp) 
# CpG 
assessed 
Tm 
(˚C) 
mir124-3 MSHRM  F TTTAGGATTGAGAGGTTTGGAGGAT chr20:61278843-61278948  106 10 60 
mir124-3  MSHRM R CCRCACTCRAACCCTAACC     
      
mir10b MSHRM-1 F GTTTAAGGGTGYGTGGAGTG chr2:176720352-176720468 118 6 61 
mir10b MSHRM-1 R CCCRAAAACTACRCAAAATTC     
      
mir10b MSHRM-2  F TTTGTAGAATYGAATTTGTGTGGTATT chr2:176723306-176723425 120 5 60 
mir10b MSHRM-2 R CCATATCRCACTTTAATCTCTAACTATTC     
      
mir9-3 MSHRM-1  F GTTTTYGGTTTTTTTGTGGAGA chr15:87711542-87711645 104 5 60 
mir9-3 MSHRM-1 R ACCCACTACRAACCATCAAAA     
      
mir9-3 MSHRM-2 F GGGYGTTYGAGGTTTTTTAAG chr1: 87711933-87712057 126 15 59 
mir9-3 MSHRM-2 R CRACRCATTTCTCCCCTAC     
      
mir663 MSHRM F TTTTGygGTGTTTTTGGA chr20: 26138005-26138144 139 14 60 
mir663 MSHRM R CRACRAACTCCCTCAAAAC     
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mir373 MSHRM F AACCACAAACTCTTTAATTCCTACAAAAA chr19: 58982977-58983089 113 7 60 
mir373 MSHRM R TTATTTTGATGTTTAAGTGGAAAGTGTTG     
      
mir124-1 MSHRM F TGGTTGGGTYGGTTGAAT chr8:9800144-9800270 127 7 60 
mir124-1 MSHRM R CTCCTACRCRTCCCTTCTC     
      
mir124-2 MSHRM F GTAGGGAGAYGATTAGGTTTGTTT chr8:65444916-65445035 120 7 60 
mir124-2 MSHRM R CCCRAAACAACTATTTCCTCAA     
      
mir9-1 MSHRM F GCGGTAGAGTTAATTAGAGGATGGTT chr1:154658114-154658265 152 8 60 
mir9-1 MSHRM R CCGAACCTAAACGAACAAAATAAAA     
      
mir210 MSHRM F GGTCGGTTATTGGTTGAGGGATT chr11:558379-558512 134 12 60 
mir210 MSHRM R CGACTCTCGACCCAACTTCAA     
      
mir320a MSHRM F TCGCGCGTTATAATTTTATTTGT chr8:22158504-22158660 157 16 58 
mir320a MSHRM R CCGCCTAATAAATACTATAACCCAA     
      
mir335 MSHRM-1 F TTAYGTAAATAAAGGGGGTTTTGTTT chr7:129918319-129918430 112 8 60 
mir335 MSHRM-1 R CAAACRCCTAACCACAACAAC     
      
mir335 MSHRM-2 F GGTTTTAATTTATTAGGGGAGGGTTTT chr7:129918873-129919015 143 5 60 
mir335 MSHRM-2 R AAATACCCCTCTAACAATAACTCCTTTAAA     
      
mir335 MSHRM-3 F GYGGTGTAGTTTAGGATTTTAAGATTTAG chr7:129920121-129920245 125 6 60 
mir335 MSHRM-3 R CTCACTCRCRCTTATTACTAAAATCTA     
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6.1.3. Introduction 
The study cohort comprised women who worked at the ABC studios in Toowong who 
developed breast cancer between 1994 and 2007.  Standard demographic details of the 
patients were extracted from the pathology record and clinical information was collated. 
Tissue microarrays were constructed from the FFPE blocks including both patient samples 
and control specimens using a semiautomated tissue microarrayer, Beecher Galileo. 
Material was not available for 1 patient; 8 patients had material suitable for inclusion in the 
TMA and 27 controls samples were included. 4 µm sections were cut from the TMA and 
immunohistochemistry was performed for ER, PR, HER2 (Ventana 4B5), CK 5/6, SMA, 
p63, HPV and SV40. In situ hybridization testing was performed for HER2 (Ventana 
Inform, Ventana Medical Systems) and EBV. 
DNA was extracted using needle macro dissection and a lysis protocol. RNA (500 ng) was 
extracted from 2-10 sections/sample (mean number of sections was 4.6). The Illumina 
Whole Genome-DASL (cDNA-mediated Annealing, Selection, Extension, and Ligation) 
assay which measure approximately 24,000 transcripts was performed as per 
manufacturer’s instructions. Unsupervised Hierarchical Clustering whereby transcripts 
which had a >2 fold change versus the mean were clustered. Pair wise analysis to 
determine differential expression was performed using the linear model and empirical 
Bayes method. Coded specimens of the patient samples and controls were used for 
MMTV analysis. 
6.1.4. Results 
Sir, 
Cancer clusters involving small numbers of patients are relatively common, but only a few 
have been investigated.  In the case of breast cancer, for some putative clusters no 
significant increase in the risk of developing cancer has been found,1 and in only a minority 
of cancer clusters which are found to be statistically significant is a causative agent found. 
Two such studies have shown an increased risk in breast cancer in office workers exposed 
to strong magnetic fields.2,3 However, for many cancer clusters, although a common 
aetiology was not proven, it could not be discounted, highlighting the difficulty in definitively 
associating a causal agent to a cancer cluster.4,5 
Nevertheless, in 2004 when staff at the Australian Broadcasting Corporation (ABC) 
premises in Toowong, Queensland, raised concerns about the number of breast cancer 
140 
 
cases occurring among female employees at that site, investigations were initiated. In 
2005, two studies attempted to evaluate the likelihood of the ABC cancer cluster and to 
identify whether personal breast cancer risk factors or workplace exposure to 
electromagnetic fields were possible causal agents, but no firm conclusions could be 
drawn.6 When an additional patient was diagnosed with breast cancer in 2006, an 
independent panel was constituted for a more systematic inquiry. That review included 550 
women employed full- or part-time during the period from 1 January 1994 to 30 June 2006. 
A total of 13 women were diagnosed with breast cancer, with a possible additional case, 
and 10 of these were diagnosed while still working at the Toowong studio.7 The expected 
number based on the Queensland rate of breast cancer was 1.6 cases.6 The likelihood of 
this occurring by chance was estimated at approximately one in a million and this 
represented a greater than 6-fold increased risk compared to the general female 
population. No specific cause of the cluster was identified, despite measurements of 
electromagnetic fields, ionising radiation, and chemical contamination of water and soil, as 
well as traditional breast cancer risk factors.7 
In an attempt to elucidate the nature of this cluster, we instigated a review of the biology of 
the ABC patients’ breast tumours. Breast cancer is a heterogeneous disease composed of 
several molecular pathology subtypes which may arise via different biological pathways. 
The working hypothesis was that a comparison to molecular subtypes may show that the 
tumours within the cancer cluster would have more similar morphological and/or molecular 
characteristics than those seen among tumours from a comparison group, and that this 
might reflect a common exposure to an unknown factor which might, in the long term, help 
to identify a novel breast cancer risk factor. This study also included an analysis of viral 
agents as there are some data to suggest a role for a retrovirus like mouse mammary 
tumour virus (MMTV) in breast   cancer.8,9 
Fourteen patients from the ABC breast cancer cluster were contacted and consent was 
obtained to study their tumours. All available samples were in the form of formalin fixed, 
paraffin embedded (FFPE) blocks and histological slides. For each ABC case, up to three 
controls, matched for year of diagnosis and age of diagnosis (+/– one year), were retrieved 
from a large database at the Princess Alexandra Hospital. Ethics approval for the project 
was obtained from the Princess Alexandra Hospital Human Research Ethics Committee, 
with access to patient records approved by the Director General of Queensland Health 
under legislative requirements. Slides were de-identified and reviewed independently by 
two pathologists (SRL, GF). A proforma was developed to aid systematic reporting and the 
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primary tumour characteristics were recorded for each sample. No slides were available 
for two ABC cases, no FFPE blocks were available for two cases and no material, even a 
pathology report, was available for one case (Table 1). Of the remaining 12 cases, one 
case had ductal carcinoma in situ (DCIS) only, and one tumour was too small for additional 
studies. Eight ABC cases had material suitable for inclusion in the tissue microarray 
(TMA). Twenty-nine control tumours were also included with two excluded (one was DCIS 
and another was too small for inclusion) (Table 1). 
TMAs were constructed in duplicate from the case and control FFPE blocks. Four mm 
sections were cut from the TMA and immunohistochemistry was performed using standard 
protocols. TMA results were available on six cases with no tumour or loss of the cores in 
two cases. Scoring of the sections was based on the percentage of cells stained (0–100%) 
and intensity of staining (0, 1, 2, 3,) for IHC. Oestrogen receptor (ER) and progesterone 
receptor (PR) cut-points were 1% or more of positive nuclei for classification of ER    
positive.10 
Sufficient material was available for MMTV-like agent analysis from seven ABC cases and 
18 control samples for MMTV-like envelope (env) gene analysis by polymerase chain 
reaction (PCR).8 
For the gene expression analysis, the sections were cut on the day of RNA extraction and 
macrodissected with a needle to enrich for areas with >50% tumour cells. RNA was 
extracted with a standard Tri reagent protocol. The Illumina Whole Genome-DASL (cDNA-
mediated annealing, selection, extension, and ligation) assay which measures 
approximately 24 000 transcripts was performed according to the manufacturer’s 
instructions (Illumina, USA). Failed samples (n=3) were removed from analysis due to low 
average signal intensity (<100).  Data were quantile normalised and    unsupervised 
hierarchical clustering whereby transcripts which had a 
>2 fold change versus the mean were clustered. Pair-wise analysis to determine 
differential expression was performed using the linear model and empirical Bayes method 
with Benjamini and Hochberg multiple testing correction.11 Single sample predictor was 
used to determine which sporadic molecular breast tumour subtype each sample 
resembled by comparing to the five centroid training set of 249 breast tumour samples 
from literature.12 
The results showed that no statistically significant differences were identified between the 
ABC case and control groups for any of the clinicopathological variables assessed (Table 
2). The majority of the case and control tumours were ductal carcinoma of no special type. 
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Tumour grade and size were similar between the case and control groups, as was the 
distribution of molecular subtypes as predicted by immunohistochemistry (IHC). No cases 
or controls showed staining with HPV or EBV in situ hybridisation, nor were they positive 
with IHC for SV40 or HPV. MMTV-like env gene was identified in 66.7% of case samples 
and 59.3% of control samples but this difference was not statistically significant (p=1). 
RNA was extracted from eight cases and 26 controls, and for three of these tumours (two 
cases and one control) two independent RNA extractions were performed from different 
areas of the tumour. Where possible the WG-DASL assay was performed in duplicate for 
each RNA sample. However, for three samples (one case and two controls) insufficient 
RNA was available and so these samples were assayed once only. An additional three 
samples (one case and two controls) failed quality control and were removed from 
analysis. In total, 68 samples were analysed successfully: eight cases (four in duplicate, 
two in quadruplicate, two singly) and 25 controls (22 in duplicate, one in quadruplicate and 
two singly). We found only 13 genes had a significant difference in expression between 
cases and controls (p=<0.05 with Benjamini   and Hochberg multiple testing correction).  
The gene expression profiles of all 68 samples were clustered using unsupervised 
hierarchical clustering (Fig. 1). The proportion of molecular subtypes present among the 
cases and controls was determined (Table 3). The classification was   discordant for six of 
29 duplicate pairs, but for three of these six samples the classification was either luminal A 
or luminal B. We assigned the final classification using the sample with the strongest 
prediction. There were no significant differences in the frequency of specific subtypes in 
cases versus controls. Fifty percent of the cases (4/8) were classified as luminal A 
compared to 36% (9/25) controls. There were no luminal B or basal-like tumours within the 
small set of ABC cases on gene expression profiling. Table 4 shows the relationship 
between the gene expression and immunohistochemistry subtypes. 
In conclusion, a clinicopathological review of the breast cancers showed no significant 
differences between tumour samples from the ABC cases and matched controls. The 
molecular subtyping showed that there were fewer luminal B and basal subtypes in the 
cases than controls, which does not support the hypothesis that BRCA1-carriers (which 
usually have the basal subtype) could account for the cluster.7 Viral agents were 
investigated as possible aetiological factors for the ABC cluster because there are some 
data to suggest a role for MMTV-like agent in breast cancer.8,9 However, there were no 
statistically significant differences in the prevalence of any virus between the ABC case 
and control groups. 
143 
 
There are no differences between the ABC cases and control tumours at the molecular 
level. Gene expression profiling is able to stratify tumours based upon phenotypic 
characteristics, but expression of only a few genes differed between the ABC cases and 
the controls, and unsupervised hierarchal clustering did not separate the tumours from the 
cases and controls. A supervised cluster analysis of the intrinsic genes that differentiate 
the breast tumour subtypes also showed that the ABC cases and controls did not cluster 
separately (data not shown). Together these findings indicate that the ABC cases and 
control tumours do not differ at a molecular level, and show that the ABC tumours are 
similar to the previously characterised sporadic molecular subtypes. 
A high level of exposure to an exogenous agent in the environment might account for the 
cluster, but the environ- mental analyses performed previously found no evidence for such 
agents (associated reports are available at http://www. abc.net.au/corp/pubs/bci.htm). In 
2009, a report was released on the risk of breast cancer among female employees of the 
ABC studios throughout Australia, including 5969 women employed between January 
1994 and December 2005. This study reconfirmed the excess rate of breast cancer among 
ABC employees in Queensland, but no excess rate was observed among staff in the rest 
of Australia. A recent editorial4 reviewed an updated analysis of the ABC cluster13 which 
reported a much higher probability of the initial cluster than the one in a million originally 
reported, and concluded that the absence of an increased risk of breast cancer at other 
ABC sites in Australia, together with a failure to identify any causative agent and a revised 
probability of 1 in 25, means that the situation may have arisen by chance. Our results 
showing no shared pattern of morphological or molecular characteristics are consistent 
with such a conclusion. 
In summary, the breast cancers from the ABC cluster appear to be morphologically and 
molecularly similar to the range of breast cancers seen in the general population based on 
pathological review, immunohistochemistry subtyping, presence of various viruses and 
gene expression profiling. The limitations of our analyses of the tissue samples include the 
size of the tumours and the availability only of FFPE tissue; no frozen material or blood 
samples were available for the cases from the time of diagnosis. With the development of 
new technology, such as next generation sequencing, the possibility exists for a more in-
depth analysis of the samples in the future. At this point in time, it seems reasonable to 
conclude that the cancers among the women of the ABC cluster are not unique.  However, 
it should be noted that we cannot rule out a carcinogenic influence. 
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Table 1: Summary of samples 
  Slides available for 
review 
FFPE material 
available 
Included in TMA  RNA extracted 
Case 12 12 8 8 
Control 31 31 29 26 
Total 43 43 37 34 
 
 
Table 2: Clinicopathological characteristics of ABC case and control groups 
 
 
ABC Case Group  Control Group p-value 
Characteristic n % n %  
Age at Diagnosis      
      50 years or less 11 79 26 84  
       > 50 years 3 21 5 16  
       Mean Age 42.79  44.35   
Tumour type      
       Ductal NOS 11 79% 26 84%  
       Ductal/Lobular 0 0% 1 3%  
       Mucinous 1 7% 1 3%  
       Micropapillary 0 0% 2 6%  
       Unknown 1 7% 0 0%  
       DCIS 1 7% 1 3%  
Histological Grade     0.34 
      GI 2 14% 8 26%  
      GII 5 36% 10 32%  
      GIII 4 29% 12 39%  
      DCIS 1 7% 1 3%  
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      Unknown 2 14% 0 0%  
Tumour Size     0.09 
      <10mm 3 21% 4 13%  
      10-20mm 7 50% 12 39%  
       >20-50mm 1 7% 11 35%  
       >50mm 1 7% 3 10%  
       Unknown 1 7% 0 0%  
       DCIS 1 7% 1 3%  
Hormone receptor status     1.0 
       ER+PR+ 10 71% 19 61%  
       ER+PR- 0 0% 1 3%  
       ER-PR+ 0 0% 0 0%  
       ER-PR- 1 7% 10 32%  
       Unknown 2 14% 0 0%  
       DCIS 1 7% 1 3%  
IHC subtype     0.10 
       Luminal A 7 50% 19 61%  
       Luminal B 3 21% 1 3%  
       HER2 1 7% 5 16%  
       Triple Negative 0 0% 5 16%  
       DCIS only 1 7% 1 3%  
       Unknown 2 14% 0 0%  
Lymph node status     0.78 
      Positive 6 43% 14 45%  
      Isolated tumour cells 0 0 1 3%  
      Negative 6 43% 15*  48%  
      Unknown 2*  14% 1 3%  
*One was DCIS only 
 
Table 3. Proportion of molecular subtypes within the ABC cases and controls determined by gene expression profiling 
  Basal-like HER2 Luminal A Luminal B Normal-like TOTAL 
Control 8 (32%) 1 (4%) 9 (36%) 4 (16%) 3 (12%) 25 (100%) 
Case 0 1 (12.5%) 4 (50%) 0 3 (37.5%) 8 (100%) 
 
Table 4. Overall correlation between gene expression profiling and IHC subtypes. 
 
 IHC subtype 
Gene expression 
Subtype 
Triple Negative HER2 Luminal A Luminal B 
Basal-like 5 2 1 0 
HER2 0 1 0 1 
Luminal A 0 0 13 0 
Luminal B 0 0 4 0 
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Normal-like 0 1 3 2 
 
 
 
 
Figure 1. Unsupervised clustering of all 68 samples successfully arrayed from 8 cases and 25 controls. Genes 
which varied 2-fold from the mean in at least 2/68 samples were clustered. Replicate samples are coloured similarly and 
cluster together; quadruplicate samples are marked with a bar and an asterix. Cases are shown in blue, and controls in 
red.  
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6.1.5. Introduction 
In triple negative breast carcinoma (TNBC), reduced androgen receptor (AR) expression 
has been associated with lymph node metastases and a worse overall survival (Luo et al., 
2010, Thike et al., 2014), however the correlation of AR with clinicopathological features 
and survival is complex (McNamara et al., 2014). This study confirmed that loss of AR 
expression is associated with a worse overall survival. 
6.1.6. Results 
Abstract 
 
Breast cancer outcome, including response to therapy, risk of metastasis and survival, is 
difficult to predict using currently available methods, highlighting the urgent need for more 
informative biomarkers. Androgen receptor (AR) has been implicated in breast 
carcinogenesis however its potential to be an informative biomarker has yet to be fully 
explored. In this study, AR protein levels were determined in a cohort of 73 Grade III 
invasive breast ductal adenocarcinomas. AR was expressed in 56% of tumours and 
expression was significantly inversely associated with 10 year survival (P=0.004). An 
investigation into the mechanisms responsible for the loss of AR expression revealed that 
hypermethylation of the AR promoter is associated with loss of AR expression in breast 
cancer cells but not in primary breast tumours. In AR negative breast tumours, mutation 
screening identified the same mutation (T105A) in the 5’UTR of two AR negative breast 
cancer patients but not reported in the normal human population. Reporter assay analysis 
of this mutation however found no evidence for a negative impact on AR 5’UTR activity. 
The role of miR-124 in regulating AR expression was also investigated, however no 
evidence for this was found. This study highlights the potential for AR expression to be an 
informative biomarker for breast cancer survival and sets the scene for a more 
comprehensive investigation of the molecular basis of this phenomenon.  
 
 
 
Key words: Androgen receptor; prognostic biomarker; breast cancer; gene regulation; 
promoter methylation; regulatory mutation; miRNA. 
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Background 
 
Breast cancer is a heterogeneous disease comprising tumour subtypes associated with 
variable clinical characteristics (Sorlie et al., 2001). Variables including tumour size, 
histological subtype and grade, lymph node status and the expression of estrogen receptor 
alpha (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 
(HER2) currently assist routine clinical management (Rakha et al., 2010b). However, these 
factors are limited in their ability to predict individual survival and response to therapy 
(Rakha et al., 2010b). This is particularly apparent for patients with advanced breast 
cancer, which is characterised by high histological grade and the presence of lymph node 
metastases, and has an aggressive clinical course and generally a poor prognosis (Rakha 
et al., 2010b). Identifying new prognostic biomarkers and the molecular mechanisms 
underlying breast cancer progression are paramount for improving the clinical 
management of these patients and developing improved therapeutic strategies.  
 
Androgen receptor (AR) is a member of the nuclear receptor superfamily and is known to 
be involved in a complex network of signalling pathways that collectively regulate cell 
proliferation (Yeh et al., 2003, Liao and Dickson, 2002). Expressed in the normal human 
mammary gland, where it predominantly localises to the inner layer of epithelial cells lining 
acini and intralobular ducts (Li et al., 2010), the role of AR in normal mammary epithelial 
biology is unknown. AR has been implicated in breast tumourigenesis, however 
delineating its precise function has proven difficult with AR-mediated androgenic effects 
shown to both stimulate and inhibit growth of breast cancer cells (Doane et al., 2006, 
Birrell et al., 1995). The significance of AR in human breast cancer is further emphasized 
by the recent finding that it can be targeted in estrogen receptor negative breast tumours 
(Ni et al., 2011). Loss of AR expression is associated with early onset, high nuclear grade 
and negative ER, PR and HER2 expression status in breast tumours (Agoff et al., 2003, 
Gonzalez-Angulo et al., 2009). However, the mechanisms responsible for this loss of AR 
expression in breast carcinogenesis remain unclear. 
 
The AR gene comprises 9 exons spanning 180.25 kilobases located on chromosome 
Xq12. Functional analyses have identified two independently regulated transcription 
initiation sites (TIS), AR-TIS I (-12/-11/-10) and AR-TIS II (-1/+1) (Fig. 1) (Faber et al., 
1991). Transcriptional initiation from AR-TIS I is dependent on sequences located between 
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positions -17 and +45 and initiation from AR-TIS II facilitated by a palindromic homopurine 
repeat and SP1 binding to a GC-box (Faber et al., 1993, Chen et al., 1997). Additional 
putative cis-acting elements include HL (helix-loop-helix-like) motifs 1 and 2 (Takane and 
McPhaul, 1996) and a cAMP responsive element (Mizokami et al., 1994). Two CpG 
islands (CGI) are also located in the AR promoter and extend into Exon 1. 
Hypermethylation of these CGI have been shown to silence AR transcription in prostate 
cancer cells and primary tumours (Kinoshita et al., 2000). Genetic alterations in the 
promoter and 5’untranslated regions (UTR) of the AR gene have been also observed in 
prostate cancer cell lines, xenografts (Waltering et al., 2006) and in two prostate cancer 
patients (Crocitto et al., 1997, Cox et al., 2006). In breast cancer, the role of regulatory 
defects in the AR gene are yet to be fully elucidated. 
 
In this study, we show that loss of AR expression is significantly associated with poor 10 
year survival outcome in Grade III invasive breast ductal adenocarcinomas. We then 
evaluated potential regulatory mechanisms that may account for the loss of AR 
expression. For the first time we show that DNA hypermethylation in the AR promoter is 
associated with loss of AR expression in breast cancer cells, although this is not the case 
in our cohort of tumours from patients with Stage III breast cancer. We subsequently 
assessed whether somatic mutations in AR regulatory regions or miRNAs bioinformatically 
predicted to target the human AR 3’UTR might contribute to the observed changes in AR 
expression.  
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Results and Discussion 
 
Low AR protein levels are associated with poor 10 year survival in patients with Stage III 
breast cancer.  
To assess the prognostic value of AR expression in breast cancer patients, IHC analysis 
was performed in a cohort of 73 Grade III lymph node positive ductal adenocarcinomas 
from patients with Stage III disease. Patient and tumour characteristics are summarised in 
Table 1. The patients ranged in age from 30 to 94 years (mean, 54 years); with the 
majority of patients (97%) aged over 35 years. AR expression was detected in 56% (n=41) 
of primary breast tumours. Positive expression of ER, PR and HER2 was also observed in 
55.5% (n=40), 40% (n=29) and 21.7% (n=15) of breast tumours, respectively. In AR-
negative tumours, the majority (72%, n=23; 87%, n=27; 86.6%, n=26) were also ER, PR 
and HER2 negative, respectively. The authors acknowledge the potential limitations of 
TMA analysis, given the inherent heterogeneity of tumour samples, but there is high 
concordance between TMA cores and whole sections (Kyndi, M., et al., Tissue 
microarrays compared with whole sections and biochemical analyses. A subgroup analysis 
of DBCG 82 b&c. Acta Oncol, 2008. 47(4): p. 591-9.). In addition the impact was further 
minimized by analysing at least two cores from each tumour, in accordance with the 
correlation nomograms developed by Karlsson et al, 2009 (Karlsson et al., 2009). AR 
expression was a significant prognostic factor for overall patient survival (P=0.004) (Figure 
2). The 10-year survival of patients with AR positive tumours was 52% versus 22% for 
patients with AR negative tumours. This finding is consistent with previous studies in a 
diversity of breast cancer patient populations wherein a significant association between AR 
expression and age at diagnosis, nuclear grade, recurrence-free survival was observed 
(Castellano et al., 2010, Bryan et al., 1984, Gonzalez-Angulo et al., 2009, Agoff et al., 
2003, Park et al., 2011).  
 
DNA methylation of the AR promoter is associated with low AR mRNA levels in breast 
cancer cell lines.  
To investigate potential mechanisms responsible for the loss of AR expression, we 
evaluated the methylation status of the AR promoter region and AR expression levels in 
breast cancer cell lines. DNA methylation was determined by MS-HRM analysis of bisulfite 
treated DNA in three regions; Regions 1 and 2 correspond to the CpG island in the AR 
minimal promoter (Takane and McPhaul, 1996) and Region 3 corresponds to the CpG 
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island at the translational start site (Fig. 1). DNA methylation was also assessed in a 
further region, Region 4, by Sequenom MassARRAY (Fig. 1). Cell lines, MDAMB231, 
MCF7, MDAMB157, MDAMB468 and MDAMB436 all showed between 25-100% 
methylation in at least 2 of regions analysed (Fig. 3a). Notably, methylation of the AR 
promoter region was associated with the level of AR mRNA (Fig. 3 a and b). A similar 
association has been observed in prostate cancer, where treatment of prostate cancer cell 
lines that display AR hypermethylation with the demethylating agent 5-aza-2’-
deoxycytidine induces the re-expression and function of AR (Jarrard et al., 1998). 
 
AR promoter methylation is not associated with low AR protein levels in primary breast 
tumours.  
To examine whether AR promoter methylation is also associated with loss of AR protein 
levels in breast tumours, the DNA methylation status of Region 4, which contains six CpG 
dinucleotides, was assessed by Sequenom MassARRAY. Sequenom was chosen for this 
analysis as it can analyse methylation at each individual CpG dinucleotide, reliably 
detecting methylation as low as 5%, in a high-throughput manner (Coolen et al., 2007). 
Primer design constraints meant that Region 4 of the AR promoter (Fig. 1) was selected 
for analysis, with DNA methylation of overlapping Regions 1 and 2 associated with AR 
mRNA levels in breast cancer cell lines. DNA methylation was observed in breast cancer 
patients at each of the six CpGs (Fig. 4). However, with the exception of CpG’s 1-3, at 
which methylation in most tumours was greater than 30%, for the most part only low level 
methylation (< 30%) was observed. Furthermore, no significant association was observed 
in the average methylation between AR negative and AR positive primary breast tumours 
in our cohort at any of the six CpG dinucleotides examined.  
 
There are several plausible explanations for the lack of association between promoter 
methylation and expression in primary breast tumours. There is the possibility that a region 
outside that examined shows expression associated methylation and indeed, there was an 
incomplete association between Region 4 methylation and AR mRNA levels in breast 
cancer cells. Additionally, another mechanism such as somatic mutation of these regions, 
or aberrant targeting by a miRNA, may be involved. 
 
Identification of somatic mutations in the AR 5’UTR in AR negative breast tumours.  
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Somatic mutation of regulatory regions of the AR gene is another potential mechanism 
responsible for reduced AR expression in breast tumours. To address this possibility, we 
sequenced the 5’ regulatory region of AR (-659 to +280) in breast cancer cell lines. Our 
results revealed no sequence variations in MDAMB157, MDAMB231, MDAMB436, 
MDAMB468, MCF7, T47D, ZR75-1, Hs578T and BT549 cells. We also sequenced the AR 
promoter region from -6 to +133 in 32 primary breast tumours. Amplification of the AR 
promoter region from -165 to -7, which corresponds to the homopurine repeat and GC box 
(Fig. 1), revealed a mutation (mRNA pos 105, T>A, Fig. 1), mapping to the AR 5’UTR, in 
two patients. This sequence variation does not correspond to any known SNPs (GRCh37 
reference primary assembly, www.ncbi.nlm.nih.gov/sites/entrez?db=snp) or, to our 
knowledge, any previously reported AR variants.  
 
To investigate the potential significance of the AR 5’UTR T105A variant, we performed 
bioinformatics analysis on the wild-type and variant sequence. In the wild-type sequence 
the T position is invariant in mammals and is a component of the binding site for RNApolII 
(based on ChIP-seq data) and the predicted and conserved binding site for several 
transcription factors, including RUNX1, En1 and Pax6. Based on the currently available 
ChIP-seq data however, there is currently no evidence that these transcription factors bind 
to this sequence in vivo. The substitution from T to A results in an abolishment of these 
predicted sites and the creation of predicted and conserved binding sites for NHLH1 (data 
not shown).  
 
To experimentally address the effect of this variant on 5’UTR activity, we fused the 5’UTR 
upstream of the firefly cDNA and downstream of either the AR or the SV40 promoter, in 
pGL3-basic and pGL3-promoter vectors, respectively. The AR 5’UTR T105A sequence 
variant did not have a negative impact on SV40 or AR driven reporter activity in either 
MCF7 or T47D cells (Fig. 5). Instead, the AR 5’UTR T105A sequence variant actually 
increased AR reporter driven activity in T47D cells (P=0.0001) (Fig. 5).   
 
Somatic mutation analysis of AR negative breast tumours identified the same alteration 
(chrX:66680703, mRNA pos 105, T>A) in the AR 5’UTR of two breast tumours. 
Examination of the functional importance of this sequence variation however revealed that 
there was no negative impact on the activity of the AR 5’UTR in MCF7 or T47D cells. This 
suggests that this mutation is unlikely to negatively affect the regulation of AR expression. 
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However, particularly given the AR 5’UTR T105A sequence variant significantly increased 
AR reporter driven activity in T47D cells, more complex studies, such as analysing the 
consequence of this mutation in the context of the entire AR gene and AR protein 
expression, will be required to firmly establish this. Although further analysis of our 
tumours was constrained by the availability and nature of the FFPE tumour material, it is 
plausible that mutations that effect AR expression exist outside the promoter region 
examined, particularly in regions upstream of the AR 5’UTR and in the AR 3’UTR, which 
are reported to contain putative regulatory elements involved in controlling mRNA stability 
(Yeap et al., 2004). A recent epidemiological meta-analysis of the AR gene concluded that 
common polymorphisms in the AR gene are not associated with breast cancer risk among 
Caucasian women (Cox et al., 2006). However, the functional significance of these 
variants, the AR expression status and survival outcome of these patients was not 
considered in this study. 
 
miR-124 does not regulate the AR 3’UTR in breast cancer cells.  
MiRNAs are small non-coding RNAs of ~20nt in length that are capable of modulating 
gene expression post-transcriptionally. Many have been shown to act as either oncogenes 
or tumour suppressor genes that are crucial to the development of breast cancer 
metastasis and survival outcome (Hurst et al., 2009a). To address the possibility that 
altered expression of AR is mediated by differential expression of miRNAs, we screened 
the AR 3’UTR for potential miRNA target sites. Bioinformatic analysis revealed that miR-
124 was the only miRNA predicted to target the human AR 3’UTR using miRanda and 
TargetScan. To examine whether miR-124 regulates the expression of the AR transcript, 
we used a reporter gene assay. MCF7 and T47D cells were transfected with pcDNA 
3.1(+)-mir-124 vector and expression of miR-124 verified. Cells transfected with pcDNA 
3.1(+)-mir-124 expressed high levels of mature miR-124 at 12, 24, 39 and 48 hr time 
intervals post-transfection, whereas no endogenous expression was detected in control-
transfected cells (Fig. 6a). For luciferase assays, we co-transfected MCF7 and T47D cells 
with pcDNA 3.1(+)-mir-124 vector with the pSG5-AR 3’UTR vector. The introduction of the 
AR 3’UTR into pSG5 luc significantly increased reporter activity in MCF7 (P=0.007) but not 
in T47D cells (Fig. 6b). miR-124 overexpression did not alter luciferase activity of the AR 
3’UTR construct in any of the cell lines examined (Fig. 6b). These results suggest that 
miR-124 is unlikely to regulate AR expression in these cells. 
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MiR-124 was the only miRNA predicted by two commonly used algorithms to target the AR 
3’UTR. However, over-expression of miR-124 did not regulate AR expression in MCF7 or 
T47D cells, which otherwise display no endogenous expression of this miRNA. This 
suggests that either miR-124 is unable to regulate AR in this particular experimental 
system, or that the prediction not correct. There is certainly evidence suggesting that 
although a plethora of targets are predicted for miRNAs, that many of these are false 
positives (Valastyan et al., 2009a). There have been reports of other miRNAs regulating 
the expression of AR, including miR-488 (Sikand et al., 2010). It would be of interest to 
determine whether there is an association between the levels of these miRNAs and AR in 
Stage III breast cancer, and whether these miRNAs have the potential to be informative 
biomarkers or therapeutic targets for this disease. Interestingly, the inclusion of the AR 
3’UTR significantly increased reporter activity in MCF7 but not in T47D cells suggesting 
the potential cell specific importance of this region in the post-transcriptional regulation in 
breast cancer cells.  
 
 
Conclusions 
 
In this paper we show that AR expression is significantly associated with 10-year survival 
outcome in patients with Stage III breast cancer. To predict and potentially address the 
poor survival outcome of patients with AR negative breast tumours it is important to 
understand the mechanism underlying the reduced AR expression. Here we demonstrate 
for the first time that hypermethylation of sections of the AR 5’ regulatory region is 
associated with loss of AR expression in breast cancer cell lines, although not in a small 
set primary tumours. We describe a new somatic mutation in the AR 5’UTR which is found 
in two independent tumours and is not a normal polymorphism. This study highlights the 
potential for AR expression to be an informative prognostic biomarker for breast cancer 
survival and sets the scene for a more comprehensive investigation of the molecular basis 
of this phenomenon. 
 
Methods 
 
Breast cancer cell lines  
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Breast cancer cell lines MDAMB157 (ER-PR-), MDAMB231 (ER-PR-HER2-), MDAMB436 
(ER-PR-), MDAMB468 (ER-PR-), MCF7 (ER+PR+HER2-), T47D (ER+PR+HER2-), ZR75-
1 (ER+PR-), Hs578T (ER-PR-HER2-), and BT549 (ER-PR-) were obtained from American 
Type Culture Collection (ATCC) and cultured according to the manufacturer’s 
recommendations. Hormone receptor status sourced from Neve et al, 2006. 
 
Clinical samples 
Primary breast tumours were sourced from the Princess Alexandra Hospital (Brisbane, 
Australia) following procedures endorsed by both local and national Human Ethics 
committees. Tumour tissues were formalin fixed and paraffin embedded (FFPE), sectioned 
and stained using hematoxylin and eosin (H&E), and confirmed by a qualified pathologist 
(G.D.F.) as invasive Grade III ductal adenocarcinomas. After the exclusion of patients for 
whom there was no follow-up data, non-breast cancer associated deaths and unreadable 
IHC expression, 73 patients were available for further analysis. None of the patients had 
received preoperative radiochemotherapy. The characteristics of the patients and tumours 
is shown in Table 1, with the following definitions of breast cancer stage III: 
Stage IIIA: No tumor is found in the breast. Cancer is found in axillary lymph nodes that 
are attached to each other or to other structures, or cancer may be found in lymph nodes 
near the breastbone; or the tumor is 2 centimeters or smaller. Cancer has spread to 
axillary lymph nodes that are attached to each other or to other structures, or cancer may 
have spread to lymph nodes near the breastbone; or the tumor is larger than 2 centimeters 
but not larger than 5 centimeters. Cancer has spread to axillary lymph nodes that are 
attached to each other or to other structures, or cancer may have spread to lymph nodes 
near the breastbone; or the tumor is larger than 5 centimeters. Cancer has spread to 
axillary lymph nodes that may be attached to each other or to other structures, or cancer 
may have spread to lymph nodes near the breastbone. 
 
Stage IIIB: In stage IIIB, the tumor may be any size and cancer: has spread to the chest 
wall and/or the skin of the breast; and may have spread to axillary lymph nodes that may 
be attached to each other or to other structures, or cancer may have spread to lymph 
nodes near the breastbone. 
Cancer that has spread to the skin of the breast is inflammatory breast cancer. See the 
section on Inflammatory Breast Cancer for more information. 
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Stage IIIC: In stage IIIC, there may be no sign of cancer in the breast or the tumor may be 
any size and may have spread to the chest wall and/or the skin of the breast. Also, cancer: 
has spread to lymph nodes above or below the collarbone; and may have spread to 
axillary lymph nodes or to lymph nodes near the breastbone. 
Cancer that has spread to the skin of the breast is inflammatory breast cancer. See the 
section on Inflammatory Breast Cancer for more information. 
Stage IIIC breast cancer is divided into operable and inoperable stage IIIC. 
In operable stage IIIC, the cancer: is found in ten or more axillary lymph nodes; or is found 
in lymph nodes below the collarbone; or is found in axillary lymph nodes and in lymph 
nodes near the breastbone. 
In inoperable stage IIIC breast cancer, the cancer has spread to the lymph nodes above 
the collarbone. 
 
 
Tissue microarray blocks and immunohistochemical staining 
Tumour-rich tissue from each biopsy was distinguished from surrounding normal tissue in 
H&E-stained sections by a qualified pathologist (G.D.F). Tissue microarrays were 
constructed in duplicate from tumour-rich tissue cores (1mm x 0.6mm) using an automated 
tissue microarray (TMA) instrument (ATA-27; Beecher Instruments). 4µM sections of the 
TMA blocks were used for immunohistochemical (IHC) analysis. Sections were transferred 
on to glass slides, deparaffinised and immunostained using anti-ER (SP1), anti-PR, (SP2), 
anti-HER2/neu (4B5) (Ventana Medical Systems, pre-diluted) or anti-AR (Biocare Medical, 
1:50 dilution) antibodies, and counterstained with 3,3'-Diaminobenzidine (DAB) and 
hematoxylin. Staining was performed with the BenchMark automated slide stainer 
(Ventana) using the iVIEW DAB detection kit with additional Avidin and Biotin Blockers 
according to the manufacturer’s instructions. Analysis of stained sections was performed 
by a qualified pathologist (G.D.F) and the presence of tumour tissue confirmed by 
examining the counterstain. Expression was scored as positive when visible staining  1% 
was observed in the nucleus for ER, PR and AR. For HER2 IHC was semiquantitatively 
evaluated with a score of 3+ regarded as positive, 2+ as equivocal, and 1+ or 0 as 
negative. In instances of an equivocal evaluation, silver-enhanced in situ hybridisation was 
performed as previously described (Francis et al., 2009b). 
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DNA methylation analysis 
Genomic DNA was isolated from cell lines using the NucleoSpin Tissue kit 
(MachereyNagel) according to the manufacturer’s instructions. For each human tumour 
sample, four FFPE tumour-rich tissue cores (1mm x 0.6mm) were crushed and digested 
with proteinase K at 55°C for 2 days and treated with 20mg RNase A for 1 hr at 37°C. DNA 
was isolated using the PureGene kit (Qiagen) and subjected to bisulfite modification using 
the MethylEasy Xceed kit (Human Genetic Signatures) according to the manufacturer’s 
instructions.  
 
PCR amplification and methylation sensitive high resolution melt analysis (MS-HRM) was 
performed in duplicate on the RotorGeneTM Q (Qiagen). Primers were designed 
according to the principles outlined in (Wojdacz et al., 2008) to control for PCR bias and 
are shown in Supplementary Table 1. PCR was performed using 2ng of bisulphite modified 
template and standard PCR conditions, followed by one cycle of 1min 30sec at 72°C and 
an MS-HRM step from 70°C to 90°C rising by 0.1°C/sec. Bisulfite treated CpGenomeTM 
Universal Methylated DNA (Chemicon, Millipore) and DNA from T47D were used as 
positive/methylated and negative/unmethylated controls, respectively. The methylation 
status of these controls was confirmed by direct sequencing of MS-HRM products, purified 
using the QiaQuick Gel Extraction Kit (Qiagen), performed by the Australian Genome 
Research Facility (AGRF, Brisbane, Australia). To create a range of methylated standards, 
these controls were mixed in 25, 50 and 75% methylated to unmethylated template ratios 
and were included in the analysis of each region.  
 
Sequenom MassARRAY DNA Methylation Analysis 
Sequenom MassARRAY methylation analysis was performed as described previously 
(Coolen et al., 2007). The forward primer has a 10-mer tag (5-aggaagagag-3) and the 
reverse primer has a T7-promoter tag (5-cagtaatacgactcactatagggagaaggct-3) 
(Supplementary Table 1). Bisulfite treated CpGenomeTM Universal Methylated DNA 
(Chemicon, Millipore) and Whole genome amplified DNA  prepared as per instructions with 
the GenomePlex® Complete Whole Genome Amplification kit (Sigma) were used as 
positive/methylated and negative/unmethylated controls, respectively. Triplicate PCR 
reactions were pooled and Shrimp Alkaline Phosphatase (Sequenom, San Diego) 
treatment performed followed by transcription and RNaseA Cleavage for the T-cleavage 
reaction. Purified samples were nanodispensed onto silicon chips preloaded with matrix 
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(SpectroCHIPs; Sequenom, San Diego). Mass spectra were collected using a 
MassARRAY mass spectrometer (Bruker-Sequenom) and results analysed by the 
EpiTYPER software V 1.0. Methylation readings with overlapping signals and silent peaks 
were eliminated from the calculation. 
 
Quantitation of AR mRNA 
To quantitate AR mRNA from cell lines, total RNA was extracted using Trizol (Invitrogen). 
cDNA was synthesised using 500ng of RNA and Superscript First Strand Synthesis 
System III (Invitrogen), according to the manufacturer’s instructions. ß-actin was used to 
normalise mRNA concentration and primers are shown in Supplementary Table 1. Real-
time PCR was performed in duplicate using the RotorGeneTM Q (Qiagen) using 50 cycles 
of standard PCR conditions.  
 
Somatic mutation analysis 
In breast cancer cell lines, a region spanning -659 to +280 with respect to the start of 
transcription (+1) were examined for somatic mutations. In FFPE tumours, the fragmented 
nature and limited availability of DNA meant that analysis was constrained to a smaller 
region (-165 to +133) and was examined in the 32 tumours for which IHC indicated 
negative AR expression. Primer sequences are shown in Supplementary Table 1. PCR 
was performed using KAPAHiFi DNA polymerase (KAPA Biosystems, Geneworks, 
Australia) and 50ng of template using 30 amplification cycles as per the manufacturer’s 
instructions. PCR reactions were purified using the QiaQuick Gel Extraction Kit (Qiagen) 
and sequencing performed by AGRF (Brisbane, Australia). 
 
Transcription factor binding site analysis 
Bioinformatic analysis initially involved an analysis of UCSC Genome Browser 
(http://genome.ucsc.edu). Transcription factor binding sites were predicted by MOODS 
(MOtif Occurrence Detection Suite) (Korhonen et al., 2009). MOODS uses the standard 
scoring model (log-odds against the background distribution) of PWMs. Scoring thresholds 
were specified by P-value less than or equal to 0.01. We tested T105A 5’UTR variant and 
WT sequences for overlap with the TFBS models in the JASPAR database (Bryne et al., 
2008). TFBS logos were downloaded from the JASPAR database web server: 
http://jaspar.cgb.ki.se/. 
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AR 5’UTR reporter assays 
The AR 5’UTR T105A mutation was introduced into the wild-type AR 5’UTR sequence 
(1116 bp, GenBank Accession No. NG009014.1) by site-directed mutagenesis using a 
two-step PCR procedure using the primers listed in Supplementary Table 1 and standard 
PCR conditions. The AR 5’UTR wild-type and T105A mutant alone and together with the 
AR promoter were cloned into the HindIII/NcoI sites of pGL3-promoter and the KpnI/NcoI 
sites of pGL3-basic (Promega), respectively. Constructs were confirmed by sequencing 
performed by AGRF (Brisbane, Australia). 
 
MCF7 and T47D cells were transiently transfected with 800ng pGL3+/- either the SV40 or 
the AR promoter, together with either the wild-type or mutant AR 5’UTR sequence and 
100ng Renilla reporter in a 24-well plate, using Lipofectamine 2000 (Invitrogen). Forty-
eight hours after the initial transfections, relative luciferase activities were determined 
using the Dual-Glo luciferase assay kit (Promega) and a DTX880 Multimode Detector 
(Beckman Coulter) according to the manufacturer’s instructions. Statistical analysis was 
performed using unpaired, two-tailed t tests, with p values <0.05 considered significant. 
 
miRNA analysis 
Two algorithms, miRanda and TargetScan 5.1, were used to predict target sites for miRNA 
in the AR 3’UTR (Miranda et al., 2006, Lewis et al., 2005). A total of 55 miRNA were 
predicted to target AR, 12 of which have conserved seed sequences. Only miR-124 was 
predicted by both algorithms. To quantitate the expression of miR-124, total RNA from 
transfected MCF7 and T47D cells was extracted using Trizol (Invitrogen) and the 
expression of miR-124 determined relative to RNU6B using the miScript PCR System 
according to the manufacturer’s instructions (Qiagen). 
 
AR 3’UTR reporter assays 
The AR 3’UTR (436bp; GenBank Accession No. NG009014.1) was ligated downstream of 
the luciferase coding sequence in the pSG5 vector (Stratagene). The mir-124-1 stem-loop 
(84bp; miRBase Accession No. MI0000443) + 200bp of flanking sequences was cloned 
into the KpnI/XbaI sites of the pcDNA 3.1(+) expression vector (Invitrogen). MCF7 and 
T47D cells were transiently transfected with 400ng pcDNA 3.1(+) constructs, 200ng pSG5-
luciferase constructs and 10ng of Renilla reporter in a 24-well plate, using FuGene 6 
(Roche). Forty-eight hours after the initial transfections, relative luciferase activities were 
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determined using the Dual-Glo luciferase assay kit (Promega) and a DTX880 Multimode 
Detector (Beckman Coulter) according to the manufacturer’s instructions. Statistical 
analysis was performed using unpaired, two-tailed t tests, with p values <0.05 considered 
significant. 
 
Statistical analysis 
Survival time was calculated from the date of tumour removal to the date of last follow-up 
or death attributable to breast cancer. Overall survival probabilities were estimated non-
parametrically with the use of the Kaplan-Meier product limit method (GraphPad Prism 
version 5.0a) and statistical significance accepted as P ≤ 0.05.  
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Figure legends 
 
Fig. 1 Schematic diagram of the human AR gene. The relative positions of the two 
transcription initiation sites (TIS I and II) and functionally known motifs; CpG islands, cAMP 
responsive element (CRE), helix-loop-helix-like (HL) motifs, a palindromic homopurine 
repeat (grey box) and GC-box (black box) which contains an SP1 binding site, are 
indicated (GenBank Accession No. NG009014.1). A grey circle denotes the T105A 
alteration identified in two primary breast tumours in the present study. DNA methylation 
was assessed in Regions 1-4, as denoted by black lines. UTR, untranslated region. ATG, 
translation start site. 
 
Fig. 2 Impact of Androgen Receptor expression on breast cancer survival . Kaplan-Meier 
estimates of 10 year survival of patients by AR expression for primary tumours. n denotes 
the number of patient samples.  
 
Fig. 3 DNA methylation of the AR gene is associated with loss of AR protein expression in 
breast cancer cells. (a) DNA methylation status of breast cancer cell lines. Three regions 
of AR were assessed by MS-HRM, overlapping Regions 1 and 2 in the AR minimal 
promoter and Region 3 at the translational start site (refer to Fig. 1). Region 4 was 
assessed by Sequenom MassARRAY. Data represent the average of two independent 
experiments. (b) AR mRNA expression in breast cancer cell lines was assessed by qPCR. 
Expression is shown relative to ß-actin and bars represent the mean + standard deviation 
of two independent experiments.  
 
Fig. 4 DNA methylation of an 115bp region in the AR promoter is not associated with loss 
of AR protein expression in a selective group of primary breast tumours. Methylation of six 
CpG dinucleotides in the AR promoter of AR positive (Pos) and negative (Neg) Grade III 
breast tumours as determined by Sequenom MassARRAY (Region 4, Fig. 1). Due to 
cleavage patterns, the average methylation was determined for CpG dinucleotides 2 and 
3. Each dot represents an individual patient. A methylation value of 1.0 indicates a fully 
methylated amplicon, while a value of 0.0 indicates a fully unmethylated amplicon. 
Horizontal lines represent average cohort methylation. 
 
165 
 
Fig. 5 Impact of the AR T105A 5’UTR variant. Luciferase reporter activities of pGL3 basic 
with the AR promoter (AR prom) and pGL3 promoter vector which contains the SV40 
promoter (SV40 prom) together with either the wild-type (WT) or T105A mutant (MT) AR 
5’UTR sequence in MCF7 and T47D cells. Data is shown relative to the respective empty 
vector + the standard error of the mean (SEM) and was generated from three independent 
experiments. ***P=0.0001. 
 
Fig. 6 miR-124 does not target the AR 3’UTR in breast cancer cells. (a) miR-124 
expression in MCF7 and T47D cells was assessed by qPCR following transfection with 
pcDNA 3.1(+)-mir-124. Expression is shown relative to RNU6B and dots represent the 
mean + standard deviation of two independent experiments. (b) Luciferase reporter 
activities relative to the Renilla internal control + the standard error of the mean (SEM) are 
shown. Data were generated from three independent experiments. **P=0.007. 
 
 
 
Figure 1. 
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Figure 6. 
Table 1  Patient and tumour characteristics* 
Factor AR negative 
n=32 (%) 
AR positive 
n=41 (%) 
Age (years)   
≤35 1 (3.0) 1 (2.4) 
≥35 31 (97.0) 40 (97.6) 
Estrogen receptor   
Negative 23 (72.0) 9 (22.5) 
Positive 9 (28.0) 31 (77.5) 
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Progesterone receptor   
Negative 27 (87.0) 16 (39.0) 
Positive 4 (13.0) 25 (61.0) 
HER2   
Negative 18 (85.7) 25 (75.8) 
Positive 3 (14.3) 8 (24.2) 
Triple negativea   
No 6 (28.6) 30 (90.9) 
Yes 15 (71.4) 3 (9.1) 
*All patients were diagnosed with Stage III disease, as defined in the Materials and 
Methods section of the manuscript 
 aTriple negative breast cancer represents tumours displaying negative expression for 
estrogen receptor, progesterone receptor and HER2 by IHC. AR, androgen receptor; 
HER2, human epidermal growth factor receptor type 2. 
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7.1.1. Introduction 
NeuralWorks Predict® is an integrated tool for rapidly creating and deploying prediction 
and classification applications. It combines neural network technology with genetic 
algorithms, statistics, and fuzzy logic to automatically find optimal or near-optimal solutions 
for a wide range of problems. The program can be used for a variety of analysis and 
interpretation problems. One advantage of NeuralWorks Predict® is that it requires no 
prior knowledge of neural networks. The input data is analysed to identify appropriate 
transforms and this data is then partitioned into training and test sets. The relevant input 
variables are selected and the program then constructs, trains, and optimizes a neural 
network tailored to the problem. However, the parameters can be modified by the user with 
direct access to all key training and network parameters. NeuralWorks Predict® runs as an 
add-in for Microsoft Excel to take advantage of Excel's rich data handling and graphing 
capabilities. 
 
NeuralSight® extends the power and flexibility of the NeuralWorks Predict® neural 
network engine by incorporating sophisticated yet easy-to-use facilities for building and 
evaluating hundreds of neural network models with minimal effort and intervention. 
Features in NeuralSight® include Self-Organizing Map (SOM) clustering and visualization 
capabilities. 
 
These programs were used to develop a model to predict grade in breast cancer using five 
IHC results (BUB1B, RaCGAP1, RRM2, NEK2,CENPA (Ma et al., 2008)).  
 
Histologic grade in breast cancer is based on three morphologic features: 
• Tubule formation 
• Nuclear pleomorphism 
• Mitotic count 
A value of 1-3 is assigned to each parameter and the values are combined to produce a 
score: 
• 3-5 = Grade 1  
• 6 & 7 = Grade 2 
• 8 & 9 =Grade 3   
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Molecular techniques have been used to stratify Grade 2 breast cancers into Grade 1 and 
grade 3 tumours as this appears to more accurately reflect patient outcome (Ignatiadis and 
Sotiriou, 2008a, Ivshina et al., 2006). 
 
7.1.2. Results 
Abstract — Histological grade is a historically used and well-documented prognostic 
indicator in breast cancer.  There are three categories of grade (G1, G2 and G3) based on 
the degree of tubule formation, nuclear pleomorphism and mitotic count.  A number of 
studies have reported that histological assessment is not uniformly reported. As a result of 
low inter-pathologist correlation associated with pathological diagnosis and non-
standardised grading systems, patients are not always allocated into the correct grouping, 
and G2 has often been considered a “safe” group if one is unsure.  A previously published 
study used real-time polymerase chain reaction (RT-PCR) for 5 genes to molecularly 
classify the G2 tumours into either G1 or G3.  Due to the workflow constraints within 
pathology laboratories it was not considered feasible to molecularly profile every G2 
tumour. In light of this we obtained the antibodies that corresponded to the 5 genes 
(BUB1B, CENPA, RACGAP1, RRM2 and NEK2) and performed immunohistochemistry 
(IHC) on formalin fixed paraffin embedded (FFPE) sections of 43 tumours (11 G1 and 32 
G3). Results for all tumours were randomly divided into training and testing sets and an 
artificial neural network (NeuralSight and NeuralWare Predict) was used to classify the 
grade of tumours. Thirty-three additional G2 tumours were used for validation of the ANN. 
The ANN classified these tumours into 5 G1 and 28 G3 tumours. This predicted grade 
showed significant correlation with patient survival. Neural networks can be used to 
reclassify breast cancer G2 tumours into G1 and G3 using a panel of 5 IHC markers. This 
has the potential to impact on patient care, treatment decisions and outcome. 
Keywords- Breast cancer, grade, artificial neural network. 
 
I.  INTRODUCTION 
Breast cancer is the leading cause of cancer-related deaths in women world-wide [1] and 
is the second most common cancer in Australian women. More than 13,000 new cases are 
diagnosed each year in Australia [2], increasing from 11,000 in 2000 [3], of which 2,200 
are in Queensland. Approximately 2,700 deaths from breast cancer occur annually in 
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Australia of which 465 were in Queensland in 2003. The number of hospital separations in 
Australia for women increased from 15,831 in 1995-96 to 23,598 in 2003-4 [2]. 
In current clinical practice for breast cancer, the standard prognostic factors that guide 
adjuvant systemic treatment decisions include tumour size, histologic subtype, histologic 
grade, oestrogen and progesterone receptor status, HER2 status and axillary lymph node 
status.  A measure of the limitation of these factors in predicting outcome is exemplified by 
the observation that recurrence rates are approximately 25% in lymph node negative 
breast cancer patients who will often not receive adjuvant therapy [4]. 
Despite the published reports of new biomarkers to predict prognosis or response to 
therapy in breast cancer patients, only a limited number have entered clinical practice. A 
predictive factor is defined as a clinical or pathologic feature that determines the likelihood 
of a response to a particular treatment. A prognostic factor is defined as a clinical or 
pathologic biomarker that determines patient outcome or survival. A biomarker may be 
both predictive and prognostic. For a factor to be useful, it must be technically validated, 
clinically validated and influence clinical decision making. A large proportion of studies 
have used immunohistochemistry (IHC) to assess the expression of different antigens in 
breast cancer cells compared to normal tissue. Limitations of these studies include 
variation in patient selection, different primary antibody clones, different cut-off criteria, 
inter-laboratory variation and reproducibility of the methodology. 
In addition, molecular techniques including DNA microarray analysis have indicated a 
large number of genes are involved in the progression of breast carcinoma. More than 
3,000 genes have been implicated in distinguishing oestrogen receptor (ERp) positive 
tumours from ERp-negative tumours [5]. 
Breast cancer is graded according to the Elston-Ellis modified Scarff, Bloom and 
Richardson grading system also known as the Nottingham modified Bloom and 
Richardson system [6, 7]. There are three components assessed for assigning a grade to 
a tumour: tubule formation, nuclear pleomorphism and mitotic rate. Each component is 
assigned a number from 1 to 3 and the components are tallied to obtain a value out of 9. 
Tumours with a score of 5 or less are graded as Grade 1 (G1), scores of 6-7 are Grade 2 
(G2) and scores of 8-9 as Grade 3 (G3) tumours. The grade of tumour shows significant 
correlation with breast cancer specific survival [8-11] for patients with lymph node 
metastases and those without nodal metastases at 5, 10 and 15 years (Fig. 1). The 
evaluation of tubule formation and mitotic rate also provide independent prognostic 
information [12]. 
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Evaluation of large patient cohorts with multivariate analysis has shown that grade is a 
significant predictor of disease recurrence and patient death (Ellis et al., 1992, 
Schumacher et al., 1993, Roberti, 1997, Lundin et al., 2001). Untreated G1 patients have a 
5 year survival rate of approximately 95%, whereas, those patients with G2 or G3 tumours 
have 5 year survival rates of approximately 75% and 50% respectively. 
There is, however, significant inter-observer variability in the evaluation of histological 
grade by pathologists (Harvey et al., 1992, Robbins et al., 1995, Frierson et al., 1995, 
Dalton et al., 1994, Dalton et al., 2000) and the usefulness in patient prognosis has been 
questioned (Younes and Laucirica, 1997, Hayes et al., 2001). Grade 2 tumours comprise 
approximately 50% of all breast cancers and it has been proposed that refinement of this 
group may improve the prognostic value of tumour grading (Sotiriou et al., 2006, Ivshina et 
al., 2006). 
Gene expression profiling has been used to more accurately grade tumours to overcome 
the limitations of the current system (Ivshina et al., 2006, Sotiriou et al., 2006). Sotiriou et 
al (Sotiriou et al., 2006) developed a 97-gene expression profile associated with 
histological grade and found that the gene expression profile correlated more strongly with 
relapse-free survival compared to histological grade (Sotiriou et al., 2006). Similarly, Ma et 
al, (Ma et al., 2003) and Ivshina et al, (Ivshina et al., 2006) have also developed histologic 
grade signatures and the latter enabled the refinement of the G2 tumours into different 
sub-grades with clinical implications (Ivshina et al., 2006). The Genomic Grade Index 
(Filho et al., 2010, Ignatiadis and Sotiriou, 2008b, Toussaint et al., 2009) has been further 
developed for both frozen and formalin fixed paraffin embedded tissue (FFPE). Ma et al, 
(Ma et al., 2008) developed a polymerase chain reaction (PCR) based five gene molecular 
grade index (MGI) for applications with FFPE material. The rationale for this approach was 
that it may be more easily implemented into a diagnostic laboratory. The MGI has been 
validated in a separate patient cohort (Jerevall et al., 2011). 
 
In this study, the five gene panel of the MGI was used to develop IHC staining protocols 
for patient samples and an artificial neural network was used to develop an algorithm for 
determination of tumour grade. 
Materials and Methods 
Tissue microarrays (TMAs) were constructed using an automated Beecher ATA-27 and 
semi-automated Beecher Galileo (Beecher Instruments, Sun Prairie, USA). Areas of 
tumour were identified on haematoxylin and eosin (H & E) stained slides and tissue cores 
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were punched from these areas and inserted into recipient blocks. 4 µm sections were cut 
onto SuperFrost Plus slides and IHC was performed using primary antibodies against 
BUB1B, NEK2, CENPA, RacGAP1 and RRM2. Slides were digitally scanned on a 
Hamamatsu Nanozoomer (Hamamatsu City, Japan) at 40x magnification and attached to 
image maps in a database, SlidePath Distiller (Leica Microsystems, Wetzlar, Germany). 
The images were scored on-line using SlidePath Distiller. Each TMA core was scored for 
percentage of tumour staining (0-100%), intensity of tumour staining (0 – 3) and the 
localization in the cellular compartments; membrane, cytoplasmic or nuclear. Data, 
including morphologic grade, patient follow-up, survival and cause of death, was extracted 
from the database into Microsoft Excel (Microsoft Corporation, USA). 
43 patients with complete data sets were randomly divided into training and teaching sets. 
Within this patient population there were 11 Grade 1 tumours and 32 Grade 3 tumours. 
NeuralSight (NeuralWare, Carnegie, PA) was used to evaluate 20 models through 
NeuralWare Predict (NeuralWare, Carnegie, PA). In NeuralSight, the Model Type selected 
in the program was Classification and build options included cascaded variable selection 
with noisy data and comprehensive and exhaustive variable selection options. In 
NeuralWare Predict, a multilayer perceptron neural network, the selected options included 
adaptive gradient learning rule, cascaded variable selection, an output layer function of 
SoftMax and an evaluation function of average classification rate. Cascaded variable 
selection was performed before the main variable step and was used to estimate the 
probability that a particular variable was present in a good solution, eliminating those 
variables that have a very low probability of inclusion in an optimum solution. Input variable 
selection used a genetic algorithm with multiple regression to select the model’s input 
variables. The adaptive gradient learning rule used back-propagated gradient information 
to guide an iterative line search algorithm with weight decay used to avoid overfitting. The 
neural network architecture selected used 22 input nodes, 3 hidden nodes and 1 output 
node. NeuralWare Predict was used to run predicted grade and validate the algorithm on a 
separate data set of 33 Grade 2 tumours through a plugin in Microsoft Excel 2007. SPSS 
19 (IBM Australia) was used for Kaplan-Meier survival curves for Breast Cancer Specific 
Survival (BCSS). 
Results 
Photomicrographs of morphologic G1 and G3 tumours are illustrated in Figure 2.  
IHC staining showed variable intensity and percentage of cytoplasmic staining for BUB1B, 
RRM2 and NEK2 and variable intensity and percentage of nuclear staining for RacGAP1 
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and CENPA (Figure 3). Kaplan-Meier survival curves for BCSS for the tumours used in 
this study show differences in survival for the morphologic G1, G2 and G3 tumours with 
the poorest outcome for G3 tumours (Figure 4).  
NeuralSight generated 20 models and these were evaluated using ROC modeling. Model 
10 showed an ROC of 1 and this model was used to evaluate the G2 tumours. Of the 33 
G2 tumours, 5 were predicted to be G1 and 28 were predicted to be G3 tumours. Kaplan-
Meier survival curves showed that the predicted G1 tumours had a 100% long term BCSS, 
whereas, the predicted G3 tumours had a BCSS similar to morphologic G3 tumours 
(Figure 5). 
Discussion 
Breast cancer grade is a significant prognostic factor in breast cancer patients; however, 
morphologic assessment of grade is subjective and there is variability in interpretation 
between reporting pathologists. To overcome these limitations, molecular profiling has 
been used to develop algorithms to stratify G2 tumours into those tumours that are similar 
to morphologic G1 tumours and those similar to morphologic G3 tumours. The rational for 
this is that it will enable more accurate prognostic information to improve patient care and 
outcome. 
Gene expression profiling and even real-time polymerase chain reaction (RT-PCR) are not 
easily integrated into a diagnostic anatomical pathology laboratory and for this reason, 
based on a small gene list, IHC was used to ascertain if it was feasible to use this 
technology to achieve the same goals. 
This study shows that it is possible to use a panel of five IHC biomarkers, in conjunction 
with an artificial neural network, to stratify G2 breast cancers into two separate groups with 
differing survival outcomes. The neural network model in this application uses biomarkers 
that had previously been reported to be useful in predicting grade stratification. The 
parameters included a mixture of percentage of tumour cells staining and the intensity of 
staining which correlates with the protein expression of that particular biomarker. This 
format forms part of routine patient care in breast cancer for other biomarkers including 
oestrogen receptor, progesterone receptor and HER2. In addition, the design of model 
parameters enables variations in the interpretation of the IHC results to be accommodated 
by the network model. Further validation studies are in progress. If successful, this 
methodology has the potential to be readily integrated into the diagnostic laboratory to 
improve patient care. 
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Figure 1: Kaplan-Meier survival curves for 591 breast cancer patients according to tumour 
grade over 200 months.  
a)                                               b) 
 
Figure 2: Haematoxylin and eosin stained sections illustrating (a) Grade 1 and (b) Grade 3 
infiltrating ductal carcinoma (x20 magnification). 
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Figure 3: 
Kaplan-Meier 
BCSS survival 
curves for 
morphologic 
G1, G2 and G3 
tumours over 
250 months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
184 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Immunohistochemical detection of BUB1B, NEK2, RacGAP1, RRM2 and CENPA 
in breast cancer TMAs (x20 magnification). 
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Figure 5: Kaplan-Meier BCSS survival curves for morphologic G2 tumours stratified into 
predicted G1 and G3 tumour over 250 months. 
 
REFERENCES 
Hinestrosa, M.C., et al., Shaping the future of biomarker research in breast cancer to 
ensure clinical relevance. Nat Rev Cancer, 2007. 7(4): p. 309-15. 
AIHW and NBCC, Breast cancer in Australia: 
an overview, 2006. , in Cancer series no. 34. 
cat. no. CAN 29. 2006, AIHW: Canberra. 
Welfare, A.I.o.H.a., Cancer. 2000, Commonwealth Government Publications: Canberra. 
McGuire, W.L. and G.M. Clark, Prognostic factors and treatment decisions in axillary-
node-negative breast cancer. N Engl J Med, 1992. 326(26): p. 1756-61. 
Talisuna, A.O., et al., Population-based validation of dihydrofolate reductase gene 
mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda. Trans R 
Soc Trop Med Hyg, 2003. 97(3): p. 338-42. 
186 
 
Bloom, H.J. and W.W. Richardson, Histological grading and prognosis in breast cancer; a 
study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer, 1957. 
11(3): p. 359-77. 
Elston, C.W. and I.O. Ellis, Pathological prognostic factors in breast cancer. I. The value of 
histological grade in breast cancer: experience from a large study with long-term follow-up. 
Histopathology, 1991. 19(5): p. 403-10. 
Burke, H.B. and D.E. Henson, Histologic grade as a prognostic factor in breast carcinoma. 
Cancer, 1997. 80(9): p. 1703-5; discussion 1706-7. 
Nicholas, E.R., Histologic grade as a prognostic factor in breast carcinoma--reply. Cancer, 
1997. 80(9): p. 1706-1707. 
Roberti, N.E., The role of histologic grading in the prognosis of patients with carcinoma of 
the breast: is this a neglected opportunity? Cancer, 1997. 80(9): p. 1708-16. 
Ellis, I.O., et al., Pathological prognostic factors in breast cancer. II. Histological type. 
Relationship with survival in a large study with long-term follow-up. Histopathology, 1992. 
20(6): p. 479-89. 
Frkovic-Grazio, S. and M. Bracko, Long term prognostic value of Nottingham histological 
grade and its components in early (pT1NOMO) breast carcinoma. J Clin Pathol, 2002. 55: 
p. 88-92. 
Schumacher, M., et al., The prognostic effect of histological tumor grade in node-negative 
breast cancer patients. Breast Cancer Res Treat, 1993. 25(3): p. 235-45. 
Lundin, J., et al., Omission of histologic grading from clinical decision making may result in 
overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin 
Oncol, 2001. 19(1): p. 28-36. 
Harvey, J.M., N.H. de Klerk, and G.F. Sterrett, Histological grading in breast cancer: 
interobserver agreement, and relation to other prognostic factors including ploidy. 
Pathology, 1992. 24(2): p. 63-8. 
Robbins, P., et al., Histological grading of breast carcinomas: a study of interobserver 
agreement. Hum Pathol, 1995. 26(8): p. 873-9. 
Frierson, H.F., Jr., et al., Interobserver reproducibility of the Nottingham modification of the 
Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J 
Clin Pathol, 1995. 103(2): p. 195-8. 
Dalton, L.W., D.L. Page, and W.D. Dupont, Histologic grading of breast carcinoma. A 
reproducibility study. Cancer, 1994. 73(11): p. 2765-70. 
187 
 
Dalton, L.W., et al., Histologic grading of breast cancer: linkage of patient outcome with 
level of pathologist agreement. Mod Pathol, 2000. 13(7): p. 730-5. 
Younes, M. and R. Laucirica, Lack of prognostic significance of histological grade in node-
negative invasive breast carcinoma. Clin Cancer Res, 1997. 3(4): p. 601-4. 
Hayes, D.F., C. Isaacs, and V. Stearns, Prognostic factors in breast cancer: current and 
new predictors of metastasis. J Mammary Gland Biol Neoplasia, 2001. 6(4): p. 375-92. 
Sotiriou, C., et al., Gene Expression Profiling in Breast Cancer: Understanding the 
Molecular Basis of Histologic Grade To Improve Prognosis. J Natl Cancer Inst, 2006. 
98(4): p. 262-272. 
Ivshina, A.V., et al., Genetic Reclassification of Histologic Grade Delineates New Clinical 
Subtypes of Breast Cancer. Cancer Res, 2006. 66(21): p. 10292-10301. 
Ma, X., et al., Gene expression profiles of human breast cancer progression. Proc Natl 
Acad Sci, 2003. 100(10): p. 5974-5979. 
Filho, O.M., M. Ignatiadis, and C. Sotiriou, Genomic Grade Index: An important tool for 
assessing breast cancer tumor grade and prognosis. Crit Rev Oncol Hematol, 2010. 
Ignatiadis, M. and C. Sotiriou, Understanding the molecular basis of histologic grade. 
Pathobiology, 2008. 75(2): p. 104-11. 
Toussaint, J., et al., Improvement of the clinical applicability of the Genomic Grade Index 
through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded 
tissues. BMC Genomics, 2009. 10: p. 424. 
Ma, X.-J., et al., A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are 
Complementary Prognostic Factors in Early Stage Breast Cancer. Clin Cancer Res, 2008. 
14(9): p. 2601-2608. 
 Jerevall, P.L., et al., Prognostic utility of HOXB13:IL17BR and molecular grade 
index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer, 2011. 
104(11): p. 1762-9. 
  
188 
 
Chapter 8 
PLANT, H. C., KASHYAP, A. S., MANTON, K. J., HOLLIER, B. G., 
HURST, C. P., STEIN, S. R., FRANCIS, G. D., BEADLE, G. F., 
UPTON, Z. & LEAVESLEY, D. I. 2014. Differential subcellular 
and extracellular localisations of proteins required for insulin-
like growth factor- and extracellular matrix-induced signalling 
events in breast cancer progression. BMC Cancer, 14, 627.  
189 
 
8.1.1. Introduction 
Epithelial-mesenchymal transition (EMT) has been associated with circulating tumour cells 
and metastasis in epithelial cancers including breast cancer. A number of biomarkers have 
been evaluated and loss of E-cadherin has been associated with lymph node metastases 
(Markiewicz et al., 2014). Markers of EMT were evaluated in this project to identify 
differences in expression and correlation with patient out come and clinicaopathological 
features. 
8.1.2. Results 
Abstract 
 
Introduction: Cancer metastasis is the main contributor to breast cancer fatalities as 
women with the metastatic disease have poorer survival outcomes than women with 
localised breast cancers. There is an urgent need to develop appropriate prognostic 
methods to stratify patients based on the propensities of their cancers to metastasise. The 
insulin-like growth factor (IGF)-I:IGF binding protein (IGFBP):vitronectin complexes have 
been shown to stimulate changes in gene expression favouring increased breast cancer 
cell survival and a migratory phenotype. We therefore investigated the prognostic potential 
of these IGF- and extracellular matrix (ECM) interaction-induced proteins in the early 
identification of breast cancers with a propensity to metastasise using patient-derived 
tissue microarrays. 
Methods: Semiquantitative immunohistochemistry analyses were performed to compare 
the extracellular and subcellular distribution of IGF- and ECM-induced signalling proteins 
among matched normal, primary cancer and metastatic cancer formalin-fixed paraffin-
embedded breast tissue samples. 
Results: The IGF- and ECM-induced signalling proteins were differentially expressed 
between subcellular and extracellular localisations. Vitronectin and IGFBP-5 
immunoreactivity was lower while β1 integrin immunoreactivity was higher in the stroma 
surrounding metastatic cancer tissues, as compared to normal breast and primary cancer 
stromal tissues. Similarly, immunoreactive stratifin was found to be increased in the stroma 
of primary as well as metastatic breast tissues. 
Immunoreactive fibronectin and β1 integrin was found to be highly expressed at the 
leading edge of tumours. Based on the immunoreactivity it was apparent that the cell 
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signalling proteins AKT1 and ERK1/2 shuffled from the nucleus to the cytoplasm with 
tumour progression. 
Conclusion: This is the first in-depth, compartmentalised analysis of the distribution of IGF- 
and ECM-induced signalling proteins in metastatic breast cancers. This study has provided 
insights into the changing pattern of cellular localisation and expression of IGF- and ECM-
induced signalling proteins in different stages of breast cancer. The differential distribution 
of these biomarkers could provide important prognostic and predictive indicators that may 
assist the clinical management of breast disease, namely in the early identification of 
cancers with a propensity to metastasise, and/or recur following adjuvant therapy. 
 
Introduction 
 
Experimental and clinical evidence has implicated a role for the insulin-like growth factor 
(IGF) axis in cancer progression [1]. In fact a number of inhibitors of, and antibodies 
directed against, the IGF type I receptor (IGF-IR) have been reported to show anti-tumour 
activity in vitro and in vivo, and are currently in clinical trials [2]. These studies, combined 
with many others, have highlighted the complexity of the dysregulation of the IGF system 
in cancers. Simply targeting the IGF-IR or the IGF system in isolation may therefore not be 
the most efficacious strategy for treating this disease; more complex therapeutic 
approaches to target the IGF system and prevent tumorigenesis and, in particular, 
metastasis, are likely to be required. 
Cancer metastasis is the main contributor to breast cancer fatalities [3]. Women with 
metastatic breast cancers have considerably poorer survival outcomes than women whose 
cancers are localised to the breast [4, 5]. Adjuvant systemic therapies for patients with 
breast cancer metastasis remain palliative [3]. Understanding the processes underpinning 
the progression of breast cancer, identifying patients likely to develop metastases and 
developing strategies to prevent the secondary spread of cancers are of significant clinical 
and financial relevance. There has also been a growing urgency to create cost-effective 
and appropriate prognostic methods that can accurately resolve those patients with a poor 
prognosis that require more intense treatment regimes. The prognostic methods currently 
available are unable to adequately address this issue [6, 7]. 
A critical component that is often overlooked during the identification and analysis of 
prognostic biomarkers, and one which may explain the inability to develop adequate 
prognostic techniques thus far, is the interplay between tumour cells, the surrounding 
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microenvironment and the growth factors present in this milieu. Cellular attachment and 
interactions with the extracellular matrix (ECM) regulate biological responses vital for 
tumour progression. Considerable evidence indicates that interactions between proteins 
required for IGF-induced signalling events and those within the ECM contribute to 
processes leading to cancer progression. Studies by Kricker et al. [8] found that IGF-I 
stimulates migration of MCF-7 breast cancer cells when bound to the ECM protein 
vitronectin (VN) indirectly through the presence of IGF binding proteins (IGFBPs). The 
presence of function blocking antibodies against IGF-IR and VN-binding integrins 
abolished the enhanced migration of these cells [9], while, the overexpression of total-
akt/protein kinase B (AKT) and phosphorylated-akt/protein kinase B (P-AKT) enhanced 
IGF-I:IGFBP:VN-stimulated migration [9]. Gene microarray technology has also been 
applied to elucidate the molecular mechanisms involved in IGF-I:IGFBP:VN-stimulated 
migration of breast cancer cells in in vitro cell based assays [10]. These studies have 
identified a number of genes, including Stratifin (SFN), enhancer-of-split and hairy-related 
protein 2 (Sharp-2), Tissue Factor, Claudin-1 (CLDN1), that are uniquely regulated by the 
IGF-I:IGFBP:VN complex. 
The genes are known for their roles in migration, invasion as well as cell survival. 
However, to date the effects of IGF and ECM protein interactions on the dissemination and 
progression of breast cancer in vivo are unclear. Given this, we chose to investigate the 
clinical relevance of proteins required for IGF-induced signalling events and those within 
the ECM for the development and progression of breast cancer, as well as investigate 
these proteins as potential prognostic biomarkers. 
 
Patients, Materials and Methods 
 
Human ethics approval: Ethical approval for this work was obtained from the Queensland 
University of Technology, Australia (0800000565), the Princess Alexandra Hospital 
Australia (2005/163), Royal Brisbane & Women's Hospital, Australia (PR07/004) and 
Queensland Institute of Medical Research, Australia (P716). This project utilised archived 
human tissue samples collected between January 1970 and June 2005. The human tissue 
samples and patients records were collected as a routine part of clinical management of 
the breast disease. Patient consent was not required. All patient clinical information was 
obtained from the Queensland Cancer Registry (Australia) in a de-identified and encoded 
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manner. Approval to use these samples and data was sought from Dr Glenn Francis and 
Queensland Health (Australia). 
Selection of patient specimen: This project utilised formalin-fixed paraffin-embedded 
(FFPE) archival breast carcinoma specimens from 91 women who presented with 
metastatic breast carcinoma (refer to Additional file 1 and 2 for further details). 
These specimens were surgically removed from the breast and axillary lymph nodes 
(LNs). For each patient, tissues containing normal breast epithelial ducts, primary breast 
carcinoma and LN metastasis were identified from haematoxylin and eosin stained 
sections. Cores containing DCIS tissues were omitted due to low samples numbers. 
Details on the selected patient cohort are provided in Additional files 3 and 4. 
Tissue microarray (TMA) construction: See details of TMA construction in Additional file 5. 
Where possible, the TMA cores were obtained from the leading edge of the tumour, 
thought to be where interactions between ligands in the ECM and the cancer cells were 
more likely to have functional significance [11]. 
Candidate biomarkers: The candidate molecules selected for this investigation were: 
IGFBP-5, VN, fibronectin (FN), αv integrin, β1 integrin, total-akt/protein kinase B 1 (Total-
AKT1), P-AKT (Ser473), extracellular signal-related kinase-1 and extracellular signal-
related kinase-2 (ERK1/2), phosphorylated-extracellular signal-related kinase-1 and 
extracellular signal-related kinase-2 (P-ERK1/2) (Thr202/Thr204), SHARP-2 and SFN. 
Oestrogen receptor (ER), progesterone receptor (PR) and HER2 were also selected for 
investigation. 
Immunohistochemistry (IHC): The candidate markers were detected using commercially 
documented antibodies based upon prior independent validation for immunohistological 
applications in FFPE sections. Refer to Additional file 6 and Additional file 7 for specific 
details on the antibodies and IHC optimisation protocols, respectively. 
Distiller: A secure, web based, flexible information management system: The virtual TMA 
slide files created using the NanoZoomer 2.0 series (Hamamatsu®, Hamamatsu City, 
Shizuoka Pref., Japan) digital slide scanner and scanning software NDP.scan 2.0 series 
(Hamamatsu®) were uploaded into Distiller (SlidePath Ltd Digital Pathology Solutions, 
Santry, Dublin, Ireland) for image analysis. Distiller was used to facilitate the integration of 
clinical records, research data, digital TMA slides and different data types into a 
hierarchical database (see Additional file 8 for information). 
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Scoring immunohistochemical immunoreactivity: The digital TMA images were examined 
and scored by trained anatomical pathology (AP) registrars without prior knowledge of the 
patient’s clinical data (i.e. ‘blind’) within the Distiller framework. If there were no 
pathologists available to score the TMAs, they were scored by Helen C Plant. Qualitative 
differences in the immunoreactivity of the proteins within the cytoplasm, nucleus and 
membrane of the cells were determined for each TMA core containing either normal breast 
epithelial ducts (normal), primary breast carcinoma (primary) or metastatic breast 
carcinoma (LN met). Qualitative differences in staining of the stromal cells and ECM 
adjacent to normal, primary and LN met tissue were also recorded. Protein 
immunoreactivity was evaluated semiquantitatively using five scoring methods. These 
included: presence of protein immunoreactivity; intensity of protein immunoreactivity; 
percentage of cells with protein immunoreactivity; percentage class and quickscore (Q 
score) scoring method [12]. Details on these scoring methods and data consolidation 
strategies are listed in Additional file 9. 
Statistical data analysis: PASW Statistics 18 version 18.0.2 (SPSS, IBM Corporation, 
Chicago, Illinois, USA) was used to evaluate statistical confidence of the data. The choice 
of test of association for the five scoring methods of protein immunoreactivity depended on 
the measurement scale of the scoring method. Presence is a binary outcome 
(present/absent) hence Pearson’s χ2 test of independence was used. For the ordinal 
scaled intensity, a Kruskal-Wallis test was employed to determine if any of the groups 
demonstrated differences. No protected rank-based non-parametric test exists for the 
post-hoc evaluation of pair-wise differences. Instead, the Mann-Whitney U test was used 
to evaluate between-groups differences with inflation of family-wise type I error being 
controlled using Bonferroni corrections. Finally, the remaining three measures of protein 
immunoreactivity, percentage, percentage class and Q score were all treated as 
quantitative outcomes and one-way Analysis of Variance (ANOVA) followed by Tukey’s 
HSDs for post-hoc testing was used to detect differences. As no rank-based non-
parametric method exists to test for effect modification (i.e. interactions), interactions were 
probed by running the (one-way) Kruskal-Wallis tests for each strata of a potential effect 
modifier. For all tests, a significance level (α) of 0.05 was used, with the exception of 
where the Mann- Whitney U was used to test for post-hoc differences, where αFW = α/k = 
0.05/6 = 0.008 was used (k = 6 represents the number of pairwise comparisons). 
 
Results 
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The capability of the ECM and IGF system proteins to regulate cell function, and 
consequently tumorigenesis, is highly influenced by their spatial arrangement within and 
around the cell. It was observed that proteins required for IGF- and ECM-induced 
signalling events are differentially expressed between subcellular and extracellular 
localisations and that the interpretation of the protein immunoreactivity data is influenced 
by the scoring method applied. The results described below will only refer to the results 
obtained for the Q score scoring method [12]. The Q score values (x), including the 
standard deviation (SD) and sample numbers (n) for each protein across the tissue types 
and cellular localisation are outlined in Table 1. 
 
Changes in ECM proteins: The most obvious differences in the immunoreactive 
distribution between normal breast, primary and metastatic cancer tissue samples was 
observed in proteins located in the extracellular space surrounding normal breast ducts 
and primary and metastatic tumours. These findings are intriguing given that the 
processes occurring during normal breast development are tightly regulated by the ECM 
and that the ability of the ECM to provide homeostatic regulation is disrupted during the 
development and progression of breast cancer. It was observed that the immunoreactivity 
of key ECM molecules, IGF regulators and integrins decreased with tumour development 
and/or progression. Significant differences in the immunoreactivity of stromal VN (p < 
0.001), IGFBP-5 (p < 0.001) and β1 integrin (p< 0.001) within the tissue types examined 
were detected (Figure 1 A, 1 C and 2 Ai, respectively). Stromal IGFBP-5 and VN 
immunoreactivity in the metastatic cancer tissues was found to be significantly less than 
stromal IGFBP-5 and VN immunoreactivity in the normal breast tissues (p < 0.001 and p < 
0.001, respectively) and primary cancer tissues (p < 0.01 and p < 0.001, respectively) 
(Figure 1 C and 1A, respectively). Additionally, stromal VN immunoreactivity was greater 
within normal breast tissue as compared to the immunoreactivity detected in primary 
cancer tissues (p < 0.001) (Figure 1 A). Despite not reaching statistical significance (p = 
0.054), comparable trends were observed for stromal αv integrin staining with increasing 
invasiveness of the tissue types examined (Figure 1 B). 
 
In contrast, the β1  integrin immunoreactivity detected in the stroma of metastatic cancer 
tissue was significantly higher than the β1  integrin immunoreactivity detected in the 
stroma in the normal breast (p < 0.001) and primary cancer (p < 0.001) tissue samples 
(Figure 2 Ai). In the primary cancer tissues, stromal reactivity of the β1 integrin was 
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significantly greater than within the normal breast tissues (p < 0.001) (Figure 2 Ai). No 
statistically significant differences in FN reactivity between the various tissue types were 
examined (p = 0.094) (Figure 2 Bi). These findings suggest that VN, IGFBP-5 and αv 
integrin reactivity in the stroma decreased while stromal β1 integrin immunoreactivity 
increased with tumour progression. Figure 2 Bi reveals trends, albeit not statistically 
significant, which suggest that the stromal localisation of FN differs to that of the other 
ECM proteins analysed. 
Tumour leading edge: Given these findings, we next investigated whether the distribution 
of β1 integrin and FN immunoreactivity within the stroma could be functionally associated 
with cancer invasion. FN immunoreactivity was observed throughout the stroma 
immediately adjacent and distal to the leading edges of each tumour (Figure 2 Bii - v). 
There was also a higher presence of FN immunoreactivity both inside tumour cells at the 
leading edges and in the stroma directly surrounding the leading edges (Figure 2 Bii - v). 
In particular, greater membrane and cytoplasmic FN was associated with tumour cells at 
the leading edge and in close proximity to the leading edge, in contrast to the cells within 
the middle of the tumour. Paralleling the distribution of FN, β1 integrin immunoreactivity 
was detected throughout the stroma immediately surrounding and distant to the leading 
edges of the tumours (Figure 2 Aii - ix). There were many instances where the β1 integrin 
was also detected both inside tumour cells at the leading edges and within the stroma of 
the leading edges of tumours (Figure 2 Aii - ix). Again, greater membrane β1 integrin 
immunoreactivity was observed in tumour cells at the leading edge and in close proximity 
to the leading edge, compared to the main bulk of the tumour. However, there were no 
obvious differences between the cytoplasmic expression of β1 integrin in cells at the 
leading edge of tumours and those in the centre of the tumours. 
 
SFN in stroma: Significant differences were evident in the immunoreactivity of SFN in the 
stroma of the tissue types examined (p < 0.001) (Figure 3). In particular, SFN 
immunoreactivity scores within the stroma of normal breast tissue were significantly lower 
than the SFN immunoreactivity scores within stroma of primary (p < 0.05) and metastatic 
cancer tissues (p < 0.001). In addition, this finding suggests that SFN immunoreactivity 
increases in the stroma with tumour development and progression. 
 
Intracellular movement of cell signalling proteins: The occupation of IGF-IR and integrin 
molecules results in the recruitment of adapter proteins to the cell membrane and the 
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formation of multiprotein complexes and facilitates the phosphorylation and activation of 
signalling cascades including AKT and MAPK [13]. The phosphorylation of AKT and MAPK 
impacts the cellular localisation, specificity and consequently the protein targets of these 
signalling molecules [14, 15]. In light of this, the immunoreactivity of Total- and 
Phosphorylated- AKT and ERK1/2 within the cytoplasm and nucleus of cells from normal 
breast, primary and metastatic cancers were investigated to determine their role in the 
downstream signalling events during the development and progression of breast cancer. 
The intracellular localisation of SHARP-2 and SFN species uniquely regulated by the IGF-
I:IGFBP:VN complex [10], were also investigated. 
 
Significant differences in nuclear localisation of P-AKT, ERK1/2 and SHARP-2 reactivity (p 
< 0.01, p < 0.05 and p < 0.001, respectively) were detected between the normal breast, 
primary cancer and metastatic cancer tissues examined (Figure 4 C, D and 5 A). More 
specifically, nuclear P-AKT, ERK1/2 and SHARP-2 immunoreactivity within metastatic 
cancer tissues was lower than that observed within normal breast tissues (p < 0.05, p < 
0.05 and p < 0.01, respectively) (Figure 4 C, D and 5 A). There was also less nuclear 
SHARP-2 immunoreactivity within metastatic breast tissue than within primary cancer 
tissues (p < 0.01). Thus, the nuclear localisation of P-AKT, ERK1/2 and SHARP-2 
decreased with tumour development and/or progression. In contrast, Figures 4 and 5 
reveal trends, albeit not statistically significant, which suggest that the cytoplasmic 
localisation of Total- AKT1, P-AKT and SHARP-2 may increase with tumour development 
and/or progression. Additionally, in many of the primary cancer and metastatic (data not 
shown) tissues in this study there was more nuclear immunoreactivity for SHARP-2 at the 
periphery of the tumour than was evident in the centre of the tumour (Figure 5 B). 
 
We further observed that differences in nuclear and cytoplasmic SFN reactivity (p <0.05 
and p < 0.001, respectively) between the normal breast, primary cancer and metastatic 
cancer tissues were significant (Figure 4 A). In particular, nuclear and cytoplasmic SFN 
within normal breast tissue was lower than the amount of nuclear and cytoplasmic SFN 
within primary cancer (p < 0.05 and p < 0.001, respectively) and metastatic cancer tissues 
(p < 0.01 and p < 0.001, respectively). There were no significant differences in nuclear and 
cytoplasmic immunoreactivity of SFN between primary and metastatic tumours. 
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Internalisation of ECM proteins: Our data also provides evidence that ECM molecules are 
internalised during breast cancer development and metastasis. Statistically significant 
differences in cytoplasmic (p < 0.05) VN immunoreactivity was observed between the 
specific tissue types examined in this study (Figure 6). In particular, lower cytoplasmic VN 
immunoreactivity was observed in normal breast tissues than cytoplasmic VN 
immunoreactivity within metastatic cancer tissues (p < 0.05) (Figure 6). As such, our data 
indicates that VN redistributes to the cytoplasm with tumour progression. 
 
Discussion 
In this study a change in the immunoreactivity of key ECM molecules, IGF regulators and 
integrins was observed with breast tumour progression. These observations suggest that 
the ECM surrounding normal breast ductal structures is remodelled during tumour 
development and progression. The ECM protein FN and the cell surface β1 integrin (the 
FN-binding receptor) were found to be highly expressed along the leading edge of many 
primary tumours in the present study. Interestingly, FN is implicated in epithelial-to-
mesenchymal transition (EMT) [16] and both the β1 integrin and FN are required in the 
formation of lamellipodia, filopodia and invadopodia [17, 18]; potentially supporting their 
role in ECM remodelling and subsequent tumour cell invasion [19]. Indeed, the β1  integrin 
has been reported to be more highly expressed in primary tumours with LN metastases 
[20] and with poor survival outcomes [21]. This fits in well with our findings that suggest an 
increase in β1 integrin immunoreactivity with increasing invasiveness. Various proteases, 
including matrix metalloproteinases (MMPs) have been implicated in ECM remodelling 
events that allow cancer cells to migrate [22]. It has been shown that the expression, 
activity and/or internalisation of MMPs is regulated by integrin-ECM interactions in 
endothelial cells [23]. Integrins, such as the αvβ3 integrin, cooperate with MMPs to 
regulate breast cancer cell migration [24]. Interestingly, IGF- I:VN:IGFBP-5-stimulated 
breast cell migration, which requires the IGF-IR and VN- binding integrins [9], can regulate 
the gene expression of proteases such as MMP13, MMP7, ADAMTS5, CPM and protease 
inhibitors such as SERPINE1 and TRP1 ([10] and supplementary data from [10]). 
 
The data we report here has also provided evidence that ECM molecules and their 
associated membrane-bound receptors, the integrins, are internalised during breast 
cancer development and metastasis. Step-wise increases in cytoplasmic and concomitant 
decreases in stromal immunoreactivity of VN and the αv integrin (data not shown) were 
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evident between normal breast, primary and metastatic cancer tissues. As described 
previously, VN can be internalised by integrin receptor- mediated endocytosis and 
degraded within the lysosomes [25]. There is also evidence indicating that the VN-binding 
αv integrin can be recycled to the cell membrane through intracellular signals [26]. This 
decrease in the stromal VN and the concomitant increase in the cytoplasmic VN with 
breast cancer progression suggests a potential re-shuffling or trafficking of VN from the 
tumour stroma to the tumour cell cytoplasm with increasing invasiveness of the tumour-
type. 
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Given the importance of the phosphoinositol 3-kinase (PI3K) and mitogen-activated protein 
kinase (MAPK) signalling pathways in IGF-I:IGFBP:VN-stimulated migration of breast 
cancer cells in vitro [9], and in IGF-I-stimulated ECM re- modelling [27] and EMT events 
[27, 28], protein intermediates within these pathways were also investigated. Decreases in 
the nuclear immunoreactivity and increases in the cytoplasmic immunoreactivity in breast 
cancer tissues were observed in this study. 
We propose a number of explanations for these findings: namely, the preferential 
activation of substrates in the cytoplasm (of cancer cells) rather than in the nucleus; 
enzyme-mediated dephosphorylation; and protein internalisation. Both AKT1 and MAPK 
contain transportation signals which potentially enable their movement throughout a cell 
[29, 30]. Defects in these transportation signals during cancer tumorigenesis might explain 
the results of this study. Ras homolog gene family member B (RhoB), which has been 
shown to influence the trafficking of Total- and P- AKT in primary human endothelial cells 
[31], may impede the import of Total- and P- AKT into or promote the export of Total- and 
P-AKT from the nucleus of breast cancer cells; resulting in an accumulation of AKT in 
cytoplasmic compartments. 
Phospho-kinases, such as MAPK, are not necessarily required to enter the nucleus to 
regulate gene transcription. In fact, the activation of transcription factors in the cytoplasm 
and their movement into the nucleus for transcriptional control [32] has been reported. The 
duration and strength of AKT and MAPK signalling in breast epithelial cells can also be 
regulated in different subcellular locations through the action of various cytoplasmic and 
nuclear phosphatases [33]. Indeed, phosphatase and tensin homolog (PTEN), a dual lipid 
and protein phosphatase, can be localised to the cell nucleus [34], and if functional, may 
therefore de-phosphorylate nuclear AKT. As discussed by Tzivion et al. [35], the ability of a 
protein to interact with modifying enzymes, such as phosphatases, can be influenced by 
the presence of 14-3-3 proteins. 
Intriguingly, 14-3-3 proteins, including SFN, have been shown to regulate the cytoplasmic 
sequestration and nuclear retention of cell cycle regulators, many of which are associated 
with and downstream of the PI3K pathway [36]. It is highly likely that 14-3-3 proteins, such 
as SFN, may regulate similar sequestration events for P-AKT itself. It was intriguing to find 
that the increases in the nuclear and cytoplasmic immunoreactivity of SFN with breast 
cancer development and progression as measured in this study correlated with the 
increase in mRNA expression of SFN reported by Kashyap et al. [10]. In contrast, other 
studies have reported the downregulation of SFN expression in breast cancers [37, 38]. 
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However, Neal et al. [39] showed that overexpression of SFN reduces the overall and 
disease- free survival of breast cancer patients and is able to predict which patients have a 
high susceptibility to develop metastasis. Interestingly, it has been proposed that 14-3-3 
proteins are important regulators of external environmental signals by eliciting positive and 
negative effects on the IGF signalling pathway. The ability of 14-3-3 proteins to bind 
phospho-serine enables them to bind to the IGF-IR [40]. Yang et al. [41] have shown that 
SFN can also bind to and inhibit the activity of AKT, preventing AKT-mediated cellular 
events. They also indicate that SFN expression was inversely correlated with P-AKT 
expression [41]; this supports our findings of decreases in nuclear P-AKT and increases in 
intracellular SFN with tumour development and progression. 
We were intrigued to find that SFN was differentially expressed within the stroma 
surrounding the tissue types examined. Although previous reports of SFN expression have 
been limited to the cytoplasm of malignant breast cells [38], in vitro evidence indicates that 
SFN can be excreted by keratinocytes into the pericellular matrix [42]. Extracellular SFN is 
a key regulator of MMP function and ECM degradation. Studies have shown that following 
the release of SFN from keratinocytes, MMP-1 mRNA [43] and MMP-1 protein synthesis 
[44] increases in dermal fibroblasts. Increases in mRNA encoding the β1 integrin have also 
been observed in dermal fibroblasts after treatment with SFN, or in co-cultures with 
keratinocytes known to release SFN [45]. Under the same conditions the expression of 
many ECM molecules, including collagen type I, FN and α1 integrin, decreases. This 
collective evidence suggests that it is highly likely that SFN may mediate similar functions 
regulating the degradation of ECM during epithelial tumour development and progression. 
 
We also observed step-wise increases in cytoplasmic and decreases in nuclear 
immunoreactivity of SHARP-2 between the normal breast, primary and metastatic cancer 
tissues; this may be explained by nucleocytoplasmic shuttling events. SHARP- 2 is known 
to possess a functional nuclear export sequence (NES) and two nuclear localisation signal 
(NLS) motifs [46]. A study by Ivanova et al. [46] suggests that SHARP-2 may be required 
in the nucleus of proliferating and differentiating cells to regulate gene transcription after 
stimulation by an external factor. They also propose that SHARP-2 may be sequestered in 
the cytoplasm following cell differentiation. 
In summary, we have reported changes in the temporal and spatial distribution of IGF- and 
ECM-induced signalling proteins that occur during breast cancer metastasis. Specifically, 
our findings provide further evidence that the ECM surrounding normal breast ductal 
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structures is remodelled during tumour development and progression, and that FN and the 
β1 integrin are important for the formation of invadopodia and for the epithelial-to-
mesenchymal transition events (shown by others [47]) to support dissemination. Analysis 
of stromal and subcellular SFN immunoreactivity suggested a causal relationship in ECM 
remodelling events and the localisation and activity of proteins important for IGF- and 
ECM-induced signalling cascades. It also appears plausible that in cells at the leading 
edge of tumours, SHARP-2 moves into the nucleus to repress the transcription of genes 
associated with the hypoxic response. 
Collectively the above data highlight the possibility that there are broader biological 
implications of, and explanations for, the differential immunoreactivity of IGF signalling and 
ECM components in the stroma and/or in subcellular locations within normal breast, 
primary breast cancer and metastatic breast cancers. This is highly pertinent given that 
protein function and protein localisation are closely correlated. Studies have also shown 
that accounting for protein localisation can be an essential requirement to identifying 
correlations with other proteins when applying the IHC technique [48]. To date, very few 
studies have evaluated the prognostic significance of differential protein distribution within 
diagnostic breast cancer tissue samples. 
Early studies do, however, suggest that specific locations of specific proteins associated 
with the IGF signalling cascade and the ECM have shown potential as markers for patient 
prognosis and therapeutic response [49, 50]. We argue that to date the potential of many 
molecular species to serve as markers of patient prognosis and therapeutic response is 
being missed by overlooking their subcellular/extracellular distribution. In view of this, we 
recommend a more complete analysis of protein localisation within diagnostic pathology 
and improvements to reporting and inclusion of protein localisation in routine pathological 
examinations as our data indicates the potential role of protein localisation in the 
progression of disease. 
 
Conclusions 
 
There is potential that the cellular and ECM events outlined herein could be manipulated to 
provide clinical benefits and improve the clinical management of breast cancer. In 
particular, may lead to early prognostic and predictive identification of patients with poor 
survival outcomes. However, prior to this occurring, the prognostic significance of the 
cellular and ECM events reported in this study must be identified. 
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Figure captions 
 
Figure 1: Stromal immunoreactivity of VN, αv integrin and IGFBP-5. Immunoreactivity of 
VN (A), αv integrin (B) and IGFBP-5 (C) within the stroma surrounding normal breast 
(Normal), primary cancer (Primary) and LN metastasis tissues is depicted. 
Immunoreactivity was evaluated semiquantitatively using the Q score (intensity x 
percentage class, score: 0 – 18) method. Intensity of reactivity (score: 0 = negative; 1 = 
weak; 2 = moderate, and; 3 = strong). Percentage class (score: 1 = 0-4%; 2 = 5-19%; 3 = 
20-39%; 4 = 40-59%; 5 = 60-79%; 6 = 80-100%). 
Data are displayed using the mean ± 2 standard error (SE). Asterisks (** and ***) indicate 
statistically significant differences at p<0.01 and <0.001, respectively. Scale bar = 30 μm. 
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Figure 2: Stromal immunoreactivity of β1 integrin and FN. Immunoreactivity of β1 integrin 
is depicted in A. i) Immunoreactivity of β1 integrin within the stroma surrounding normal 
breast (Normal), primary cancer (Primary) and LN metastasis tissues. ii – ix) 
Representative images demonstrating distribution of β1 integrin in the stroma and/or cells 
at the leading edges of Normal (ii and iii), ductal carcinoma in situ (iv and v), Primary(vi 
and vii) and LN metastasis (viii and ix) tissues. 
Immunoreactivity of FN is depicted in B. i) Immunoreactivity of FN within the stroma 
surrounding Normal, Primary and LN metastasis tissues. ii – v) Representative images 
demonstrating distribution of β1  integrin immunoreactivity in the stroma and/or cells at the 
leading edges of Primary (ii and iii) and LN metastasis (iv and v) tissues. Immunoreactivity 
was evaluated semiquantitatively using the Q score (intensity x percentage class, score: 0 
– 18) method. Intensity of reactivity (score: 0 = negative; 1 = weak; 2 = moderate, and; 3 = 
strong). Percentage class (score: 1 = 0- 4%; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-
79%; 6 = 80-100%). Data are displayed using the mean ± 2 standard error (SE). Asterisks 
(* and ***) indicate statistically significant differences at p<0.05 and <0.001, respectively. 
The scale bar for Aii, Aiv, Avi, Aviii, Bii and Biv is 200 μm and for Aiii, Av, Avii, Aix, Biii and 
Bv is 30 μm. 
 
Figure 3: Stromal immunoreactivity of SFN. Immunoreactivity of SFN within the stroma 
surrounding normal breast (Normal), primary cancer (Primary) and LN metastasis tissues 
is depicted. Immunoreactivity was evaluated semiquantitatively using the Q score 
(intensity x percentage class, score: 0 – 18) method. Intensity of reactivity (score: 0 = 
negative; 1 = weak; 2 = moderate, and; 3 = strong). Percentage class (score: 1 = 0-4%; 2 
= 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-79%; 6 = 80-100%). Data are displayed using 
the mean ± 2 standard error (SE). Asterisks (* and ***) indicate statistically significant 
differences at p<0.05 and <0.001, respectively. Scale bar = 30 μm. 
 
Figure 4: Tissue localisation. Differential localisation of SFN (A), Total-AKT1 (B), P-AKT 
(C), ERK1/2 (D) and P-ERK1/2 (E) is depicted. Nuclear (open circles) and cytoplasmic 
(closed triangles) immunoreactivity within normal breast (Normal), primary cancer 
(Primary) and LN metastasis tissues was determined. Antibody immunoreactivity was 
evaluated semiquantitatively using the Q score (intensity x percentage class, score: 0 – 
18) method. Intensity of reactivity (score: 0 = negative; 1= weak; 2 = moderate, and; 3 = 
209 
 
strong). Percentage class (score: 1 = 0-4%; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-
79%; 6 = 80-100%). Data are displayed using the mean ± 2 standard error (SE). Asterisks 
(*, ** and ***) indicate statistically significant differences at p<0.05, <0.01 and <0.001, 
respectively. 
 
Figure 5: SHARP-2 immunoreactivity. Immunoreactivity of SHARP-2 within the nucleus 
(open circles) and cytoplasm (closed triangles) of cells from normal breast (Normal), 
primary cancer (Primary) and LN metastasis tissues is depicted in A. Immunoreactivity 
was evaluated semiquantitatively using the Q score (intensity x percentage class, score: 0 
– 18) method. Intensity of reactivity (score: 0 = negative; 1= weak; 2 = moderate, and; 3 = 
strong). Percentage class (score: 1 = 0-4%; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-
79%; 6 = 80-100%). Data are displayed using the mean ± 2 standard error (SE). Asterisks 
(**) indicate statistically significant differences at p<0.01. Representative images 
demonstrating the distribution of SHARP-2 in the cancer cells of primary cancer tissue 
samples is depicted in B (i-iv). The scale bar for A, Bii and Biv is 30 μm and for Bi and Biii 
is 200 μm. 
 
Figure 6: VN immunoreactivity. Immunoreactivity of VN within the cell cytoplasm (open 
circles) and the stroma (closed triangles) of normal breast (Normal), primary cancer 
(Primary) and LN metastasis tissues is depicted. Immunoreactivity was evaluated 
semiquantitatively using the Q score (intensity x percentage class, score: 0– 18) method. 
Intensity of reactivity (score: 0 = negative; 1 = weak; 2 = moderate, and; 3 = strong). 
Percentage class (score: 1 = 0-4%; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-79%; 6 = 
80-100%). Data are displayed using the mean ± 2 standard error (SE). Asterisks (* and 
***) indicate statistically significant differences at p<0.05 and <0.001, respectively. Scale 
bar = 30 μm. 
 
Tables 
 
Table 1: Q-score values for immunoreactivity of each protein across tissue types and 
cellular localisation 
 
Protein 
Cellular 
localisation 
Type of breast 
tissue 
x SD n 
αv integrin Stroma Normal 1.29 1.25 7 
αv integrin Stroma Primary 0.34 0.83 32 
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αv integrin Stroma LN Metastasis 0.16 0.69 19 
VN Cytoplasm Normal 0.78 1.65 23 
VN Cytoplasm Primary 2.21 2.69 86 
VN Cytoplasm LN Metastasis 2.44 2.38 68 
VN Stroma Normal 7.13 3.75 23 
VN Stroma Primary 2.84 2.73 86 
VN Stroma LN Metastasis 0.84 2.13 68 
IGFBP-5 Stroma Normal 13.00 4.52 6 
IGFBP-5 Stroma Primary 8.49 4.18 35 
IGFBP-5 Stroma LN Metastasis 4.17 4.57 23 
β1 integrin Stroma Normal 4.79 3.62 14 
β1 integrin Stroma Primary 9.71 4.36 84 
β1 integrin Stroma LN Metastasis 14.47 4.21 68 
FN Stroma Normal 4.08 1.88 12 
FN Stroma Primary 8.66 4.42 85 
FN Stroma LN Metastasis 7.36 5.05 67 
SFN Nucleus Normal 1.07 1.73 14 
SFN Nucleus Primary 3.40 3.27 82 
SFN Nucleus LN Metastasis 3.88 2.84 68 
SFN Cytoplasm Normal 2.93 2.30 14 
SFN Cytoplasm Primary 5.43 2.20 82 
SFN Cytoplasm LN Metastasis 5.75 1.93 68 
SFN Stroma Normal 0.00 0.00 14 
SFN Stroma Primary 0.78 0.89 82 
SFN Stroma LN Metastasis 1.12 0.95 68 
SHARP-2 Nucleus Normal 8.29 3.71 14 
SHARP-2 Nucleus Primary 5.76 5.61 86 
SHARP-2 Nucleus LN Metastasis 3.33 3.69 70 
SHARP-2 Cytoplasm Normal 6.36 4.50 14 
SHARP-2 Cytoplasm Primary 7.90 3.72 86 
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x = Q score; SD = standard deviation; n = sample size; LN = lymph node; P = phosphorylated; T = Total 
 
 
Additional material information 
 
Additional file 1 Format: PDF 
Title and description: The actual number of normal breast epithelial duct, ductal carcinoma 
in situ (DCIS), primary breast carcinoma and/or lymph node (LN) metastasis tissues (n). 
 
Additional file 2 Format: PDF 
Title and description: The expected number of normal breast epithelial duct, ductal 
carcinoma in situ (DCIS), primary breast carcinoma and/or lymph node (LN) metastasis 
tissues (n). 
 
Additional file 3 Format: PDF 
Title and description: The clinico-pathological and survival data for patients. 
 
 
SHARP-2 Cytoplasm LN Metastasis 8.80 4.57 70 
T-AKT1 Nucleus Normal 5.69 6.91 13 
T-AKT1 Nucleus Primary 3.39 4.08 85 
T-AKT1 Nucleus LN Metastasis 2.59 2.93 68 
T-AKT1 Cytoplasm Normal 7.54 3.76 13 
T-AKT1 Cytoplasm Primary 8.78 3.95 85 
T-AKT1 Cytoplasm LN Metastasis 9.37 3.67 68 
P-AKT Nucleus Normal 13.50 6.21 16 
P-AKT Nucleus Primary 11.51 5.52 86 
P-AKT Nucleus LN Metastasis 9.32 5.44 68 
P-AKT Cytoplasm Normal 1.19 1.47 16 
P-AKT Cytoplasm Primary 2.19 2.12 86 
P-AKT Cytoplasm LN Metastasis 2.00 2.32 68 
ERK1/2 Nucleus Normal 2.67 2.92 15 
ERK1/2 Nucleus Primary 1.77 2.76 84 
ERK1/2 Nucleus LN Metastasis 0.75 1.82 67 
ERK1/2 Cytoplasm Normal 3.73 3.31 15 
ERK1/2 Cytoplasm Primary 6.18 4.20 84 
ERK1/2 Cytoplasm LN Metastasis 5.42 3.73 67 
P-ERK1/2 Nucleus Normal 1.83 2.79 12 
P-ERK1/2 Nucleus Primary 1.89 3.47 76 
P-ERK1/2 Nucleus LN Metastasis 0.41 1.03 64 
P-ERK1/2 Cytoplasm Normal 9.67 4.46 12 
P-ERK1/2 Cytoplasm Primary 10.08 4.27 76 
P-ERK1/2 Cytoplasm LN Metastasis 9.78 3.95 64 
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Additional file 4 Format: PDF 
Title and description: The oestrogen receptor (ER), progesterone receptor (PR) and 
human epidermal growth factor receptor-2 (HER2) status data for patients. 
 
Additional file 5 Format: PDF 
Title and description: Working with tissue microarray (TMA). Describes the steps involved 
in TMA construction, template editing, design computation, punch area selection and heat 
cycling. 
 
Additional file 6 Format: PDF 
Title and description: Product and supplier details for the antibodies used in this study. 
 
Additional file 7 Format: PDF 
Title and description: Immunohistochemistry (IHC) conditions for antigen detection. 
 
Additional file 8 Format: PDF 
Title and description: Detailed information on steps involved in using the program Distiller. 
 
Additional file 9 Format: PDF 
Title and description: Semiquantitative evaluation of immunohistochemical 
immunoreactivity and consolidation of TMA scoring.
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Supplementary Table 1A. The actual number of normal breast epithelial duct, ductal 
carcinoma in situ (DCIS), primary breast carcinoma and/or lymph node (LN) metastasis 
tissues (n). N/A: not applicable. 
TMA Name Normal breast 
TMA cores (n) 
DCIS 
TMA cores (n) 
Primary cancer 
TMA cores (n) 
LN metastasis 
TMA cores (n) 
αv integrin 7 3 32 19 
β1 integrin 14 5 84 68 
CLDN1 12 7 82 66 
ER 16 2 73 64 
ERK1/2 15 2 84 67 
FN 12 5 85 67 
HER2 14 1 85 71 
IGF-IR 14 1 34 21 
IGF-IIR 16 6 79 69 
IGFBP-5 6 N/A 35 23 
P-AKT 16 2 86 68 
P-ERK1/2 12 5 76 64 
PR 11 4 71 65 
SFN 14 6 82 68 
SHARP-2 14 6 86 70 
Total-AKT1 13 4 85 68 
VN 23 2 86 68 
 
Supplementary Table 1B. The expected number of normal breast epithelial duct, ductal 
carcinoma in situ (DCIS), primary breast carcinoma and/or lymph node (LN) metastasis 
tissues (n). 
TMA name Normal breast  
TMA cores (n) 
DCIS  
TMA cores (n) 
Primary cancer  
TMA cores (n) 
LN metastasis  
TMA cores (n) 
αv integrin 12 0 38 25 
β1 integrin 24 10 88 76 
CLDN1 24 10 88 76 
ER 24 10 88 76 
ERK1/2 24 10 88 76 
FN 24 10 88 76 
HER2 24 10 88 76 
IGF-IR 12 0 38 25 
IGF-IIR 24 10 88 76 
IGFBP-5 12 0 38 25 
P-AKT 24 10 88 76 
P-ERK1/2 24 10 88 76 
PR 24 10 88 76 
SFN 24 10 88 76 
SHARP-2 24 10 88 76 
Total-AKT1 24 10 88 76 
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VN 24 10 88 76 
 
Supplementary Table 2A. The clinico-pathological and survival data for patients. Total 
number (N) and proportion (%) of patients are indicated. 
 Patients (N) Proportion (%) 
Age (years)   
 < 40 4 4 
 40 - <50 27 30 
 50 - <60 25 27 
 60 - <70 22 24 
 70 - <80 11 12 
 80 - <90 1 1 
 Missing 1 1 
 Mean (± standard deviation) 55.91 (± 10.92)  
Tumour type (No/Yes/Missing)   
 Ductal 6/79/6 7/87/7 
 Lobular 74/11/6 81/12/7 
 Tubular 83/2/6 91/2/7 
 Pleomorphic 83/2/6 91/2/7 
 Trabecular 84/1/6 92/1/7 
 Atypical medullary 58/1/32 64/1/35 
Overall tumour grade   
 1 3 3 
 2 15 16 
 3 59 65 
 Missing 14 15 
Tumour size (mm) (maximum)   
 ≤ 10 4 4 
 11-20 21 23 
 21-30 26 29 
 31-40 15 16 
 41-50 7 8 
 51-60 3 3 
 61-70 3 3 
 71-80 1 1 
 81-90 1 1 
 91-100 1 1 
 Missing 25 27 
Positive lymph nodes   
 1-3 42 46 
 4-9 20 22 
 ≥10 27 30 
 Missing 2 2 
Lymph node ratio   
 ≤ 0.25 46 51 
 >0.25, ≤ 0.75 32 35 
 ≥ 0.75 10 11 
 Missing 3 3 
Survival status   
 Deceased (due to disease) 44 48 
 Censored 0 0 
 Deceased (due to other causes) 1 1 
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 Patients (N) Proportion (%) 
 Lost at date of death follow-up 36 40 
 Lost prior to follow-up 10 11 
 
Supplementary Table 2B. The oestrogen receptor (ER), progesterone receptor (PR) and 
human epidermal growth factor receptor-2 (HER2) status data for patients. Total number 
(N) and proportion (%) of patients are indicated. 
 Patients (N) Proportion (%) 
ER percentage   
 0 21 23 
 1 - 10 3 3 
 11 -20 3 3 
 21 - 30 1 1 
 31 - 40 0 0 
 41 - 50 1 1 
 51 - 60 3 3 
 61 - 70 1 1 
 71 - 80 6 7 
 81 - 90 11 12 
 91 - 100 23 25 
 Missing 18 20 
ER intensity   
 0 21 23 
 1 12 13 
 2 19 21 
 3 21 23 
 Missing 18 20 
PR percentage   
 0 29 32 
 1 - 10 10 11 
 11 -20 4 4 
 21 - 30 4 4 
 31 - 40 1 1 
 41 - 50 6 7 
 51 - 60 2 2 
 61 - 70 5 5 
 71 - 80 3 3 
 81 - 90 2 2 
 91 - 100 5 5 
 Missing 20 22 
PR intensity   
 0 29 32 
 1 14 15 
 2 18 20 
 3 10 11 
 Missing 20 22 
HER2 percentage   
 0 46 51 
 1 - 10 7 8 
 11 -20 4 4 
 21 - 30 4 4 
 31 - 40 1 1 
 41 - 50 1 1 
 51 - 60 2 2 
 61 - 70 2 2 
 71 - 80 4 4 
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 Patients (N) Proportion (%) 
 81 - 90 6 7 
 91 - 100 7 8 
 Missing 7 8 
HER2 intensity   
 0 46 51 
 1 16 18 
 2 7 8 
 3 15 16 
 Missing 7 7 
 
Supplementary Materials and Methods 1. 
 
Tissue microarray (TMA) construction: The Galileo TMA (CK3000) Tissue Microarrayer 
(Integrated Systems Engineering S.r.l., Milan, Italy) using the IseTMA software program 
(©BioRep, Milan, Italy) and the Beecher (ATA-27) Automated Tissue Arrayer (Beecher 
Instruments, Inc., Sun Prairie, Wisconsin, USA) were used to construct the TMAs. The 
methodologies listed below are those performed whilst using the Galileo TMA Tissue 
Microarrayer with the IseTMA software program. TMAs constructed by the MaCHR 
Laboratory using the Beecher (ATA-27) Automated Tissue Arrayer were utilised for this 
study following the manufacturer’s instructions. 
 
Tissue microarray (TMA) template editing: TMA templates were created following the TMA 
grid design phase. The dimensions of the blank, recipient FFPE blocks were determined 
and recorded in the IseTMA software program. The dimensions of the resulting TMAs 
were dependent on the physical dimensions of the recipient FFPE blocks. The geometry of 
the array (which included the required number of rows and columns) was defined using the 
following criteria: the block dimensions; X and Y margins; the needle diameter (0.6 mm); 
the number of spots; and the spacing (or the X and Y pitch) between the spots. For this 
study, 0.6 mm diameter cores were selected. Rows and columns of spacing gaps were 
included to further aid in the orientation of the TMA. Finally, the ES 111 Optiscan™ Upright 
Microscope Stage (Prior Scientific Inc., Rockland, Massachusetts, USA) was calibrated to 
ensure the precise positioning of the TMA within the centre of the recipient FFPE blocks. 
The template file created was saved as a .csv file. 
 
Tissue microarray (TMA) design computation: Within the IseTMA software program, the 
TMA template file was opened and an appropriate TMA construction sequence selected. 
The FFPE blocks included in the study (commonly known as donor FFPE blocks) were 
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associated with one spot or multiple spots within the TMA. To achieve this, the patient AP 
codes were ‘linked’ to the individual TMA cores within the TMA template. Colour codes 
were used to identify TMA cores associated with normal breast epithelial ducts, DCIS, 
primary breast carcinoma and LN metastasis. The number of replicas of the created TMA 
was defined. To create duplicate TMAs, two recipient FFPE block copies were selected 
and codes created for each copy. Each of the operations listed above were performed 
remotely from the arrayer. The design file created was saved as a .csv file. 
 
Tissue microarray (TMA) construction: Initially, the arrayer was calibrated and the TMA 
template and design files were opened. The TMA needle was calibrated to ensure the 
precise positioning of the paraffin blocks under the needles in the operation conditions. A 
high resolution ProgRes® C10plus camera (JENOPTIK Optical Systems GmbH, Jena, 
Germany) was utilised for TMA needle calibration. The two recipient FFPE blocks were 
inserted into the Upright stage. The IseTMA software program provided an operating 
flowchart to assist in TMA construction. 
 
Tissue microarray (TMA) core punch area selection - Donor block and haematoxylin and 
eosin (H&E) slide alignment: Where possible, the cores were obtained from the leading 
edge of the tumour, thought to be where interactions between ligands in the ECM and the 
cancer cells were more likely to occur (Giovannucci 1999; Gladson et al. 1991; Tomasini-
Johansson et al. 1994). This was achieved by inserting the donor FFPE blocks into the 
upright stage and choosing the donor TMA spot positions. To localise the sample, an H&E-
stained tissue section was placed on top of its corresponding FFPE block. Following this, 
the pre-marked H&E slide was manually aligned with the donor block with reference to the 
monitor. This allowed for the accurate identification of the tumour edge. Once aligned, a 
number of donor spot positions, along the tumour’s edge (if applicable), were selected 
using a joystick. All of the punch positions for the donor FFPE block were saved at the 
same time. Subsequently, holes were prepared in the recipient FFPE blocks and sample 
cores were transferred from the donor FFPE block and inserted into the corresponding 
holes in the recipient FFPE blocks. This process was performed manually and repeated for 
each of the donor FFPE blocks. 
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Tissue microarray (TMA) heat cycling: To stabilise and prevent the loss of TMA cores 
during sectioning and immunohistochemistry (IHC) procedures a thin layer of wax was 
applied to the surface of all of the created TMAs containing the sample cores from the 
donor FFPE blocks. This was followed by a heat cycling step which involved heating the 
TMAs in a conventional laboratory oven at 30 degrees Celsius (°C) for short increments of 
time over 24 hours. 
Supplementary Table 3. Product and supplier details for the antibodies used in this study. 
IgG: immunoglobulin G; mAb: monoclonal antibody; pAb: polyclonal antibody, and; N/A: not 
applicable.  
Antibody target Supplier Supplier details 
Product 
Number 
Isotype Source Clone 
IGF-IRβ 
Santa Cruz 
Biotechnology® 
Santa Cruz, California, 
USA 
sc-713 
IgG Rabbit 
pAb 
C-20 
IGF-IIR 
Santa Cruz 
Biotechnology® 
Santa Cruz, California, 
USA 
sc-25462 
IgG Rabbit 
pAb 
H-300 
IGFBP-5 R&D Systems® Gymea, NSW, Australia MAB875 
IgG2b Mouse 
mAb 
164503 
VN Epitomics® 
Burlingame, California, 
USA 
1730-1 
IgG Rabbit 
mAb 
EP781Y 
FN Novocastra 
North Ryde, NSW, 
Australia 
NCL-FIB 
IgG1 Mouse 
mAb 
568 
αv integrin Calbiochem
® 
Gibbstown, New Jersey, 
USA 
407286 
IgG1 Mouse 
mAb 
272-
17E6 
β1 integrin Abcam
® 
Cambridge, 
Massachusetts, USA 
ab3167 
IgG1 Mouse 
mAb 
4B7R 
Total-AKT1 
Cell Signalling 
Technology® 
Danvers, Massachusetts, 
USA 
2967 
IgG1 Mouse 
mAb 
2H10 
P-AKT (Ser473) 
Cell Signalling 
Technology® 
Danvers, Massachusetts, 
USA 
4051L 
IgG2b Mouse 
mAb 
587F11 
ERK1/2 
Cell Signalling 
Technology® 
Danvers, Massachusetts, 
USA 
4695 
IgG Rabbit 
pAb 
137F5 
P-ERK1/2 
(Thr202/Thr204) 
Cell Signalling 
Technology® 
Danvers, Massachusetts, 
USA 
9106 
IgG1 Mouse 
mAb 
E10 
CLDN-1 Invitrogen™ Mulgrave, VIC, Australia 18-7362 
IgG Rabbit 
pAb 
N/A 
SFN Abcam® 
Cambridge, 
Massachusetts, USA 
110-02810 
IgG1 Mouse 
mAb 
3C3 
SHARP-2 Sigma-Aldrich® Castle Hill, NSW, Australia S8443 
IgG Rabbit 
pAb 
N/A 
ER 
Ventana Medical 
Systems® 
Tucson, Arizona, USA 790-4325 
IgG Rabbit 
mAb 
SP1 
PR 
Ventana Medical 
Systems® 
Tucson, Arizona, USA 790-4296 
IgG Rabbit 
mAb 
1E2 
HER2 
Ventana Medical 
Systems® 
Tucson, Arizona, USA 790-2991 
IgG Rabbit 
mAb 
4B5 
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Supplementary Table 4. Immunohistochemistry (IHC) conditions for antigen detection. Incubation times are provided in minutes (mins). 
°C: degrees Celsius. 
Antigen Clone 
Blocking non-specific background Antigen Retreival Antigen detection 
Antigen 
probe 
HRP-
Polymer 
Peroxidase 
Chromogen 
conditions 
Endogenous 
peroxidase 
Protein Solution Conditions System Incubation time Dilution Diluent 
αv integrin 272-17E6 5 min 10 min Diva 40 min at 99°C with 30 min cooling MACH 4™ 30 min 1:50 Da Vinci 10 min 10 min 1 min 
β1 integrin 4B7R Performed onboard Protease 1 10 min ultraView™ 32 min 1:2500 Da Vinci Performed onboard 
CLDN-1 N/A Performed onboard Borg 4 min at 125°C with 30 min cooling ultraView™ 32 min 1:100 Da Vinci Performed onboard 
ER SP1 Performed onboard iView™ 30 min Pre-diluted antibody Performed onboard 
ERK1/2 137F5 5 min 10 min Not Performed MACH 3™ 60 min 1:150 Da Vinci 15 min 15 min 5 min 
FN 568 Performed onboard Reveal 4 min at 125°C with 30 min cooling ultraView™ 32 min 1:200 Da Vinci Performed onboard 
HER2 4B5 Performed onboard iView™ 32 min Pre-diluted antibody Performed onboard 
IGF-IRβ C-20 5 min 10 min Diva 4 min at 125°C with 30 min cooling MACH 4™ 60 min 1:50 Da Vinci 15 min 15 min 1 min 
IGF-IIR H-300 Performed onboard Borg 4 min at 125°C with 30 min cooling ultraView™ 32 min 1:50 Da Vinci Performed onboard 
IGFBP-5 164503 5 min 10 min Not Performed MACH 4™ 30 min 1:75 Da Vinci 10 min 10 min 1 min 
P-AKT 587F11 Performed onboard Reveal 4 min at 125°C with 30 min cooling ultraView™ 32 min 1:50 Da Vinci Performed onboard 
P-ERK1/2 E10 5 min 10 min Not Performed MACH 4™ 60 min 1:100 Da Vinci 10 min 15 min 2 min 
PR 1E2 Performed onboard iView™ 30 min Pre-diluted antibody Performed onboard 
SFN 3C3 Not Performed Not Performed Reveal 4 min at 125°C with 30 min cooling MACH 4™ 60 min 1:50 Da Vinci 10 min 15 min 5 min 
SHARP-2 N/A Performed onboard Reveal 4 min at 125°C with 30 min cooling ultraView™ 32 min 1:1600 Da Vinci Performed onboard 
Total-AKT1 2H10 Performed onboard Reveal 4 min at 125°C with 30 min cooling ultraView™ 32 min 1:50 Da Vinci Performed onboard 
VN EP781Y 5 min 10 min Not Performed MACH 3™ 30 min 1:50 Da Vinci 10 min 10 min 4 min 
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Supplementary Materials and Methods 2.  
Distiller, a secure, web based, flexible information management system, was used to 
facilitate the integration of clinical records, research data, digital TMA slides and different 
data types into a easy-to-use hierarchical database. Authorised consent was obtained 
from G.D.F. to gain access to the Brisbane Database of all PAH breast cancer patients. 
 
Data uploading and browsing 
The ‘Browse’ tab was used to upload ‘general’ patient data files (including patient, biopsy, 
survival and treatment data) into Distiller. The ‘Browse’ tab was also used to find all of the 
demographic, biopsy, treatment, follow-up, TMA and full face biomarker information, as 
well as the images and scoring information for all TMA cores for each patient. 
Uploading general patient data files: Click on the ‘Browse’ tab > Click on the ‘Files’ tab > 
Upload required files. 
Browsing patient information: Click on the ‘Browse’ tab > Click on the ‘Data’ tab > Upload 
required files. 
 
Management of high throughput design and analysis of TMA data 
The ‘OpTMA’ and ‘Administration’ tabs were used to manage high throughput design and 
analysis of TMA data within the Distiller framework. This included uploading, creating, 
editing, approving and/or managing the TMA spot groups, TMA scoring forms, TMA maps 
and TMA slides. 
Creating TMA spot group: Click on the “Administration” Tab > Click on the “DB Admin Tab” 
Tab > Click on the “Create new data group” icon > Type “TMA” into the “Group type name” 
section > Select “TMA” in the “Parent” tab > Select “TMA Spots” in the “Table type” tab > 
Click on the “Submit” icon. 
Editing TMA spot group attributes: The mandatory TMA spot group default attributes 
include: Spot ID; Treatment name; Slide ID; Row Number; Column Number and Block 
reference. Click on the “Administration” Tab > Click on the “DB Admin Tab” Tab > Click on 
the TMA spot group of interest > Select “Choice” in the “Type” tab > Add 
treatment/stains/biomarker types. 
Creating TMA scoring form group: Click on the “Administration” Tab > Click on the “DB 
Admin Tab” Tab > Click on the “Create new data group” icon > Type “TMA Score Antibody 
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name” into the “Group type name” section > Select “TMA” in the “Parent” tab > Select 
“TMA scoring form” in the “Table type” tab > Click on the “Submit” icon. 
Editing TMA scoring form attributes: Editing the name of a TMA scoring group: Click on the 
“Administration” Tab > Click on the “DB Admin Tab” Tab > Scroll down to the TMA scoring 
group of interest > Click on the 2nd column icon “Edit name” > Click on the 2nd icon 
“Save” button to save changes. Modifying and adding questions for a TMA scoring group: 
Click on the “Administration” Tab > Click on the “DB Admin Tab” Tab > Scroll down to the 
TMA scoring group of interest > Click on the 1st column icon “view attributes/questions’ > 
Click on the “create new question” icon > Type in the question name > Select if question is 
unique > Select whether the question is mandatory > Select an appropriate data type > 
Click on the “Submit” icon. Creating choice attributes: Click on the “Administration” Tab > 
Click on the “DB Admin Tab” Tab > Scroll down to the TMA scoring group of interest > 
Click on the 1st column icon “view attributes/questions’ > Click on the “Choice” button for 
the attribute of interest > Select the type of “Choice frequency” > Click on “Create new 
choice type” > Type in the Choice name > Type in the Choice value > Click on the 
“Edit/Save” icon > Choose the position of the choices. 
Managing TMA maps: Uploading TMA maps: Click on the “OpTMA” Tab > Click on the 
“TMA Maps” Tab > Click on the “Upload” Tab to upload a TMA map from a Microsoft 
Excel™ spreadsheet. Editing and approving TMA maps: Click on the “OpTMA” Tab > Click 
on the “TMA Maps” Tab > Click on the TMA map of interest > Modify/Approve where 
necessary. 
Managing TMA slides: Uploading TMA slides for dearraying: Click on the “OpTMA” Tab > 
Click on the “TMA slides” Tab > Click on tabs for the folders of interest which are located 
on the QUT server > Click on the link for the slide of interest > Select the TMA of interest 
in the “block reference” section > Click “TMA” for the “Group type name” section > Select 
the antibody of interest in the “treatment” section (add a new treatment name) > Select 
“x40” in the “Magnification” section > Select the relevant orientation (N.B. There were 8 
possible scanning orientations for the slides) > Click on the “Submit” icon for dearraying to 
occur. Approving TMA slides: Click on the “OpTMA” Tab > Click on the “TMA slides” Tab > 
Expand the “Block Reference” tab to view the slides associated with this block reference > 
Click on the link under “Dearray comments” to view the predicted grid > Edit/Fix the 
predicted grid structures. Editing the predicted grid structures: The annotations (red 
circles) mark each core. Moving the cursor over each of the annotations will display the 
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row and column number of each core. To reposition, redraw, delete the annotation, and/or 
draw new cores, right-click on the annotation. The row & column numbers are assigned 
manually or automatically, by regridding the slide. Regridding attempts to reconstruct the 
TMA grid using all the annotations including any newly created cores. To save the edited 
grid structure press “F5”. Recheck the dearray comments and modify if necessary. If the 
predicted grid matches the map, the slide can be approved. Once the grid structure has 
been approved, an appropriate scoring form and list of scorers are selected. 
Scoring the IHC stained TMAs: Scoring TMAs: Click on the “OpTMA” Tab > Click on the 
“score TMAs” Tab > Click on the appropriate block reference tab > Click on the “Score” tab 
to score the TMA slide > Fill in the blank spaces or highlight the appropriate choice in the 
TMA scoring sheet that appears of the screen > Click “Next” to proceed to the next TMA 
core (if necessary, click on “Previous” to go back to the previous TMA core) > Click the 
“F5” button to save the scoring data. Reviewing and Re-scoring TMAs: Click on the 
“OpTMA” Tab > Click on the “score TMAs” Tab > Click on the appropriate block reference 
tab > Click on the “Review” tab to review the scored TMA slide or to re-score the TMA 
slide > Review or re-score the TMA cores by filling in the spaces provided or highlighting 
the appropriate choice in the TMA scoring sheet that appears of the screen > Click “Next” 
to proceed to the next TMA core (if necessary, click on “Previous” to go back to the 
previous TMA core) > Click the “F5” button to save changes. 
 
Creating searches to extract patient, biopsy, survival, treatment and TMA scoring data 
The ‘Search’ tab was used to create and re-run old searches to extract the patient, biopsy, 
survival, treatment and TMA scoring data of interest from Distiller. Only the attributes or 
data of interest were selected to be displayed in the search results to limit the extent of 
data extracted for analysis. 
Creating searches: Click on the “Search” Tab > Click on the “Constraints” Tab > Scroll 
down to the Data groups section > Click on the “Patient Information” Tab > Type “P” into 
the “Patient ID” section > Click on the “TMA score ….” Tab for the protein of interest > Tick 
the appropriate protein in “Biomarker” section > Click on the “TMA” Tab > Scroll down to 
the “Block Reference” section > Type in the appropriate TMA design name of interest > 
Click on the “Output” tab > Scroll down to the Data groups section > Click on the “Patient 
Information” tab > Select “Select all” to highlight all fields in this data group > Click on the 
“Biopsy Information” tab > Select “Select all” to highlight all fields in this data group > Click 
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on the “Pathology” tab > Select “Select all” to highlight all fields in this data group > Click 
on the “Treatment Information” tab > Select “Select all” to highlight all fields in this data 
group > Click on the “Follow up Information” tab > Select “Select all” to highlight all fields in 
this data group > Click on the “TMA” tab > Select “Select all” to highlight all fields in this 
data group > Click on the “TMA score ….” tab for the protein of interest > Select “Select 
all” to highlight all fields in this data group > Click on the “Results” Tab to view the search 
results > Click “Download” to download the search results in a CSV format > Click “Save 
Search Parameters” to save the search created. 
 
Supplementary Materials and Methods 3.  
Semiquantitative evaluation of immunohistochemical immunoreactivity and consolidation 
of TMA scoring 
A biomarker scoring form was displayed alongside each TMA core for completion. A 
standard biomarker scoring form was used for all protein targets investigated. Modified 
biomarker scoring forms were used for ER, PR and HER2 (scoring forms not shown). 
Specific questions were compulsory. Completion of the scoring forms for each TMA core 
was required prior to moving on to the next TMA core. Briefly, the TMA scorers were 
asked to record: their initials; the type of tumour present (provided as a choice between 
normal breast tissue, DCIS, primary tumour, metastatic tumour tissue from the LN and 
missing tissue); the amount of tumour present (as a percentage); the quality of the IHC 
staining (provided as a choice between yes or no); the percentage of cells with 
cytoplasmic staining (as a percentage); the intensity of the cytoplasmic staining (provided 
as a choice between 0, 1, 2 or 3); the percentage of cells with nuclear staining (as a 
percentage); the intensity of the nuclear staining (provided as a choice between 0, 1, 2 or 
3); the percentage of cells with membrane staining (as a percentage); the intensity of the 
membrane staining (provided as a choice between 0, 1, 2 or 3); the percentage of stromal 
staining (as a percentage); and the intensity of the stromal staining (provided as a choice 
between 0, 1, 2 or 3). 
 
IHC TMA scoring data was evaluated semiquantitatively using five scoring methods. 
Details on these scoring methods are listed below. 
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Presence: Data were expressed as the proportion of the total number of samples in which 
protein immunoreactivity was present within the normal breast tissue, DCIS, primary 
tumour or LN metastatic tumour tissue. 
 
Intensity: Data were expressed as a score between 0 and 3, corresponding to the 
presence of negative, weak, intermediate, or strong staining, respectively, within the 
normal breast tissue, DCIS, primary tumour or LN metastatic tumour tissue. 
 
Percentage: Data were expressed as the proportion of cells or stroma staining positively 
within the normal breast tissue, DCIS, primary tumour or LN metastatic tumour tissue. 
 
Percentage class: Data were expressed as scores between 1 and 6 (1 = 0-4%; 2 = 5-19%; 
3 = 20-39%; 4 = 40-59%; 5 = 60-79%, and; 6 = 80-100%), corresponding to the proportion 
of cells staining positively within the normal breast tissue, DCIS, primary tumour or LN 
metastatic tumour tissue. 
 
Quickscore (Q) score: Data were expressed as scores between 0 and 18 using a 
multiplicative Q system (Detre et al., 1995b); this involves determining the staining 
intensity in addition to the proportion of cellular staining. The multiplicative method allows 
for a “no staining” category. 
 
The exported .csv files from Distiller were converted to Microsoft Excel™ spreadsheets for 
each search performed. Each of the spreadsheet rows corresponded to a TMA core (with 
a specific tissue type). The variables recorded in the scoring form and the clinico-
pathological data was represented as separate columns in the spreadsheet. Duplicate 
rows represented TMA cores originating from the same tissue sample and placed in 
duplicate TMAs. If there were multiple TMA scorers then duplication rows would be 
present for each TMA scorer. If a specific tissue sample was placed into more than one set 
of duplicate TMAs than duplicate rows would be present for each set of duplicate TMAs. 
These duplicate rows were consolidated into one row (if possible); the method of 
consolidation for each variable is listed below. For statistical data analysis purposes, the 
consolidated rows (each with a specific tissue type) were split up into four rows, each 
representing the results for a specific cellular localisation. 
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Initials: If there was only one TMA scorer, the initials of that scorer was recorded in the 
consolidated row. If there was more than one person who scored the TMA slide for IHC 
immunoreactivity for a particular protein than the initials of all of the TMA scorers were 
recorded in the consolidated row. 
 
The type of tumour present: If the type of tissue was the same across the duplicate rows 
then that type of tissue was recorded in the consolidated row. If there was more than one 
type of tissue then a consolidated row was required for each tissue type represented. 
 
The amount of tumour present: A mean percentage was calculated based on the 
proportion of the tissue in the TMA core which contained primary or LN metastatic tumour 
tissue. 
 
The quality of the immunohistochemical immunoreactivity: TMA cores with unsatisfactory 
staining were discarded, while TMA cores with satisfactory immunoreactivity were 
consolidated (by the methods mentioned in this section). 
 
The percentage of cells with nuclear, cytoplasmic and membrane immunoreactivity: A 
mean percentage was calculated based on the proportion of cells, within the normal breast 
tissue, DCIS, primary tumour or LN metastatic tumour tissue which contained nuclear, 
cytoplasmic and/or membrane immunoreactivity. 
 
The percentage of stromal immunoreactivity: A mean percentage was calculated based on 
the proportion of the stromal cells and ECM (which will be referred to as the ‘stroma’), 
surrounding the normal breast tissue, DCIS, primary tumour or LN metastatic tumour 
tissue which contained immunoreactivity. 
 
The intensity of the nuclear, cytoplasmic, membrane and stromal immunoreactivity: The 
highest intensity score was recorded in the consolidated row.  
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Chapter 9 
STIRZAKER, C., ZOTENKO, E., SONG, J. Z., QU, W., NAIR, S. S., 
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DOBROVIC, A., AVERY-KIEJDA, K. A., PETERS, K. M., FRENCH, 
J. D., STEIN, S., KORBIE, D. J., TRAU, M., FORBES, J. F., 
SCOTT, R. J., BROWN, M. A., FRANCIS, G. D. & CLARK, S. J. 
2015. Methylome sequencing in triple-negative breast cancer 
reveals distinct methylation clusters with prognostic value. Nat 
Commun, 6, 5899.  
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9.1.1. Introduction 
Epigenetic alterations were evaluated in a breast cancer cohort to determine if these 
biomarkers could be used to discriminate normal breast tissue from breast carcinoma; 
lymph node positive from lymph node negative patients and to identify different prognostic 
groups. 
9.1.2. Results 
 
Abstract 
Epigenetic alterations in the cancer methylome are common in breast cancer and provide 
novel options for tumour stratification. Here we perform whole genome methylation capture 
sequencing on small amounts of DNA isolated from formalin- fixed, paraffin-embedded 
tissue from triple negative breast cancer (TNBC) and matched normal samples. We 
identify differentially methylated regions (DMRs) enriched in promoters associated with 
transcription factors binding sites and DNA hypersensitive sites. Importantly, we stratify 
TNBCs into three distinct methylation clusters associated with better or worse prognosis 
and identify 17 DMRs that show a strong association with overall survival, including DMRs 
located in the Wilms Tumour 1 (WT1) gene, bidirectional-promoter and anti-sense WT1-
AS. Our data reveals coordinated hypermethylation can occur in ER-ve disease and that 
characterising the epigenetic framework provides a potential signature to stratify TNBCs. 
Together our findings demonstrate the feasibility of profiling the cancer methylome with 
limited archival tissue to identify regulatory regions associated with cancer. 
  
Introduction 
 
Triple negative breast cancers (TNBCs) comprise a heterogeneous group of cancers with 
varying prognoses, presenting a challenge for effective clinical management. TNBC is 
clinically defined by the absence of estrogen (ER) and progesterone receptor (PR) 
expression, and neither overexpression nor amplification of human epidermal growth 
factor receptor 2 (HER2) 1, 2. TNBC represents approximately 15-20% of all newly 
diagnosed breast cancer cases and is generally associated with high risk of disease 
recurrence and shorter overall survival compared to non-TNBC3. Broadly, TNBC patients 
can be categorized into two distinct groups; those that succumb to their disease within 3-5 
years regardless of treatment, and those that remain disease free to the extent that their 
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overall survival exceeds that of non-TNBC patients (i.e. approximately >8 to 10 years post-
diagnosis)4, 5. Currently, methods by which TNBC patients are stratified into high- and low-
risk subgroups remain limited to staging by clinicopathological factors such as tumour size, 
level of invasiveness and lymph node infiltration. However, unlike other breast cancer 
subtypes, TNBC outcome is less closely related to stage6. Thus, there is a clear need to 
identify a robust method by which TNBC patients can be stratified by prognosis, to enable 
more informed disease management. 
 
Current efforts to stratify early breast cancer prognosis have primarily focused on multi-
gene expression signatures and all have received varying degrees of acceptance 
(reviewed in 7). In addition to multi-gene expression assays, DNA methylation signatures 
are being assessed as potential molecular biomarkers of cancer8. A number of studies 
have documented aberrant methylation events in breast carcinogenesis and identified 
specific DNA methylation biomarkers that have significant diagnostic and prognostic 
potential9, 10, 11, 12. Several studies have also identified DNA methylation signatures that 
can distinguish between breast cancer subtype13, 14, 15, 16, and others that may be 
predictive of treatment response17, 18, 19. 
 
Despite growing interest in the prognostic significance of DNA methylation in breast 
cancer, there have been no studies specifically investigating the DNA methylation profile of 
human TNBC and its association with disease outcome. Here we carry out genome-wide   
DNA   methylation   profiling   of   formalin-fixed paraffin-embedded (FFPE) triple-negative 
clinical DNA samples, using affinity capture of methylated DNA with recombinant methyl-
CpG binding domain of MBD2 protein, followed by next generation sequencing (MBDCap-
Seq)20, 21. This high-resolution technique allows for genome wide methylation analysis of 
CpG rich DNA22, 23. Using MBDCap-Seq, we identify regional methylation profiles specific 
to TNBC, which we validate using methylation data extracted from TCGA breast cancer 
cohort13. Importantly, we also report the first potential prognostic methylation signature of 
survival, specific for TNBC that now warrants further study in larger cohorts. 
  
Results 
Genome Coverage of MBDCap-Seq 
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To delineate regions assayable with MBDCap-Seq we first profiled fully methylated (CpG 
methyltransferase SssI treated blood sample) DNA. Computational analysis of SssI 
MBDCap-Seq revealed that MBDCap-Seq can robustly assess the methylation status of 
230,655 regions spanning a total of 116Mbp, comprising 5,012,633 CpG dinucleotides, or 
approximately 18% of the total number of CpG sites in the human genome (see Methods; 
Supplementary Fig. 1A). The assayed CpG sites span 91% of all CpG islands; 84% CpG 
island shores; 72% RefSeq promoters; 38% introns and 31% exons. We next compared 
coverage of MBDCap-Seq with the Illumina HumanMethylation450K (HM450K) array 
(Supplementary Fig. 1B) and found that MBDCap-Seq interrogates an additional 
4,740,327 CpG sites as compared to the high-density HM450K array. 
 
A major advantage of the MBDCap-Seq method is the ability to interrogate regional blocks 
of hypermethylation, that is methylation spanning consecutive CpG sites, which commonly 
occurs in cancer. We compared regional MBDCap-Seq coverage to coverage of HM450K 
arrays (Supplementary Fig. 1A) and found that while MBDCap-Seq and HM450K arrays 
have similar regional coverage of CpG islands (91%  vs.  81%) and RefSeq promoters 
(71% vs.  83%), MBDCap-Seq regional coverage of shores (77% vs. 28%), enhancers 
(12% vs. 2%) and insulators (11% vs. 1%) is much greater, highlighting the potential 
advantage of MBDCap-Seq in screening novel functional regions of the cancer 
methylome. 
 
To determine if MBDCap-Seq can also provide accurate methylation analysis from FFPET 
DNA, we compared DNA methylation profiles from DNA isolated from fresh frozen (FF) 
and FFPET of matching tumour and lymph node samples. We show that MBDCap-Seq 
from FFPET provides equivalent methylation to FF DNA (Pearson Correlation Coefficient 
of 0.95 and 0.86, respectively) (Supplementary Fig. 2A) and that MBDCap-Seq and 
HM450K array performed on the same FFPET tumour and lymph node DNA show high 
concordance (0.79 & 0.77 respectively) (Supplementary Fig. 2B-D). We also show that 
there are regions uniquely covered by MBDCap-Seq for example at enhancers and 
insulator elements (Supplementary Fig. 2E and F). 
  
Identification and validation of differentially methylated regions in TNBCs 
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To identify differentially methylated regions (DMRs) in TNBCs we first profiled FFPET DNA 
using MBDCap-Seq from a discovery cohort of 19 Grade 3 TNBCs tumour and 6 matched 
normal samples (Supplementary Table 1) and analysed the  data with a novel 
computational pipeline for comparative statistical analysis of MBDCap-Seq samples (see 
Methods; Supplementary Fig. 3). We identified 822 hypermethylated and 43 
hypomethylated statistically significant DMRs (FDR <0.05), harboring 64,005 and 623 CpG 
sites respectively, compared to matched normal samples (see Fig. 1A & 1B; 
Supplementary Data 1) and validated sample specific differential methylation using 
Sequenom DNA methylation analysis (Supplementary Fig. 4). Next, we determined the 
genomic location of the DMRs and found that CpG islands, CpG island shores and 
promoters are significantly over-represented (hyper- geometric test; p-value < 0.0001) in 
the 822 hypermethylated regions and under- represented in the 43 regions of 
hypomethylation (Fig. 1C; See Methods). Notably, ChromHMM annotated HMEC 
promoters24 and polycomb repressed regions were also significantly enriched (hyper-
geometric test; p-value << 0.001) for gain of methylation in the breast cancer samples. 
Finally, we validated example DMRs in an independent cohort of 31 TNBCs and 15 normal 
breast samples and a panel of cell lines (Supplementary Table 2). We performed 
Sequenom methylation analysis on 5  of the 822 hypermethylated regions spanning the 
CpG island promoters of NPY, FERD3L, HMX2, SATB2 and C9orf125 (Supplementary 
Figure 5). The levels of methylation detected in the normal samples were uniformly low, 
whereas the 5 DMRs showed striking hypermethylation in the TNBCs (Fig. 1D), and 24 
breast cancer cell lines (Fig. 1E). 
 
Functional Characterization of Genes with Promoter Hypermethylation 
To predict the potential functional significance of the 822 DMRs identified in the TNBC, we 
first determined which regions overlapped with promoters and genes and found that our 
DMRs were associated with 513 RefSeq promoters, which corresponded to 308 genes 
(Supplementary Data 2). We used the DAVID functional annotation tool25 to annotate this 
set of genes. Visualization of statistically significantly (FDR < 0.05) over-represented gene 
sets revealed two largely non- overlapping groups of genes26(See Methods; 
Supplementary Fig 6; Supplementary Table 3). One group is annotated with keywords 
“DNA-BINDING", "TRANSCRIPTION", "TRANSCRIPTION REGULATION", 
"HOMEOBOX", "DEVELOPMENTAL   PROTEIN",  and   "DIFFERENTIATIONS" and 
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contains around 100 genes, mostly transcription factors, such as BARHL2, DLX6, OTX2, 
RUNX1T1 and TAC1. The second group is annotated with keywords "SIGNAL", "CELL   
MEMBRANE",   "TRANSDUCER",   "GLYCOPROTEIN",   "G-PROTEIN COUPLED 
RECEPTOR" and contains genes involved in signaling pathways such as 
ADRB3, GHSR, NPY and ROBO3. 
 
To determine if promoter hypermethylation was potentially involved in gene silencing we 
examined TCGA expression data for the 308 genes affected by promoter hypermethylation 
(see Methods for analysis of TCGA expression data for TNBC samples; 89 tumour and 8 
matched normal samples). We found that genes with promoter hypermethylation are 
enriched in down-regulated genes (71 out of 245  genes for which expression data is 
available are down-regulated; hyper-geometric  test; FC 1.73; p-value << 0.001) and are 
depleted in up-regulated genes (28 out of 245 genes are up-regulated; hyper-geometric 
test; FC 0.53; p-value << 0.001) (Fig. 1F). 
 
To identify potential driver events we overlapped the 308 hypermethylated genes with 
genes recurrently mutated in breast cancer in TCGA13 (Fig. 1G). We found that out  of 308 
genes with promoter methylation, 51 are mutated (hyper-geometric test; FC of 1.92; p-
value << 0.001) and 12 (C9orf125, COL14A1, ENPP2, ERG2, PLD5,  ROBO3,  RUNX1T1,  
SEMA5A,  TBX18,  TSHZ3,  ZBTB16,  and  ZNF208)  are   both mutated and down-
regulated. Of these, both ROBO3 and SEMA5A are part of the axon guidance pathway 
recently implicated in tumour initiation and progression27, 28. Interestingly, promoter 
hypermethylation affects, in total, seven members of the axon guidance pathway (CRMP1, 
GDNF, GFRA1, MYL9, ROBO1, ROBO3 and SEMA5A) with four members (GFRA1, 
MYL9, ROBO3, and SEMA5A) being down-regulated. 
 
Differentially Methylated Regions Specific to TNBCs 
We next asked if any of the 822 DMRs were also found in ER-ve or ER+ve breast cancer. 
We used TCGA breast cancer methylation cohort, which comprises HM450K data for 354 
ER+ve and 105 ER-ve breast tumours (73 of which are TNBCs) and 83 normal breast 
samples (see Methods for analysis of TCGA methylation data). Of the 822 DMRs regions 
identified in the MBDCap-seq methylation discovery set, 770 DMRs are interrogated by a 
total of 4,987 HM450K probes from the TCGA data set. We found that while the majority of 
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these probes are not methylated in breast normal tissue they were hypermethylated to 
various degrees in both ER+ve and ER-ve breast cancers (Fig. 2A). Both ER+ve and ER-
ve subtypes also contained samples with minimal  methylation  across  all  probes,  as  
well  as  those  that  displayed extensive methylation more representative of a CpG island 
methylator phenotype (CIMP)29. 
 
Next we asked if any of the DMRs were TNBC specific. Out of 4,987 HM450K probes, we 
found that 5% (282/4,987) were significantly hypermethylated in TNBCs (t-test; mean diff. 
methylation>10%; p-value<0.05) compared to the ER+ve tumours and the rest of the ER-
ve tumours. Using methylation values of 282 TNBC-specific probes, we are able to classify 
tumour samples in the TCGA HM450K cohort into TNBCs and non-TNBCs with sensitivity 
of 0.72 sensitivity, specificity of 0.94 and AUC 0f 0.90 (Fig. 2B). From the 282 TNBC 
specific probes we identified 36 TNBC specific regions (harbouring at least 3 or more 450K 
TNBC-specific probes) that primarily overlap promoters and/or gene bodies 
(Supplementary Table 4; Supplementary Fig. 7). The regions predominantly overlap genes 
encoding zinc fingers and transcription factors and intergenic regions that are commonly 
marked by polycomb in HMECs. An example of two such TNBC specific regions, are 
located in the promoters of genes encoding zinc finger proteins ZNF154 and ZNF671 on 
chromosome19 (Fig. 2C). Both promoters have low methylation levels in normal breast 
and increased levels of methylation in TNBC samples as compared to ER+ve cancer. The 
distribution of expression values mirrors the methylation status, with normal samples 
showing the highest levels of expression and TNBC tumours showing the lowest levels of 
expression (Fig. 2D), suggesting silencing by methylation of both ZNF154 and ZNF671 in 
TNBC tumours. 
 
DNA methylation profile can stratify TNBC 
To identify DMRs that potentially stratify TNBCs we used unsupervised cluster analysis on 
methylation of the 4,987 HM450K probes and identified three distinct groups of TNBC 
tumours from the TCGA data sets (Fig 3A; see Methods). Survival analysis revealed that 
the largely hypomethylated cluster (blue cluster) was associated with better prognosis as 
compared to the other two more highly methylated clusters (orange  and  red  clusters)  
(Fig.  3B). In particular, the medium methylated cluster (orange cluster) comprises 
samples with the worst prognosis (Cox proportional hazards model; HR 8.64; p-value 
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0.005) as compared to the good prognosis TNBC cluster (blue cluster). Moreover there 
was no association between the induced clusters and survival for ER+ve or non TNBC 
samples (Supplementary Fig 8). 
 
Next, we determined to what extent regional methylation stratify TNBCs into good and bad 
prognosis groups. Survival analysis identified 190 probes that were associated with 
survival in TCGA TNBC samples (Cox proportional hazards model; p-value < 0.05) in both 
univariate and multivariate analyses (see Methods). We observed regional association (at 
least three concordantly located survival probes) for 17 regions; 14 genomic regions with 
poor survival and 3 genomic regions for good survival (Table 1; Supplementary Fig. 9). 
Each of the individual Kaplan Meier plots for individual CpG sites in each region showed 
excellent survival separation, highlighting the potential value as prognostic biomarkers 
(Fig. 3C-E; Supplementary Fig. 9). The genomic location of these regions vary with four 
regions located in a promoter (SLC6A3, C6orf174, WT1-AS and ZNF254), seven in the 
gene body only (DMRTA2, LHX8, WT1, WT1-AS, HOXB13, ECEL1, SOX2-OT) and five in 
intergenic regions (Table 1). Interestingly, with the exception of the region encoded by 
chr10: 102,409,068-102,409,766, all prognostic regions overlap DNase1 hypersensitive 
sites (ENCODE), are marked with a polycomb signature in HMEC cells and many contain 
numerous conserved transcription factor binding sites (TRANSFAC®,30) (Table. 1). 
Furthermore, we show that the average level of methylation of CpG sites in the 17 
potential prognostic regions is higher in the two poor survival groups and is lower in the 
normal and low risk groups (Supplementary Fig. 10). 
 
A striking example of regional hypermethylation across consecutive CpG probes that 
shows statistical significance as a prognostic marker of survival are the DMRs spanning 
the bidirectional promoter and gene bodies of WT1 gene and its antisense counter-part, 
WT1-AS (Fig. 3F). Wilms tumour protein (WT1) is a zinc finger transcription factor over-
expressed in several tumour types including breast (reviewed in 31). We observe an 
association between high level of methylation in chr11-11623 and chr11-1210, regions 
spanning the gene bodies of WT1 and WT1-AS respectively, and poor survival in TCGA 
TNBC cohort (Fig. 3F). Moreover, increased levels of methylation in these regions are also 
associated with increased expression of WT1 (chr11-11623) and WT1-AS (chr11-1210) in 
TNBC patients (Supplementary Fig. 11). Conversely, we observe that TNBC patients with 
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high methylation in chr11-4047, a region spanning bi-directional promoter of WT1 and 
WT1-AS, survive longer than TNBC patients with low methylation in this region. 
 
Table 1: Summary of 17 DMRs associated with overall survival in TCGA TNBC. 
 
 
 
 
 
Chr 
 
 
 
 
 
Start 
 
 
 
 
 
End 
 
 
 
 
 
RefSeq 
Location 
 
 
 
 
 
CpG 
Island 
 
 
 
 
 
CpG 
Shore 
 
 
 
 
Dnase 
Hypersensitive 
Site 
 
 
 
Conserved 
Transcription 
Factor 
Binding Sites 
(Z score 
cutoff = 2.33) 
 
 
 
 
ChromHMM 
HMEC 
Polycomb 
 
 
 
 
 
Prognostic 
Probes 
 
 
 
 
 
Gene Function/Location 
Poor Prognosis 
 
 
 
chr1 
 
 
 
50,658,646 
 
 
 
50,659,783 
 
 
 
DMRTA2* 
 
 
 
YES 
 
 
 
NO 
 
 
 
YES 
 
 
 
GRα 
 
 
 
YES 
 
 
 
3 
 
Doublesex- And Mab-3- 
Related Transcription 
Factor 
 
chr1 
 
75,368,128 
 
75,368,976 
 
LHX8* 
 
YES 
 
YES 
 
YES 
 
n/a 
 
YES 
 
3 
 
Homeobox protein Lhx8 
 
 
 
chr10 
 
 
 
102,409,068 
 
 
 
102,409,766 
   
 
YES 
 
 
 
YES 
 
 
 
NO 
 
STAT1β, NK- 
κB, CREB, 
NF-Y, CEBPα 
 
 
 
YES 
 
 
 
5 
 
Intergenic region, 
ChromHMM polycomb 
marked 
 
 
 
 
chr11 
 
 
 
 
32,404,535 
 
 
 
 
32,407,465 
 
 
 
 
WT1* 
 
 
 
 
YES 
 
 
 
 
YES 
 
 
 
 
YES 
 
EGR1, EGR2, 
EGR2, NF1, 
LMO2, RFX1, 
MIF1, CREB, 
cJUN, ATF, 
ATF2 
 
 
 
 
YES 
 
 
 
 
5 
 
 
 
Wilms Tumor protein, 
transcription factor 
 
chr11 
 
32,416,010 
 
32,417,947 
 
WT1-AS* 
 
YES 
 
YES 
 
YES 
 
n/a 
 
YES 
 
4 
 
Wilms Tumor protein, 
antisense transcipt 
 
 
 
chr13 
 
 
 
27,398,788 
 
 
 
27,401,867 
   
 
YES 
 
 
 
YES 
 
 
 
YES 
 
 
 
n/a 
 
 
 
YES 
 
 
 
4 
 
Intergenic region, 
ChromHMM polycomb 
marked 
 
chr14 
 
56,330,541 
 
56,332,135 
  
YES 
 
YES 
 
YES 
 
USF1, MAX1, 
c-MYC 
 
YES 
 
3 
 
Intergenic region, 
ChrommHMM polycomb 
 
chr17 
 
44,159,065 
 
44,159,578 
 
HOXB13* 
 
YES 
 
YES 
 
YES 
 
HSF1, HSF2 
 
YES 
 
3 
 
Homeobox gene family, 
transcription factor 
 
 
chr2 
 
 
233,058,433 
 
 
233,060,592 
 
 
ECEL1* 
 
 
YES 
 
 
YES 
 
 
YES 
 
NRSF, PAX2, 
STAT5A, 
YY1, AHR, 
GATA2, AP2 
 
 
YES 
 
 
3 
 
 
Zinc-containing typeII 
integral-membrane protein 
 
chr3 
 
182,923,564 
 
182,924,686 
 
SOX2-OT* 
 
NO 
 
NO 
 
YES 
 
n/a 
 
YES 
 
4 
 
Non-protein coding RNA 
gene. 
 
chr5 
 
1,498,811 
 
1,499,696 
 
SLC6A3
 
YES 
 
YES 
 
YES 
 
n/a 
 
YES 
 
3 
 
Neurotransmitter reporter 
 
chr6 
 
27,620,848 
 
27,621,582 
  
NO 
 
NO 
 
YES 
 
n/a 
 
NO 
 
3 
 
ChromHMM promoter 
marked, Intergenic region 
 
 
chr6 
 
 
127,881,341 
 
 
127,882,455 
 
 
C6orf174*
 
 
NO 
 
 
YES 
 
 
YES 
 
 
STAT5A, 
FOXC1 
 
 
YES 
 
 
6 
 
Chromosome 6 Open 
Reading Frame SOGA3 
protein coding region 
 
chr7 
 
121,726,837 
 
121,728,266 
  
YES 
 
YES 
 
YES 
 
CHX10 
 
YES 
 
4 
 
ChromHMM polycomb 
marked 
Good Prognosis 
 
chr11 
 
32,413,697 
 
32,415,714 
WT1/WT1- 
AS
 
YES 
 
YES 
 
YES 
E47, AP4, c- 
MYC, ARNT 
 
YES 
 
5 
Bidirectional Promoter of 
WT1/WT1-AS 
transcription factor 
 
chr19 
 
24,061,637 
 
24,062,272 
 
ZNF254*
 
NO 
 
NO 
 
YES 
 
n/a 
 
NO 
 
4 
Zinc finger 
protein,transcriptional 
regulation 
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chr22 
 
44,641,414 
 
44,642,542 
  
YES 
 
YES 
 
YES 
 
n/a 
 
YES 
 
3 
 
Intergenic region, 
ChromHMM promoter 
 
*Gene Body 
 
Promoter         
 
Discussion 
 
The prognostic stratification of TNBC patients remains one of the most significant 
challenges in breast cancer research. While current efforts have primarily focused on the 
development of multi-gene expression classifiers to inform patient outcome, here we 
demonstrate the significant prognostic potential of DNA methylation biomarkers for 
stratification of TNBCs. We performed genome-wide DNA methylation profiling on TNBC 
and identified novel regions of differential methylation, and validated regions specific for 
TNBC using TCGA methylation data as an independent cohort. Strikingly, unsupervised 
cluster analysis of DMRs stratified TNBC patients into populations of high, medium or low 
risk disease outcome. Additionally, using both univariate and multivariate Cox proportional 
hazard models, we identified 17 DMRs significantly associated with TNBC patient survival 
(p<0.05). Critically, our classifiers paralleled the biologically relevant time-dependent 
pattern of patient outcome, whereby TNBC patients are most vulnerable to disease 
associated death within the first 5 years following diagnosis; highlighting their potential use 
as a valuable prognostic application. 
 
The DNA methylation aberrations we identified in the TNBC samples follow specific 
patterns common to many cancer types32. For instance, hypermethylation events were 
localized to CpG islands and shores, while hypomethylation occurred globally across 
intragenic regions32. We observed a strong co-localization of the hypermethylated regions 
with H3K27me3 marked (polycomb repressed) regions in HMEC cells, supporting the 
finding that many polycomb-regulated genes are predisposed to aberrant methylation in 
cancer33. We identified 308 genes affected by promoter hypermethylation and functional 
analysis revealed significant enrichment of genes and transcription factors involved in 
development and differentiation, as well as DNA binding, homeobox proteins and 
transcriptional regulation. Hypermethylation of homeobox genes has been previously 
reported in breast cancer and associated with disease progression and poor patient 
prognosis15, 16, 34, 35. Genes encoding glycoproteins were also enriched in the functional 
analysis. A significant function of glycoproteins is that of directing immune response36. This 
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is particularly poignant since several gene expression modules associated with immune 
response have been used to predict TNBC patient outcome37, 38, 39, 40, 41. Many of the 
aberrant cancer promoter hypermethylation events affect genes already silenced in the 
tissue of origin and therefore considered to be passenger events that do not actively 
contribute to cancer initiation or progression42. To identify potential driver methylation 
events we highlighted genes that were both down-regulated in TNBC tumours and 
recurrently mutated in breast cancer. Twelve methylated genes were identified as both 
mutated and down-regulated, including ROBO3 and SEMA5A that are part of the axon 
guidance pathway, recently implicated in tumour initiation and progression27. In total, 
promoter hypermethylation affects seven members of the axon guidance pathway. 
Although the mechanism by which axon guidance drives cancer progression is not 
completely understood, our data supports a potential causal role for DNA methylation for 
many of these family members in TNBCs. 
 
Using an independent TNBC cohort from the TCGA data we validated 36 TNBC DMRs 
comprising 20 genes. Strikingly, 4 of the 20 genes encoded zinc finger proteins (ZNFs). 
Individual ZNFs and even some clusters of ZNF genes have been found hypermethylated 
and silenced in several tumour types43, 44, 45, 46. In addition, methylation of other ZNF genes 
have potential prognostic value in prostate and bladder cancer47, 48. Although the 
mechanisms by which aberrant ZNF expression facilitates oncogenesis are not completely 
understood, ZNFs are included in 2 independently derived, TNBC specific, multi-gene 
expression classifiers (TN45 and Buck 14)38, 39. 
 
Recent studies have identified non-TNBC as more heavily methylated compared to 
TNBC16. In our study, we found that a distinct population of both ER+ and ER-ve tumours 
are associated with extensive methylation across the DMRs, more representative of a CpG 
island methylator phenotype (CIMP)29. Interestingly, a previous report describes the 
breast-CIMP (B-CIMP) group comprised solely of ER+ve tumours16, however, our results 
show that coordinated hypermethylation can also occur in ER-ve disease. We also 
identified 3 distinct methylation clusters of TNBC tumours based on our DMRs. The largely 
hypomethylated profile was associated with better survival within the first 5 years post-
diagnosis compared to the more heavily methylated subtypes. Interestingly, the medium 
methylated cluster was associated with the worst survival. Proof of concept that 
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methylation can be used to stratify breast cancer subtypes was recently demonstrated by 
TCGA, where DNA methylation data was used to classify breast cancer into 5 distinct 
subtypes, however, each of the five methylation groups were represented by multiple 
tumour subtypes  and the relationship between methylation and prognosis was not 
explored13.  Here, we also identified 17 individual DMRs capable of stratifying TNBC 
patients into good and poor prognosis groups. Notably, these regions predominately 
overlap with DNAaseI hypersensitive regions and contain conserved transcription factor 
binding sites highlighting their potentially significant role in transcriptional regulation. Of the 
genes listed, many, including WT1, WT1-AS, DMRTA1 and HOXB13, have been 
previously identified as hypermethylated in numerous cancer subtypes including breast 
cancer49, 50, 51, 52; although associations with patient prognosis were not defined in these 
studies. 
 
Finally, three “survival” DMRs, span the bi-directional promoter and gene bodies of WT1 
gene and its anti-sense counter-part WT1-AS. Wilms tumour protein (WT1) protein is an 
extensively studied transcription factor essential for normal development of the urogenital 
system and deregulated across many cancer types31. In breast cancer high mRNA levels 
of WT1 were reported to be associated with poor patient survival53 and positive modulation 
of expression of WT1 by its antisense transcript WT1-AS54, 55. Our observed patterns of 
methylation and survival support an extensive body of evidence on the tight epigenetic 
transcriptional regulation of WT1 and its role in breast cancer prognosis. More specifically, 
high levels of methylation across regions spanning gene bodies of WT1 and WT1-AS 
genes correlates with elevated levels of expression and poor survival. Whereas, 
hypermethylation spanning the bi- directional promoter are associated with decreased 
WT1 and WT1-AS expression and better survival. 
 
Cumulatively, the work presented here highlights the prognostic potential of DNA 
methylation in the stratification of TNBC patient prognosis. We identified individual 
potential prognostic biomarkers of patient outcome as well as providing the first evidence 
to suggest that DNA methylation potentially could be used to stratify TNBC subtypes that 
are associated with distinct prognostic profiles. Both observations warrant further clinical 
investigation in larger independent cohorts as these signatures may in the future provide 
valuable tools in the management of TNBC. 
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Methods 
 
Breast cancer tissue samples 
Human tissue samples representing normal and tumour breast from fresh frozen and 
formalin fixed paraffin embedded tissue were obtained for this study. Only samples that 
were classified as triple negative Grade 3 ductal adenocarcinomas (Supplementary Table 
1) were included. The study protocol was approved by the Hunter New England Human 
Research Ethics Committee (NSW HREC Reference No: HREC/09/HNE/153), Newcastle, 
New South Wales, Australia and the Princess Alexandra Hospital Human Research Ethics 
Committee (PAH HREC)(Research Protocol: 2007/165), Brisbane, Queensland. 
 
DNA isolation from formalin-fixed paraffin embedded material 
DNA isolation from microdissected formalin fixed paraffin embedded tissue was performed 
using the Gentra Puregene Genomic DNA purification tissue kit according to the 
manufacturer’s instructions (Qiagen). 5 x 1mm cores or 5 x 10um full faced sections were 
used for each extraction. The de-paraffinization step was carried out as follows: the 
paraffin samples was cut into small piece, 500ul Xylene was added and incubated at 55°C 
for 5 mins, and the tissue was pelleted at 16,000g for 3 mins, discarding the Xylene. After 
repeating this step, 500ul 100% EtOH was added for 5 mins at room temperature with 
constant mixing and the tissue collected by centrifugation @16,000g for 3 mins. The EtOH 
step was repeated and the tissue pellet dried for 10 mins. 300ul of cell lysis solution was 
added and the tube incubated for 70°C for 10 mins, followed by addition of 20ul Proteinase 
K (20mg/ml) to each sample and vortexing for 20 secs and incubation in a 55°C block 
overnight with constant vortexing. The following day a further 10ul proteinase K was 
added, vortexed for 20 secs and further incubated at 55°C until the samples appear clear. 
1ul RNase A solution (100mg/ml) was added, mixed by inverting 25 times and incubated at 
37°C for 1 hr. The sample was placed on ice to quickly cool it. Then 100ul protein 
precipitation solution was added to the cell lysates, vortexed for 20 secs, incubated on ice 
for 5 mins, and centrifuged at full speed for 5 mins at 4°C to pellet the protein precipitate. 
The supernatant containing the DNA was carefully removed into a clean microcentrifuge 
tube. The DNA was precipitated with 300ul 100% isopropanol and 2ul glycogen (20mg/ml) 
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were added if low yield was expected (<1ug). The solutions were mixed by inversion (50 
times) followed by centrifugation for 10 mins at 4°C. 
  
The DNA pellet was washed with 70% EtOH, air-dried and dissolved in 20ul H20. To 
dissolve the pellet it was incubated for 1 hr at 65°C with constant vortexing. 
 
Enrichment of methylated DNA by MBDCap 
The MethylMinerTM Methylated DNA Enrichment Kit (Invitrogen) was used to isolate 
methylated DNA from 500 ng–1 μg of genomic FFPET DNA and was sonicated to 100–
500 bp. MBD-Biotin Protein (3.5 μg) was coupled to 10 μl of Dynabeads M-280 
Streptavidin according to the manufacturer’s instructions. The MBD-magnetic bead 
conjugates were washed three times and resuspended in 1 volume of 1x Bind/Wash 
buffer. The capture reaction was performed by the addition of 500ng - 1 μg sonicated DNA 
to the MBD-magnetic beads on a rotating mixer for 1 h at room temperature. All capture 
reactions were done in duplicate. The beads were washed three times with 1x Bind/Wash 
buffer. The bound methylated DNA was eluted as a single fraction with a single High Salt 
Elution Buffer (2,000 mM NaCl). Each fraction was concentrated by ethanol precipitation 
using 1 μl glycogen (20 μg/μl), 1/10 volume of 3 M sodium acetate, pH 5.2 and 2 sample 
volumes of 100% ethanol and resuspended in 60 μl H2O.  Enrichment of methylated DNA 
after capture was previously assessed by quantitative PCR of control genes of known 
methylation status; namely EN1 (heavily methylated) and GAPDH (unmethylated)22. 
 
Preparation of MBDCap-Seq libraries and Illumina sequencing 
10ng DNA of MBDCap enriched DNA was prepared for Ilumina sequencing using the 
Illumina ChIP-Seq DNA sample prep kit (IP-102-1001) according to the manufacturer’s 
instructions. The library preparation was analyzed on Agilent High Sensitivity DNA 1000 
Chip.  Each sample was sequenced on one lane of the GA11x. 
 
Computational analysis of MBDCap-Seq data 
Sequenced reads were aligned to the hg18 version of the human genome with bowtie. 
Reads with more than three mismatches and reads mapping to multiple positions were 
removed. Finally, multiple reads mapping to exactly the same genomic coordinate were 
eliminated and only one read was retained for downstream analysis. Alignment statistics 
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for samples used in this study are given in Supplementary Table 5. MBDCap-Seq platform 
was previously shown to interrogate CpG dense regions of the genome23.  In  order  to  
accurately  delineate  regions  of  the  genome  assayable  by 
MBDCap-Seq we used fully methylated sample (SssI blood sample) to guide us to the 
genomic regions attracting sequenced tags. More specifically, we applied findPeaks peak 
calling utility from HOMER suite of programs56 to fully methylated sample (with parameter 
settings of -style histone -size 300 -minDist 300 -tagThreshold 18) to identify 230,655 
regions covering approximately 116Mbp of the genome. We interchangeably refer to these 
regions as regions of interest or SssI regions. For each MBDCap-Seq sample to be 
analyzed, we computed the number of sequenced tags overlapping SssI regions, which 
resulted in table of counts where columns are samples and rows are SssI regions. We 
used edgeR Bioconductor package57 
(http://www.bioconductor.org/packages/release/bioc/html/edgeR.html) to model distribution 
of reads between normal (n=6) and tumor (n=19) group of samples in the discovery cohort. 
Since edgeR package does not support modeling of paired and unpaired data 
simultaneously we performed two separate analyses, a paired analysis with 6 
normal/tumor pairs and unpaired analysis with all the samples, and then intersected the 
results.  We found 822 hyper-methylated and 43 hypo-methylated regions at FDR 
threshold of 0.05 in both paired and unpaired analyses. 
 
 
Clustering of MBDCap-Seq data 
The number of reads mapping to a particular region of genome depends not just on the 
average level of methylation in the region, but also on other factors, such as density of 
methylated CpG nucleotides. In order to compare MBDCap-Seq readout to other more 
quantitative technologies such as HM450K and Sequenom we used fully methylated 
MBDCap-Seq sample to normalize MBDCap-Seq readouts for samples in the discovery 
cohort. More specifically, let   be the number of tags overlapping region and be the total 
number of tags overlapping SssI regions in the sample to be normalized and   and    be the 
corresponding numbers in the control sample. Then, the   normalized number of tags 
overlapping the region is given by 
log (  Xi ⁄  N.M ⁄ Yi  +1) 
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We used normalized tag counts for heatmap visualization in Fig. 1, for comparison to 
HM450K in Supp. Fig. 2, and for comparison to Sequenom in Supp. Fig. 4 
 
Functional annotations of the genome 
CpG island annotation for hg18 was obtained from UCSC genome browser. The location  
of  CpG  island  shores  was  derived  from  CpG  islands  by  taking  +/-2Kb flanking 
regions and removing any overlaps with CpG islands. RefSeq transcript annotation for 
hg18 was obtained from UCSC genome browser. Promoters were defined as +2000/-
100bp around transcription start site (TSS). Intergenic regions were defined as regions 
complementing transcript regions extended to +/-2Kb around the transcripts. HMEC 
ChromHMM annotations for hg18 were downloaded from ENCODE. The original 
annotation partitions the HMEC genome into 15 functional states (see Fig. 1b in 24). In 
Fig. 1C and Supp. Fig. 1B, for brevity, we collapsed the three original promoter states into 
one promoter state and the four original enhancer states into one enhancer state. 
 
 
Enrichment analysis statistical methods 
For the enrichment analysis of hypermethylated regions we used hyper-geometric test to 
assess enrichment of various functional annotations of the genome in the set of 
differentially methylated regions. For a given functional annotation represented by a set of 
genomic regions, fraction of SssI regions (regions assayable by MBDCap-Seq) 
overlapping functional annotation was compared to the fraction of hyper-/hypo- methylated    
regions    overlapping    functional    annotation    using hyper-geometric distribution. For 
enrichment analysis of genes affected by promoter hyper- methylation, firstly, we used 
DAVID functional annotation tool25 to carry analysis against gene sets defined by 
SP_PIR_KEYWORDS annotation. Secondly, we used hyper-geometric test to assess 
enrichment of additional gene sets in the set of genes affected by promoter hyper-
methylation26. In both analyses, the set of 15,643 RefSeq genes with promoters 
overlapping SssI regions was used as a background. 
 
 
Sequenom quantitative massARRAY methylation analysis 
Glenn Francis SN: 30358409          Protein expression and molecular profiling to predict lymph node status in breast 
cancer. 
 
 
 
 
 
247 
Sequenom MassARRAY methylation analysis was performed according to Coolen et al.58. 
Briefly, 500ng of FFPET clinical sample and cell line DNA (Supplementary Table 2) was 
extracted and bisulphite treated using the standard bisulphite protocol59. As controls for the 
methylation analysis, whole genome amplified (WGA) DNA (0% methylated) and M.SssI 
treated DNA (100% methylated) were bisulphite treated in parallel. The primers were 
designed using the EpiDesignerBETA soft- ware from Sequenom (see Supplementary 
Table 6 for sequences). Each reverse primer has a T7-promoter tag (5-CAG TAA TAC 
GAC TCA CTA TAG GGA GAA    GGCT-3) and each forward primer has a 10-mer tag (5-
AGG AAG AGA G-3). Upon testing these primers on bisulphite treated DNA, all the 
primers gave specific PCR products at a Tm of 60°C. In order to check for potential PCR 
bias towards methylated or non- methylated sequences, we used serological DNA 
(Millipore) as a 100% methylated control and Whole Genome Amplified human blood DNA 
as a 0% methylated control. The PCRs were optimized and performed in triplicate using 
the conditions: 95°C for 2 min, 45 cycles of 95°C for 40 sec, 60°C for 1 min and 72°C for 1 
min 30 sec and final extension at 72°C for 5 min. After PCR amplification, the triplicates 
were pooled and a Shrimp Alkaline Phosphatase (SAP) treatment was performed using 5 
μl of the PCR product as template. 2 μl of the SAP-treated PCR product was taken and 
subjected to in vitro transcription and RNaseA Cleavage for the T-cleavage reaction. The 
samples were purified by resin treatment and spotted on a 384-well SpectroCHIP by a 
MassARRAY Nanodispenser. This was followed by spectral acquisition on a MassARRAY 
Analyser Compact matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry. The results were then analysed by the EpiTYPER software V 1.0 which 
gives quantitative methylation levels for individual CpG sites. The average methylation 
ratio was calculated by averaging the ratios obtained from each CpG site. For the 
Sequenom validation, sample sizes were determined for a two sample t-test with a 2-sided 
alpha of 0.01, assuming 5 regions were to be investigated. Assuming the difference in 
average methylation levels is 0.25 (tumors: SD=0.2, normals: SD=0.05), in order to have 
90% power to establish a significant difference between tumor and normal samples, 15 
samples per group were required. The calculations are based on preliminary data from the 
lab on methylation levels in breast cancer and normal samples (unpublished). 
 
Acquisition of TCGA data 
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Throughout the paper we used several molecular datasets from TCGA breast cancer 
(BRCA) cohort. Clinical annotation of samples was obtained from the marker TCGA BRCA 
publication (Supplementary Table 1 in 13; Supplementary Table 7). Raw HM450K 
methylation data (Level 1) was obtained from TCGA data portal in January 2012. 
Methylation data spanned 67 normal and 354 tumor ER+ve samples, 16 normal and 105 
tumor ER-ve samples, and 9 normal and 73 tumor TNBC samples. Processed array 
expression data (Level 3) was obtained from TCGA data portal in March 2012. Expression 
data spanned 52 normal and 406 tumor ER+ve samples, 9 normal and 118 tumor ER-ve 
samples, and 8 normal and 89 tumor TNBC samples. Processed RNA- Seq expression 
data (Level 3) was obtained from TCGA data portal in December 2012. Expression data 
spanned 73 normal and 588 tumor ER+ve samples, 19 normal and 174 tumor ER-ve 
samples, and 12 normal and 119 tumor TNBC samples. Summary of TCGA BRCA 
mutation data was obtained from COSMIC database 
(http://cancer.sanger.ac.uk/cosmic/study/overview?study_id=414). The summary lists 
mutations in gene coding regions across patients including both synonymous and non- 
synonymous amino-acid substitutions. We consider a gene as mutated if it appears at 
least two times in the list (Supplementary Table 8). 
 
Analysis of HM450K methylation data 
The raw HM450K data was preprocessed and background normalized with Biconductor 
minfi package using preprocessIllumina(..., bg.correct = TRUE, normalize = "controls", 
reference=1) command; resulting M-Values were used for statistical analyses 60 and 
Beta-Values for heatmap visualizations and clustering. To identify TNBC specific HM450K 
probes we carried out t-test comparison between TNBC (n=73) and non-TNBC (n=386) 
tumors. This analysis resulted in 282 probes having adj. p-value less than 0.05 and 
estimated mean difference of methylation between TNBC and non-TNBC tumors of at 
least 10%; these probes were declared as TNBC specific. Regions overlapping 3 or more 
TNBC specific probes were declared as TNBC specific. For TNBC specific signature we 
trained a Partial Least Squares model as implemented in the c a r e t R package61, 62 to 
classify tumours into TNBC and non-TNBC based on methylation values of 282 TNBC 
specific probes. The tumour samples in the TCGA HM450K cohort were randomly 
partitioned into equal size training/testing sets. The model parameters were derived from 
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training set and then applied to make predictions on the testing set. The performance of 
the model was assessed using test set predictions. 
 
Analysis of expression data 
Differential expression analysis between normal (n=8) and tumor (n=89) TNBC samples 
was carried out with Bioconductor limma package. Since only subset of tumor samples 
had paired adjacent normal samples, patient data was treated as random effect using 
limma’s duplicateCorrelation(…) function. This analysis resulted in 3,017 down-regulated 
and 3,407 up-regulated genes with adj. p-value less than 0.05 out of 17,655 genes on the 
array. In Fig. 1F and 1G we only considered genes with SssI regions in their promoter 
regions reducing the number of down-regulated, up- regulated and total genes to 2,119, 
2,722 and 15,543 respectively. We used log transformed RNA-Seq expression values to 
highlight relationship between methylation and expression for number of candidate regions 
in Fig. 2C and Supplementary Fig. 11. 
 
 
Survival analysis 
TNBC tumour samples in TCGA HM450K cohort (n=73) were clustered based on 
methylation beta-values of 4,987 HM450K probes overlapping the 822 hyper- methylated 
regions. We applied consensus clustering algorithm63 as implemented in Bioconductor 
ConsensusClusterPlus package to the 4,987 X 73 methylation matrix with parameters 
maxK=4, reps=1000, pItem=0.8, pFeature=0.8, clusterAlg="km", distance="euclidean".   
We used SVD decomposition to reduce the dimension of the methylation matrix to prior to 
clustering.  We chose the three-cluster configuration for downstream survival analysis. 
Survival analysis was carried out using Cox proportional hazards model as implemented in 
R s u r v i v a l package against overall survival data (Supplementary Table 7). Survival 
analysis of cluster data was carried out with cluster membership as an explanatory 
variable. The BRCA TNBC cohort consists of 73 patients with HM450K methylation data 
and 12 events. Survival analysis of individual probes (4,987 probes overlapping 822 hyper-
methylated DMRs) was carried out with probe methylation status as explanatory variable 
(univariate analysis) and age, stage and probe methylation status (multivariate analysis). 
Methylation status was represented by a binary variable, high (higher that the median 
beta-value for the probe) and low (smaller or equal to the median beta-value for the 
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probe). Stage was derived from AJCC stage in the clinical annotation of samples. Due to 
moderate size the cohort we reduced the number of values of the stage variable to two by 
collapsing stages I, IA, IB, II, IIA, and IIB into one state and stages III, IIIA, IIIB, IIIC, and IV 
into one state. This resulted in 190 probes with methylation status statistically significantly 
(p-value < 0.05 in both univariate and multivariate analyses) associated with overall 
survival in TCGA TNBC patients. Regional aggregation of survival probes identified 17 
hyper- methylated DMRs overlapping three or more survival probes. Fourteen regions   
were associated with poor prognosis, these regions overlapped probes for which high 
methylation corresponded to lower probability of survival, and three regions were 
associated with good prognosis. 
 
Summary of other statistical methods 
For the enrichment analysis of hypermethylated regions we used hyper-geometric test to 
assess enrichment of various functional annotations of the genome in the set of 
differentially methylated regions. For a given functional annotation represented by a set of 
genomic regions, fraction of SssI regions (regions assayable by MBDCap-Seq) 
overlapping functional annotation was compared to the fraction of hyper-/hypo- methylated 
regions overlapping functional annotation using hyper-geometric distribution. 
For enrichment analysis of genes affected by promoter hyper-methylation, firstly, we used 
DAVID functional annotation tool25 to carry analysis against gene sets defined by 
SP_PIR_KEYWORDS annotation. Secondly, we used hyper-geometric test to assess 
enrichment of additional gene sets in the set of genes affected by promoter hyper-
methylation26. In both analyses, the set of 15,643 RefSeq genes with promoters 
overlapping SssI regions was used as a background. 
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Figure Legends 
Figure 1. MBDCap-seq identifies DMRs in discovery cohort. A heatmap showing 
methylation profile of 822 hypermethylated (A) and 43 hypomethylated regions (B) across 
a cohort of 19 tumour and 6 matched normal samples in the discovery cohort. Columns 
are samples and rows are regions. The level of methylation (number of reads normalized 
with respect to fully methylated sample) is represented by a colour scale – blue for low 
levels and red for high levels of methylation. (C) A bar plot showing association of DMRs 
across functional/regulatory regions of the genome – (i) CpG islands and shores, (ii) 
RefSeq transcripts, and (iii) Broad ChromHMM HMEC annotation. The height of the bars 
represents the level of enrichment measured as a ratio between the frequency of 
hypermethylated (pink) or hypomethylated (blue) regions overlapping a functional element 
over the expected frequency if such overlaps were to occur at random in the genome. 
Statistically significant enrichments (p-value < 0.05; hyper-geometric test) are marked with 
an asterisk. (D) Sequenom validation of five hypermethylated regions -- FERD3L, 
C9orf125, HMX2, NPY and SATB2 -- is shown for an independent cohort of TNBC 
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samples (normal=15; tumour =33) and (E) a panel of breast cancer cell lines (normal=3; 
cancer=24). For each region boxplots displaying the distribution of methylation levels are 
shown in grey/blue for normal/tumour samples/cell lines. (F) A bar plot showing 
enrichment of genes with promoter hypermethylation in sets of genes that are up-/down-
regulated in the TCGA cohort of TNBC tumour as compared to matched normal samples. 
The height of the bars represents the level of enrichment measured as a ratio between the 
observed number of up-/down-regulated genes with promoter hypermethylation to the 
expected number of such genes. (G) A Venn diagram showing overlap between genes 
with promoter hypermethylation, genes down-regulated in TCGA TNBC cohort (hyper- 
geometric test; FC 1.73; p-value <<0.001) and genes with two or more mutation (hyper-
geometric test; FC 1.92; p-value <<0.001) in TCGA breast cancer cohort. 
 
Figure 2. Methylation profile of candidate DMRs in the TCGA breast cancer cohort. (A) A 
heatmap showing methylation profile of TCGA breast cancer samples across 4,987 
HM450K probes overlapping hypermethylated DMRs identified in the discovery cohort. 
Rows are probes and columns are TCGA breast cancer samples profiled on HM450K – 83 
normal, 105 ER-VE tumour, and 354 ER+VE tumour samples. (B) A classifier (Partial 
Least Squares model) based on methylation values  of 282 TNBC-specific probes assigns 
TCGA HM450K tumour samples into TNBC and non-TNBC with high accuracy; ROC 
analysis yields AUC of 0.9; assigning samples to highest scoring class (TNBC or non-
TNBC) yields sensitivity of 0.72 and specificity of 0.94. The TCGA HM450K cohort was 
randomly split into training set (TNBC n=37; non-TNBC n=193) and testing set (TNBC 
n=36; non-TNBC n-193). The model was trained on training set and prediction accuracy 
assessed on testing set.(C) Box plots showing distribution of methylation levels for two 
adjacent regions on chromosome 19 in TCGA normal (n=83), TNBC tumour (n=73), and 
other breast tumour samples (n=354). These two regions which span the promoters of 
ZNF154 and the adjacent ZNF671 gene, are hypermethylated in the discovery cohort and 
exhibit regional TNBC specific hypermethylation in TCGA cohort, i.e. they are more heavily 
methylated in TNBC tumours as compared to normal and other tumour subtypes, as 
shown in the box plots (t-test; mean diff. > 0.1; p-value < 0.05). (D) Box plots showing 
distribution of expression levels of ZNF154 and ZNF671 genes in TCGA normal (n=92), 
TNBC tumour (n=119), and ER+VE tumour (n=588) samples. The difference in expression 
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of TNBC tumours versus ER+VE is found significant for both genes (t-test; ZNF154 mean 
diff. -0.51 with p-value 9.04e-10; ZNF671 mean diff. -0.85 and p-value of 5.50e-21). 
 
Figure 3. Methylation profile stratifies TNBC tumours into survival subgroups 
(A) Unsupervised clustering with 4,987 HM450K probes overlapping 822 hypermethylated 
DMRs identified in the discovery cohort separates TCGA TNBC tumours (n=73) into three 
main clusters. The heatmap shows the methylation profile of TCGA TNBC tumours and 
cluster dendrogram. The three clusters are color-coded with the red cluster exhibiting the 
highest methylation (TNBC.high), the blue cluster exhibiting the lowest methylation 
(TNBC.low) and the orange cluster exhibiting an intermediate level of methylation 
(TNBC.medium). (B) A Kaplan-Meier plot showing survival curves for the patients in the 
three clusters defined in (A). Additionally, individual regions of hypermethylation in the 
discovery cohort overlap with survival associated probes in the TCGA cohort; including (C) 
intergenic loci, (D) intragenic loci (e.g. the HOXB13 gene body) and (E) promoter 
associate loci (e.g. ZNF254 promoter). (F) Association with survival for three adjacent 
regions -- chr11-11623, chr11-4047, and chr11-1210 -- spanning the WT1/WT1-AS locus 
is shown. These three regions are hypermethylated in the discovery cohort and overlap 
several probes showing statistically significant association with overall survival in both 
univariate and multivariate analyses. For each region the methylation profile of TCGA 
TNBC tumour (n=73) and adjacent normal samples (n=9) across overlapping survival 
probes is shown as a heatmap. The Kaplan-Meyer plots for each of the overlapping 
survival probes is shown as well with corresponding hazard ratios and p-values from Cox 
proportional hazards model; values in parentheses correspond to multivariate analysis. 
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Chapter 10 
Discussion 
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10.1. General Discussion 
Breast cancer is one of the commonest cancers in the developed world. In Australia there 
are more than 14,000 new cases per year with more than 2,500 deaths each year. Breast 
cancer is the commonest cancer in women and whilst the overall survival is approximately 
85% it is still a leading cause of cancer mortality in women. Despite extensive funding for 
breast cancer relatively little progress has been made on the introduction of new predictive 
or prognostic biomarkers. The standard clinicopathological biomarkers include tumour 
size, grade and lymph node status, oestrogen receptor, progesterone receptor and HER2 
ISH. In some locations Ki-67 is also included as a biomarker to distinguish tumours that 
have a higher proliferative index that are more likely to respond to chemotherapy, but this 
is not uniformly included as a prognostic marker across all laboratories in Australia. 
Different tumour types are associated with different patterns of metastases and even 
within the same tumour location there are different patterns of spread. Breast cancer, 
prostate cancer, papillary thyroid cancer, gastric carcinoma and melanoma have a 
relatively high frequency of lymph node metastases in contrast to renal cell carcinomas 
and soft tissue tumours which disseminate by haematogenous metastasis. This variation 
in the pattern of dissemination in different tumour types does suggest that there are 
inherent differences in the biological make-up of the different tumours and that 
haematogenous spread is not contingent on prior lymph node metastases. 
Lymphangiogenesis and mechanisms of lymphatic spread by tumours have been 
extensively investigated and some of the pathways have been elucidated (Alitalo, 2011) 
(Figure 8). 
Figure 8: “Mechanisms contributing to lymphatic metastasis. (a) Top left, the normal lymph node has been stained with 
antibodies detecting B cells (red), T cells (green) and lymphatic sinusoid (white). Top right, the eosin-stained (blue) LN 
shows metastatic foci in gray. Bottom, increased VEGF-C and D secretion by tumour cells or tumour associated 
inflammatory cells induces tumour lymphangiogenesis, hyperplasia of collecting lymphatic vessels and tumour cell 
translocation into lymphatic vessels and lymph nodes. (b) Aberrant expression of chemokine receptors such as CCR7 
may increase tumour cell migration toward lymphatic vessels”. Modified from Alitalo (Alitalo, 2011). 
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With the development of molecular techniques, multiple potential biomarkers have been 
identified that associate with lymph node status or with prognosis and patient survival. A 
limited number of new commercial molecular or protein expression tests have been 
introduced across the world. These include Oncotype Dx™, Mammaprint™, 
Endopredict™, Mammostrat™ and PAM50™ (Gyorffy et al., 2015). These tests are based 
on RT-PCR or gene expression arrays and are expensive (Oncotype Dx™ ~$4500, 
Mammaprint™ ~$4500-$10,000 and Endopredict™ ~$3000). The uptake of these tests is 
relatively small in Australia with an estimated uptake of less than 300 tests per year. The 
tests are also usually restricted to specific subtypes of breast carcinoma such as lymph 
node negative hormone receptor positive tumours and stratify patients into those patients 
that will benefit from chemotherapy and those where the benefit from chemotherapy is 
minimal. Clinical trials have been commenced to determine the utility of Oncotype Dx™ 
and Mammaprint™ and the cost benefit of these new assays is still uncertain (Bonastre et 
al., 2014). Even with the development of the molecular assays, lymph node status still 
remains an independent prognostic variable for breast cancers patients. Whilst the 
development of sentinel lymph node biopsy has reduced the need for axillary lymph node 
dissection, the procedure is still associated with morbidity, although at a lower level:  
“lymphedema (3.5% vs. 19.1%), impaired shoulder range of motion (3.5% vs. 11.3%), 
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shoulder/arm pain (8.1% vs. 21.1%), and numbness (10.9% vs. 37.7%)” (Langer et al., 
2007). 
This thesis was aimed at predicting lymph node status from characteristics of the primary 
tumour using an artificial neural network. To be clinically useful for predicting lymph node 
status, a test must be able to accurately predict positive nodal status in more than 95% of 
patients. An assay with an accuracy below this threshold would have an adverse impact 
on patient outcome due to the prognostic significance of lymph node status in patient 
survival. The comparator is sentinel lymph node biopsy, and sentinel lymph node biopsy is 
able to reliably predict axillary lymph node status in 98% of all patients and 95% of those 
who are node-positive (Cody, 1999).  
 
A breast cancer database was constructed to facilitate the analysis with multiple variables 
being included in different models. Tissue microarrays were utilised for evaluation of 
multiple expression markers using immunohistochemistry. The usefulness and the ability 
of TMAs to accurately reflect the characteristics of the primary tumour has been 
demonstrated, but the results from TMAs must also be clinically useful and reflect the 
patient outcome. To confirm that the patient database was an accurate reflection of 
sporadic breast cancers and that TMA immunohistochemistry correlated with clinical 
characteristics and patient outcome, HER2 was used as a model. HER2 IHC, HER2 
Chromogenic in-situ hybridization (CISH) and HER2 Silver in-situ hybridization (SISH) 
were performed on TMAs from 230 patients (Chapter 3) (Francis et al., 2009a). The 
samples used in this analysis covered a range of tumour types, with 87% being infiltrating 
ductal carcinoma. Of these patient samples, 42% were lymph node negative, 34% were 
lymph node positive and in the remainder the nodal status was unknown. The median 
follow up was 139.3 months. Clinical and pathological features represented that seen in 
sporadic breast cancers. In this study, the two bright field ISH methods showed similar 
Kaplan-Meier survival curves. Whilst the groups of patients were not corrected for 
hormone receptor status and treatment, the curves showed that patients with HER2 gene 
amplified tumours obtained from a TMA analysis, had a worse outcome compared to 
patients with HER2 negative tumours (Figure 9).  
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Figure 9: Kaplan-Meier plots for breast cancer specific survival. 
Codes: CISH A= low and high amplified cases; CISH N=diploid, polysomy and equivocal cases; SISH A= low and high 
amplified cases; SISH N=diploid, polysomy and equivocal cases;SISHH2CA= low and high amplified cases utilizing the 
HER2/CHR17 ratio; SISHH2CN= diploid, polysomy and equivocal cases utilizing the HER2/CHR17 ratio;IHC E= 2+ IHC 
staining, IHC N= 0 & 1+ IHC staining and IHC P= 3+ IHC staining (Francis et al., 2009a). 
 
 
In a separate study, androgen receptor (AR) status was evaluated in 73 grade 3 infiltrating 
ductal carcinomas with positive lymph nodes (Chapter 6) (Peters et al., 2012). Duplicate 
TMAs were used for analysis and AR expression was detected in 56% (n=41) of the 
primary breast tumours. 55.5% of the tumours were ER positive, 40% were PR positive 
and 21.7% were HER2 positive. The lower percentage of ER and PR positive tumours and 
the higher percentage of HER2 negative tumours is due to section of the tumours for 
positive lymph node status. There was an association between AR expression and ER, PR 
and HER2 expression. “The majority of AR-negative tumours were also negative for ER 
(72%), PR (87%) and HER2 86.6%)” (Peters et al., 2012). In this study, AR expression 
was identified as a significant prognostic factor for overall patient survival with the 10-year 
survival of patients with AR positive tumours being 52% versus 22% for patients with AR 
negative tumours (Peters et al., 2012). DNA methylation, somatic mutations in the AR 
promoter region and miRNA was also evaluated in this study but did not appear to 
correlate with AR expression in the breast cancer samples (Peters et al., 2012).  
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A variety of cell adhesion molecules have also been evaluated in breast cancer. This has 
included ECM proteins and insulin-like growth factors. TMAs have been used to evaluate 
the prognostic  utility of insulin-like growth factor receptors and extracellular matrix (ECM) 
interaction-induced proteins in breast carcinoma (Chapter 8) (Plant et al., 2014). Multiple 
biomarkers of cell adhesion and extracellular matrix interaction were evaluated using 
immunohistochemistry on TMAs (Table 5) (Plant et al., 2014).  The IHC markers were 
scored and evaluated in a semiquantitative fashion. 
 
Table 5: Product and supplier details for the antibodies used in the study. IgG: immunoglobulin G; mAb: monoclonal 
antibody; pAb: polyclonal antibody, and; N/A: not applicable (Plant et al., 2014). 
Antibody target Supplier Supplier details Product 
Number 
Isotype Source Clone 
IGF-IRβ Santa Cruz 
Biotechnology® 
California, USA sc-713 IgG Rabbit 
pAb 
C-20 
IGF-IIR Santa Cruz 
Biotechnology® 
California, USA sc-25462 IgG Rabbit 
pAb 
H-300 
IGFBP-5 R&D Systems® NSW, Australia MAB875 IgG2b Mouse 
mAb 
164503 
VN Epitomics® California, USA 1730-1 IgG Rabbit 
mAb 
EP781Y 
FN Novocastra NSW, Australia NCL-FIB IgG1 Mouse 
mAb 
568 
αv integrin Calbiochem® New Jersey, USA 407286 IgG1 Mouse 
mAb 
272-
17E6 
β1 integrin Abcam® Massachusetts, 
USA 
ab3167 IgG1 Mouse 
mAb 
4B7R 
Total-AKT1 Cell Signalling 
Technology® 
Massachusetts, 
USA 
2967 IgG1 Mouse 
mAb 
2H10 
P-AKT (Ser473) Cell Signalling 
Technology® 
Massachusetts, 
USA 
4051L IgG2b Mouse 
mAb 
587F11 
ERK1/2 Cell Signalling 
Technology® 
Massachusetts, 
USA 
4695 IgG Rabbit 
pAb 
137F5 
P-ERK1/2 
(Thr202/Thr204) 
Cell Signalling 
Technology® 
Massachusetts, 
USA 
9106 IgG1 Mouse 
mAb 
E10 
CLDN-1 Invitrogen™ VIC, Australia 18-7362 IgG Rabbit 
pAb 
N/A 
SFN Abcam® Massachusetts, 
USA 
110-02810 IgG1 Mouse 
mAb 
3C3 
SHARP-2 Sigma-Aldrich® NSW, Australia S8443 IgG Rabbit 
pAb 
N/A 
ER Ventana Medical 
Systems® 
Arizona, USA 790-4325 IgG Rabbit 
mAb 
SP1 
PR Ventana Medical 
Systems® 
Arizona, USA 790-4296 IgG Rabbit 
mAb 
1E2 
HER2 Ventana Medical 
Systems® 
Arizona, USA 790-2991 IgG Rabbit 
mAb 
4B5 
 
This study evaluated the cellular localisation of the IHC products within the tumours and 
identified differences in the subcellular localisation of a range of cell adhesion molecules. 
Differences were identified between the localisation of the staining pattern between 
Glenn Francis SN: 30358409          Protein expression and molecular profiling to predict lymph node status in breast 
cancer. 
 
 
 
 
 
268 
primary tumours and lymph node metastases, however, markers to predict lymph node 
status were not identified (Plant et al., 2014). 
Extrapolating from all of these studies and general literature, it can be expected that 
results from TMAs accurately reflect both the results from whole tumour sections and 
correlate with clinical characteristics within a number of tumour types including breast 
cancer. TMAs should therefore be able to be utilised to predict lymph node status if there 
is an association between the biomarker and lymph node status.   
Immunohistochemistry was performed on whole tissue sections and TMA sections of a 
sporadic population of breast carcinomas derived from a large database and these were 
used for input into an ANN (Appendix 13.5). Multiple models were run to attempt to enable 
accurate prediction of lymph node status, however despite some models being developed 
that showed good correlation with lymph node status, these models failed to validate in a 
separate cohort of breast cancer samples. In comparison, models were able to be 
developed that accurately predicted breast cancer specific survival over time in the same 
patient cohort (Appendix 13.6). This suggests that the parameters used in models for 
prediction of survival are correlated with survival, but those used for lymph node prediction 
are not. miRNA changes are also able to predict prognosis in breast carcinoma (Chapter 
4) (Wee et al., 2012) using patients derived from the same database. A separate study 
using DNA methylation was also able to predict differences between TNBC patients with 
different DNA methylation profiles, but a model for prediction of lymph node status was not 
able to be developed (Chapter 9) (Stirzaker et al., 2015). In this study, there were three 
possible associations examined using epigenetics: differences between normal breast 
tissue and TNBC, differences between lymph node positive tumours and lymph node 
negative tumours and correlation between survival and epigenetics. Methylation 
differences were identified to predict prognosis in TNBC patients and to distinguish normal 
from tumour tissue, but no markers were identified to enable prediction of lymph node 
status from the primary tumour. 
There may be a number of possible causes of the failure to predict lymph node status in 
breast cancer from characteristics of the primary tumour. 
 
 Incorrect selection of biomarkers 
More than one thousand biomarkers have been described that associate with lymph node 
status in breast cancer, however, none of these have been implemented due to failure to 
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validate in separate patient cohorts or generalise for sporadic breast cancers. There are 
also usually conflicting results for each biomarker with some studies showing an 
association with lymph node status and other studies showing a lack of association with 
lymph node status.  
The large number of variables suggests that there are no single strong classifiers 
associated with lymph node status.  
This project evaluated protein expression by IHC and this methodology is used in routine 
practice for clinical decisions. In breast carcinoma, IHC for oestrogen receptor and 
progesterone receptor forms part of the standard of care for management of breast cancer 
patients. The IHC assay replaced the radioligand binding assay which was originally used 
for assessment of oestrogen receptor status. The IHC assays have been extensively 
evaluated for clinical utility (Hammond et al., 2010) and the use of IHC would be expected 
to correlate with clinical characteristics of breast carcinomas and the response to 
treatment.  
The lack of correlation between lymph node metastases and biomarkers also seems to 
apply to epigenetic markers and whilst miRNA markers have shown some association with 
lymph node status the results appear to be similar. A preliminary study did show some 
differences between miRNA expression in a primary breast compared to cells from 
lymphatic channels and lymph node metastases Appendix). Even using laser capture 
microdissection, the cells isolated from the lymphatic channels are not a uniform 
population, and if clusters are required for the development of metastases then these cells 
will represent an admixture of cell types with variable expression of biomarkers and a 
complex interaction of cell signalling. 
The number of potential biomarkers makes it difficult to develop models as complete data 
covering such a large dataset is difficult to obtain even with such projects as TCGA. This 
means that selecting a relatively limited number of biomarkers is problematic as the there 
is a risk that the selected biomarkers will not associate with the clinical feature being 
evaluated. However, even with analysis of large datasets such as the TCGA with gene 
expression and epigenetic markers, a signature for lymph node metastasis has still not 
been identified. 
In contrast, a number of different algorithms have been developed to predict survival and 
even though these use different input variables, the results appear to reasonably similar. 
This suggests that for survival there are multiple markers that correlate with survival and 
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that multiple algorithms are able to lead to the same conclusion. The same does not 
appear to hold true for lymph node status, as if the same process occurred, then it should 
be possible to develop models to predict lymph node status using a number of different 
methodologies, different biomarkers and algorithms which would result in a similar 
outcome. 
 
 Inability of protein expression to correlate with clinical outcome 
IHC is an antigen-antibody reaction used as a measurement of protein expression in 
tissue. However, IHC does not show a linear correlation with protein expression as the 
method of detection is not linear. With enhanced sensitivity the IHC reaction approaches a 
dichotomous reaction of positive and negative. IHC will therefore not correlate with subtle 
changes in protein expression and this has the potential to impact on associations with 
clinical characteristics such as lymph node status if there are only minor changes in the 
biomarkers that are associated with a particular feature. However, gene expression 
changes and methylation changes have also not shown a correlation with lymph node 
status and these methodologies have a more dynamic range. 
 
 ANN may not be able to develop a successful model 
ANNs are a particular type of model system that has been used in biological systems and 
other inherently unpredictable systems, such as share market predictions and image 
analysis, because of inherently noisy data. Most statistical analyses assume that the input 
data is accurate and correct, however, in biological systems there are multiple sources of 
variation in the data. For IHC, the data is subject to interpretation and there is less than 
100% concordance between interpretation of IHC even when other variables are 
controlled. The process of tissue fixation and IHC introduces variation in the staining 
intensity of the biomarker and these variables are not uniform and are not recorded. An 
ANN was selected as the best model because no assumptions are made about the data 
accuracy. Input variables are used with a defined output variable and each input variable is 
evaluated to determine if it is useful in the models tested. Different levels of noise were 
selected including noisy, moderately noisy and extremely noisy, but no successful model 
was able to be developed for lymph node status. In contrast, a model was developed of 
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breast cancer specific survival which would suggest that selection of an ANN to develop a 
model for a biological system is a reasonable choice. 
 Tumour heterogeneity 
Whilst tumours are a clonal proliferation of neoplastic cells, all tumours are heterogeneous. 
Any methodology assessing tumour biomarkers is usually a composite of tumour cells and 
also a varying number of normal cells. IHC is assessed on a morphological section and the 
expression of the protein is correlated with the different cell compartments and is directly 
linked with tumour. Gene expression profiling and other molecular testing is often 
performed on fresh/frozen tissue. This tissue is used because of the preservation of 
nucleic acids, but it is difficult to assess the morphology of the tissue being tested. This 
variation in tumour content may potentially account for the lack of the ability to predict 
lymph node status using such techniques as gene expressing profiling and DNA 
methylation. Results are also confounded by the requirement for a normal control sample 
and the selection of a control may influence the results. Even in FFPE material where the 
amount of tumour content can be assessed, the population of cells is not homogeneous. 
These factors have the potential to dilute the expression of biomarkers that may be 
associated with lymph node metastases and may account for the inability of models to 
predict nodal status.  
However, IHC expression is assessed in the tumour cells and scoring methods do take 
into account variation in the expression of the particular biomarker with an assessment of 
percentage of tumour cells staining and the intensity of staining. 
Against this hypothesis is the fact that molecular classification of breast carcinomas has 
been successfully performed despite these inherent limitations and variations in samples, 
and similarly models have been developed for molecular grading and prediction of 
prognosis. 
 
 Development of lymph node metastases may not be due to molecular or protein 
changes in the primary tumour 
There are two models proposed for tumour progression, the linear progression model and 
the parallel progression model (Kimbung et al., 2015). Traditionally metastasis has been 
associated with the linear progression model which assumes a step-wise progression of 
cancer. This progression is due to the accumulation of sequential genetic abnormalities 
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and the eventual development of a metastatic phenotype. In support of this model is the 
association of tumour size with metastases and the similarity of gene expression 
signatures between primary tumours and the metastasis (Kimbung et al., 2015). In 
contrast, the parallel progression model proposes that metastatic potential in a tumour is 
acquired early in the development of a tumour and that breast carcinoma is a systemic 
disease from the outset (Kimbung et al., 2015). If the parallel progression model is the 
correct model for breast cancer progression, at least for lymph node metastases, then this 
would be a possible explanation for the inability to predict lymph node status from 
characteristics of the primary tumour. Even very small tumours would have expression 
patterns and phenotypic and genetic characteristics associated with lymph node 
metastases and these would not be acquired in a stepwise fashion. 
This theory is also supported by the data from circulating tumour cells where clumps of 
tumour cells may be required to initiate and result in metastatic lesions and this may also 
apply to lymph node metastases. If this is the situation then the cells being analysed will 
be a mixture of cell types with different biological properties and any assessment of those 
cells will be a combined analysis rather than a pure cell population.  
This is analogous to the molecular profiles seen in ductal carcinoma in situ (DCIS) and 
invasive ductal breast carcinoma. Molecular profiling of infiltrating ductal carcinoma has 
not shown a difference in the molecular profile compared to DCIS (Abba et al., 2015).  
Statistical modelling has also been used to predict metastatic disease (Michor et al., 2006) 
and a stochastic nature of breast cancer progression accounts for some of the observed 
characteristics of breast cancer progression (Vanharanta and Massague, 2013). 
Tumours undergo evolution with the acquisition of an increasing number of genetic 
abnormalities and some of these will result in a metastatic phenotype although not every 
metastatic phenotype will necessarily be reached by the same evolutionary route 
(Vanharanta and Massague, 2013). Even with the dissemination of tumour cells with 
metastatic potential, only a small number of cells actually form a metastasis. A stochastic 
model would explain the existing genetic evidence where tumour cells have the ability to 
form metastasis, but at a low frequency (Vanharanta and Massague, 2013). 
Genetic analysis has been performed on multiple tumour types and this has also included 
an analysis of metastatic lesions. Differences in the mutational profile have been identified 
in metastases and primary tumours and between different metastatic sites, however 
metastasis-specific mutations have not been identified (Vanharanta and Massague, 2013). 
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This suggests that metastasis is not a distinct genetic event defined by a specific mutation 
or combination of easily definable mutations and whilst this is usually applied to distant 
metastases, the same issues appear to apply to lymph node metastases. The process of 
metastasis may be too complex to be defined a limited number of mutations and instead 
rely on a complex interaction between EMT of the tumour cells, epigenetic changes, 
tumour phenotype and the interaction between different tumour cells and the 
microenvironment. 
 
The latter theory is probably the most likely explanation for the failure of the ANN to 
develop a model to predict lymph node metastasis in breast cancer. Different approaches 
were used to define appropriate biomarkers that could be used for the development of the 
ANN model. These variables included clinicopathological characteristics of the primary 
tumour such as tumour size. Even for tumour size, different approaches were considered 
such as maximum tumour size, a calculation of tumour volume using an ellipsoid model 
and volume using a rectangular tumour model. Protein expression for multiple markers 
was assessed using immunohistochemistry as well as miRNA (Wee et al., 2012) and 
epigenetic markers (Stirzaker et al., 2015). 
An analysis of a breast cancer cohort also failed to show any differences in the tumours 
from the cluster compared to the tumours from case-matched controls (Waddell et al., 
2012).  
An ANN has been used to develop a model for lymph node metastases in oesophageal 
squamous cell carcinoma using gene expression profiling (Kan et al., 2004). In this study 
the ANN predicted lymph node metastasis in 10 of 13 validation cases (77%) and in 24 of 
28 (86%) for the entire patient cohort with a sensitivity of 88% and a specificity of 82% 
(Kan et al., 2004). Interestingly the authors of this article thought that the ANN model was 
useful for the clinical prediction of lymph node status and could be applied clinically, 
however the sensitivity and specificity of the model does not appear to be sufficiently high 
enough for implementation. 
Models for the prediction of lymph node metastases for different tumour types have not 
been developed with a high degree of accuracy. Standard histological assessment of 
lymphovascular invasion in tumours is associated with lymph node metastases in multiple 
tumour types, but this has not been supplanted by any new advanced methodologies and 
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none have been implemented into routine diagnostic practice to improve the current 
pathological assessment of tumour features. 
 
Given the extensive data on biomarkers reported to be associated with lymph node 
metastases, if there was a strong link between a particular biomarker and nodal status, it is 
likely that it would have been identified. The fact that there are so many reported 
biomarkers, gene expression signatures, epigenetic associations and associations with 
miRNA suggests that there is no single or limited number of biomarkers that correlates 
strongly with lymph node status. This would also provide support for the theory of a 
complex process of lymph node metastasis that cannot be readily be defined with a large 
number of tumour cells having metastatic potential, but only a small number producing 
metastatic disease due to mechanistic and microenvironmental interactions. 
 
In contrast, it is easier to predict outcome in breast cancer patients as is indicated by the 
availability of commercial assays for selection of lymph node negative patients into low 
and high risk patients for selection of treatment options. These assays essentially use 
markers of proliferation and similar predictions can be made with IHC for Ki-67. 
Proliferation in the form of a mitotic count is incorporated into the grading system for breast 
cancer with the generation of three grades. A model was developed for the determination 
of molecular grade to stratify morphological Grade 2 tumours into predicted Grade 1 and 
Grade 3 tumours with a correlation with breast cancer specific survival (Francis et al., 
2012). Similarly, an ANN model was developed to enable the prediction of breast cancer 
specific survival for individual breast cancer patients and epigenetic profiling was used to 
stratify triple-negative breast cancer patients into different prognostic groups (Stirzaker et 
al., 2015). 
 
In tumours, it is postulated that distant metastases can arise by either direct 
haematogenous dissemination or by lymph node metastases and then subsequent 
haematogenous spread from the nodal metastases. These pathways are different in 
different tumour types. In breast cancer, lymph node metastases are usually present when 
distant metastases occur but they may not necessarily occur sequentially, but may occur 
simultaneously. If the process of distant metastases was correlated with an intermediary 
step of lymph node metastases prior to subsequent haematogenous dissemination, then it 
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would be expected that prediction of patient survival, which is associated with distant 
metastases, would also be able to predict lymph node status. This does not appear to be 
the cases as is illustrated in this thesis. The process of lymph node metastasis and distant 
metastases appear to be independent processes. Distant metastases, in the form of an 
adverse patient outcome can be predicted by different models using different biomarkers. 
This suggests that the metastatic phenotype can be defined by different biomarkers that 
correlate with an adverse outcome. 
In contrast, no model has been able to be developed either in the published literature or by 
this project that is able to predict positive lymph node status in breast cancer with a 
significant high degree of accuracy that would enable implementation into clinical practice. 
Sentinel lymph node biopsy is currently used to assess the lymph node status in breast 
cancer and this relies and direct sample of the lymph node. Examination of the node is by 
direct histological examination or by molecular detection of cytokeratins and this is then 
used to select patients for further evaluation by an axillary lymph node dissection. The 
process of dissemination of tumour cells to the lymph nodes and the formation of lymph 
node metastases would appear to be separate to that for distant metastases and the 
mechanisms involved appear to be independent. The input variables used for development 
of an ANN for prediction of breast cancer specific survival were also included as input 
variables for the development of models for prediction of lymph node status. If the 
progression of breast cancer followed a sequential process from lymph node positive 
disease to distant metastases it is likely that some of the markers associated with distant 
metastases would also be associated with lymph node status. An alternative hypothesis is 
that subsequent evolutionary changes occur in the lymph node metastasis that then result 
in distant metastases. Removal of the lymph nodes in breast cancer is used as a 
prognostic marker, but it also possible that removal of positive nodes reduces the 
subsequent development of distant metastases. However, when axillary lymph node 
dissection was routinely performed on all breast cancer patients, a proportion of patients 
with no lymph node metastases still went on to develop distant metastases, although at a 
lower frequency. Approximately one third of women with lymph-node negative breast 
cancer will develop distant metastases (Weigelt et al., 2005b). If lymph node metastases 
were required for tumour evolution prior to distant dissemination, then it would be expected 
that the incidence of distant metastases in lymph node negative patients would be 
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significantly lower. This again supports the concept that lymph node metastases and 
distant metastases are independent events. 
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Chapter 11 
Conclusion 
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11.1. Conclusion 
Lymph node status is an independent prognostic marker in breast cancer. Whilst the 
standard of care has changed from axillary lymph node dissection to sentinel lymph node 
dissection, there is still an associated morbidity associated with the latter procedure. 
An artificial neural network was used to attempt to develop a model to predict lymph node 
status from characteristics and biomarkers from the primary tumour. This would result in a 
reduction of morbidity whist retaining the prognostic usefulness of lymph node status. 
An ANN model was not able to be successfully developed to predict lymph node status, 
although models were developed to predict the molecular grade of breast cancer and to 
individually predict breast cancer specific survival.  
The data from this project suggests that it is not possible to predict lymph node status form 
the primary tumour characteristics with sufficient clinical accuracy to forgo sentinel lymph 
node biopsy. It also suggests that lymph node metastases and distant metastases are 
separate independent events. Lymph node metastases are associated with a complex 
phenotype that is not defined a single genetic mutation and the elucidation of the events 
resulting in this biological cascade are still be to be defined.  
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Chapter 13 
Appendices 
 
13.1. Immunohistochemistry protocols 
For IHC tissue sections were dewaxed in xylene, rehydrated in graded alcohols followed 
by antigen retrieval. The slides were then placed on an automated immunostainer, 
Ventana ES, Ventana BenchMark or Ventana BenchMark XT (Ventana Medical Systems, 
AZ) and run using the iView detection kit (Ventana Medical Systems, AZ). Counter staining 
was performed with haemotoxylin. 
IHC staining was evaluated semiquantitatively using a combination of intensity and 
strength of staining. This scoring system is a modified quickscore system (Detre et al., 
1995a). This system utilizes a combination of percentage of cells staining and intensity of 
staining. 
13.2. miRNA expression in LVI 
13.2.1. Introduction 
Baffa et al (Baffa et al., 2009) performed miRNA analysis on 43 matched primary and 
lymph node metastases of 10 colorectal carcinomas, 10 urothelial carcinomas, 13 breast 
carcinomas and 10 lung carcinomas using miRNA microarrays. This study identified 32 
miRNAs that were differentially expressed between the 43 primary tumours and the related 
lymph node metastasis. Some organ specific differences were also identified in the 
expression profile (Table 6).  
 
Table 6: Thirty-two differentially expressed miRNAs in paired primary and metastatic cancers (Baffa et al., 2009). 
 
Unique id Fold 
change* 
p value t value 
hsa-miR-142-5p 3.3 3.50E-06 4.96 
hsa-miR-146a 2.3 2.12E-05 4.5 
hsa-miR-150 1.7 <1e-07 6.09 
hsa-miR-155 1.7 <1e-07 6.53 
hsa-miR-146b-5p 1.5 0.00244 3.12 
hsa-miR-10b 1.4 0.04552 2.03 
hsa-miR-186 1.4 0.03961 2.09 
hsa-miR-518a-3p 1.4 0.03061 2.2 
hsa-miR-151-3p 1.4 0.01352 2.52 
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hsa-miR-125b-2 1.3 0.03246 2.17 
hsa-miR-520d-3p 1.3 0.01977 2.38 
hsa-miR-342-3p 1.3 7.53E-05 4.16 
hsa-miR-149 1.2 0.03197 2.18 
hsa-miR-671-3p 1.2 0.02785 2.24 
hsa-let-7i 1.1 0.001 3.44 
hsa-miR-99b 0.9 0.00865 −2.69 
hsa-miR-145 0.9 0.04476 −2.04 
hsa-miR-30d 0.8 0.00041 −3.67 
hsa-miR-30a 0.8 0.00892 −2.68 
hsa-miR-24 0.8 0.03506 −2.14 
hsa-miR-93 0.8 0.0425 −2.06 
hsa-miR-133b 0.8 0.04423 −2.04 
hsa-miR-141 0.7 0.00101 −3.41 
hsa-miR-130b 0.7 0.00102 −3.4 
hsa-miR-133a 0.7 0.0187 −2.4 
hsa-miR-143 0.7 0.0227 −2.32 
hsa-miR-340 0.6 0.00023 −3.84 
hsa-miR-200b 0.6 0.00033 −3.74 
hsa-miR-9 0.6 0.00735 −2.75 
hsa-miR-30e 0.6 0.00806 −2.71 
hsa-miR-203 0.6 0.01638 −2.45 
hsa-miR-200c 0.5 0.00027 −3.8 
* Presented as actual change in expression. 
 
This paper presented data for the dysregulation of miRNAs, some of these having been 
reported previously in the literature (Sayed and Abdellatif, 2011) and confirmed the 
involvement of miRNAs in invasion and metastasis (Gotte, 2010).  
13.2.2. Methods 
13.6.1.1. miRNA sequencing protocol 
13.6.1.1.1. Procedure overview 
The procedure is based on Applied Biosystems Ligase-Enhanced Genome 
Detection (LEGenD™) technology (patent pending). 
13.6.1.1.2. Hybridization and ligation to Adaptor Mix 
First, the small RNA sample is hybridized with either Adaptor Mix A or Adaptor 
Mix B. These Adaptor Mixes are sets of oligonucleotides with a single-stranded 
degenerate sequence at one end and a defined sequence required for SOLiD sequencing 
at the other end. Each Adaptor Mix constrains the orientation of the 
Glenn Francis SN: 30358409          Protein expression and molecular profiling to predict lymph node status in breast 
cancer. 
 
 
 
 
 
305 
RNA in the ligation reaction such that hybridization with Adaptor Mix A yields template for 
SOLiD sequencing from the 5' end of the sense strand, while hybridization with Adaptor 
Mix B yields template for sequencing the reverse 
complement (yielding sequence starting from the 3' end of the sense strand). 
Note: To achieve higher confidence in the complete sequence of the larger species of 
small RNAs in a sample, prepare two separate small RNA libraries, using Adaptor Mix A 
for one reaction and Adaptor Mix B for the other. 
After hybridization, the adaptors are ligated to the small RNA molecules using Ligation 
Enzyme Mix, which is a mixture of an RNA Ligase and other components. Ligation 
requires an RNA molecule with a 5'-monophosphate and a 3'-hydroxyl end; therefore, 
most small RNAs can participate in this reaction, and intact mRNA molecules with a 5' cap 
structure are excluded. 
13.6.1.1.3. Reverse transcription and RNase H digestion 
Next, the small RNA population with ligated adaptors is reverse transcribed, to generate 
cDNA. Treatment with RNase H follows, to digest the RNA from RNA/cDNA duplexes and 
to reduce the concentration of unligated adaptors and adaptor by-products. At this point, 
reactions contain cDNA copies of the small RNA molecules in the sample. 
13.6.1.1.4. cDNA Library amplification 
To meet the sample quantity requirements for SOLiD sequencing, and to append the 
required terminal sequences to each molecule, the cDNA library is amplified using one of 
the supplied primer sets and 15–18 cycles of PCR. Limiting the cycle number minimizes 
the synthesis of spurious PCR products and better preserves the small RNA profile of the 
sample. 
Ten sets of PCR primers are included in the kit; they are identical except for a 6 nt 
“barcode” sequence on the 3' (reverse) primer. The 5' PCR primer is identical in each set; 
its sequence corresponds to SOLiD emulsion PCR primer 1. The 3' reverse PCR primers 
are identical except for a 6 nt “barcode” sequence; the SOLiD emulsion PCR primer 2 
sequence (P2) is on the 5' side of the barcode, and the adapter sequence is on the 3' side.  
13.6.1.1.5. Amplified library cleanup and size selection by PAGE 
The final steps in the procedure involve cleanup and size selection of the amplified cDNA 
library to concentrate samples and remove PCR by-products. 
PCR products ~105–150 bp are isolated, corresponding to inserts derived from the small 
RNA population. 
Glenn Francis SN: 30358409          Protein expression and molecular profiling to predict lymph node status in breast 
cancer. 
 
 
 
 
 
306 
13.6.1.1.6. SOLiD sample preparation and sequencing  
The amplified cDNA library generated with the SOLiD Small RNA Expression Kit is ready 
for attachment to beads at the emulsion PCR step of the SOLiD sample preparation 
workflow. 
13.6.1.1.7. RNA extraction from LCM FFPE material 
13.6.1.1.7.1. Paradise Reagent System 
The flow chart illustrates the Paradise Reagent System RNA Extraction/Isolation 
procedure: 
(a) Extract RNA from a CapSure HS LCM Cap. 
(b) Mix and load cell extract onto a preconditioned purification column. 
(c) Spin the extract through the column to capture RNA on the purification column 
membrane. Wash, DNase treat, and wash again. 
(d) Wash the column twice with wash buffer, and 
(e) Elute the RNA in low ionic strength buffer. 
The entire isolation process, including incubations, can be completed in less than an hour, 
and the isolated total cellular RNA is ready for use in downstream applications.  
 
Quality control is performed using a tissue scrape protocol. The protocol enables an 
estimation of RNA quantity and quality using a quantitative real-time PCR assay with 
primers designed to β-actin. The assumption is that the β-actin mRNA in the sample 
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represents the average status of other RNA molecules in the same sample. The total 
estimated RNA amount in a given sample is expressed as an equivalent of universal RNA 
that contains the same amount of β-actin mRNA. 
 
The protocol measures the average β-actin cDNA length by quantification of the PCR 
product yield from the 3’ end (primer 1650-1717) and another relative 5’ sequence (primer 
1355-1472). If all cDNA contains both the 3’ and 5’ sequence target, the ratio of the PCR 
product for 3’/5’ would be 1. As the RNA from FFPE samples tends to exhibit some 
degradation, the 3’/5’ ratio is usually greater than one. Depending on the ratio, an 
estimation of the quality of the RNA can be made. The reaction mixture is analyzed with an 
ABI PRISM 7900HT. 
 
For patient samples, cells are laser capture microdissected onto CapSure® LCM Macro 
caps for primary tumour and lymph nodes. A minimum of 5000 cells were captured using 
the infrared laser to anneal the cells to the thermoplastic polymer followed by cutting of the 
membrane by the ultraviolet laser. Cells from lymphatic spaces were identified by dual IHC 
staining of the initial slide with lymphatic endothelium identified by D2-40 and vascular 
endothelium by Factor VIII. The sequential H & E, dual IHC and LCM slides are correlated 
on the Arcturus XT instrument  to identify lymphatic spaces. RNA was extracted from a 
CapSure LCM Cap using proteinase K. The cell extract is loaded onto a preconditioned 
purification column. The column is centrifuged to capture RNA on the purification column 
membrane. It is then washed, treated with DNase and the RNA eluted in low ionic strength 
buffer. 
 
Linear amplification of mRNA was performed using the Arcturus Paradise system followed 
by gene expression profiling using an Affymetrix platform with X3P chips optimised for 
LCM from FFPE material. 
 
The Paradise® Plus Reagent System RNA Amplification reagents are optimized to amplify 
formalin fixed RNA. The reagents utilize two rounds of a five-step process for linear 
amplification of the mRNA fraction of total cellular RNA: 
a first-strand synthesis reaction that yields cDNA incorporating a T7 promoter 
sequence; 
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b second-strand synthesis reaction utilizing exogenous primers that yields 
doublestranded cDNA; 
c cDNA purification using specially designed MiraCol™ Purification Columns; 
d in vitro transcription (IVT) utilizing T7 RNA polymerase yields antisense RNA 
(aRNA); and 
e aRNA isolation with the MiraCol Purification Columns. 
 
 
Labelling of the product was performed with a number of different protocols to optimise 
recovery. These included Arcturus Turbo labelling kit, Enzo Bioarray HighYield RNA 
Glenn Francis SN: 30358409          Protein expression and molecular profiling to predict lymph node status in breast 
cancer. 
 
 
 
 
 
309 
transcript Biotin Labelling kit, Mirus LabelIT Array Biotin Labelling kit and the Genisphere 
FlashTag Biotin RNA Labelling kit. 
 
13.2.3. Results 
miRNA sequencing was performed from matched samples from a single patient: frozen 
primary breast cancer, laser capture microdissection of FFPE primary tumour, laser 
capture microdissection of FFPE from tumour cells present within lymphatic channels and 
laser capture microdissection of FFPE from a lymph node metastasis. 
 
Preliminary analysis was performed on the data (Table 7). 
 
Table 7: Summary of total tags mapped to miRNA. 
 
Counts 
were 
normali
sed by calculating the reads per 100,000 mapped miRNA reads and the results are shown 
in Tables 8 and 9.  
 
Table 8: Mature-miRNA reads normalised with comparative data for the four samples sequenced. 
 
miRNA LN LCM LVI LCM Primary Frz Primary LCM 
hsa-miR-21 23,128 140 4,532 9,529 
hsa-miR-24-1* 6,086 23,329 328 24,357 
hsa-miR-425 7,350 46 3,433 4,620 
hsa-miR-370 51 23,450 11 2,221 
hsa-miR-29c 4,032 17 6,013 3,872 
hsa-miR-30b 2,410 1,478 9,388 4,846 
hsa-miR-26b 3,646 4 261 1,980 
hsa-miR-26a 3,701 426 660 538 
hsa-miR-23b 3,200 1,135 1,125 640 
hsa-miR-301a 2,940 12 4,363 1,761 
hsa-miR-15b 3,083 10 47 1,808 
hsa-miR-23a 2,758 15 5,014 2,073 
hsa-miR-7-1* 19 8,190 24 3,551 
hsa-miR-130b* 2 6,355 34 4,381 
hsa-miR-191 2,749 733 58 890 
hsa-miR-10b* 0 5,226 15 4,450 
hsa-miR-424 2,565 17 6,264 524 
hsa-miR-143 451 3,089 5,582 3,567 
hsa-miR-30d 2,453 66 84 383 
Total tags mapped to miRNAs     
 LNlcm LVIlcm PRIMARYfz PRIMARYlcm 
Mature miRNAs 1,044,224 296,898 46,665 384,727 
Pre-miRNAs 1,309,491 333,142 72,412 473,176 
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hsa-let-7g 2,244 8 24 847 
hsa-miR-505 215 6,389 9 1,430 
hsa-miR-342-3p 2,121 963 255 174 
hsa-let-7a* 27 5,793 21 2,153 
hsa-miR-126* 1,778 12 4,693 1,284 
hsa-miR-205 1,789 158 54 6 
hsa-miR-19b 1,578 10 3,255 243 
hsa-miR-200a 1,459 4 1,254 134 
hsa-miR-4284 1,190 132 26 800 
hsa-miR-149 1,036 940 13 406 
hsa-miR-30a 1,066 44 3,911 36 
hsa-miR-125a-5p 732 482 11 734 
hsa-miR-197 963 11 13 3 
hsa-miR-660 901 4 4 2 
hsa-let-7f 300 595 527 876 
hsa-miR-101 376 2 2,072 851 
hsa-miR-214 2 1,889 4 653 
hsa-miR-451 525 2 5,574 1 
hsa-miR-106b 256 1 3,523 831 
hsa-miR-151-5p 422 3 6 703 
hsa-miR-223 469 32 4 508 
hsa-miR-10b 0 2,320 0 1 
hsa-miR-182 629 2 4 13 
hsa-miR-17 613 3 6 2 
hsa-miR-125b 479 57 2 221 
hsa-miR-181b 519 0 167 28 
hsa-miR-484 423 2 2,289 1 
hsa-miR-224 0 628 2 944 
hsa-miR-150 511 2 0 2 
hsa-miR-29a 337 1 1,024 236 
hsa-let-7b 299 0 2,683 55 
hsa-miR-345 195 465 0 261 
hsa-miR-31* 140 45 6 688 
hsa-miR-19a 331 1 13 200 
hsa-miR-425* 390 2 0 3 
hsa-miR-769-5p 381 2 2 1 
hsa-miR-193a-3p 340 32 0 1 
hsa-miR-361-5p 284 2 2 174 
hsa-miR-92a 296 1 2 135 
hsa-miR-186 275 31 9 163 
hsa-let-7a 331 0 4 31 
hsa-miR-20a 279 0 1,296 0 
hsa-miR-15b* 305 0 409 0 
hsa-miR-148b 185 1 4 337 
hsa-miR-96 236 1 2 189 
hsa-miR-145 32 414 3,409 0 
hsa-miR-192 0 1 4 812 
hsa-miR-25 160 2 2 322 
hsa-miR-142-5p 1 0 5,604 0 
hsa-miR-487b 0 1 2 654 
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hsa-miR-93 194 1 171 46 
hsa-miR-532-5p 139 208 2 3 
hsa-miR-30e 85 1 11 293 
hsa-miR-199b-3p 1 1 1,382 324 
hsa-miR-200b 3 7 0 475 
hsa-miR-24 63 19 6 286 
hsa-miR-361-3p 166 0 4 1 
hsa-miR-485-3p 0 577 0 1 
hsa-miR-126 5 0 3,227 4 
hsa-miR-140-5p 0 494 0 0 
hsa-miR-221 1 243 1,069 56 
hsa-miR-374b 130 0 0 14 
hsa-miR-183 0 0 2 361 
hsa-miR-217 4 394 2 25 
hsa-miR-21* 22 241 17 80 
hsa-miR-374b* 0 1 2 325 
hsa-miR-190 104 1 223 0 
hsa-miR-145* 0 2 4 307 
hsa-miR-409-3p 0 188 0 156 
hsa-miR-210 0 383 0 2 
hsa-miR-18a* 63 0 0 124 
hsa-miR-140-3p 0 351 4 0 
hsa-miR-100 0 341 0 0 
hsa-miR-151-3p 0 1 2 256 
hsa-miR-340* 0 4 0 249 
hsa-miR-331-3p 10 1 0 224 
hsa-let-7i 84 1 51 10 
hsa-miR-141 84 16 0 0 
hsa-miR-10a 89 0 2 0 
hsa-miR-542-5p 0 1 0 238 
hsa-miR-27a 0 176 0 88 
hsa-miR-148a 0 0 0 210 
hsa-miR-363 0 0 0 206 
hsa-let-7i* 0 266 0 0 
hsa-miR-1248 64 0 0 25 
hsa-miR-340 59 0 0 36 
hsa-miR-200c 0 0 0 176 
hsa-miR-494 0 0 0 172 
hsa-miR-33b 61 0 0 0 
hsa-miR-199b-5p 0 1 1,301 1 
hsa-miR-574-3p 0 0 0 155 
hsa-miR-152 0 0 1,219 0 
hsa-miR-27b 13 0 0 113 
hsa-miR-493 0 191 0 0 
hsa-miR-18a 46 0 0 13 
hsa-miR-107 44 21 0 3 
hsa-miR-181a-2* 0 87 0 64 
hsa-let-7d* 0 0 2 128 
hsa-miR-203 45 0 0 0 
hsa-miR-449a 45 0 0 0 
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hsa-miR-335 45 0 0 0 
hsa-miR-767-5p 0 157 0 0 
hsa-miR-15a 0 1 0 117 
hsa-miR-450a 0 7 0 102 
hsa-miR-148b* 0 24 0 89 
hsa-miR-2114 0 0 0 107 
hsa-miR-376c 38 0 0 0 
hsa-miR-130b 37 0 0 0 
hsa-let-7d 0 0 821 0 
hsa-miR-497 32 0 0 1 
hsa-miR-16-2* 31 0 0 0 
hsa-miR-449c 29 1 0 0 
hsa-miR-545 0 0 654 0 
hsa-miR-590-3p 28 0 0 0 
hsa-miR-9* 27 0 0 0 
hsa-miR-381 1 74 0 0 
hsa-miR-181a* 0 0 0 51 
hsa-miR-1287 16 0 0 0 
hsa-miR-190b 15 0 6 0 
hsa-miR-3607-5p 0 15 221 0 
hsa-miR-423-3p 10 12 0 0 
hsa-miR-122 0 42 0 3 
hsa-miR-99b 0 0 0 31 
hsa-miR-34a 8 0 0 5 
hsa-miR-142-3p 0 0 0 28 
hsa-miR-29c* 0 0 0 25 
hsa-miR-193a-5p 0 31 0 1 
hsa-miR-504 0 0 0 22 
hsa-miR-99b* 0 27 0 0 
hsa-miR-375 7 0 0 0 
hsa-miR-29b-2* 0 24 0 0 
hsa-miR-139-3p 0 23 0 0 
hsa-miR-545* 0 0 131 0 
hsa-miR-195 0 19 0 0 
hsa-miR-1226 0 19 0 0 
hsa-miR-421 0 18 0 0 
hsa-miR-150* 0 15 0 1 
hsa-miR-339-3p 0 10 2 0 
hsa-miR-219-1-3p 0 0 0 8 
hsa-miR-222 0 0 0 8 
hsa-miR-34c-5p 0 3 0 5 
hsa-miR-20b 0 7 0 0 
hsa-miR-20a* 0 3 0 3 
hsa-miR-17* 0 5 0 0 
hsa-miR-325 0 3 0 0 
hsa-miR-654-3p 1 0 0 0 
hsa-miR-22 0 0 0 2 
hsa-miR-30d* 1 0 0 0 
hsa-miR-374a 0 0 0 2 
hsa-miR-671-5p 0 2 0 0 
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hsa-let-7f-2* 0 2 0 0 
hsa-miR-196a* 0 2 0 0 
hsa-miR-22* 0 0 11 0 
hsa-miR-483-3p 0 0 0 1 
hsa-let-7c 0 0 0 0 
hsa-miR-34c-3p 0 1 0 0 
hsa-miR-29b 0 0 0 0 
hsa-miR-542-3p 0 0 0 0 
hsa-miR-218 0 0 9 0 
hsa-miR-4301 0 0 0 0 
hsa-miR-365 0 0 0 0 
hsa-miR-624 0 0 0 0 
hsa-miR-551b 0 0 0 1 
hsa-miR-940 0 2 0 0 
hsa-miR-378 0 0 0 0 
hsa-miR-4286 0 0 0 0 
hsa-miR-1260b 0 1 0 0 
 
Table 9: pre-miRNA reads normalised with comparative data for the four samples sequenced. 
 
miRNA LN LCM LVI LCM Primary Frz Primary LCM 
hsa-mir-21 18,565 343 2,933 7,813 
hsa-mir-24-1 4,853 20,791 211 19,804 
hsa-mir-29b-1 12,627 135 22,049 7,797 
hsa-mir-425 6,172 58 2,214 3,759 
hsa-mir-370 41 20,899 7 1,806 
hsa-mir-29c 3,215 15 3,876 3,168 
hsa-mir-30b 1,922 1,317 6,050 3,940 
hsa-mir-181a-2 2,221 1,198 5,234 2,857 
hsa-mir-26b 2,907 4 168 1,610 
hsa-mir-15b 2,702 9 294 1,470 
hsa-mir-30c-2 2,609 64 3,997 1,086 
hsa-mir-26a-2 2,951 379 425 437 
hsa-mir-23b 2,552 1,011 725 521 
hsa-mir-301a 2,345 11 2,813 1,432 
hsa-mir-10b 0 6,724 12 3,619 
hsa-mir-23a 2,199 14 3,232 1,685 
hsa-mir-7-1 15 7,299 15 2,887 
hsa-mir-130b 31 5,663 22 3,563 
hsa-mir-191 2,192 653 37 723 
hsa-mir-424 2,046 15 4,037 426 
hsa-mir-143 360 2,753 3,597 2,900 
hsa-mir-103-2 1,562 324 2,861 1,308 
hsa-let-7a-3 285 5,163 17 1,775 
hsa-let-7c 1 4,988 22 2,433 
hsa-mir-30d 1,956 59 54 312 
hsa-mir-126 1,422 11 5,104 1,048 
hsa-let-7g 1,789 7 15 689 
hsa-mir-505 172 5,694 6 1,162 
hsa-mir-342 1,692 858 164 142 
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hsa-mir-376b 1 3,073 10 2,304 
hsa-mir-205 1,427 141 35 5 
hsa-mir-19b-2 1,259 9 2,098 198 
hsa-mir-200a 1,163 4 808 109 
hsa-mir-4284 949 118 17 650 
hsa-mir-149 826 837 8 330 
hsa-mir-199a-1 772 4 1,329 478 
hsa-mir-30a 850 39 2,520 30 
hsa-mir-125a 584 429 7 596 
hsa-mir-197 768 10 8 2 
hsa-mir-660 719 3 3 1 
hsa-let-7f-2 239 532 340 712 
hsa-mir-101-2 300 2 1,335 692 
hsa-mir-214 1 1,683 3 531 
hsa-mir-151 337 3 6 780 
hsa-mir-451 419 2 3,592 1 
hsa-mir-106b 204 1 2,270 676 
hsa-mir-223 374 28 3 413 
hsa-mir-182 501 2 3 11 
hsa-mir-17 489 7 4 2 
hsa-mir-125b-2 382 51 1 180 
hsa-mir-181b-2 414 0 108 23 
hsa-mir-484 338 2 1,475 1 
hsa-mir-224 0 560 1 767 
hsa-mir-150 407 15 0 2 
hsa-mir-361 358 2 4 142 
hsa-mir-29a 268 1 660 192 
hsa-let-7b 239 0 1,729 45 
hsa-mir-345 156 414 0 212 
hsa-mir-145 25 370 2,200 250 
hsa-mir-31 112 40 4 559 
hsa-mir-19a 264 1 8 163 
hsa-mir-769 304 2 1 0 
hsa-let-7a-2 287 0 6 25 
hsa-mir-193a 271 56 0 1 
hsa-mir-148b 148 22 3 346 
hsa-mir-92a-2 236 1 1 110 
hsa-mir-186 220 28 6 133 
hsa-mir-20a 222 3 835 2 
hsa-mir-96 188 1 1 154 
hsa-mir-192 0 1 3 660 
hsa-mir-25 128 2 1 262 
hsa-mir-142 0 0 3,611 23 
hsa-mir-374b 103 1 1 276 
hsa-mir-487b 0 1 1 532 
hsa-mir-199b 1 1 1,729 264 
hsa-mir-140 0 753 3 0 
hsa-mir-421 0 751 0 0 
hsa-mir-93 155 2 110 37 
hsa-mir-532 111 185 1 2 
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hsa-mir-30e 68 1 7 238 
hsa-mir-200b 2 6 0 386 
hsa-mir-24-2 50 17 4 232 
hsa-let-7i 67 237 33 8 
hsa-mir-340 47 4 0 232 
hsa-mir-485 0 514 0 1 
hsa-mir-18a 87 0 0 112 
hsa-mir-221 1 216 689 46 
hsa-mir-183 0 0 1 293 
hsa-mir-217 3 351 1 20 
hsa-mir-190 83 1 144 0 
hsa-mir-409 0 167 0 127 
hsa-mir-210 0 341 0 2 
hsa-mir-1274b 0 5 0 216 
hsa-mir-100 0 304 0 0 
hsa-mir-331 8 1 0 182 
hsa-mir-141 67 14 0 0 
hsa-mir-10a 71 0 1 0 
hsa-mir-542 0 1 0 193 
hsa-let-7d 0 0 530 104 
hsa-mir-27a 0 157 0 72 
hsa-mir-148a 0 0 0 171 
hsa-mir-363 0 0 0 168 
hsa-mir-1248 52 0 0 22 
hsa-mir-181b-1 0 0 0 149 
hsa-mir-382 0 206 0 0 
hsa-mir-200c 0 0 0 143 
hsa-mir-494 0 0 0 140 
hsa-mir-33b 49 0 0 0 
hsa-mir-574 0 0 0 126 
hsa-mir-152 0 0 786 0 
hsa-mir-493 0 170 0 0 
hsa-mir-27b 10 0 0 92 
hsa-mir-1274a 0 161 0 0 
hsa-mir-107 35 18 0 2 
hsa-mir-3607 0 14 146 75 
hsa-mir-203 36 1 0 1 
hsa-mir-16-1 35 1 11 3 
hsa-mir-449a 36 0 0 0 
hsa-mir-335 36 0 0 0 
hsa-mir-767 0 140 0 0 
hsa-mir-15a 0 1 0 95 
hsa-mir-450a-2 0 7 0 83 
hsa-mir-2114 0 0 0 87 
hsa-mir-376c 30 0 0 0 
hsa-mir-545 0 0 505 0 
hsa-mir-497 26 0 0 0 
hsa-mir-16-2 25 0 0 0 
hsa-mir-9-2 24 0 3 0 
hsa-mir-449c 23 1 0 0 
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hsa-mir-590 23 0 0 0 
hsa-mir-9-3 22 0 0 0 
hsa-mir-381 1 66 0 0 
hsa-mir-99b 0 24 0 25 
hsa-mir-181a-1 0 0 0 41 
hsa-mir-1287 13 0 0 0 
hsa-mir-190b 12 0 4 0 
hsa-mir-423 8 11 0 0 
hsa-mir-122 0 37 0 2 
hsa-mir-3929 6 3 18 4 
hsa-mir-34a 7 0 0 4 
hsa-mir-504 0 0 0 18 
hsa-mir-3676 3 8 0 1 
hsa-mir-375 6 0 0 0 
hsa-mir-29b-2 0 22 0 0 
hsa-mir-139 0 21 0 0 
hsa-mir-1234 0 13 0 3 
hsa-mir-195 0 17 0 0 
hsa-mir-1226 0 17 0 0 
hsa-mir-339 0 9 1 0 
hsa-mir-34c 0 3 0 4 
hsa-mir-219-1 0 0 0 6 
hsa-mir-222 0 0 0 6 
hsa-mir-196a-1 2 0 0 0 
hsa-mir-3195 0 5 0 1 
hsa-mir-20b 0 7 0 0 
hsa-mir-620 0 6 0 0 
hsa-mir-3648 0 5 0 0 
hsa-mir-22 0 0 7 1 
hsa-mir-654 1 0 0 0 
hsa-mir-325 0 2 0 0 
hsa-mir-671 0 2 0 0 
hsa-mir-374a 0 0 0 1 
hsa-mir-558 0 0 1 0 
hsa-mir-196a-2 0 2 0 0 
hsa-mir-483 0 0 0 1 
hsa-mir-218-2 0 0 6 0 
hsa-mir-3908 0 0 1 0 
hsa-mir-579 0 0 0 0 
hsa-mir-4301 0 0 0 0 
hsa-mir-551b 0 0 0 0 
hsa-mir-940 0 1 0 0 
hsa-mir-3138 0 0 0 0 
hsa-mir-4286 0 0 0 0 
hsa-mir-1303 0 1 0 0 
hsa-mir-378 0 0 0 0 
hsa-mir-624 0 0 0 0 
hsa-mir-1260b 0 1 0 0 
hsa-mir-365-2 0 0 0 0 
hsa-mir-1322 0 0 0 0 
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hsa-mir-198 0 0 0 0 
hsa-mir-552 0 0 0 0 
hsa-mir-3118-5 0 0 0 0 
hsa-mir-1243 0 0 0 0 
hsa-mir-1247 0 0 0 0 
hsa-mir-663 0 0 0 0 
hsa-mir-758 0 0 0 0 
hsa-mir-578 0 0 0 0 
hsa-mir-92b 0 0 0 0 
hsa-mir-153-1 0 0 1 0 
hsa-mir-550b-2 0 0 0 0 
hsa-mir-628 0 0 0 0 
hsa-mir-4268 0 0 0 0 
hsa-mir-144 0 0 0 0 
hsa-mir-1285-1 0 0 0 0 
hsa-mir-580 0 0 0 0 
hsa-mir-454 0 0 0 0 
hsa-mir-378c 0 0 0 0 
hsa-mir-3936 0 0 0 0 
hsa-mir-3658 0 0 0 0 
hsa-mir-3652 0 0 0 0 
hsa-mir-3154 0 0 1 0 
 
A scatterplot of the results shows differences in expression between the different sample 
types and in particular there are differences in the expression profile for the LVI derived 
cells compared to both the primary and metastatic tumour (Figure 10). 
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Figure 10: Scatterplot showing normalised expression of miRNAs in different sample types. 
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There is a reduction in expression of miR-21, miR15b, miR-23a, miR-29c, miR-301a and 
miR-425 in the LVI cells compared to primary FFPE LCM and lymph node LCM specimens 
with increased relative expression of miR-10b and miR 370. Expression of miR-21 was 
higher in the lymph node metastasis compared to the primary tumour. 
13.2.4. Discussion 
There was a low number of miRNA reads (<1% of the total read count). This was not 
unexpected as the material was of low yield, being predominantly from LCM FFPE 
material. LCM collects cells onto a thermoplastic polymer cap for analysis. The number of 
cells varies in any capture, but is usually only in the 100s-1000s. A mammalian cell 
contains approximately 10-30 pg of total RNA with mRNA comprising approximately 1-3% 
of total RNA. miRNA constitutes a small percentage of available material. The majority of 
RNA in cells is composed of rRNA (more than 80%). Whilst there are methods to remove 
or reduce the amount of rRNA from samples, these methods rely on intact rRNA to be 
effective. The crosslinking and fragmentation of nucleic acids in FFPE material makes 
these approaches ineffective. Therefore the majority of the material sequenced from FFPE 
material is either fragmented rRNA or empty adapters due to the low amount of starting 
material. This results in a small percentage of reads mapping back to a reference miRNA 
database. 
 
This preliminary data from a single patient indicates that it is possible to use next 
generation sequencing to identify miRNA from LCM FFPE material with low amounts of 
starting material. The expression data is also consistent with published data in the 
literature. miR-10b is increased in the LVI cells and has previously been shown to enhance 
migration and invasion in vitro and metastasis in vivo (Ma et al., 2007a). miR-21 shows a 
reduced expression in the LVI cells, compared to the primary tumour and there is 
increased expression in the lymph node metastasis. miR-21 expression is associated with 
invasion and migration (Hurst et al., 2009b) and high levels of miR-21 expression in breast 
cancer has been associated with aggressive disease, high tumour grade and negative 
hormone receptor status (Qian et al., 2009). Data also suggests that miR-21 may have a 
potential role in promoting tumour invasion and metastasis by simultaneously down-
regulating multiple metastasis-related tumour suppressor genes (Zhu et al., 2008). 
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13.3. Additional results for breast cancer cluster at the ABC Studio in 
Toowong.  
13.3.1. Results 
Images of the TMA sections are illustrated in Figures 11, 12 and 13 for different patient 
cases.  
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Figure 11: IHC/ISH stained TMA sections for cases A10595 (left) and A10599 (Right). 
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Figure 12: IHC/ISH stained TMA sections for cases A10605 (left) and A10608 (Right). 
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Figure 13: IHC/ISH stained TMA sections for case A10611. 
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13.4. Additional results for Prediction of Molecular Grade using an Artificial 
Neural Network (ANN).  
13.4.1. Results 
TMA results are illustrated for a Grade 3 breast carcinoma case showing IHC for multiple 
markers including BUB1B, RaCGAP1, RRM2, NEK2 and CENPA (Figures 14, 15 and 16). 
 
Figure 14: IHC on TMAs for multiple markers in a Grade 3 breast carcinoma.
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Figure 15: IHC on TMAs for multiple markers in a Grade 3 breast carcinoma. 
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Figure 16: IHC on TMAs for multiple markers in a Grade 3 breast carcinoma. 
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13.5. Development and analysis of ANN models for prediction of lymph node 
status.  
13.5.1. Introduction 
NeuralWorks Predict® and NeuralSight® were used to develop a classification algorithm 
for the presence of lymph node metastases in breast cancer based on characteristics of 
the primary tumour. Variables were used that could be identified in core biopsy samples, 
as the primary method of breast cancer diagnosis is now a biopsy specimen. In the 1990’s 
the most common method of initial breast carcinoma diagnosis was by frozen section, but 
this method would rarely be used today. Sixty-nine patients with complete datasets were 
used to develop the models. An additional 27 patients were used for validation. 
The input variables used for the development of the models are listed in Table 18. 
 
Table 10: Input variables for development of ANN models. 
Input Variable Criteria/Localisation of IHC 
Age Continuous 
Tumour type modified Ductal/Lobular/Mucinous/Papillary 
Grade 1/2/3 
Tubule formation 1/2/3 
Nuclear pleomorphism 1/2/3 
Mitotic Rate Rmm2 Continuous 
Tumour border Infiltrating/Pushing 
Lymphoplasmacytic infiltrate Mild/Moderate/Marked 
nm-23 H-1-C Percentage Cytoplasmic 
nm-23 H-1-C Strength  
nm23H1-Cscore  
nm-23 H-1-C percentage negative Negative cytoplasmic 
nm-23 H-1-C negative cells  
nm-23 H-1-N % Pos Nuclear 
nm-23 H-1-N Strength  
nm23H1-Nscore  
ER percentage Nuclear 
ER strength  
ERscore  
PR percentage Nuclear 
PR strength  
PRscore  
c-erbB-2m percentage Membrane 
c-erbB-2m strength  
c-erbB-2Mscore  
c-erbB-2c percentage Cytoplasmic 
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c-erbB-2c strength  
c-erbB-2Cscore  
A0485m% Membrane 
A0485m Strength  
A0485m Score  
A0485c% Cytoplasmic 
A0485c Strength  
A0485c Score  
TAB 250m% Membrane 
TAB250mStrength  
TAB 250 Score  
HER-2 status Negative/Equivocal/Positive 
p53 percentage Nuclear 
p53 strength  
p53score  
bcl2-N% Nuclear 
bcl2-N strength  
bcl2Nscore  
bcl2-C % Cytoplasmic 
bcl2-C strength  
bcl2Cscore  
CD9 percentage Membrane 
CD9 strength  
CD9score  
CD9 Neg%  
KAI1C % Cytoplasmic 
KAI1C strength  
KAI1Cscore  
KAI1 N % Pos Nuclear 
KAI1 N Strength  
KAI1Nscore  
KAI1 N % Neg  
Rb 1 percentage Nuclear 
Rb1 Strength  
Rb1 Score  
VEGF-C % Cytoplasmic 
VEGF-C Strength  
VEGF-C Score  
VEGF-N% Nuclear 
VEGF-N Strength  
VEGF-N Score  
p27 % Nuclear 
p27 Strength  
p27 Score  
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MIB1 % F Nuclear 
MVD mm2 Continuous 
p-glycoprotein C% Cytoplasmic 
p-glycoprotein C Strength  
p-glycoprotein C Score  
p-glycoprotein M% Membrane 
p-glycoprotein M Strength  
p-glycoprotein M Score  
TMA AB CA IX score Cytoplasmic 
TMA AB IHC NGFR score Cytoplasmic 
TMA AB Osteopontin score Cytoplasmic 
TMA AB p63 score Nuclear 
TMA AB P cadherin Membrane 
TMA AB CK14 score Cytoplasmic 
TMA AB IHC SMA Cytoplasmic 
TMA AB CK 5 & 6 Cytoplasmic 
TMA AB IHC PR Nuclear 
TMA AB IHC ER Nuclear 
TMA AB IL8 Score Cytoplasmic 
TMA AB IL8 Stroma Cytoplasmic 
TMA AB IL8 Endothelium Cytoplasmic 
TMA AB 1SSB Score Nuclear 
TMA AB 1SSB Cytoplasm Cytoplasmic 
TMA AB chk2 Nuclear 
TMA AB chk2 Cytoplasm Cytoplasmic 
TMAAB HER2 (4B5) Membrane 
TMA AB Cyclin E Score Nuclear 
TMA AB Cyclin E Membrane Membrane 
TMA AB Cyclin D1 Score Nuclear 
TMA AB Cyclin D1 Cytoplasmic Cytoplasmic 
TMA AB c-met Membrane 
TMA AB S100A4 score Cytoplasmic 
TMA AB CEP55 Intensity Cytoplasmic 
TMA AB AB Crystallin Intensity Cytoplasmic 
TMA AB AB Crystallin Percentage  
TMA AB AB Crystallin Score  
TMA SCL7A5 Cytoplasmic 
TMA p53 Nuclear 
TMA NDRG1 Cytoplasmic 
TMA HTF9C Cytoplasmic 
TMA CEACAM5 Cytoplasmic 
TMA NCSTN Cytoplasmic 
TMA TRIM29 Cytoplasmic 
Mammostrat score  
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Mammostrat category Good/Moderate/Poor 
 
 
13.5.2. Results 
Morphological diagnosis was performed on whole tissue sections with some IHC 
performed on these sections with subsequent analysis of TMA sections for multiple 
markers. Examples of results for IHC staining on whole tissue sections are illustrated in 
Figures 17 – 34. 
Figure 17: IHC for oestrogen receptor showing weak nuclear staining in an infiltrating lobular carcinoma (Magnification 
8X). 
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Figure 18: IHC for oestrogen receptor showing strong nuclear staining in an infiltrating ductal carcinoma (Magnification 
10X). 
 
 
 
Figure 19: IHC for oestrogen receptor showing focal nuclear staining in an infiltrating ductal carcinoma (Magnification 
10X). 
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Figure 20: IHC for oestrogen receptor showing no nuclear staining in an infiltrating ductal carcinoma (Magnification 8X). 
 
 
 
Figure 21: IHC for nm23H1 showing weak cytoplasmic staining in an infiltrating ductal carcinoma (Magnification 8X). 
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Figure 22: IHC for nm23H1 showing strong cytoplasmic staining in an infiltrating ductal carcinoma (Magnification 8X). 
 
 
 
Figure 23: IHC for VEGF-C showing weak cytoplasmic staining in an infiltrating ductal carcinoma (Magnification 8X). 
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Figure 24: IHC for VEGFC showing strong cytoplasmic staining in an infiltrating lobular carcinoma (Magnification 8X). 
 
 
 
Figure 25: IHC for HER2 (Clone TAB250) showing strong membrane staining in an infiltrating ductal carcinoma 
(Magnification 10X). A normal breast lobule with negative staining is illustrated on the right. 
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Figure 26: IHC for HER2 (Polyclonal A0485) showing strong membrane staining in the same infiltrating ductal carcinoma 
(Magnification 10X) as in Figure 53. 
 
 
 
Figure 27: IHC for CD9 showing strong membrane staining in an infiltrating ductal carcinoma (Magnification 8X). 
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Figure 28: IHC for p27 showing strong staining in an infiltrating ductal carcinoma (Magnification 8X). 
 
 
 
Figure 29: IHC for p27 showing weak staining in an infiltrating ductal carcinoma (Magnification 10X). 
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Figure 30: IHC for p27 showing negative staining in an infiltrating ductal carcinoma (Magnification 8X). 
 
 
 
Figure 31: IHC for RB1 showing strong staining in an infiltrating ductal carcinoma (Magnification 10X). 
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Figure 32: IHC for RB1 showing weak nuclear staining in an infiltrating ductal carcinoma (Magnification 10X). 
 
 
 
Figure 33: IHC for p-glycoprotein showing moderate cytoplasmic staining in an infiltrating ductal carcinoma (Magnification 
10X). 
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Figure 34: IHC for p-glycoprotein showing negative staining in an infiltrating ductal carcinoma (Magnification 10X). 
 
 
 
Results of a case are illustrated in Figures 35 – 37 for multiple biomarkers using TMAs. 
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Figure 35: IHC on TMAs for multiple biomarkers in an illustrative breast carcinoma. 
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Figure 36: IHC on TMAs for multiple biomarkers in an illustrative breast carcinoma. 
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Figure 37: IHC on TMAs for multiple biomarkers in an illustrative breast carcinoma. 
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Multiple different models were constructed using variations in the input parameters with 
modifications to the ANN to include noisy data, moderately noisy data and comprehensive 
and exhaustive variable selection.  
Model 74 showed a Sensitivity of 91.7%, a Specificity of 100%, a Positive Predictive Value 
of 100% and a Negative Predictive Value of 91.7%. The overall accuracy of the model was 
95.8% (Figure 38). 
 
Figure 38: Error distribution by class for ANN Model 74. 
 
 
 
For Model 74 a Sensitivity analysis (Figure 40) and ROC (Figure 41) are generated by 
NeuralSight®. 
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Figure 39: Sensitivity analysis for ANN Model 74. 
 
 
 
Figure 40: ROC Curve for ANN Model 74. 
 
 
 
Model 86 showed a Sensitivity of 100%, a Specificity of 97%, a Positive Predictive Value 
of 97% and a Negative Predictive Value of 100%. The overall accuracy of the model was 
98.5% (Figure 41). 
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Figure 41: Error distribution by class for ANN Model 86. 
 
 
 
For Model 86 the Sensitivity analysis is shown in Figure 42 and ROC Curve in Figure 43. 
Figure 42: Sensitivity analysis for ANN Model 86. 
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Figure 43: ROC Curve for ANN Model 86. 
 
 
 
Cross tabulation was performed using the 96 patient dataset (training and validation sets). 
Using this combined dataset with ANN Model 74 (Table 11, Figure 44), the Sensitivity is 
80.9%, the Specificity is 87.8%, the Positive Predictive Value is 86.4% and the Negative 
Predictive Value is 82.7%. 
 
Table 11: Cross Tabulation table for ANN model 74 for 96 patients. 
 
Counts Table   
 LN2_74   
Positive_nodal_status 
 n y Total 
N 43 9 52 
Y 6 38 44 
Total 49 47 96 
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Figure 44: Plot of positive lymph node status for Model LN_74. 
 
 
 
ANN Model 86 showed the same results (Table 12, Figure 45), with a Sensitivity of 80.9%, 
a Specificity of 87.8%, a Positive Predictive Value of 86.4% and a Negative Predictive 
Value of 82.7%. 
Table 12: Cross Tabulation table for ANN model 86 for 96 patients. 
 
Counts Table   
 LN2_86   
Positive_nodal_status 
 n y Total 
N 43 9 52 
Y 6 38 44 
Total 49 47 96 
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Figure 45: Plot of positive lymph node status for Model LN_86. 
 
 
 
Data for both models was combined with a predicted positive nodal status being defined 
as called positive with either ANN Model 74 and/or ANN Model 86 (Table 13, Figure 46). 
 
Table 13: Plot of positive lymph node status for combined Model LN74_86. 
 
Counts Table   
 LN74_86   
Positive_nodal_status 
 n y Total 
N 39 13 52 
Y 4 40 44 
Total 43 53 96 
 
Figure 46: Plot of positive lymph node status for Model LN74_86. 
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The combined data from both the ANN Model 74 and ANN Model 86 showed a Sensitivity 
of 75.5%, a Specificity of 90.7%, a Positive Predictive Value of 90.9% and a Negative 
Predictive Value of 75%. 
 
13.5.3. Discussion 
Whilst the ANN was able to generate models that accurately predicted lymph node status 
from characteristics of the primary tumour, the models failed to generalise for use in a 
separate validation data set.  Different parameters were tried with similar results. 
NeuralWorks Predict® was also used with different input variables. NeuralWorks Predict® 
is able to accommodate incomplete dataset entries for individual patients and models were 
evaluated to cover additional variables (Table 14).  
 
Table 14: Additional variables used for development of ANN models. 
Input Variable Localisation 
Tumour vol macro  
Max Macro  
Macro Vol  
Tumour vol micro  
Max Micro  
Micro Vol  
Tumour border  
Satellite lesion  
Multifocal  
Multicentric  
Lymphoplasmacytic infiltrate  
Lymphatic invasion  
Vascular invasion  
Nipple involvement-lymphatic  
Nipple - DCIS  
Nipple-Stromal infiltration  
Pagets  
p120 % Membrane 
p120 Strength  
p120 Score  
catenin % Membrane 
catenin strength  
catenin Score  
E-cad percent Membrane 
E-cad strength  
E-cad Score  
 
A number of models used TAB250 membrane strength as the dominant variable for 
prediction of lymph node status (Figure 39 and Figure 42). TAB250 is an antibody used for 
Glenn Francis SN: 30358409          Protein expression and molecular profiling to predict lymph node status in breast 
cancer. 
 
 
 
 
 
350 
IHC that binds to the extracellular domain of the HER2 protein. This correlates with the 
worse prognosis associated with HER2-positive breast cancer patients. 
No model was able to predict lymph node status with sufficient accuracy to enable 
consideration of implementation into clinical practice. 
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13.6. Development and analysis of ANN models for prediction of breast 
cancer specific survival in lymph node negative patients.  
13.6.1. Introduction 
NeuralWorks Predict® and NeuralWare Professional II Plus® were used to develop a 
prediction algorithm for breast cancer specific survival in lymph node negative breast 
cancer patients. Time was used as a variable in the program input variables. Table 15 
shows the input variables used for the prediction model. A total of 138 patients were used 
in the model development with stratification of the samples into training, testing and 
validation sets. 
Table 15: Input variables used for ANN. 
 
Hormonal Status 
Age 
Tumour type 
Grade 
Tubule formation 
Nuclear pleomorphism 
Mitotic Rate Rmm2 
Max Micro 
Micro Vol 
Tumour border 
Satellite lesion 
Multifocal 
Multicentric 
Lymphoplasmacytic infiltrate 
Resections margins 
Lymphatic invasion 
Vascular invasion 
Nipple involvement-lymphatic 
Nipple-Stromal infiltration 
Pagets 
Skin involvement-lymphatic 
Skin Involvement-stroma 
Number of Positive Nodes 
Total Number of Nodes 
Positive nodal status 
Apical node involvement 
ExtraNodal spread 
Micrometastases 
Macrometastases 
nm-23 H-1-C Percentage 
nm-23 H-1-C Strength 
nm23H1-Cscore 
nm-23 H-1-C percentage negative 
nm-23 H-1-C negative cells 
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nm-23 H-1-N % Pos 
nm-23 H-1-N Strength 
nm23H1-Nscore 
ER percentage 
ER strength 
ERscore 
PR percentage 
PR strength 
PRscore 
c-erbB-2m percentage 
c-erbB-2m strength 
c-erbB-2Mscore 
c-erbB-2c percentage 
c-erbB-2c strength 
c-erbB-2Cscore 
A0485m% 
A0485m Strength 
A0485m Score 
A0485c% 
A0485c Strength 
A0485c Score 
p53 percentage 
p53 strength 
p53score 
bcl2-N% 
bcl2-N strength 
bcl2Nscore 
bcl2-C % 
bcl2-C strength 
bcl2Cscore 
CD9 percentage 
CD9 strength 
CD9score 
CD9 Neg% 
KAI-1C  percentage 
KAI-1C strength 
KAI-1Cscore 
KAI-1 C % negative 
KAI-1 N % Pos 
KAI-1 N Strength 
KAI-1Nscore 
KAI-1 N % Neg 
TAB 250m% 
TAB250mStrength 
TAB 250 Score 
Rb 1 percentage 
Rb1 Strength 
Rb1 Score 
VEGF-C % 
VEGF-C Strength 
VEGF-C Score 
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VEGF-N% 
VEGF-N Strength 
VEGF-N Score 
p27 % 
p27 Strength 
p27 Score 
MIB1 % F 
MVD mm2 
p-glycoprotein C% 
p-glycoprotein C Strength 
p-glycoprotein C Score 
p-glycoprotein M% 
p-glycoprotein M Strength 
p-glycoprotein M Score 
Palpability 
Surgical Treatment 
Breast reconstruction 
Combination chemotherapy 
Toremifene 
Tamoxifen 
Highdose chemo 
Ovarian ablation 
Radiotherapy pre mastectomy 
Local radiotherapy after lumpectomy 
Post mastectomy XRT 
 
13.6.2. Results 
A number of models were developed to enable prediction of BCSS for individual patients. 
The accuracy of the models is indicated in Table 16. 
Table 16: Analysis of ANN model for prediction of BCSS. 
 
Model 1 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9683189 0.9683189 0.03992268 0.9918341 0.09329377 0.9681471 0.1813712 9952 
Train 0.971567 0.971567 0.03890297 0.9788387 0.0898455 0.9696698 0.1746878 5572 
Test 0.9625783 0.9625783 0.04248443 0.9918341 0.1002246 0.9636895 0.1949362 2396 
Valid 0.9653994 0.9653994 0.03969276 0.9530491 0.09411453 0.969254 0.1830754 1984 
 
Model 4 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9701439 0.9701439 0.04322206 0.9858124 0.08961993 0.9756913 0.1742292 9873 
Train 0.9757502 0.9757502 0.04155975 0.8926328 0.08184663 0.9782805 0.1591358 5525 
Test 0.9656347 0.9656347 0.04382167 0.9858124 0.09605615 0.9735738 0.1868291 2384 
Valid 0.9589324 0.9589324 0.04717053 0.985256 0.1016397 0.9709776 0.1977153 1964 
 
Model 5 
Death 
from 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
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disease 
All 0.9701439 0.9701439 0.04322206 0.9858124 0.08961993 0.9756913 0.1742292 9873 
Train 0.9757502 0.9757502 0.04155975 0.8926328 0.08184663 0.9782805 0.1591358 5525 
Test 0.9656347 0.9656347 0.04382167 0.9858124 0.09605615 0.9735738 0.1868291 2384 
Valid 0.9589324 0.9589324 0.04717053 0.985256 0.1016397 0.9709776 0.1977153 1964 
 
Model 6 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9562074 0.9562074 0.05449945 0.901729 0.1076865 0.9564469 0.2093522 9873 
Train 0.9604197 0.9604197 0.05269169 0.901729 0.1034222 0.960181 0.2010855 5525 
Test 0.9570406 0.9570406 0.05511421 0.8827108 0.1069765 0.9584732 0.2080692 2384 
Valid 0.9424571 0.9424571 0.05883866 0.8483678 0.1196406 0.9434827 0.2327314 1964 
 
Model 7 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9728041 0.9728041 0.04552943 0.9395897 0.08509292 0.9708295 0.1654282 9873 
Train 0.9773541 0.9773541 0.0429435 0.9395897 0.07851739 0.9737557 0.1526627 5525 
Test 0.969571 0.969571 0.04804412 0.9382062 0.09027685 0.9685403 0.1755884 2384 
Valid 0.9631481 0.9631481 0.04975152 0.8516374 0.09572736 0.9653768 0.1862142 1964 
 
Model 8 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9705003 0.9705003 0.04494727 0.9773265 0.08817631 0.9659678 0.1714226 9873 
Train 0.9748199 0.9748199 0.04275449 0.925543 0.08227392 0.9692308 0.1599666 5525 
Test 0.9683646 0.9683646 0.04664741 0.9773265 0.09158222 0.9643456 0.1781273 2384 
Valid 0.96016 0.96016 0.04905216 0.9240964 0.09930804 0.9587576 0.1931795 1964 
 
Model 9 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9643049 0.9643049 0.04941627 1.018502 0.0972417 0.9655628 0.1890466 9844 
Train 0.9673396 0.9673396 0.04809762 0.9551042 0.09186941 0.9670111 0.1786233 5517 
Test 0.9596448 0.9596448 0.05117679 1.018502 0.1056069 0.9622561 0.2054066 2358 
Valid 0.9618613 0.9618613 0.05100269 0.9876812 0.1013435 0.9654647 0.1971386 1969 
 
Model 10 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9643328 0.9643328 0.04942197 1.018502 0.09753393 0.9652735 0.189615 9762 
Train 0.9626197 0.9626197 0.04969383 1.018502 0.09917076 0.9640445 0.1928198 5479 
Test 0.9657402 0.9657402 0.05011302 0.8630665 0.0965404 0.9640565 0.1877733 2337 
Valid 0.9673443 0.9673443 0.04782663 0.9512262 0.09401018 0.9701953 0.1828751 1946 
 
Model 11 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9486263 0.9486263 0.04332662 0.9566832 0.08806778 0.9761346 0.1712065 12361 
Train 0.9528273 0.9528273 0.04230153 0.9448596 0.0837947 0.9778966 0.1629147 6922 
Test 0.9396203 0.9396203 0.04512379 0.9566832 0.09565381 0.9737108 0.186024 2967 
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Valid 0.9482878 0.9482878 0.04403996 0.9212241 0.09021928 0.97411 0.1754725 2472 
 
Model 12 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9442828 0.9442828 0.04331891 0.8920973 0.09278711 0.97662 0.180381 12361 
Train 0.9451154 0.9451154 0.04271107 0.8859505 0.09142593 0.9773187 0.1777515 6922 
Test 0.9464115 0.9464115 0.04321826 0.8796806 0.091033 0.9784294 0.1770376 2967 
Valid 0.9397061 0.9397061 0.04514178 0.8920973 0.09848142 0.9724919 0.1915421 2472 
 
Model 13 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9191191 0.9191191 0.04623149 0.9562494 0.1096698 0.9631098 0.2132015 12361 
Train 0.9230137 0.9230137 0.04535891 0.9562494 0.1062073 0.9648945 0.2064895 6922 
Test 0.9188482 0.9188482 0.04654289 0.9525762 0.1100344 0.9615774 0.2139908 2967 
Valid 0.9090645 0.9090645 0.0483011 0.9554956 0.1184246 0.9599515 0.2303307 2472 
 
Model 14 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9274038 0.9274038 0.06127508 0.9776498 0.1076563 0.9652132 0.2092873 12361 
Train 0.938977 0.938977 0.06208301 0.9348407 0.1090963 0.9620733 0.2121178 5537 
Test 0.9366283 0.9366283 0.06122585 0.9203587 0.110388 0.968829 0.2147051 2374 
Valid 0.9234235 0.9234235 0.06331819 0.9776498 0.1125795 0.9607605 0.2189623 2472 
 
Model 15 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9611858 0.9611858 0.0545365 0.9088011 0.08536106 0.9769436 0.1659446 12361 
Train 0.9628542 0.9628542 0.05386386 0.9088011 0.0835251 0.9779242 0.1623837 8652 
Test 0.9575254 0.9575254 0.05610556 0.8603248 0.08949753 0.9746562 0.1740343 3709 
Valid 0.9611858 0.9611858 0.0545365 0.9088011 0.08536106 0.9769436 0.1659446 12361 
 
Model 16 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9627222 0.9627222 0.03542585 0.9710088 0.07736106 0.9770245 0.1503923 12361 
Train 0.9635464 0.9635464 0.03509719 0.9710088 0.07599323 0.976884 0.1477407 8652 
Test 0.9608842 0.9608842 0.03619252 0.8454505 0.08046146 0.9773524 0.156463 3709 
Valid 0.9627222 0.9627222 0.03542585 0.9710088 0.07736106 0.9770245 0.1503923 12361 
 
Model 17 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9537181 0.9537181 0.0451647 0.9282653 0.08414366 0.9716851 0.1635779 12361 
Train 0.9534523 0.9534523 0.0451846 0.8522717 0.08470036 0.9707582 0.1646685 8652 
Test 0.9543585 0.9543585 0.04511828 0.9282653 0.08283049 0.9738474 0.1610697 3709 
Valid 0.9537181 0.9537181 0.0451647 0.9282653 0.08414366 0.9716851 0.1635779 12361 
 
Model 18 
Death R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
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from 
disease 
All 0.959847 0.959847 0.04663718 0.7855781 0.08368305 0.9648087 0.1626824 12361 
Train 0.960061 0.960061 0.04644928 0.7855781 0.0833953 0.9660194 0.1621313 8652 
Test 0.9593695 0.9593695 0.04707549 0.7670119 0.08435045 0.9619844 0.1640254 3709 
Valid 0.959847 0.959847 0.04663718 0.7855781 0.08368305 0.9648087 0.1626824 12361 
         
Model 19 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9706777 0.9706777 0.03681564 0.9505244 0.06690413 0.9847909 0.1300637 12361 
Train 0.9727891 0.9727891 0.03624907 0.8932483 0.0642433 0.9867083 0.1248973 8652 
Test 0.9659095 0.9659095 0.0381373 0.9505244 0.07273365 0.9803181 0.1414357 3709 
Valid 0.9706777 0.9706777 0.03681564 0.9505244 0.06690413 0.9847909 0.1300637 12361 
 
Model 20 
Death 
from 
disease 
R Net-R Avg. Abs. Max. Abs. RMS Accuracy (20%) Conf. Interval (95%) Records 
All 0.9505929 0.9505929 0.04562325 0.9085212 0.08645324 0.9708206 0.1680654 14051 
Train 0.9508882 0.9508882 0.04560892 0.8646238 0.08623064 0.9707168 0.1676402 9835 
Test 0.9499053 0.9499053 0.04565668 0.9085212 0.08697029 0.9710626 0.1691118 4216 
 
Probability survival curves were plotted over time for individual breast cancer patients with 
a composite curve illustrated in Figure 47 and individual curves illustrated in Figures 48 - 
50. 
Figure 47:   Composite graph of predicted individual survival curves for different models compared to the actual survival. 
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Figure 48: Probability survival curve for individual Patient comparing actual survival and predicted survival by ANN. 
 
 
 
Figure 49: Probability survival curve for individual Patient comparing actual survival and predicted survival by ANN. 
 
 
 
 
 
 
 
 
Figure 50: Probability survival curve for individual Patient comparing actual survival and predicted survival by ANN. 
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Figure 51: Probability survival curve for individual Patient comparing actual survival and predicted survival by ANN. 
 
 
 
A Bland-Altman analysis was performed for comparison of the actual and predicted 
probabilities using NCSS 10 software for Model 1 (Figure 52). 
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Figure 52: Bland-Altman Plot showing correlation between BCSS (0=Deceased) and Predicted survival. 
 
Bland-Altman Analysis Report 
 
Bland-Altman Plot 
 
 
Descriptive Statistics 
                     Standard 95.0% LCL 95.0% UCL 
Variable Count Mean Deviation of Mean of Mean 
Death_from_disease 16127 0.9013456 0.2982067 0.896732 0.9059592 
Prediction 16127 0.8945166 0.2926436 0.889989 0.8990441 
Difference 16127 0.006829006 0.104128 0.005218022 0.00843999 
 
Correlation Coefficient = 0.938055 
  
Bland-Altman Analysis Report 
 
Bland-Altman Analysis: Bias and Limits of Agreement for Death_from_disease and Prediction 
Limits of Agreement = Diff ± 1.96 x (Std Dev of Difference) 
 
                      Standard 95.0% LCL 95.0% UCL 
Parameter Count Value Deviation of Value of Value 
Bias (Difference) 16127 0.006829006 0.104128 0.005218022 0.00843999 
Lower Limit of Agreement 16127 -0.1972618 0.001401362 -0.2000084 -0.1945152 
Upper Limit of Agreement 16127 0.2109198 0.001401362 0.2081732 0.2136664 
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Test of Normality of Differences Assumption 
 
Assumption Value Prob Level Decision (α = 0.050) 
Shapiro-Wilk 0.595 0.0000 Reject normality 
 
 
Evaluation of Assumptions Plots 
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Bland-Altman Analysis Report 
 
 
 
 
13.6.3. Discussion 
The ANN enabled development of a model to predict breast cancer specific survival in 
lymph-node negative individual patients over time using a combination of clinical features 
and biomarkers.   
 
